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Abstract  
 
Introduction: Neonatal infections contribute to 25% of all neonatal deaths, which 
account for approximately 44% of all under-5 childhood deaths globally. Pathogens 
responsible for sepsis in neonates and young infants can be acquired vertically prior to 
or during labour, or from the environment (community or hospital). 
This project evaluated the burden and aetiology of sepsis in neonates and young 
infants (≤90 days), and explored this association to in-utero exposure to human 
immunodeficiency virus. The study also included a specific focus on the epidemiology 
of invasive Group B Streptococcal disease in young infants.  
Additionally, we assessed the efficacy of intrapartum chlorhexidine vaginal washes for: 
(i) preventing early-onset neonatal sepsis; and (ii) vertical transmission of potentially 
pathogenic bacteria to the newborns. Furthermore, we evaluated risk factors for poor 
outcomes due to neonatal sepsis. 
 
Materials and methods: (i) A bacterial surveillance system was established at Chris 
Hani Baragwanath Academic Hospital (CHBAH) from 2004-2008 to identify young 
infants with bacterial sepsis hospitalised in the neonatal and paediatric wards. Medical 
and microbiological records were utilised to obtain clinical and laboratory data. Maternal 
HIV results were obtained from antenatal testing records or admission records.  
 
(ii) A blinded, randomised, placebo-controlled trial of 0.5% chlorhexidine maternal 
vaginal intrapartum wipes and newborn skin wipes was conducted at CHBAH between 
2004 and 2007. Consented, eligible participants were randomised during labour to 
receive either chlorhexidine vaginal wipes or water external genitalia wipes. Newborns 
received either chlorhexidine full-body wipes (intervention arm) or foot wipes (control 
vii 
 
arm). Maternal and infant participants were followed up for admissions during the first 
month after delivery/ birth. A subset of 5144 maternal participants had an intrapartum 
lower vaginal swab collected, and skin swabs were collected from their newborns to 
assess colonisation with potentially pathogenic bacteria (Group B streptococcus, 
Escherichia coli and Klebsiella pneumoniae).  
 
Results: Group B streptococcus (GBS) was the most commonly isolated bacterial 
pathogen, causing 35.2% of culture-confirmed sepsis in infants ≤90 days, 41.6% of 
early-onset disease (EOD, 0-6 days), 40.5% of late-onset neonatal disease (LOD, 7-27 
days) and 18.7% of young-infant community-acquired disease (YI-CAD, 28-90 days). 
Staphylococcus aureus (S. aureus), Escherichia coli (E. coli) and Klebsiella 
pneumoniae (K. pneumoniae) contribute 16.2%, 12.2% and 3.4% to sepsis in young 
infants.  
 
Overall, incidence (per 1000 live births) of invasive GBS disease was 2.72 (95% 
confidence interval [95% CI]: 2.46 to 3.01), including an incidence of 1.50 and 1.22, 
respectively, in infants 0-6 days and 7-90 days of age. HIV-exposed infants were at 
greater risk of EOD (Relative risk [RR]: 1.69; 95% CI: 1.28-2.24) and LOD (RR= 3.18; 
95% CI: 2.34-4.36) than HIV-unexposed infants. GBS serotypes Ia and III caused 
84.0% of invasive GBS disease in young infants.  
 
Intrapartum chlorhexidine interventional wipes was not efficacious in prevention of any 
of: (i) vertical transmission of pathogenic bacteria (54% vs. 55%; efficacy -0.05, 95% CI: 
-9.5 to 7.9) to the newborns; (ii) sepsis in first 3 days of life (3% vs. 4%; p=0.65,); (iii) 
sepsis in the later neonatal period (both <1%; p=0.4444); or (iv) maternal puerperal 
sepsis(both <1%; p=0.56).  
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Conclusion: GBS, S. aureus, E. coli and K. pneumoniae are the most commonly 
isolated bacterial pathogens in neonates and infants ≤90 days old. HIV-exposed infants 
are at greater risk of GBS sepsis. Intrapartum chlorhexidine intervention was not 
efficacious in reducing vertical transmission of pathogenic bacteria, neonatal or 
maternal sepsis. Alternative interventions to prevent sepsis in young infants, including 
maternal immunisation, need to be investigated in setting such as ours where there is a 
high prevalence of maternal HIV infection.   
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Preface 
 
After my second year of medical school, I took a ‘gap year’, during which I completed a 
Bachelor of Science degree at the University of the Witwatersrand. I hoped to develop 
research skills to support my career as a medical doctor, not realising at the time the 
profound impact this decision would have on my future career path. I joined the 
Respiratory and Meningeal Pathogens Research Unit (RMPRU) in July 2000 to obtain 
post-graduate experience in research, initially on a 6-month contract, with every 
intention of returning to clinical medicine, to specialise and practice as a paediatrician. 
When I joined RMPRU, enrolment into a large trial assessing the impact of a 9-valent 
pneumococcal conjugate vaccine (PCV) was nearing completion, and I was involved in 
the follow up of participants until 5-years of age. Over the next few years, I was 
afforded the opportunity to set up and run other paediatric vaccine trials in Soweto and 
Eldorado Park, Gauteng, South Africa, including a phase III trial of Rotarix®. The 
results of the pivotal PCV and Rotarix® trials conducted by RMPRU have informed 
global (World Health Organisation) recommendations on introduction of these two life-
saving vaccines into the Expanded Program on Immunisation (EPI). In 2009, PCV and 
Rotarix® were introduced into the South African EPI.  The knowledge that work I have 
been directly involved in has impacted the lives of millions of children both in South 
Africa and globally is extremely rewarding as a medical practitioner, and has kept me in 
a full-time research position for the past 15 years! 
 
Several interventions, including childhood vaccination, have led to a 53% reduction in 
under-5 child deaths between 1990 and 2015. The neonatal period (the first 28 days of 
life) is, however, the most treacherous time of life, during which the immense changes 
from intra-uterine life to life in the real world are encountered, and unfortunately, 
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millions of neonates annually do not weather the storm! Neonatal deaths contribute 
44% of all under-5 child deaths globally.  
 
Under the mentorship of Professor Shabir Madhi, I embarked on two projects in the 
field of sepsis in neonates and young infants, which have contributed to my PhD. These 
projects were both funded by the Centers for Disease Control and Prevention (CDC), 
USA and the Bill & Melinda Gates Foundation, and I have been fortunate to work 
intimately with experienced and influential public health care advisors and policy-
makers. During and subsequent to the conduct of these projects, I have had the 
opportunity and privilege to interact with global leaders in neonatal sepsis and more 
recently in the growing and exciting field of immunisation of pregnant women, and to 
present my work in Europe, the United States, Asia and Africa.  
 
The University of the Witwatersrand’s recommended ‘divided block’ format has been 
used for this thesis. It includes a literature survey, a chapter describing the methods 
utilised, 5 discrete chapters describing the results of the work conducted, and a 
conclusion chapter.  The methods section has not been repeated in each of the results 
chapters; rather a brief methods section has been included in some results chapters in 
which additional activities unique to that component of the research are described. 
Publications emanating from the work conducted have been used as the basis of 4 of 
the 5 results chapters (chapters 4-7). The unpublished chapter (chapter 3) is being 
prepared for publication. The references are not listed at the end of each chapter, but 
rather at the end of the thesis.  
 
This thesis describes the aetiology of bacterial sepsis in neonates and young infants 
(≤90 days) in an urban low-middle income setting (Soweto, Gauteng, South Africa) with 
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a high neonatal mortality rate (21/ 1000 live births) and disease burden, and presents 
the results of an interventional randomised, blinded trial of chlorhexidine maternal 
intrapartum vaginal wipes and newborn surface wipes which was conducted at Chris 
Hani Baragwanath Academic hospital.  
 
Subsequent to completing the projects described in this thesis, I have enjoyed 
continuing my work aimed at preventing infectious diseases in neonates and young 
infants, and am thrilled to be involved in the rapidly-progressing and exciting field of 
maternal immunisation.  
 
A quote from our late inspirational leader, Nelson Mandela, is appropriate to the 
completion of this thesis: ‘It always seems impossible until it’s done’.  
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1. INTRODUCTION 
  
The enormity of the burden of deaths in neonates and young infants was highlighted 
in The Lancet’s Child survival series of 20031, 2 and Neonatal survival series in 
20053-6, which reported that globally  3% (approximately 4 million) of all live-born 
babies died during the first 28 days of life in the year 20001, 3. Ninety-nine percent of 
these neonatal deaths occurred in low- and middle-income countries (LMICs), where 
access to skilled care for the mother and newborn is limited3. The World Health 
Organization (WHO) regions of South-East Asia and Africa contributed 64% (2.57 
million) of these deaths. Africa had the highest average neonatal mortality rate 
44/1000 (range 9-70/1000 live births)3.  
 
The global neonatal mortality rate (per 1000 live births) declined by 37% from 33 to 
21 between 1990 and 2012. However, this has lagged behind the more rapid year-
on-year reduction of other causes of under-5 deaths in this time period. 
Consequently, the proportion of under-5 childhood deaths occurring during the 
neonatal period has increased from 37.6% in 2000 to 43.9% (2.761 million) in 20137-
9. 
 
The Millennium Development Goals (MDGs) 
(http://www.un.org/millenniumgoals/bkgd.shtml) are structured, time-bound targets 
adopted by world leaders in 2000, as a commitment on behalf of their nations to 
reduce extreme poverty and improve health and welfare of their population by 2015. 
The fourth of the eight Millennium Development Goals (MDG4) aimed to ‘Reduce by 
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two thirds, between 1990 and 2015, the under-five mortality rate’. The MGD4 target 
was not achieved globally in 2015: there had been a 53% reduction in mortality in 
children under 5 years of age, rather than the targeted 66.7% reduction10. A 50% 
reduction in the Under-5 mortality rate (U5MR) between 1990 and 2015 was 
achieved by all regions of the world, but only 2 regions (East Asia & Pacific and Latin 
America & Caribbean) met the MDG4 target11. On a country level, only 32% (62/195) 
of countries managed to achieve their MDG4 target, including twelve low-income 
countries, ten of which fall in sub-Saharan Africa (Mozambique, Malawi, Ethiopia, 
Madagascar, Eritrea, Liberia, Niger, Rwanda, Uganda and Tanzania)11. South Africa 
did not achieve MDG4, however, with sustained efforts in scaling up of the prioritised 
interventions, the MDG4 goal could be achievable in South Africa soon after 201512. 
 
In 2013, the rate of under-5 deaths (per 1000 live births) globally was 44.0, with the 
neonatal period at 18.4 and post-neonatal infant mortality of 13.2, which together 
contributed to almost 72% of all under-5 deaths13.  South Africa had an under-5 
mortality rate of 37.0 in 2013, including a neonatal mortality rate of 14.6 and post-
neonatal infant mortality rate of 14.713. The neonatal mortality rate in Soweto during 
2013/ 2014 was, however, 21 per 1000 live births (Maternal influenza trials, 
unpublished data), which is 44% higher than reported nationally.  
 
The annual rate of reduction (ARR) in under-5 mortality in South Africa was four 
times higher in 2000-2015 period, than in the 1990’s, mainly due to decrease in 
Human immunodeficiency virus (HIV)-related childhood deaths11, largely due  to the 
implementation and strengthening of  mother-to-child HIV transmission prevention 
programs (PMTCT)14, and early antiretroviral therapy of HIV-infected children11, 15.  
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Sixteen cost-effective interventions spanning preconception, antenatal, intrapartum 
and postnatal periods were identified during a systematic review as being effective in 
reducing mortality in the perinatal (including stillbirths and deaths in first 7 days of 
life) and neonatal periods4. Implementation or expansion of these interventions in 
LMICs is challenging, especially intrapartum interventions, which have the greatest 
impact in reducing neonatal mortality but have a high financial cost4.  Recognition of 
the importance of newborn health as an important indicator of population health16, 
has encouraged country leaders to prioritise maternal and newborn health 
programs17. Government and community commitment to strengthening of health 
systems aimed at maternal and newborn health highlighted in 20055, 6, has led to a 
reduction of the absolute number of annual neonatal deaths to ~2.6-2.9 million 
deaths in 20137, 13, 18. 
 
The South African National Department of Health adopted and implemented 15 cost 
effective interventions (including antenatal corticosteroids during preterm labour, 
improved management of labour and delivery, early detection and treatment of HIV-
infected women, oral rehydration solution) in 2013 which were identified and 
prioritised in a study to reduce maternal, neonatal and child deaths12.  
Allocation of resources and efforts to reducing mortality in neonates and young 
infants requires an in-depth knowledge of the causes of death.  
 
1.1. Causes of mortality in neonates and post-neonatal 
infants 
Unfortunately, the global regions with highest neonatal and infant mortality rates also 
have marked paucity of data, making accurate reporting difficult3. Civil registration 
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systems are administrative systems utilised by governments to record major vital 
events, most notably births and death. Many countries have legislated the 
registration of vital events, however, limited capacity to roll out these administrative 
systems in many poorer countries hampers adequate, timely registration of births 
and deaths. Data from civil registration systems are used to generate vital statistics 
for countries19, and well established and functioning Civil Registration and Vital 
Statistics (CRVS) systems can contribute to improved health outcomes in the 
population, especially when data generated are utilised to plan resource availability 
and allocation 20.  Unfortunately, CRVS systems in many LMICs are inadequate, with 
up to 35% of births and 60% of deaths occurring globally being unregistered21. 
Statistical modelling has, therefore, been utilised to estimate the distribution of 
causes of child mortality8 and neonatal cause-of-death distributions for countries 
without high-quality CRVS systems22.  
 
Globally, preterm birth (35.0%- 35.7%), intrapartum complication (23.4-24.0%) and 
sepsis (15.3-15.6%) are the main causes of neonatal death, and collectively account 
for approximately 75% of neonatal deaths8, 22. Oza et al22 have recently published 
cause-of-neonatal-death estimates for 194 countries and have stratified neonatal 
deaths into early (0-6 days) and late (7-27 days) neonatal period deaths. The 
distribution of the causes of death differ remarkably between the early and late 
neonatal periods, with preterm birth complications contributing 40.8% and 21%; 
intrapartum complications contributing 27.0% and 12.9% and sepsis contributing 
14.2% and 47.6% to early and late neonatal deaths respectively22. Despite sepsis 
ranking third in global causes of neonatal death, just over half of newborn deaths 
that occur at a community level in India were assessed to be sepsis-related23. A 
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review of community-based studies conducted in LMICs and published since 1990 
reported infection-specific mortality rates ranging from 2.7 (95% CI: 1.6 to 4.2) to 
38.6 (95% CI: 16.8 to 74.7), with 8-80% (median 36.5%, interquartile range 26%-
49%) of all neonatal deaths being attributable to infections24. In a population-based 
verbal autopsy study conducted in India, Malawi, Bangladesh and Nepal, 63% to 
82% of neonatal deaths occurred in the first week of life. The neonatal mortality rates 
were 9- 59 per 1000 live births, with infection causing 27.4% to 32.9% of deaths25. 
 
Approximately 36% of all neonatal deaths take place in the first 24 hours of life7, 
accounting for approximately 1 million deaths annually. The addition of stillbirths to 
these neonatal deaths on first day of life doubles this number annually, to almost 2.2 
million perinatal (stillbirths and first 7 days of life) deaths globally7. The main causes 
of post-neonatal under 5 mortality are lower respiratory tract infection, malaria and 
diarrhoeal disease (~1.75 million deaths annually)18. 
 
In an effort to assist community-based health care workers to identify and manage 
sick infants at entry-level health care facilities, the WHO developed the ‘Integrated 
Management of Childhood Illness’ (IMCI) algorithms during the mid-1990s. 
Management of neonatal illness during the first week of life was not included in the 
original IMCI guidelines, and a large multi-centre study (including a South African 
site) was conducted during the early 2000’s to identify clinical predictors of severe 
illness requiring hospitalisation in infants under 60 days of age. Severe infection 
(including sepsis, meningitis and pneumonia) was identified as the cause of 
hospitalisation in 43% of neonates <7 days of age and 61% of infants aged 0-59 
days old in Durban, South Africa26, 27.   
6 
 
1.2. Sepsis in neonates and post-neonatal infants 
 
Sepsis in young infants (<3 months of age) is delineated into specific age groups, 
according to the normal physiological changes that occur during childhood28, and 
includes early-onset disease (EOD, 0-6 days of life) and late onset disease (LOD, 7-
90 days). LOD can also be stratified into late onset neonatal disease (7-27 days) and 
post-neonatal disease (28-90 days).   
 
The foetus and young infants’ vulnerability to infections is dependent on the 
relationship between the triad of host, environment (pre- and post-delivery) and 
organism. In order to allow for successful outcomes of pregnancy, the mother’s 
immune system adapts to tolerate the presence of the foetus, whilst still continuing to 
function effectively in the event of an infection29. This adapted immune system, 
however, makes the mother more susceptible to infection, which can in turn increase 
the risk of infection in foetus and newborn.   
 
Maternal antibodies, which provide passive protection against infection to the infant 
during the first months of life, cross the placenta by an active receptor-mediated 
process which increases from 30 weeks of gestational age30, 31. 
Hypergammaglobulinemia32, placental malaria33, maternal HIV-infection34 and 
preterm birth35 reduce transplacental transfer of antibodies between mothers and 
infants, increasing risk of infections in infants.   
 
The immune system of the foetus and newborn is specifically developed and adapts 
to enable the foetus and newborn to cope with the challenges he/ she encounters, 
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including self-protection against maternal alloantigens in utero, and progressing to a 
controlled or muted inflammatory response to the onslaught of exposures to 
previously un-encountered microorganisms during and after delivery.  
  
Physical barriers including skin, mucous membranes and secreted mucous layer 
provide the first anatomical and physiological barrier to invasion by pathogens36. 
Susceptible ports of entry through this physical barrier include the umbilical cord 
attachment, eyes, nose, mouth, gastro-intestinal and uro-genital tracts.  
 
The innate immune system has a cellular component comprising neutrophils, 
dendritic cells, monocytes and macrophages, and a humoral component made up of 
biologically active molecules (e.g. complement proteins) which are involved in 
regulation of inflammatory response36, 37. The foetal immune system needs to remain 
tolerant to the maternal alloantigens38, which is probably one of the reasons why the 
innate immune system has muted functionality at birth38-40, and which in turn 
increases the newborn’s susceptibility to bacterial and viral infections38, 40. 
 
The cellular component of the adaptive immune system of a newborn comprises T- 
and B-lymphocytes, which develop from the bone marrow. T-lymphocytes develop 
further in the thymus38. Although mechanisms are not well understood, development 
of foetal and neonatal T cells deviates towards T-helper type 2 or regulatory 
responses (Treg), which do not adequately protect against intracellular pathogens38, 
41. This response if further heightened in HIV-exposed than HIV-unexposed infants. 
Additionally, B-cell numbers are increased and natural killer cell numbers are 
decreased in HIV-exposed infants compared to HIV-unexposed infants, 29 which 
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could contribute to increased susceptibility to infections in HIV-exposed infants even 
in the absence of them being HIV-infected . 
 
The humoral component of the adaptive immune system in the neonate comprises 
predominantly of maternally-derived IgG antibodies36, 40, which cross the placenta in 
increasing number as gestational age approaches term. Additionally, secretory IgA 
and IgG antibodies from breastmilk may confer protection against infections in the 
newborn42, 43. This passively-acquired immunity, which wanes over the first few 
months of life, is able to protect the newborn against pathogens to which the mother 
had been exposed.   
 
HIV-exposed infants are at higher risk of being born prematurely or at low birth 
weight44, 45. Chronic inflammation due to HIV infection and other opportunistic 
pathogens could lead to an increase in the number of activated cytokine-producing 
T-cells in HIV-infected compared to HIV-uninfected individuals.  In pregnant HIV-
infected women, there is an increase in pro-inflammatory cytokines and growth 
factors in the placenta, which can also increase the risk of mother-to-child-
transmission of HIV and other infections29.  
Maternal recto-vaginal colonisation with potentially pathogenic organisms, prolonged 
and/or premature rupture of membranes, preterm delivery, chorioamnionitis and 
maternal urinary tract infections are the most commonly recognised risk factors for 
early-onset disease (EOD, 0-6 days of life)40, 46. Pathogenic organisms including 
Group B streptococcus (GBS) and Escherichia coli (E. coli) are usually acquired by 
vertical transmission from mother to infant, either by migration of colonising bacterial 
isolates into the amniotic fluid through ruptured or macroscopically intact membranes 
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which could have micro-tears47, acquisition during birth process48 or rarely by 
haematogenous spread from a mother with GBS bacteraemia49.  
 
Late-onset disease (LOD, 7-90 days of life) could be acquired from the mother, but is 
more commonly community-acquired or nosocomially-acquired. Risk factors for 
community-acquired LOD include exposure to environmental pathogens from family 
or community50 and interruptions of natural barriers (skin and mucous membranes)40. 
Exposure of neonate to invasive procedures, indwelling catheters and prolonged use 
of antibiotics predispose neonates to nosocomial LOD40.  
 
1.2.1. Neonatal sepsis incidence, aetiology and antibiotic resistance 
patterns  
 
Identification of a causative pathogen from a normally sterile body fluid is considered 
the gold standard for diagnosis of sepsis28, 51, 52. The sensitivity to detect pathogens 
in blood culture samples from infants with sepsis is low (0.6% to 7.9%)53, 54. This  
may be in part related to the low blood sample volumes available from infants and 
children (up to 6ml blood should be used for blood culture testing)53, 55, use of 
incorrect culture bottles56, low bacterial load/ low level bacteraemia56, 57 and 
additionally impacted by antibiotic administration to mother prior to delivery of 
infant58, or to the infant prior to drawing blood for culturing56. Despite the difficulties 
encountered in trying to establish the bacterial cause of sepsis in neonates and 
young infants, data are available from many regions of the globe. Some publications 
do not, however, differentiate between sepsis acquired from mother (vertically 
transmitted, usually EOD), community or environment (EOD or LOD) and health-care 
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facility (nosocomial, usually LOD). Pathogen distribution and antibiotic sensitivity 
patterns can vary markedly between these groups.  
 
Neonatal sepsis in high income countries (HIC) 
Early onset neonatal sepsis rates in high income country (HIC) settings ranges from 
0.59 to 1.6 per 1000 live births40, 59-63, with GBS being the most commonly isolated 
pathogen64-66 , which together with Escherichia coli account for almost 75% of 
cases40, 64. Preterm neonates are at increased risk of developing sepsis, with black 
preterm neonates having highest incidence in USA with rate of 5.14 per 1 000 live 
births and a case fatality ratio of 24.4%40. E. coli is the most common cause of EOD 
in preterm and very low birth weight (VLBW, birth weight <1500 grams) neonates, 
and the leading cause of sepsis-related mortality in VLBW infants40.   
 
Late onset neonatal sepsis rates in HIC settings range from 3.0 to 3.7 per 1000 live 
births, with E.coli and Klebsiella species being the main bacterial pathogens64. 
Preterm and low birth weight neonates are at highest risk for late onset sepsis, which 
is predominantly nosocomial and related to prolonged hospitalisation and indwelling 
foreign bodies including catheters40.  
 
Neonatal sepsis in low and middle income countries (LMIC) 
In a population-based study conducted in Bangladesh, the culture-confirmed 
neonatal sepsis rate was 3.0 per 1000 live births, with Staphylococcus aureus (S. 
aureus) reported as the most common neonatal pathogen. However, this was 
considered an under-estimation of true burden of neonatal sepsis since more than 
half of the reported neonatal deaths occurred in the first 24 hours after delivery, and 
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62% of these neonates were not assessed by a health care worker prior to death67. 
The incidence of sepsis in neonates and post-neonatal young infants assessed in 
hospitals may not be representative of community-based incidence, especially in 
LMICs. Culture-confirmed- and clinically-suspected neonatal sepsis rates of 16 per 
1000- and 49-170 per 1000 live births, respectively, have been reported from 
community-based studies in LMICs24, 63.   
 
The WHO Young Infants Study group conducted a study in four LMIC countries (The 
Gambia, Philippines, Ethiopia and Papua New Guinea) in the early 1990s, to 
describe the causes of sepsis in infants under 3 months of age and clinical features 
which predicted severe disease68. The bacterial pathogens most commonly isolated 
from blood were Staphylococcus aureus (S. aureus; 23%), Streptococcus 
pneumoniae (S. pneumoniae; 30%), Streptococcus pyogenes (S. pyogenes; 20%) 
and E. coli (18%)  in infants aged 1 to 3 months.  S. pneumoniae was the most 
common cause of meningitis in young infants, the majority (12/17, 71%) of which 
occurred in the second and third months of life. GBS was conspicuous in its 
absence, with only two neonatal bacteraemia and one neonatal meningitis cases 
being identified in 2398 enrolled sick infants69. Notably, however, this study only 
enrolled neonates following their discharge from health facilities after birth, and 
consequently likely under-recognised the burden and aetiology of EOD68.   
 
More recently, several literature reviews and meta-analyses have been conducted to 
describe the incidence and aetiology of sepsis in neonates and post-neonatal infants 
in LMIC, however, heterogeneity of studies and definitions used limited comparability 
of studies included in reviews70. Bacteraemia was identified in 3-16% of sick infants 
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presenting to first-referral hospitals, and from 20-60% of infants presenting to tertiary 
hospitals70. Between 62% and 75% of positive blood cultures in infants were from 
neonates, highlighting the large burden of disease in this age-group70, 71.   
 
The reported incidence (per 1 000 live births) of neonatal sepsis in LMICs varied 
from 3.5 to 23, including  7.1-38 in Asia, 6.5-23 in Africa and 3.5-8.9 in South 
America and Caribbean64, 70-72. The majority of identified pathogens in these studies 
were Gram-negative bacteria (53% - 61%), including E. coli (8% - 19%) and 
Klebsiella species (14% - 25%). Gram-positive bacteria contributed to 39% - 47% of 
the identified pathogens, of which S. aureus (13.3% - 26.4%) was the most 
common70, 71.  
 
Two meta-analyses of published70, 71 and unpublished studies71 from LMICs, 
indicated that S. aureus (13.3- 26%), E. coli (8-17.8%) and Klebsiella species (13.5-
21%) were the most commonly-isolated bacteria identified in neonates with sepsis. 
In contrast, identification of GBS was uncommon, being identified in only 2-8% of 
bacterial pathogens in neonates with sepsis.  
 
In the post-neonatal period, the meta-analysis by Zaidi et al71 identified S. 
pneumoniae (27%), S. aureus (11-13%) and S. pyogenes (11-13%) as the most 
common pathogens, whereas the meta-analysis by Downie et al70 identified S. 
aureus (22%), E.coli (10%) and Klebsiella species (10%) as the most dominant post-
neonatal bacterial isolates70.  GBS was identified in <1% to 11.5% of post-neonatal 
infants.  
The age of the infants included in the post-neonatal period and years of data 
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collection differed between these two meta-analyses. Zaidi et al71 limited review to 
infants aged 0-90 days from articles published between 1980 and 2007, however, 
Downie et al70 included infants up to 1-year of age identified in articles published 
between 1993 and 2009. Both meta-analyses concluded that data on culture-
confirmed sepsis in young infants from LMICs was extremely limited and quality of 
studies included in meta-analyses varied. 
 
There is a paucity of data on antibiotic resistance patterns of bacterial pathogens 
causing neonatal and post-neonatal infant sepsis in LMIC. Bacteria isolated from 
neonates were more likely to be resistant to penicillin-gentamicin combinations 
(43%) and third-generation cephalosporins (44%) than bacteria isolated from post-
neonatal infants (37% and 36% respectively)70. Included among these bacteria, 
however, were studies which included nosocomial sepsis cases.   
 
Varied patterns of susceptibility were identified in the meta-analysis, with 72-74% of 
E. coli isolates being resistant to penicillin or ampicillin and 20-64% being resistant to 
third generation cephalosporins. Twenty to 80% of S. aureus isolates were resistant 
to penicillin or ampicillin, and approximately 37% were resistant to third generation 
cephalosporins. Furthermore, 70- 100% of Klebsiella species isolates were resistant 
to penicillin or ampicillin, and 43-66% were resistant to third generation 
cephalosporins70, 73.     
  
Cause of  sepsis in neonates and young infants  
Streptococcus agalactiae or Group B streptococcus (GBS) is a gram-positive 
coccus which was first identified in 1885 as the main cause of bovine mastitis by 
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Nocard and Mollereau74. In 1934, GBS was reported as a cause of severe, 
sometimes fatal puerperal uterine infection, and as a non-pathogenic vaginal 
coloniser in pregnant women by Rebecca Lancefield and Ronald Hare75. GBS has 
been reported as the principal cause of early-onset disease since the 1970s76. 
 
There are ten serotypes identified by their specific sialic acid-rich capsular 
polysaccharides (CPS: Ia, Ib, II, III, IV, V, VI, VII, VIII, IX and X); the most pathogenic 
serotypes in young infants are III (48.9%) and Ia (22.9%)77. The pathogenicity of 
GBS is based on the presence of several virulence factors. Capsular 
polysaccharides (CPS) expressed by GBS assists in evading ingestion by host 
phagocytes40, 78. Adherence to the epithelial cells and trans-epithelial migration is a 
pre-requisite for colonisation and invasion, and is mediated by pilus-like structures in 
the GBS surface78, 79. Additionally, C5a peptidase produced by GBS interferes with 
the host defence systems by inhibiting human C5a- neutrophil chemo attractant 
produced during complement activation40, 78.  
 
Prior to implementation of GBS prevention measures, the incidence (per 1000 live 
births) of GBS EOD  in USA was 1.3-1.748. In the United Kingdom, overall GBS 
incidence was 0.72 (95% confidence interval 0.66-0.78) in 2000- 2001, with the 
incidence of EOD being 0.47 (95% confidence interval 0.42-0.52)80.  
 
In a meta-analysis of 74 studies published between January 2000 and September 
2011, the  incidence (per 1000 live births) of GBS disease in young infants globally  
was  0.53 (95% confidence interval [95% CI]: 0.44 to 0.62)77. Africa reported  the 
highest incidence (1.21; 95% CI: 0.50 to 1.91) and south-east Asia the lowest  (0.02; 
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95% CI: 0 to 0.07)77. Other studies conducted in Africa which were not included in 
this meta-analysis also reported high incidence of GBS-related disease81-84, 
including a retrospective study of GBS in children in Soweto, South Africa between 
1997 and 1999, which reported a GBS-EOD incidence of 2.06 and GBS-LOD 
incidence of 1.0 live births81. 
 
The reasons for this marked difference in GBS-EOD rates are probably multifactorial. 
Recto-vaginal colonisation with GBS is a major risk factor for developing GBS-
EOD85. The prevalence of recto-vaginal colonisation with GBS varies globally, and 
ranges from 11.1% (95% CI: 6.8-15.3) in South-East Asia to 22.4% (95% CI: 18.1-
26.7) in Africa (Personal communication: Gaurav Kwatra, unpublished meta-
analysis). Factors contributing to this variation may include (i) geographic variability 
in prevalence of GBS colonisation, (ii) variability in density of colonisation with GBS, 
which could impact on infection of the foetus and newborn, (iii) geographic variability 
in colonising GBS serotypes, which have differing invasive potential (iv) differences 
in naturally-acquired protective serotype-specific capsular antibody levels and (v) 
time and method of swab collection and processing. 
Other risk factors for GBS-EOD, including prematurity25, prolonged rupture of 
membranes may also vary with geographic region. Practices which may impact the 
rate of colonisation, vertical transmission and detection of GBS-EOD may vary 
between global communities. Availability of over-the-counter antibiotics in many 
regions86-89 is a global concern, as misuse of antibiotics leads to emergence of 
antibiotic resistance. Various reasons including customers’ demands, complacency, 
insufficient knowledge and financial benefit motivate pharmacists to dispense 
antibiotics without prescriptions87, 89. Despite policies regarding sale of non-
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prescription medicines including antibiotics being in place, adequate enforcement of 
regulations may be lacking. In 2010, enforcement of existing laws restricting the 
over-the-counter sale of antibiotics in Mexico and Brazil was strengthened. A 
decreased seasonal variation in penicillin use was noted in Mexico90, and a 30% 
reduction in amoxicillin sales was noted in Brazil91 after enforcement of policies, 
which may indicate more appropriate use of antibiotics.  Traditional medicines, which 
are widely used in communities in Africa and Asia, may include medicinal plant 
extracts which have antimicrobial properties92-94, which in turn may impact GBS 
colonisation and transmission rates.  
 
Identification of GBS-EOD is challenging, especially in regions with limited health 
care facilities. The majority (70-74.8%) of GBS-EOD cases are identified within the 
first 12 hours of life, with up to 100% presenting in first 48 hours of life95. In areas 
with high rates of home deliveries, GBS-EOD cases may be missed, as has been 
illustrated by a study conducted in Bangladesh where more than half of the 
neonatal deaths occurred in the first 24 hours of life, and 62% of infants who died 
were not investigated for bacteraemia67. This potential detection bias in neonatal 
sepsis epidemiological studies was recently corroborated by the neonatal sepsis 
aetiology study in South Asia (ANISA), where GBS was seldom identified. Despite 
the intensity of community-based surveillance in ANISA, no blood samples were 
obtained from 80% of the neonatal deaths, 70% of whom died within 6 hours of 
birth (personal communication Samir Saha). 
 
GBS remains the most common cause of bacterial meningitis in young infants in the 
USA (0.003/1000 live births; 95% CI: 0.0021 to 0.0031) 96 and the United Kingdom 
17 
 
(0.16/1000 live births, 95% CI: 0.13 to 0.18) 97, and one of the most common causes 
of sepsis in neonates and young infants globally71, 77, 95, 98.  Between 60% and 70% 
of invasive GBS cases across all age groups, occur in infants <3 months of age66. 
Neurological sequelae are more common in 6-month old survivors of GBS invasive 
disease than in controls (aOR 13.18, 95% CI: 1.44 to 120.95). A greater proportion 
of infants who had GBS-meningitis (23.5%) than sepsis (9.8%) have neurological 
abnormalities99.  
 
The true incidence of GBS-EOD may, however, be under-represented by studies 
which only include positive sterile site cultures (definite GBS-EOD). Inclusion of 
newborns with clinical features of sepsis and a GBS-positive swab from a non-sterile 
site (deep ear/ pharynx) swab (probable GBS-EOD) at least doubled the GBS-
attributable disease burden in the UK (1.1/1000 to 3.6/ 1000 live births)100 and Spain 
(0.39/ 1000 to 0.86/1000 live births)101. GBS sepsis can be a rapidly-progressive 
disease, resulting in death in 9.6% (95% CI: 7.5 to 11.8) of cases; twice as high in 
early onset cases (CFR 12.1%; 95% CI: 6.2 to 18.3) than late-onset cases (6.8%; 
95% CI: 10.8 to 14.9). The case fatality rate in LMIC  was three times higher than  in 
HIC (12.6% vs. 4.6%)77. 
 
Staphylococcus aureus (S. aureus) is a gram positive coccus which was first 
described in 1880 by Scottish surgeon, Alexander Ogston (1844-1929), who 
hypothesised that the round organisms he observed in pus from surgical wounds 
were the cause of post-surgical abscesses and putrefaction102. S. aureus is a 
common colonising bacterium with almost half of all newborns being colonised (skin, 
mucous membranes) within the first few days of life103. S. aureus produces biofilms 
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which assist the pathogen evade the immune system and prevents  antibiotic 
penetration40. Cell wall-anchored proteins and membrane- damaging toxins aid S. 
aureus in adhering to and invading cells. A robust T-cell response, especially Th1 
and Th17 which are attenuated in newborns, is required to protect against S. aureus 
infection104.  
 
S. aureus has been isolated from more than half (52%) of the purulent umbilical 
exudates in Pakistani newborns with omphalitis105. It is one of the main causes of 
bacteraemia in neonates and post-neonatal infants, especially LOD in very low birth 
weight (VLBW) infants. Mortality and morbidity related to S. aureus infections in 
young infants is significant. Mortality of up to 25% has been reported in VLBW 
infants, and neurodevelopmental impairment observed in 18-37% of surviving 
infants103.  
 
Escherichia coli (E. coli) was first isolated and characterised from an infant’s stool 
sample by Theodor Escherich in 1885106. It is a gram negative rod-shaped bacterium 
which colonises the gastrointestinal system of humans and other warm-blooded 
animals106, often being the first bacterium to colonise infantile gut soon after birth107, 
either by vertical transmission from mother or by environmental acquisition from 
other infants, care-givers’ hands or other fomites108.  
 
Enterotoxigenic E. coli is one of the 4 main causes of moderate to severe diarrhoea 
in children in LMIC, which leads to approximately 800 000 deaths annually109. E. coli 
is also the most common cause of urinary tract infections in neonates (40-72%) and 
older infants, who are at risk of concomitant E. coli meningitis and bacteraemia110.  
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E. coli is the second most common cause of early-onset meningitis overall, and the 
most common cause of meningitis and early onset sepsis in very low birth weight 
infants40, 49, 111.   
More than half (n=43, 51%) of children under 18 years with E. coli bacteraemia were 
under 3 months of age, highlighting the burden of disease in this age group. 
Additionally, young infants were more likely to have severe bacteraemia than older 
children (32.6% vs. 7.3%, p=0.006)112. Infants under 90 days of age with E.coli 
bacteraemia had a 9.5% case-fatality rate112, and E. coli meningitis is associated 
with a 14% mortality rate113. Of the surviving infants in a retrospective study 
conducted in France, 21% of infants had neurological sequelae at 8 months of 
age113.Central venous thrombosis with subsequent neurological sequelae have also 
been associated with E. coli infections in neonates (meningitis or UTI)114.  
 
Klebsiella pneumoniae (K. pneumoniae) is a rod-shaped gram negative bacterium 
of the family Enterobacteriaceae which was first described by German microbiologist 
Carl Friedländer in 1882115.  Although initially identified as a cause of community-
acquired pneumonia (CAP), the incidence of K. pneumoniae-associated CAP has 
declined, however, it remains associated with HIV-infection in adults. K. pneumoniae 
bacterial liver abscesses and meningitis has been described in adults116.  Klebsiella 
(species) has been recognised as an important (4% - 25%) cause of sepsis in young 
infants in HIC64 and LMIC70, 71. Recently there has been an emergence of 
hypervirulent or antibiotic-resistant strains of K. pneumoniae globally117, 118.   
 
Several virulence factors have been well characterised in K. pneumoniae, including 
capsular factors, lipopolysaccharide, siderophores and fimbriae. These virulence 
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factors are largely defensive, allowing the bacteria to evade host immune 
responses117.    
 
Antibiotic resistance mechanisms include (i) the expression of extended spectrum 
beta-lactamases (ESBL) which leads to resistance to cephalosporins and 
monobactams and (ii) expression of carbapenemases, which leads to resistance to  
most ß-lactams, including carbapenems117.  
 
Neonatal intensive care units (NICUs) have reported an emergence in extended 
spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, most commonly K. 
pneumoniae. A recent review of ESBL-producing organisms causing outbreaks in 
NICUs119 identified 75 studies, including 860 infections and 139 deaths (16% 
mortality rate). Outbreaks were most commonly triggered by admission of a 
colonised infant to NICU, however sub-optimal infection control measures, including 
poor hand washing or use of contaminated equipment, contributed to spread of 
bacteria to outbreak proportions119.      
 
There are three main carbapenemases produced by carbapenem-resistant K. 
pneumoniae: (i) K. pneumoniae carbapenemases (KPCs), (ii) carbapenemases of 
the oxacillinase-48 (OXA-48) and (iii) New Delhi metallo-ß-lactamase (NDM) 
carbapenemases. The geographic distribution of these antibiotic-resistant K. 
pneumoniae strains varies globally, however, all three strains have been reported in 
South Africa118.   
 
The multiple factors contributing to hypervirulence and antibiotic resistance of K. 
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pneumoniae have complicated the management of patients with K. pneumoniae 
infection, and useful antibiotics are now restricted to colistin, selected 
aminoglycosides, polymyxin B, fosfomycin and  tigecycline118.  
 
1.2.2. Challenges in identifying the burden of neonatal sepsis 
 
Lack of laboratory facilities and expertise in many LMIC settings impede the ability to 
confirm the presence and identification of invasive pathogens in septic neonates and 
post-neonatal infants70, 71. Sepsis has been described as the ‘systemic inflammatory 
response (SIRS) to an active infectious process’ 51, which is manifest by 
physiological changes including but not limited to fever or hypothermia, tachypnoea, 
tachycardia and leucocytosis or leucopoenia in the presence of a proven or 
suspected infection28, 51.   
 
Lack of a standardised definition for sepsis in neonates and post-neonatal infants 
complicates the task of accurately reporting the disease burden, and reduces 
comparability of neonatal sepsis reports or study results50, 120. First-line health care 
workers’ task of identifying severely ill infants who require referral for hospital 
admission or community-based treatment is also made more challenging by the lack 
of a globally-accepted definition121.  
 
Numerous definitions for neonatal sepsis have been proposed for use in varied 
settings including community-based health care settings27 and hospital-based 
settings, which include combinations of clinical findings and/ or laboratory test 
results122. The sensitivity and specificity of laboratory tests (e.g. white cell count) and 
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clinical features (temperature- fever/ hypothermia) in predicting sepsis or its severity, 
varies between term and preterm neonates122. 
Several neonatal illness severity scoring systems are utilised, including the ‘Score for 
Neonatal Acute Physiology (SNAP/ SNAP-PE [perinatal extension])123, the Clinical 
Risk Index for Babies (CRIB/ CRIB-II)124 and The Young infant Clinical Signs Study 
Group (YICSSG)  for predicting severe illness in young infants27.  
 
Definitions for neonatal sepsis need to take into account the variations of laboratory 
and physiological features at different gestational ages, and different chronological 
age125.  It has been proposed that a consensus definition of neonatal sepsis would  
assist in comparability of both observational studies and clinical trials125, however, 
the dynamic nature of the disease requires a definition to allow for time lag between 
appearance and disappearance of numerous signs and symptoms122. Neonatal 
sepsis definition should include a scoring system to assess severity of sepsis and 
monitor improvement or deterioration in the neonate’s condition125. Concerted efforts 
are being made to develop definitions which can be utilised (mainly in maternal 
immunisation field) in both well-resourced and poorly resourced settings126, 127. 
 
Possible serious (or severe) bacterial infection (pSBI) has been defined as ‘a clinical 
syndrome used in the Integrated Management of Childhood Illness package referring 
to a sick young infant (<60 days old) who requires urgent referral to hospital’128. 
Signs used for the diagnosis of pSBI include inability to feed well, tachypnoea (>60 
breaths per minute in neonates <7 days old), convulsions, severe chest indrawing, 
fever (≥38°C), hypothermia (<35.5°C) and movement only when stimulated128.  
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Seale et al129 conducted a systematic review and meta-analysis of pSBI in neonates 
born at ≥32 weeks gestation in LMICs, and estimated that there were 6.9 million 
cases of PSBI in 2012 (incidence risk 7.6%; 95% CI: 6.1-9.2%). Approximately 0.68 
million neonatal deaths were attributable to PSBI (case fatality risk 9.8%). 
 
In a more recent analysis of prospectively-collected data from 7 rural community-
based Global Network sites in low and middle income countries (Argentina, 
Guatemala, Kenya, Zambia, India and Pakistan) of births occurring between 2010 
and 2013130, 12.9% (95% CI 12.8-13,0%) of all live-born infants fulfilled criteria for 
pSBI during the first 6 weeks of life. There was a wide variation in incidence (3% to 
36%) across sites, suggesting possible over-reporting of respiratory symptoms, 
especially in preterm infants. The case fatality rate was 14% overall in pSBI cases, 
but varied widely between sites (5% to 42%), suggesting under-reporting of signs 
and symptoms of pSBI at some sites. Higher rates of pSBI reported in the Hibberd 
paper130, compared to Seale’s paper129 were probably due to inclusion of all live-born 
infants, irrespective of gestational age, with preterm infants being more likely than 
term infants to have respiratory difficulty. 
 
The WHO has published recommendations for identification and management of 
children with possible severe bacterial infections131.Difficulties in confirming / 
diagnosing sepsis due to low yield of- or poor access to culture techniques, and lack 
of a standardised definition place health care providers under pressure to initiate 
antibiotics without confirmation of a causative pathogen, and diagnosis. This has led 
to overuse of empiric broad-spectrum antibiotics, which in turn increases 
antimicrobial resistant organisms.  
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1.2.3. Antimicrobial Stewardship 
 
Discovery and use of antibiotics 8 decades ago revolutionised medical care. 
Pneumonia-related deaths decreased significantly, and complicated interventions 
including organ transplantation and cancer treatments became more acceptable due 
to decreased risk of infection132. Inappropriate use of antibiotics, including use of 
incorrect antibiotic, use of antibiotics when not required, and excessive duration of 
antibiotic use, leads to increased resistance patterns40.  
 
The increase in antimicrobial resistance of bacterial pathogens is a cause of great 
concern globally. In high-income countries, pathogens resistant to first-line antibiotics 
are treated with more expensive second- or third-line antibiotics; however, resistance 
to these antibiotics and the shortage of additional effective antibiotics entering the 
market will soon lead to spread to completely-resistant pathogens. In LMICs, 
resistance to first-line antibiotics may lead to an increase in preventable mortality, as 
cost of second- and third-line antibiotics is prohibitive and therefore not available to 
populations with highest burden of infectious diseases132, 133. The mechanism by 
which antibiotic resistance could emerge include when the pathogen develops one or 
more of the following adaptions: altered target site, antibiotic inactivation, reduced 
membrane permeability of efflux pumps133.  
 
Administration of antibiotics in pregnant women close to or during labour has been 
proven to decrease the incidence of GBS-associated early onset sepsis134, however, 
it has also been associated with an increased risk of bacteraemia and urinary tract 
infections due to E. coli isolates with reduced antibiotic susceptibility profiles110.The 
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WHO recommends ampicillin (or penicillin) and gentamicin for 10 days as first line 
treatment for neonatal sepsis. Cloxacillin is added if a Staphylococcal infection is 
suspected131, 135, and a third generation cephalosporin is used to treat neonatal and 
infant sepsis in many countries70. Infants admitted to hospital, especially neonatal 
intensive care units, are high risk of infection with antibiotic resistant pathogens. Up 
to 95% of these infants will receive empiric antibiotics, despite low (<5%) culture-
confirmed sepsis rates133. 
 
Some countries have implemented local antimicrobial stewardship guidelines. Public 
Health England has implemented a ‘Start smart, then focus’ strategy which guides 
health care providers on rapid implementation of antibiotic treatment only when a 
patient presents with clear evidence of infection, and review and continuation criteria 
for antimicrobial treatment136. Variations in antibiotic resistance patterns in different 
regions, and concerns about emerging multi-drug resistance needs to be considered 
carefully when recommending antibiotic treatment137. 
 
Simplified 7-day long regimens of combinations of oral and injectable antibiotics138, 
or twice-daily oral antibiotics139 have been found to be as effective in preventing 
treatment failure (including death, deterioration of symptoms or no improvement) as 
injectable procaine benzyl-penicillin-gentamicin in the treatment of possible serious 
bacterial infection (PSBI)138 or tachypnoea139 respectively in neonates and young 
infants in LMICs. 
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1.3. Strategies for prevention of sepsis in young infants 
 
Sepsis in neonates and post-neonatal infants is multi-factorial, and there are several 
interventions, from basic to advanced care, which can reduce the risk of an infant 
from developing sepsis, and ultimately reduce burden of mortality in young infants. 
 
1.3.1. Clean birthing practices and skilled birth attendance 
 
Approximately 60 million newborns are delivered at home each year140. Unhygienic 
birthing practices often observed in home-based deliveries, places the newborn at 
substantial risk for infection due to exposure to opportunistic environmental 
pathogens. The major obstacles hindering increased rates of facility-based birth 
include cost charged by delivery centre, transportation challenges and large 
distances to birthing facility141.   
 
Traditional birth attendants (TBAs) are community members who provide care for 
23%-40% of pregnant and labouring women in sub-Saharan Africa (SS-Africa) and 
south-east Asia (SE-Asia), despite having no formal medical training. Approximately 
half of the TBAs in SS-Africa and SE- Asia have received some basic training, 
including the importance of clean delivery and modern medical birthing 
techniques142. 
 
Skilled Birth Attendants (SBAs) are medically-trained health care providers (e.g. 
nurse, midwife, doctor) who are facility- or community-based, and can provide at 
least basic emergency obstetric care. Access to skilled birth attendance and care is 
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inversely proportional to the neonatal and maternal mortality rates; in areas of 
highest mortality, only 46% of women have access to SBA143. In South Africa, 84% 
of births are facility-based and attended by a skilled birth attendant; however, the 
disparity between rich and poor women is striking, with only 68% of women in the 
poorest quintile, compared to 98% of women in richest quintile having a SBA present 
at delivery in 2002144. 
 
 
1.3.2. Umbilical cord care 
 
Traditional umbilical cord care methods are practised by many communities globally 
and are intended to lubricate brittle cords, accelerate detachment, or for non-specific 
medicinal or cultural reasons 145-149. Cord care methods include covering the cord 
with cloth and applying substances including powders (made from a variety of 
ingredients including insects and their nests, fruit, mud, ash and herbs), liquid 
petroleum, breast milk, oil, butter and animal dung 145-149.  
 
Omphalitis (umbilical infections) predisposes newborns to life-threatening sepsis. It 
occurs in up to 21.7% of community-based newborns in Pakistan, with S. aureus 
(52%), Streptococcus pyogenes (18%) and GBS (10%) being the most commonly 
isolated pathogens from purulent umbilical secretions105. 
 
Chlorhexidine is a widely available antiseptic solution, and is on the WHO essential 
drug list150. The effectiveness of chlorhexidine is related to the combination of its 
bacteriostatic and bactericidal effects151.  Chlorhexidine is inexpensive, safe, stable, 
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acceptable to and compatible with health systems and simple to use152. Umbilical 
cord cleansing with a 4% solution of chlorhexidine has been proven to significantly 
reduce all-cause neonatal mortality (RR 0.81, 95% CI: 0.71 to 0.92) and omphalitis 
(RR 0.48, 95% CI: 0.4 to 0.57) in home-cared newborns when compared to dry cord 
care153. Culture-proven sepsis in neonates hospitalised in intensive care154 in 
developing countries was reduced, however, minimal benefit has been observed 
when comparing chlorhexidine to dry cord care in hospital settings in HICs155. 
Chlorhexidine application has been associated with reduction 156 and lengthening157 
the cord separation time from the newborn.   Hygienic cord care is one of six 
effective interventions recommended by the WHO for improving neonatal and child 
survival 158, 159. The WHO recommended dry cord care in 1998160, but amended this 
recommendation in 2013 to daily chlorhexidine cord cleansing for home-born 
neonates in settings with a high neonatal mortality rates161. 
 
Community members in many LMICs recognise the vulnerability of the newborn to 
infection of the umbilicus (omphalitis) or related to unhygienic umbilical cord care, 
and the potential harmfulness to the newborn of applying various substances to the 
cord stump 145-147.  Widespread behavioural change to reduce the use of traditional 
cord care methods and increase the use of chlorhexidine cord cleansing will, 
however, require extensive training of medical personnel, health care workers and 
community members especially if cord separation time is delayed compared to other 
cord care methods 145-149.  
1.3.3. Peripartum Maternal vaginal and infant skin disinfection 
 
Disinfection of the birth canal during labour using chlorhexidine intravaginal washes 
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and cleansing of the newborn skin immediately after birth were proposed as an 
inexpensive and simple method of reducing sepsis in neonates162-165. These 
interventions could be implemented relatively easily into clean birth practice kits, 
which could be used in facility as well has home-based deliveries166. Pathogens 
causing early onset sepsis are usually acquired by vertical transmission from mother 
to foetus/ newborn, just prior to or during the birth process48. Cleansing of the vagina 
during labour could therefore potentially reduce the exposure that the foetus/ 
newborn has to pathogenic organisms, therefore reducing vertically-acquired sepsis. 
Chlorhexidine is a suitable product for this purpose, as it rapidly reduces urethral and 
vaginal organism counts within an hour of application, and the effect is sustained for 
many hours162. 
 
Numerous clinical trials conducted in hospital-delivery settings have examined the 
impact of intrapartum vaginal chlorhexidine disinfection with or without newborn 
wipes on maternal endpoints including perinatal sepsis and morbidity, vertical 
transmission of colonisation with pathogenic and neonatal outcomes including rates 
of admission, infection and death. Trials completed and published prior to 2008 have 
been summarised in Table 1. Results from trials published after 2008 will be 
discussed in a later chapter.   
 
A trial conducted in Sweden167 included 4483 women randomised at 10 hospitals 
and showed a significant decrease in the primary end-point of neonatal admission in 
newborns of women who received the chlorhexidine washes, however, these results 
have been criticised as the criteria for neonatal admission were not standardised 
across the participating hospitals, which could have introduced bias168. Although 
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some trials demonstrated an impact on vertical transmission of GBS169, 170, other did 
not corroborate those results171, 172. The impact of chlorhexidine intrapartum vaginal 
wipes on infection in the mothers has been inconclusive (Table 1). 
 
Only two of these trials were performed in LMICs, both in Africa (Malawi and 
Egypt)173, 174. In comparison to the other trials summarised in table 1 which were 
randomised controlled, blinded trials, the trials conducted in Malawi and Egypt were 
non-randomised, and included period of intervention administration and periods of no 
intervention (control). Both of these trials  used manual chlorhexidine vaginal wipes 
during labour, and a surface wipe of the newborn, which also differed from the trials 
conducted in Europe and the USA, which had utilised chlorhexidine vaginal irrigation/ 
washes170, 172, 175-178, gel169 or cream lubricant171 .  
The two African studies173, 174 showed a significant reduction in neonatal and 
maternal morbidity associated with sepsis, as well as neonatal mortality. The 
concentration of chlorhexidine used, dosing interval, or application method may have 
improved the protective effect of the intervention. These trials, however, had several 
limitations including being  non-randomised design, with periods of intervention and 
no intervention, resulting in the differences in outcome observed between 
chlorhexidine and control groups not be cleanly attributable  to the intervention. 
Additionally, neonatal sepsis and peri-partum infection were defined based on 
subjectively determined clinical criteria, and were diagnosed by individuals who 
could not be effectively blinded as to what treatment the subjects received. Due to 
these limitations, the results of these two trials were not considered sufficient 
demonstration of effectiveness and widespread recommendation or implementation 
of the intervention was hindered. Several reviews on chlorhexidine maternal vaginal 
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and newborn skin cleansing179-182 concluded that a randomised controlled trial, 
preferably performed in a LMIC, would be required prior to the intervention being 
accepted globally.  
 
Part of the body of work for this thesis was the conduct of a randomised controlled 
trial of chlorhexidine maternal vaginal and infant skin wipes, the results of which will 
be discussed in later chapters.  
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Table 1: Summary of chlorhexidine vaginal intrapartum disinfection trials completed prior to 2008 
Study Country Outcome aims Study 
design 
Participants Intervention during 
labour 
Outcome 
Bakr AF, Karkour 
T. J Womens 
Health (Larchmt).  
2005174 
Egypt, 
hospital 
To determine if cleansing 
birth canal with antiseptic 
at delivery reduces 
infections in mother and 
baby 
Non-
randomised 
Intervention/ 
non-
intervention 
phases 
Women in 
labour. 
 
N=4415 
0.25% CHX-soaked 
wipes at each 
vaginal examination 
and newborn wipe 
Neonatal admissions: no difference (13.3% vs 
13.8%, p=0.63)  
Neonatal Infection-related admissions: 
Reduced in CHX vs. control (0.65% vs. 1.9%, 
p=0.0002) 
Total neonatal Deaths: Reduced in CHX vs. 
control (2.8% vs. 4.2%, p=0.01) 
Infection-related neonatal deaths: Reduced in 
CHX vs. control (0.22% vs. 0.84%, p=0.004) 
Maternal admissions: Reduced in CHX vs. 
control (3.1% vs. 5.1%, p=0.0008) 
Rouse DJ, et al. 
Am J Obstet 
Gynecol.  2003175 
USA, 
hospital 
To determine whether 
intrapartum CHX vaginal 
irrigations prevented 
peripartum infection in 
nulliparous women ≥32 
weeks 
 RCT Labouring 
women, 6-
hourly 
irrigations.  
 
N= 1041 (525 
CHX, 516 
placebo) 
0.2% (200ml) CHX, 
vaginal irrigations 
vs. normal saline 
irrigations 
Peripartum infection: 19.3% in CHX vs. 17.3% 
in control (RR 1.1; 95% CI: 0.9-1.4) 
Facchinetti, et al. J 
Matern Fetal 
Neonatal Med.  
2002172 
Italy, 
hospital 
To investigate intrapartum 
CHX vaginal flushings vs. 
intravenous ampicillin in 
preventing GBS 
transmission in neonates 
RCT  GBS-colonised 
women at term.  
singleton, 
vaginal 
deliveries 
 
N=244.  
0.2% (140ml) CHX 
solution vaginal 
flushings, 6-hourly.  
2g IVI ampicillin 6-
hourly. 
 
GBS Neonatal colonisation: No change noted. 
(CHX 15.6%, Ampicillin 12%).  
E.coli colonisation reduced in CHX (1.8%) vs. 
ampicillin group (7.4%, p<0.05) 
Stray-Pedersen B, 
et al. Int J 
Antimicrob Agents.  
1999170 
Norway, 
hospital 
Determine whether CHX 
douche during labour 
reduced vertical 
transmission of vaginal 
micro-organisms and 
infectious morbidity in 
neonates and mothers 
RCT Women in 
labour, normal 
vaginal 
deliveries 
 
N=1130 
0.2% (120ml) CHX 
vs. sterile saline 
Vaginal douching, 6-
hourly 
 VT colonisation: Reduced in CHX vs. control 
(18% vs. 35%, p<0.0001) 
VT GBS-colonisation: Reduced in CHX vs. 
control (11% vs. 32%, p<0.05) 
Neonatal infections: Reduced in CHX vs. 
control (4.9% vs. 7.9%, p<0.05) 
Maternal post-partum UTI: Reduced in CHX vs. 
control (3.4% vs. 6.9%, p<0.05) 
Maternal fever: Reduced in CHX vs. control 
(3.3% vs. 6.6%, p<0.05) 
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Study Country Outcome aims Study 
design 
Participants Intervention during 
labour 
Outcome 
Taha TE, et al. 
BMJ 1997173 
Malawi, 
hospital 
To determine if CHX 
vaginal cleansing reduces 
infections in mothers and 
newborns 
Non-
randomised 
clinical trial,  
2 months no 
intervention,  
3 months 
intervention,  
1 month no 
intervention 
Women in 
labour and their 
infants: 
Intervention: 
n=3635 women 
& 3743 
newborns;  
Non-
intervention: 
N=3330 women 
& 3417 
newborns  
0.25% CHX solution 
wipe at each vaginal 
examination (4 
hourly) and newborn 
wipe 
Neonatal admissions: Reduced in CHX vs 
control (16.9% vs. 19.3%, p<0.01),  
Neonatal sepsis admissions Reduced in CHX 
vs control (7.8% vs 17.9%, p<0.0002),  
Neonatal mortality Reduced in CHX vs control 
(28.6 vs 36.9/ 1000 LB, p<0.06),  
Infection-related neonatal mortality Reduced 
in CHX vs control (2.4 vs. 7.3/ 1000 LB, p<0.02),  
Postpartum maternal infections: Reduced in 
CHX vs control (1.7 vs. 5.1/1000, p=0.02)  
Rouse DJ, et al. 
Am J Obstet 
Gynecol.  1997176 
USA, 
hospital 
To determine whether 
CHX vaginal irrigation 
prevents maternal 
peripartum infection 
(chorioamnionitis and 
endometritis) 
RCT Women in 
labour 
 
N=1024 (508 in 
CHX, 516 in 
placebo) 
0.2% (200ml) CHX 
irrigations vs sterile 
water  
Maternal infection: No difference observed 
(10% vs. 13%, RR 0.8, 95% CI: 0.5 to 1.1) in 
CHX vs. control 
Sweeten KM, et al. 
Am J Obstet 
Gynecol.  1997177 
AND 
Eriksen NL, et al. 
Infect Dis Obstet 
Gynecol.  1997178 
USA, 
hospital 
To determine whether a 
single CHX intrapartum 
vaginal wash can reduce 
intra-amniotic infections in 
women, and neonatal 
infections and antibiotic 
use 
RCT Women in term 
labour.  
N=947 
(481 CHX, 466 
control) 
0.4% (20ml) CHX 
vs. 20ml sterile 
water 
Intra-amniotic maternal infection: No 
difference between CHX and control 5.2% vs. 
4.5%, (95% CI: 0.82-1.14, p=0.65);  
Endometritis: No difference between CHX and 
control: 1.9% vs. 1.9% (95% CI: 0.62-1.56, 
p=1.0)  
Neonatal antibiotic use: No difference between 
CHX and control (3.2% vs. 1.9%, 95% CI: 0.72- 
3.72, p=0.32) 
Adriaanse AH, et 
al.  Eur J Obstet 
Gynecol Reprod 
Biol.  1995169 
The 
Netherlands, 
hospital 
To evaluate the effect of 
CHX gel during labour to 
reduce vertical 
transmission of GBS, 
maternal infectious 
morbidity and neonatal 
sepsis 
RCT Women in 
labour 
N=1020 
0.3% (10ml) CHX 
gel vs. placebo gel 
(10ml), vs. no 
intervention. 
Repeated after 10 
hours 
VT of GBS:  52.4% vs. 71.4% vs. 66.7% 
(p=0.069) in CHX vs. placebo vs. control groups.  
VT of GBS: CHX vs. combined: 52.4% vs. 
69.3% (p=0.026)  
VT other bacteria- not significant 
Neonatal sepsis, antibiotic therapy, duration 
of hospitalisation: no difference 
Maternal morbidity (GBS+ moms): no 
difference 
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Study Country Outcome aims Study 
design 
Participants Intervention during 
labour 
Outcome 
Hennequin Y, et 
al. Acta Obstet 
Gynecol Scand.  
1995171 
 Belgium, 
hospital 
 To assess effect on 
vertical transmission of 
GBS by CHX cream 
during per vaginal 
examinations 
 RCT GBS-colonised 
women in 
labour 
N=59 
 1% CHX cream to 
coat gloves for 
routine vaginal 
examination vs. 
uncoated gloves. 
 
VT of GBS colonisation: No difference 
between CHX and control. (39% vs. 42%, not 
significant) 
 
Burman LG, et al. 
Lancet 1992167 
 Sweden, 
hospital 
To determine effect on 
neonatal disease due to 
vertical transmission of 
GBS  
 RCT Women in term 
labour, 
singleton 
pregnancies 
N=4483  
 0.2% (60ml) CHX 
vaginal flushing 6-
hourly 
Vs. saline placebo 
Overall Neonatal admissions: Reduced in CHX 
vs. control (2% vs. 2.9%, p=0.04) 
Neonatal Infection: Reduced in CHX vs. control 
(<0.1% vs. 0.3%, p=0.03) 
Neonatal infection among infants of GBS+ 
moms: Reduced in CHX vs. control (1% vs. 
3.2%, p=0.04) 
 
 
CHX- Chlorhexidine 
 
RCT: Randomised controlled trial
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1.3.4. Risk based management for neonatal sepsis  
 
Certain factors including prolonged rupture of membranes (>18 hours), preterm 
labour and signs and symptoms of chorioamnionitis (maternal fever, uterine 
tenderness) have been proven to place newborn infants at significant risk of 
developing neonatal sepsis40, 46. GBS bacteriuria (indicating heavy colonisation) and 
history of a previous GBS-infected baby also increase the risk of GBS-EOD in 
newborns of affected women183. In the UK, 67% of neonates with GBS-EOD were 
exposed to at least one of these risk factors, compared to 17% of neonates without 
GBS-EOD80.  
 
Risk-based management of pregnant women with any of these factors is 
recommended and practised in some high-income countries, including the United 
Kingdom184, many European countries185 and New Zealand186, and when possible, in 
LMICs187.  Intravenous benzyl penicillin (or amoxicillin) is recommended 4-hourly 
during labour. Cephazolin or vancomycin can be used in penicillin-allergic women184, 
186. Implementation of a nation-wide single risk-based management policy of 
pregnant women in New Zealand  led to a 54% reduction (0.5/1000 to 0.23/1000 live 
births)  in GBS-EOD188. 
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1.3.5. Intrapartum antibiotic prophylaxis 
 
GBS, which asymptomatically colonises the genital and gastrointestinal tract of 10-
30% of adults189-191, poses a significant risk of sepsis to foetuses and newborns, and 
is a pre-requisite for GBS-EOD66. Recto-vaginal colonisation with GBS in South 
African women changes over time during the last half of pregnancy, range between 
28.7% and 33% at any one time point, but cumulatively 49.7% of women were 
colonised at one or more time points between 20 and 39 weeks gestation192. Almost 
26% of women, who were not colonised at 20-25 weeks, acquired GBS colonisation 
before the end of their pregnancy, and the mean duration of colonisation was 6.4 
weeks192.  
 
During pregnancy, GBS can ascend into the uterine cavity, and invade the amniotic 
fluid, leading to colonisation or infection of the foetus47, 193. Vertical transmission of 
colonising GBS isolates to the infant is dependent on intensity of colonisation of 
mother194. Guidelines for the prevention of perinatal GBS disease were first 
recommended by the Centers for Disease Control and Prevention (CDC)195, the 
American Academy of Pediatrics196 and American College of Obstetricians and 
Gynecologists in 1996. These guidelines were revised in 2002197 and again in 
2010183, and have been proven to be cost effective198, 199 in  reducing  GBS-EOD in 
the USA134, 200. Intrapartum Antibiotic Prophylaxis (IAP) must be administered to the 
mother at least 2 hours prior to delivery to reduce vertical transmission of GBS to the 
foetus/ newborn201. 
  
The revised US CDC guidelines183 now include identification of pregnant women who 
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are GBS-colonised in late pregnancy (35-37 weeks gestation) by means of 
rectovaginal swab collection and processing, and the administration of intravenous 
antibiotics during labour; commonly known as intrapartum antibiotic prophylaxis 
(IAP). This strategy has led to a 76.5% in reduction of GBS-EOD cases, however, 
has had no significant impact on GBS-LOD incidence202. 
 
In a retrospective cohort study conducted in USA, GBS-EOD was significantly lower 
(adjusted relative risk 0.46; 95% CI: 0.36 to 0.60) in newborns whose mothers 
received IAP (0.33/ 1000 live births) compared to mothers who were managed by the 
risk-based approach (0.59/ 1000 live births)203. Australia  implemented universal 
screening for GBS colonisation during pregnancy and IAP, which resulted in 30-35% 
of women receiving intrapartum antibiotics, compared to only 15-20% being eligible 
to received IAP if a risk-based approach was used204. The cost and logistics required 
to implement IAP are, however, extensive and different countries have developed 
their own recommendations regarding the implementation of IAP  based on local 
GBS colonisation data, the incidence of GBS-EOD and cost effectiveness studies204. 
Additionally, concerns about increasing antibiotic resistance patterns in bacteria 
commonly associated with sepsis in newborns including E. coli and coagulase-
negative staphylococcus, and immunological implications including the potential 
disruption of the development of the infant’s intestinal microbiome that IAP may have 
on mothers and newborns has prevented global implementation of IAP204.  
 Logistical challenges to IAP in LMIC include that both IAP and risk-based 
management strategies require births to take place at health care facilities, at which 
intravenous antibiotics are available, making implementation of these strategies 
impractical in many LMICs. Furthermore, even in settings where universal screening 
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and IAP and risk-based strategies for prevention of GBS-disease have implemented, 
GBS remains a significant cause of sepsis in young infants77, 96. 
 
1.3.6. Vaccination of pregnant women  
 
The experience in reducing neonatal tetanus-related deaths from 787,000 in 1988 to 
49,000 in 2013 is partly due to targeted tetanus-toxoid vaccination of pregnant 
women in low-income settings. This highlights the potential of vaccinating pregnant 
women for the control of infectious diseases in their neonates205. Additionally, recent 
studies have proven that immunisation of pregnant women with influenza vaccine206 
and acellular pertussis vaccine207 are effective in reducing disease in their newborns 
and young infants. 
 
Seasonal Influenza vaccination is considered a priority vaccination for pregnant 
women, with the WHO recommending vaccination with trivalent inactivated influenza 
vaccine at any stage of pregnancy208. This recommendation has been implemented 
by many countries including South Africa209.  
 
Administration of pertussis-containing vaccines during pregnancy is probably the 
most cost-effective strategy for preventing disease in young infants210, and some 
countries, including the USA211, UK212 and Australia213 recommend pertussis 
vaccination of pregnant women. Pertussis vaccination of pregnant women has not 
been implemented in South Africa.       
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Vaccine candidates for use in pregnant women to protect their newborn infants are 
under development for several diseases including GBS 66, 214 and respiratory 
syncytial virus215. The unique situation of vaccinating a woman to protect her 
offspring generates challenging situations including timing of vaccination to maximise 
benefit to foetus/ newborn66, which endpoints should be considered (e.g. maternal or 
infant)66 and how they should be reported127. Clinical trials assessing efficacy and 
immunology endpoints for vaccination of pregnant women need to be conducted in 
sites where disease burden surveillance is adequate and burden is high, but access 
to other prophylactic strategies is limited (usually LMIC)214. In order to ensure high 
quality data which could be utilised for global licensure, study sites need to have the 
capacity and experience to adhere to stringent ethical and Good Clinical Practice 
(GCP) guidelines and be able to identify adverse events in maternal participant and 
infants214, 216.  
Maternal immunisation for reduction of disease in mothers and infants is promising, 
but not without its challenges. Insurers are often reluctant to provide insurance for 
trials involving pregnant women66. Regulatory authorities, which are mandated to 
ensure safety and consider efficacy of vaccine for both the maternal vaccine 
recipient and the developing foetus/ newborn, are often perceived to hinder 
development of vaccines for pregnant women217. Engagement with regulators and 
policy makers in countries in which vaccines are most needed is required early in the 
development pathway to ensure timeous registration and implementation of vaccines 
once licensure and WHO prequalification are complete. Development of vaccines 
which are affordable to countries with the highest burden of disease (LMICs) is 
essential to ensure success of maternal immunisation programs216.     
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Justification and objectives 
Sepsis is one of the three main causes of mortality (together with intrapartum 
complications and prematurity) in neonates and post-neonatal infants. There is, 
however, a paucity of data on the aetiology of neonatal sepsis, especially in LMICs 
where disease burden is highest. Background data on the bacterial aetiology, 
incidence rates and antimicrobial resistance patterns of pathogens causing sepsis in 
young infants is important to enable health care providers plan and implement 
preventative strategies, and choose the most appropriate antibiotics for 
management, as determined by locally-acquired data.  
 
Identification of risk factors for sepsis-related neonatal and post-neonatal morbidity 
and mortality allows health care providers to implement appropriate preventative and 
treatment measures. Maternal HIV-infection is known to lead to reduced 
transplacental antibody transfer, however, the impact that HIV-exposure has on the 
burden of bacterial sepsis in neonates and post-neonatal young infants has not been 
well described.  
 
Cost-effective interventions are required for the prevention of sepsis in young infants, 
especially in LMICs where access to clean birthing facilities and skilled birth 
attendants is often limited. However, inadequately designed or conducted trials to 
assess efficacy in reducing neonatal and maternal sepsis and mortality has 
hampered global acceptance and implementation of some promising interventions 
such as chlorhexidine maternal vaginal- and newborn skin cleansing.  
 
South Africa, despite high rates of facility-based deliveries and free access to 
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reasonable health care for pregnant women and children, has a high neonatal 
mortality rate. High HIV-prevalence in pregnant women combined with inadequate 
access (until recently) to antiretroviral therapy also contributed to the country’s 
inability to reduce child mortality rates adequately to achieve the country’s MDG4 
target. The overall aim of this research was to describe the impact of maternal HIV-
infection on the aetiology and risk factors of neonatal sepsis, and to evaluate an 
inexpensive intrapartum interventional strategy for reduction of neonatal sepsis.  
 
The specific objectives of this project were:  
 
1. To describe the aetiology and clinical spectrum of culture-confirmed invasive 
bacterial disease in neonates and post-neonatal young infants and the effect of 
maternal HIV-infection on disease incidence.  
2. To describe maternal and neonatal factors associated with very early onset 
neonatal sepsis, late-onset neonatal sepsis and perinatal death in HIV-exposed 
and HIV-unexposed neonates (paper I). 
3. To assess the impact of maternal HIV infection on (i) the prevalence of maternal 
vaginal colonisation with potentially pathogenic bacteria in neonates, (ii) vertical 
transmission of bacterial pathogens to newborns and (iii) sepsis rates during the 
very early and late neonatal periods (Paper II).  
4. To describe the clinical and microbiological epidemiology, incidence and serotype 
distribution of invasive GBS disease in young infants in a setting with high 
prevalence of maternal HIV (paper III) 
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5. To determine the efficacy of intrapartum vaginal wipes plus neonatal body wipes 
with 0.5% chlorhexidine in reducing neonatal sepsis (culture-confirmed and 
clinically defined sepsis) and vertical transmission of GBS (Paper IV).  
 
The body of work contributing to this thesis is divided into two distinct parts. The 
study design most appropriate to the specific research question was selected for 
each section of this work and is detailed in this thesis. The Human Research Ethics 
Committee (Medical) of the University of The Witwatersrand approved this PhD 
protocol (HREC number M150501, Appendix 1).  
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2. MATERIALS AND METHODS 
2.1. Study Population  
 
South Africa has a high rate of morbidity and mortality in neonates and post-neonatal 
infants. We have been unable to achieve MDG4, which 10 other Sub-Saharan 
countries with lower GDPs have managed. Despite 84% of all births taking place in 
health care facilities in South Africa, the perinatal mortality rate is high. There is great 
disparity between accessibility and quality of health care available to poor and rich 
South Africans. More than 85% of the country’s population accesses public health 
care facilities including community health clinics, district-, regional- and provincial 
tertiary hospitals, however, only 40% of the total health care expenditure is allocated 
to these facilities144.  South Africa’s maternity services have been reviewed and 
compared to acceptable norms (by population number) for the number and level of 
facilities available, staff allocation, and minimum number of deliveries annually. 
Despite an acceptable number of staff being allocated to maternity services, there 
are numerous facilities which are understaffed and other facilities do not have 
enough deliveries to make them cost effective to operate218.   
 
Approximately 60% of births take place at primary care facilities including community 
health centers (CHC) and district hospitals218, 219. A survey of maternity care facilities 
in South Africa highlighted inadequate levels of care available, even at district 
hospital level. Complete Basic Emergency Obstetric and Neonatal Care (BEmONC) 
could not be conducted completely (fulfilling all 7 signal functions)  at any of the 53 
surveyed CHCs. Assisted vaginal deliveries could only be conducted by 2% of 
CHCs, and parenteral antibiotics were not available at 68% of CHCs. Almost a 
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quarter of district hospitals surveyed were unable to perform caesarean section 
deliveries due to a lack of doctors or non-functioning theatres219.  
 
Soweto was established in 1905 as a black African township, and to this day, 
remains an urban area of predominantly black-African residents. Tapped water is 
accessible to 98.2% of residents and electricity to 87.4%220.The majority of the 
residents fall into low and low-middle  socio-economic brackets, and very few 
Soweto residents have private medical insurance. Only 10.2% of South African 
children under-5 year of age, and 19.0% of children in Gauteng, are covered by 
private medical insurance. 
Chris Hani-Baragwanath Academic Hospital (CHBAH) is a 3200-bed secondary-
tertiary government-run hospital located in Soweto, Johannesburg, South Africa. 
CHBAH serves the 1.2-1.5 million people living in Soweto220. 
All maternal and child health at government institutions including CHBAH and 
primary health care facilities, is offered free-of-charge. The birth cohort of Soweto is 
approximately 30 000 per annum, three quarters (~22 500) of these births take place 
at CHBAH, and the remaining ~7500 births take place at one of 5  midwife obstetric 
units (MOUs), which are located at primary health care clinics in Soweto. Planned 
home-deliveries in Soweto are rare, and most births in Soweto (95.0%, Personal 
communication, EJ Buchmann) and in South Africa (84% to 87.3%)144, 221 occur in a 
health care facility. 
 
Approximately 35% of all deliveries that take place at CHBAH are caesarean 
sections, and all deliveries at MOUs are normal vaginal deliveries (i.e. 26.3% of all 
Soweto deliveries are caesarean deliveries). Healthy newborns are routinely 
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discharged home 12 hours post vaginal-, or 72 hours post caesarian delivery at 
CHBAH. Until mid-2014, CHBAH was the only government medical facility offering 
neonatal and paediatric in-patient care in Soweto.  
 
Antenatal screening for GBS recto-vaginal colonisation during pregnancy with 
intrapartum antibiotic prophylaxis (IAP) for GBS-colonised women are not standard-
of-care in South Africa. A maternal risk factor-based strategy is advocated at birthing 
facilities including CHBAH, for the management of prolonged rupture of membranes 
(>18 h), chorioamnionitis, a subset of preterm deliveries (26-33 weeks gestation), 
and pre-labour rupture of membranes. Prior to 2007, CHBAH Department of 
Obstetrics IAP guidelines recommended ampicillin 1g IV 6 hourly and metronidazole 
400mg orally 3 times daily for suspected chorioamnionitis and prolonged rupture of 
membranes. In January 2007, targeted risk-based IAP for possible GBS infection 
(including women with preterm labour, previous GBS-affected infant or positive 
culture) was implemented, including an initial dose of intravenous ampicillin (2g), 
followed by 4-hourly intravenous ampicillin (1g) until delivery.    
 
South Africa has a high HIV prevalence, the majority of which is spread 
heterosexually222. Risk factors for HIV-infection in antenatal attendees include older 
male partners, especially in women <20 years, economic dependence on partners, 
high-risk alcohol consumption and inconsistent condom use223. Prevention of 
Mother-to-child transmission of HIV (PMTCT) pilot sites were established in South 
Africa in 2001 by the National Department of Health. Neither of the two pilot sites in 
Gauteng were based in Soweto224.  
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In July 2002,  the Constitutional Court of South Africa ruled that HIV-positive 
pregnant woman had a constitutional right to access health care services to prevent 
mother to child transmission of HIV225. In 2001, PMTCT programs were established 
with non-governmental funding at CHBAH and 13 antenatal clinics in Soweto by the 
Perinatal HIV Research Unit (www.phru.co.za).  Subsequent to the Constitutional 
court ruling in 2002, the Department of Health took over the responsibility of offering 
all pregnant women routine voluntary counselling and testing for HIV in antenatal 
clinics. More than 96.0% of pregnant women accept voluntary counselling and 
testing for HIV during antenatal visits (C. Mnyani, personal communication 28th July 
2014). The HIV prevalence in pregnant women during the period in which the studies 
contributing to this thesis were performed (2004- 2008) remained stable at 
approximately 30%226, 227.  The standard of care for prevention of mother-to-child 
transmission of HIV was amended in 2007 from single dose nevirapine administered 
to HIV-infected women at onset of labour and to their newborn infants, to triple 
antiretroviral therapy (stavudine, lamivudine and nevirapine) from 34 weeks 
gestation to women with a CD4+ count of less than 350cells/mm3  14.   
 
Newborns presenting with signs and symptoms of severe illness at birth or prior to 
discharge from the postnatal wards are admitted to the neonatal unit at CHBAH, whereas 
infants discharged home after delivery and who subsequently present with suspected 
bacterial infections are hospitalized in the general pediatric wards at CHBAH. Investigation 
and management of neonates and young infants presenting with suspected invasive 
bacterial disease is conducted by attending physicians as per standard-of-care. This 
included complete blood count and blood culture in all infants. Cerebrospinal fluid tap for 
biochemistry, microscopy, culture and sensitivity is limited to infants with positive blood 
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cultures presenting at birth and all infants with suspected sepsis if admitted from the 
community. Sterile site cultures are processed at the National Health Laboratory Service 
(NHLS), with blood culture evaluated using the BacT/Alert microbial system (Organon 
Teknika, Durham, NC). Empiric treatment of neonates with suspected sepsis during the 
study period was intravenous penicillin and gentamicin, or ampicillin and gentamicin in 
infants between 1 and 12 months of age, whilst suspected meningitis cases were treated 
empirically with ampicillin and cefotaxime. 
 
2.2. Study design and Methods: Sepsis surveillance study 
2.2.1. Study design and enrolment 
 
A bacterial surveillance system was established at CHBAH in the neonatal and 
paediatric wards in collaboration with the staff in the Departments of Paediatrics and 
Microbiology to determine incidence, aetiology and clinical spectrum of culture-
confirmed sepsis in young infants and the impact of maternal HIV-infection.  
Pathogenic bacteria isolated from sterile site samples (blood, cerebrospinal fluid) 
collected by attending physicians during admission of young infants (≤90 days old), 
were identified by surveillance and review of clinical and microbiology records at 
CHBAH between January 2004 and December 2008.  
 
Pathogenic bacteria were defined as organisms which are capable of causing 
disease, and are uncommonly considered to being contaminants. Bacterial 
contaminants included, but were not limited to, the following: Bacillus species, 
Micrococcus, Propionibacterium species, Corynebacterium species and Coagulase 
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negative Staphylococcus unless identified from 2 or more cultures obtained at 
separate times. Additional isolates which were potential contaminants were 
evaluated for clinical significance by the investigational team based on associated 
clinical and laboratory signs. 
 
Young infants with GBS were identified through daily screening of admissions to 
neonatal and paediatric wards and microbiological reports. Additionally, all GBS 
isolates from sterile sites of any patient at CHBAH were kept aside by microbiology 
staff for collection by RMPRU staff. Young infants with pathogenic bacteria other 
than GBS were identified predominantly retrospectively through the surveillance 
system of microbiological records.   
 
The parents or legal guardians of prospectively-enrolled infants were informed about 
the surveillance study, and signed written, informed consent forms. If the infant had 
died or been discharged prior to identification in the wards and obtaining parental 
consent, data were collected retrospectively. An audit of the NHLS database of all 
invasive pathogens isolated from paediatric patients over the study period was 
conducted to ensure that all patients were identified.Study investigators obtained 
information about each patient identified as having an invasive bacterial infection 
from their medical records and microbiological reports. 
 
2.2.2. Routine Blood Culture Sample collection and processing  
 
Blood samples for culture obtained by attending physicians were placed into 
BacT/Alert microbial system (Organon Teknika, Durham, NC, USA) paediatric blood 
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culture bottles and evaluated by the microbiology department of the National Health 
Laboratory Services (NHLS) at CHBAH. Cerebrospinal fluid (CSF) samples were 
obtained from infants admitted from the community with suspected sepsis, and from 
infants identified to have GBS-bacteraemia from blood sample collected at birth. 
CSF sample analysis included tests in clinical chemistry, haematology and 
microbiology as per routine practice by the NHLS. GBS isolates from blood or CSF 
were plated onto on blood agar plates by NHLS staff and were kept aside for 
collection by RMPRU staff. Pure cultures of these GBS isolates were stored at -70°C 
in RMPRU laboratory and serotyped in batches by latex agglutination as decribed228. 
Serotyping of GBS is not performed routinely by NHLS. 
 
Antimicrobial susceptibility testing of isolated bacteria is performed routinely by the 
NHLS Department of Microbiology. A Gram stain is performed on samples from 
BacT/Alert blood culture bottles which display positive results, and on pathogens 
isolated from CSF samples. The results of the Gram stain guide the decision of 
which antimicrobial profile to select for susceptibility testing.  
 
The Kirby-Bauer disk diffusion susceptibility test method is used in NHLS. 
Pathogenic organisms identified from blood or CSF cultures are grown on Mueller-
Hinton agar, in the presence of antimicrobial-infused filter paper disks. A zone of 
absence of growth around the disk indicates inhibition of the organism by the specific 
antimicrobial. An automated Microscan Microbiology System (Beckman Coulter, 
previously Siemens) is also utilised for both the identification of the organism and the 
susceptibility testing using relevant panels in cases where the Kirby-Bauer method 
has not been utilised. Etest® strips are used to supplement the Kirby-Bauer and 
50 
 
Microscan results for certain pathogens and antibiotics (e.g. Vancomycin Etest® 
used for Vancomycin-resistant Enterococci and methicillin resistant Staphylococcus 
aureus.)  
Minimum inhibitory Concentration (MIC) of antimicrobials is reported according to the 
Clinical Laboratory Standards Institute (CLSI) standards (www.clsi.org ).  
 
Invasive disease was categorized as bacteraemia if identified in blood only or as meningitis 
if (i)  identified from CSF or (ii) there was CSF cytological evidence of purulent meningitis 
(>5 leucocytes/mm3, adjusted in traumatic lumbar punctures to allow 1 leucocyte per 500 
erythrocytes) in an infant with bacteremia.  
 
2.2.3. Data collection and analysis 
 
Data, including demographic and admission information, were abstracted from 
medical records of infants admitted to the neonatal or paediatric wards of CHBAH 
and entered onto paper case report forms (CRFs) by study doctors. Delivery 
information and maternal HIV-infection status was collected when possible from 
neonatal admission records, maternal delivery notes, or from the mother herself. HIV 
exposure was determined by abstracting antenatal HIV test results of mothers and 
supplemented by HIV ELISA results from maternal or infant blood tests conducted by 
attending physicians. The HIV infection status of HIV-exposed infants was 
determined using qualitative HIV PCR tests at the discretion of the attending 
physician. Gestational age assessment was based on the available obstetric details 
(last menstrual period date, ultrasound, serial symphysis- fundal height) or neonatal 
assessment by the attending physicians. 
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Data were entered into a customised Microsoft access database. Data on live births 
in Soweto were obtained from CHBAH and community clinics, and antenatal survey 
HIV-prevalence data were utilised to estimate denominators for HIV-infected and 
HIV-uninfected women.  
 
Data were analysed using STATA/ IC 13.0 (Statacorp, College Station, TX, USA), 
and details of analyses are included in the methods sections of following chapters.    
 
2.2.4. Ethics 
 
The surveillance study was approved by the University of the Witwatersrand Human 
Research Ethics Committee (HREC) on 2nd November 2003 (HREC references M03-
10-07 and M100367, appendix 2) and the institutional review board of the Centers 
for Disease Control and Prevention, Atlanta, USA (protocol # 4128).  
 
Written informed consent was obtained from a parent (usually mother) of infants 
enrolled prospectively into the surveillance study. If a patient was only identified by 
study staff after demise or discharge, the HREC waivered consent requirement, and 
data and GBS isolate (if relevant) were collected retrospectively. 
 
2.2.5. Funding 
The surveillance study was funded by the Centers for Disease Control and 
Prevention (Cooperative Agreement number: U50/CCU02196 and U01 CI000318)) 
and the Bill and Melinda Gates Foundation (Grant number 39415).   
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2.3. Study design and Methods: Prevention of Perinatal 
Sepsis (PoPS) 
 
2.3.1. Trial design  
The Prevention of Perinatal Sepsis (PoPS) trial was a blinded, randomised controlled 
trial conducted at CHBAH between 1st April 2004 and 25th October 2007 to evaluate 
the efficacy of a chlorhexidine intrapartum intervention in reducing neonatal and 
maternal sepsis. A nested cohort of participants was enrolled to evaluate vertical 
transmission of pathogenic bacteria, including GBS, E. coli and K. pneumoniae.  
Promising results from previous trials assessing this intervention173, 174 did not 
culminate in the implementation of the intervention as the investigators had not 
utilised a randomised controlled trial design, which downgraded the quality of the 
evidence.  
 
Study staff had no role in patient management.  Study midwives administering the 
intervention were unblinded. The rest of the study team, including those collecting 
endpoint data, were blinded to intervention group. Laboratory staff was additionally 
blinded to mother-neonate pairings.   
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2.3.2. Inclusion and exclusion criteria 
 
All pregnant women attending antenatal clinic at the participating antenatal clinic or 
presenting to the CHBAH labour admissions ward were eligible to register for the 
study if they met all of the following inclusion and none of the exclusion criteria: 
 
Inclusion criteria for enrolment 
• Planned to deliver at CHBAH or one of its satellite clinics 
• Planned to remain in Soweto for at least two months after delivery 
• Was able to understand and give written informed consent 
• Was at least 15 years old  
Exclusion criteria for enrolment 
• Was expected to deliver by caesarean section 
• Had antenatal ultrasound examination revealing major fetal congenital 
anomalies 
• Had known or suspected condition in which vaginal exams are 
contraindicated, e.g. placenta praevia 
• Had a history of allergic reaction to any topical antiseptic solution 
 
On arrival in labour ward complex, enrolled participants were assessed for eligibility 
for continuation on the trial. In addition to review of inclusion and exclusion criteria 
for enrolment, the following criteria were assessed prior to randomisation: 
Inclusion criteria for randomisation 
• Continued consent for trial procedures for both maternal and infant 
participants 
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Exclusion criteria for randomisation 
• Presented to labour ward with infant born before arrival 
• Noted to have significant vaginal bleeding pre- or during labour 
• Known intrauterine fetal death 
• Full cervical dilatation or have baby’s head on perineum 
• Infant noted to be in face presentation 
• Noted to have genital ulcers present 
 
2.3.3. Enrolment and randomisation 
 
Pregnant women were approached in the antenatal clinic at CHBAH and informed 
about the PoPS trial. Written informed consent for participation for themselves and 
their newborns was obtained from interested, eligible pregnant women after a one-
on-one information and consenting session with a staff member. The antenatal card 
of each consented participant was marked with a trial-specific sticker, which included 
a participant identification number.  
 
When consented participants presented to the labour ward complex of CHBAH, they 
were identified by research staff based in labour ward, and reminded of the trial and 
procedures that they had consented for. Eligibility criteria for continuation in the trial 
were assessed on arrival in labour, prior to randomisation.   
 
Women who were in active phase of labour and fulfilled eligibility criteria during 
labour were randomised in a 1:1 ratio to receive either intrapartum vaginal wipes with 
0.5% chlorhexidine-soaked cotton swabs (interventional arm), or and external 
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genitalia wipe with sterile water (placebo arm). Infants of women randomised to the 
interventional arm received a full body wipe with 0.5% chlorhexidine-soaked cotton 
swabs. Infants of women in placebo arm received a foot wipe with 0.5% 
chlorhexidine.  
 
Swabbing of the vagina may cause micro-abrasions of the mucous membranes, 
which, if swabbing was performed without disinfectant solution, may have increased 
risk of infection in the mother and her infant. This concern pre-empted the single-
blinded design of the trial. The limitations of the single-blinded design were mitigated 
by a strict randomisation process and the procurement of commercial colourless, 
mildly odoured chlorhexidine gluconate solution for use the trial, to ensure blinding of 
study team members not involved in performing interventional wipes. 
 
Participants were randomised in large blocks (50 per block) to ensure equal 
representation of participants in each treatment arm. SAS® was used to randomly 
assign treatment groups to randomisation numbers. Randomisation forms, which 
included randomisation number and treatment group allocation, were pre-printed by 
the unblinded study statistician, and sealed in consecutively-numbered opaque 
randomisation envelopes. Randomisation envelopes were opened in sequential 
randomisation number order by the attending study midwife once a consented 
participant was confirmed to fulfil inclusion and exclusion criteria in labour. Non-
sequential allocation of randomisation numbers was investigated during trial conduct 
to ensure that no bias was introduced intentionally or inadvertently by unblinded 
study midwives. 
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2.3.4. Study procedures and sample collection 
Midwives, who were hired specifically for this trial, were based in labour and delivery 
complex of CHBAH throughout the year for the  duration of the study. These 
research midwives conducted trial procedures and collected samples and data.  
 
Colonisation swab 
A colonisation sub-study was included in the main PoPS trial to determine maternal 
vaginal colonisation rates with bacteria known to be pathogenic in infants, including 
Group B streptococcus, Escherichia coli and Klebsiella pneumoniae, and 
transmission of colonisation to newborn. Knowledge of GBS-colonisation status of 
pregnant women in Soweto was limited, as the collection and testing of antenatal 
swabs and implementation of IAP is not routine, and not feasible in a setting like 
ours. 
Women included in the colonisation cohort had a vaginal introitus swab collected 
prior to any interventional wipes being performed. Infants of women included in the 
colonisation cohort had a surface (skin) swab collected from the umbilical area, peri-
auricular area and nares soon after birth, prior to the newborn receiving an 
interventional wipe or a bath. Swabs for colonisation were placed into Amies without 
charcoal transport medium and transported at room temperature to the laboratory of 
RMPRU for processing within 48 hours of collection. 
 
Trial intervention 
Per vaginal (PV) examinations to assess progress of labour are performed 
approximately 4 hourly in labouring women by CHBAH-employed attending 
physicians or midwives.  Maternal interventional and control wipes were performed 
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by research midwives immediately after the routine PV examinations to avoid 
increasing the numbers of times the participant had to be repositioned for 
procedures. Maternal wipes were performed approximately 4 hours apart, but not 
more frequently than 3-hourly. The research midwives monitored participants during 
and after study wipes for possible reactions to wipes. A decision to terminate wipes 
early could have been made by the study midwife or attending physician, mainly in 
the event of a change in eligibility for trial continuation or moderate or severe 
reaction to chlorhexidine.  
 
Chlorhexidine Interventional wipes:  
Commercially-available 5% chlorhexidine gluconate was diluted weekly to 0·5% with 
autoclaved drinking-quality tap-water and stored in one litre opaque bottles at room 
temperature. Autoclaved tap-water was used for control-arm wipes. Chlorhexidine 
was tested for activity by RMPRU laboratory using spectrophotometric and biological 
activity tests, and both solutions were tested for sterility before and after a week’s 
use.  
 
Study midwives wrapped cotton wool soaked in 0.5% chlorhexidine solution around 
their index and middle fingers of their gloved examining hand, and gently wiped the 
cervix and vaginal walls in a clockwise motion. The presenting part of the foetus and 
mother’s external genitalia were also wiped with chlorhexidine-soaked cotton wool 
pads. Following birth and collection of colonisation cohort skin swabs (if applicable), 
infants of participants randomised to chlorhexidine interventional wipes were wiped 
from head to toe (avoiding face and ears) with 0.5% chlorhexidine-soaked cotton 
wool swabs.  
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Placebo/ control wipes: Study midwives wiped the external genitalia of women 
randomised to control arm with sterile water- soaked cotton swabs. Chlorhexidine 
was not used for control wipes in these maternal participants, as disinfection of 
external genitalia may have had some benefit to mother and infant, and may have 
raised questions on the true impact of internal vaginal wipes. Infants of participants 
randomised to control arm had their feet wiped with chlorhexidine-soaked cotton 
swabs. Although an infant wipe was not essential in the placebo arm, it assisted in 
maintaining blinding of study investigators, who were reviewing case report forms of 
wipe dates and times. Before neonatal wipes all babies received a water bath per 
standard-of-care.  
 
Participant follow up 
Neonatal participants were followed up for hospitalisation for sepsis until 28 days of 
life, and maternal participants until 14 days post-delivery. Active monitoring of 
admissions to the neonatal unit and paediatric department at CHBAH was conducted 
daily by research trial staff members. Medical officers employed for the trial, and 
blinded to interventional arm, reviewed medical records of all admitted neonates, and 
abstracted information related to sepsis end-point.  
Sterile site cultures from admitted trial participants were collected at the discretion of 
attending physicians and processed per standard practice at the hospital 
microbiology laboratory. Routine methods were used for culture and identification of 
invasive pathogens from sterile sites, including the BacT/Alert microbial system 
(Organon Teknika, Durham, NC) for blood culture. Active laboratory-based 
surveillance was also conducted to confirm that all sterile site cultures from study 
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neonates were captured. Information related to the neonatal sepsis endpoints was 
abstracted from medical records by trained study physicians.  Hospital mortuary logs 
were also reviewed regularly to ensure deaths among trial participants were 
captured.  
 
Due to the complexity of diagnosis in different settings, with variable access to 
diagnostic capacity or tests, no standardised definition of clinically-diagnosed 
neonatal sepsis was universally used, and the PoPS team developed its own 
definitions with the assistance of a team of neonatologists, which were used to 
determine rates of clinical- and culture-confirmed neonatal sepsis in study 
participants 229, 230. Neonates of women who continued participation on PoPS at the 
time of labour were assessed for culture-confirmed- and clinically-confirmed neonatal 
sepsis endpoints.  
 
2.3.5. Endpoint definitions 
 
Maternal vaginal colonisation was defined as isolation of GBS, E. coli or K. 
pneumoniae from a vaginal introitus swabs collected during labour prior to the first 
interventional wipe. Vertical transmission of bacteria was defined as neonatal 
surface colonisation at birth with the same bacterium isolated from the mother’s 
vaginal swab.  
 
Very Early-onset disease (VEOD) was defined as sepsis occurring on day 0-2 of life 
and community-acquired late-onset neonatal disease (LOD) as that with onset from 
day 3 to 28 of life. Clinical sepsis definition required at least one laboratory and one 
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clinical sign (See Table 2). Medical records of neonates with culture confirmed 
sepsis episodes which did not fulfill the clinical sepsis criteria were reviewed by three 
neonatologists to determine if the case represented a sepsis episode. The medical 
records of all infant trial participants who were stillborn or died within 2 hours of birth 
were also reviewed to determine whether the cause of death could be attributed to 
neonatal sepsis. Data reviewed from maternal and infant medical records included 
documentation of signs of foetal distress (meconium stained liquor, decreased 
variability or severe, prolonged decelerations of foetal heart rate recorded by 
cardiotocography), complications in labour (prolonged labour/ poor progress in 
labour, foetal malpresentation, maternal death) and signs of neonatal asphyxia (poor 
Apgar scores, arterial blood gas results). 
  
Very Early-onset culture confirmed sepsis: isolation of a micro-organism that is not a 
common contaminant from a normally sterile body site within the first 3 days of life  
 
Very Early-onset clinical sepsis: A neonate hospitalised within 3 days of life and who 
in the absence of another recognizable congenital infection had at least one 
laboratory criteria and either: respiratory distress (one criterion required) or at least 
two clinical criteria (see Table 2).   
 
Late-onset sepsis: Either culture-confirmed sepsis or clinical sepsis in an infant with 
symptom onset between three and 28 days of life.  
 
Late-onset culture confirmed sepsis: isolation of a micro-organism that is not a 
common contaminant from a normally sterile body site between three and 28 days of 
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life.  
 
Late-onset clinical sepsis: A neonate hospitalised between three and 28 days of life 
with at least one laboratory criteria and either: respiratory distress (two criteria 
required), OR one feature of respiratory distress and one other clinical criterion OR 
at least two other clinical criteria.   
 
Perinatal deaths: Intrapartum stillbirths and deaths within the first 6 days of life 
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Table 2: Neonatal sepsis criteria 229, 230 
 
Clinical criteria Definition 
Respiratory distress 
Respiratory rate >60 breaths/min; cyanosis, chest wall indrawing, grunting 
on expiration, respiratory distress noted in medical records 
Hypotension  
(defined as mean arterial pressure < 2 standard deviations (S.D.) from 
mean for weight/age 
pyrexia or hypothermia axillary temperature >38·0°C, not attributable to external warming,  or 
axillary temperature <36·0°C 
Abdominal/ feeding problems 
abdominal distension OR feeding intolerance (>20% residual over 24 
hours), or poor feeding after feeding well, or > 2 episodes of emesis 
Bleeding diathesis  
 
defined as petechiae, ecchymosis, mucous membrane bleeding, 
pulmonary hemorrhage, or excessive oozing from venipuncture sites 
Lethargy or irritability  
noted by medical staff in absence of other central nervous system 
symptoms 
Central nervous system seizures, or bulging fontanelle, or single witnessed episode of apnea 
  
Laboratory criteria  
White blood cell count (WCC) WCC <5 x109/l OR >25 x109/l in the absence of receiving corticosteroids;   
Absolute neutrophil count (ANC) ANC <1·75 x109/l or >15 x109/l  
Platelet count <150 x109/l 
C-reactive protein > 10·0 mg/l (early onset sepsis) OR >40mg/l (late-onset sepsis) 
Elevated CSF white blood cell (WBC) 
count 
>30 x106/l WBC in absence of significant red blood cells 
 
 
The decision to restrict the very early-onset period for PoPS to the first 3 days of life 
was guided by the assumption that the potential impact of chlorhexidine 
interventional intrapartum wipes would be more pronounced in the first 3 days of life, 
as most vertically-acquired neonatal sepsis presents in this time period.  
 
Postpartum sepsis was defined as maternal hospitalization within 14 days of delivery 
for endometritis (at least two of: fever, uterine tenderness, foul-smelling/ purulent 
lochia or vaginal discharge), sterile site culture-confirmed infection, or perineal 
wound infection among women who delivered vaginally. 
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2.3.6. Laboratory methods 
Colonisation cohort swabs were transported to the RMPRU laboratory in Amies 
without charcoal transport medium were processed to identify GBS, E. coli and K. 
pneumoniae as follows. The swab was used to inoculate (i) a 5% horse blood agar 
plate, (ii) a MacConkey agar plate, (ii) a selective 5% horse blood agar plate 
containing colistin (10µg/ml) and nalidixic acid (15µg/ml), and (iv) the swab tip was 
placed in Todd-Hewitt broth supplemented with gentamicin (8 µg/ml) and nalidixic 
acid (15 µg/ml). All agar plates were incubated for 48 hours, and inspected for 
growth after 24 and 48 hours.  
 
Samples were processed for GBS isolation as follows: 
i. Blood agar plates and selective blood agar plates were incubated at 35-37°C 
in 5% CO2 incubator.  
ii. Todd- Hewitt broth was incubated for 24 hours at 35-37°C in a 5% CO2 
incubator. A blood agar plate was inoculated with the broth and inspected after 24 
hours and 48 hours.  
iii. Gram-positive β-haemolytic colonies present on blood agar and selective 
blood agar plates were isolated and identified as Group B streptococci by CAMP 
(Christie, Atkins and Munch-Petersen) positive test and inability of hydrolyse esculin.  
iv. GBS isolates were serotyped using Group B streptococcus latex agglutination 
method with antisera against GBS serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, IX and X 
capsular polysaccharide (Statens Serum Institute, SSI, Sweden). Non-typeable GBS 
isolates were processed with PCR228.  
 
Swabs were processed for Gram-negative organisms as follows:  
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v. Blood agar plate and the MacConkey agar (incubated in ambient air) were 
inspected for gram negative bacteria. Isolated colonies will be identified by standard 
biochemical tests, and with the API20E identification system.  
 
Colonies of pure cultures of GBS, E. coli and Klebsiella spp. isolated from swabs 
were inoculated into STGG and stored at -70°C. Specimen processing and results 
case report forms were completed for each specimen received in the laboratory, and 
entered into study-specific database. 
 
2.3.7. Data collection and safety monitoring 
 
The antenatal card, labour and delivery records of maternal participants, and delivery 
notes were reviewed and key prenatal and intrapartum variables were recorded on 
paper case-report forms. Underlying and pregnancy-induced maternal conditions 
including hypertensive disorders and gestational diabetes, and intrapartum events 
were routinely assessed and documented by attending physicians.  Gestational age 
was determined either by extrapolation of an early antenatal ultrasound or by a 
Ballard score assessment performed by attending physicians within the first 72 hours 
of life.  
 
CRFs were reviewed for completeness, accuracy and consistency by the study 
investigators and study co-ordinator. External observers monitored all trial 
procedures, all informed consent forms and a sub-set of complete records. 
Additionally, trial- independent to the trial reviewed medical records of all maternal 
deaths and neonatal deaths as well as serious adverse events assessed by study 
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investigators to be possibly related to trial intervention.   
 
Data were double-entered into a custom-designed Microsoft Access database, and 
data validation and consistency checks between the two databases were performed 
on an on-going basis. Data queries were resolved by members of the study team, 
including investigators, study co-ordinator and nurses. 
 
A statistical analysis plan was developed for the study, and was approved by the 
Scientific Steering committee (SSC) prior to locking and unblinding of the database.  
The SSC was established prior to study initiation to assist the investigators, and 
included an international obstetrician- gynaecologist (Marleen Temmermann- chair), 
international clinical epidemiologist (Paolo Miotti), two local obstetrician- 
gynaecologist (G. Justus Hofmeyr and Robert Pattinson) and a local paediatrician 
(Haroon Saloojee).   
 
An independent Data and Safety Monitoring Board (DSMB) was established prior to 
initiation of the trial, and comprised of an international paediatric infectious disease 
specialist/ vaccinologist (Kathryn Edwards, Vanderbilt university, Nashville, 
Tennessee, USA), South African paediatrician/ neonatologist (Peter Cooper, 
University of the Witwatersrand, Johannesburg), South African Obstetrician- 
gynaecologist and researcher (James McIntyre, Perinatal HIV Research Unit, 
Soweto, Johannesburg) and an international epidemiologist (Maria Deloria Knoll, 
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA). 
 
The DSMB continuously monitored serious adverse events throughout the trial.  An 
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interim analysis was conducted after 2000 mother-infant pairs were randomised to 
allow for assessment of some baseline assumptions that guided the study design, 
including rates of clinical and culture-confirmed neonatal sepsis in control arm.  A 
second interim data analysis was performed after 6000 mother-infant pairs were 
enrolled on the study to compare treatment groups for the primary outcome measure 
of confirmed or clinical neonatal sepsis in the first 72 hours of life.  If a statistically 
significant benefit had manifested at that stage, the DSMB was mandated to 
consider stopping the trial had there been overwhelming efficacy.   The DSMB did 
not unblind investigators or stop the study at either of these interim data analyses.  
 
2.3.8. Sample size calculation and statistical analysis 
A pre-study audit of neonatal admissions was performed at CHBAH, and estimated 
that the early-onset neonatal sepsis rate was approximately 30 per 1000 live births.  
In order to detect an efficacy of the intervention of 40% and using a power of 90% 
and an alpha of 0·05, a sample size of 3581 mother-newborn pairs per trial arm was 
required. In order to allow for approximately 10% drop-out from the trial, a sample 
size of 4000 mother-newborn pairs was targeted. For the colonisation sub-study, a 
baseline prevalence of 25% for maternal GBS colonisation at the time of delivery 
was assumed. Vertical transmission of GBS had been reported to vary between 30% 
and 70% in previous studies169, 170, 231, and we assumed that vertical transmission 
would occur in 50% of deliveries among GBS-colonised women. We powered the 
colonization endpoint to detect at least a 30% reduction in vertical transmission of 
GBS, based upon which we planned on enrolling 1470 mother-newborn pairs per 
study arm. This was adjusted to 1800 per arm (3600 overall) to allow for compliance 
failures.   
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The statistical analyses conducted for the different end-points in the PoPS trial are 
detailed in the relevant chapter below, and in Rubin & Zell232.  
The PoPS data were analysed using SAS version 9.1 and 9.2 (Carey, NC, USA). A 
p-value of <0.05 was considered significant throughout, twins were counted as 
independent births, and stillborn neonates were included in ITT analyses.  
 
2.3.9. Ethics 
 
This trial was approved by the University of the Witwatersrand Human Research 
Ethics committee (HREC) on 13th March 2003 (HREC reference number 030207; 
Appendix 3) and the Institutional review board of the Centers for Disease Control 
and Prevention, Atlanta, USA (protocol # 3842). The PoPS trial was registered with 
Clinicaltrials.gov (NCT00136370). 
All pregnant women enrolled on PoPS study were consented at the antenatal clinic 
of CHBAH. Inclusion and exclusion criteria and willingness to continue with study 
participation were reviewed by study staff at the time the woman arrived in labour 
ward for delivery.  
 
2.3.10. Funding 
 
The PoPS trial was funded by the Centers for Disease Control and Prevention 
(Cooperative Agreement number: U50/CCU02196 and U01 CI000318) and the Bill 
and Melinda Gates Foundation (Grant number 39415).  
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3. AETIOLOGY OF EARLY-ONSET AND COMMUNITY- ACQUIRED 
SEPSIS IN NEONATES AND YOUNG INFANTS. 
 
The non-specific symptoms and signs of sepsis which young infants (<3 months of 
age) present with, makes it difficult to evaluate the incidence of clinically-confirmed 
sepsis. In addition,  culture-confirmed neonatal sepsis may underestimate the 
incidence of neonatal sepsis,  due to low sensitivity of blood culture, which is 
affected inter alia by inadequate or limited volume of blood obtained from young 
infants53, 55, low bacterial load56, 57 and antibiotic administration to infant or mother58 
prior to blood sampling.  
 
The distribution of bacteria isolated from septic young infants differs between HICs 
and LMICs. In HICs, Group B Streptococcus (GBS) and Escherichia coli (E. coli) 
cause almost 75% of early-onset invasive disease (EOD)40, 64, whilst S. aureus (6% - 
18%), E. coli (5% - 13%) and K. pneumoniae (4% - 9%) are the most common 
bacterial pathogens of late onset disease (LOD)64.  In contrast, in LMICs, S. aureus 
(13% - 26%), E. coli (8% - 18%) and K. pneumoniae (13.5% - 21%) have been 
reported as the most common bacterial pathogens causing neonatal sepsis, with 
GBS being rarely (2% - 8%) identified, especially in South-East Asia70-72.  
 
In this chapter, the epidemiology of early-onset (newborns 0-6 days) and community-
acquired sepsis in neonates and young infants (≤90 days of age) will be presented. 
Included is an evaluation of the impact of maternal HIV-exposure on the burden of 
sepsis, and antibiotic susceptibility profile of the most common bacteria identified. 
The overall methods are detailed in Chapter 2. The denominator for incidence 
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calculations was obtained from administrative databases of live births from CHBAH 
and Soweto community clinics. Additionally, the odds ratio of culture-confirmed 
sepsis in different age categories being impacted by HIV-exposure was calculated, 
based on the assumption that the population prevalence of HIV-exposure of the 
neonates was 29.9%, as documented in Soweto antenatal attendees during the 
course of the study.  
   
3.1. Results 
 
3.1.1. Overall 
Overall, 699 infants ≤90 days age with a significant pathogenic bacterium isolated 
from a sterile site within the first 72 hours of hospitalisation, were hospitalised at 
CHBAH between January 2006 and December 2008. The overall incidence (per 
1000 live births) was 7.30; Table 3. Full clinical details were unavailable for 34% of 
the sepsis episodes (238/699). Fifty five percent (350/634) of cases occurred in 
males. The case fatality ratio of infants with a known outcome was 15% (69/461) 
(Table 4). 
Overall, 26.4% (146/699) of the sepsis cases were associated with meningitis. Of the 
meningitis cases, 42.5% (62/146) had organism isolated from CSF but not blood, 
24.7% (36/146) from CSF and blood, whilst remaining 48 cases (32.9%) were 
diagnosed by a positive blood culture only in the presence of CSF cytological profile 
suggestive of bacterial meningitis. The overall case fatality rate for meningitis cases 
was 18.8% (Table 4).  
 
Maternal HIV-infection status was available for 57.9% (405/699) of cases, of whom 
39.5% (160/405, 95% CI: 34.7% to 44.5%) were HIV-exposed; Table 3. Infants with 
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and without HIV-exposure results available did not differ substantially in age at 
diagnosis or gender in overall cohort or when stratified by age category (EOD, LOD 
and YI-CAS, data not shown). The prevalence of HIV-exposure for sepsis due to 
individual bacteria are detailed in Table 3, and included 47.1% for GBS, 41.2% for S. 
pneumoniae, 35.6% for E. coli and 53.3% for K. pneumoniae. HIV-exposed infants 
were at higher risk of developing sepsis than HIV-unexposed infants (OR 1.53, 95% 
CI: 1.13 to 2.07, p=0.004). The CFR for individual bacteria are shown in Table 4.  
 
Due to the large number of missing HIV results, the incidence of invasive disease 
was calculated assuming that (i) infants with missing results had same HIV-exposure 
prevalence as population (29.9%), (ii) infants with missing results had same HIV-
exposure prevalence as cases with HIV-exposure results (39.5%), (iii) all infants with 
missing HIV results were HIV-exposed and (iv) all infants with missing HIV results 
were HIV-unexposed. The odds of an HIV-exposed infant developing sepsis was 
1.52 times greater than that of an HIV-unexposed infant (OR 1.52, 95%CI: 1.31- 
1.78) (Table 5).  
 
Gram positive bacteria were present in 68.5% (n=479/699, 95%CI: 64.9% - 72.0%) 
of sepsis episodes, whereas 31.5% (n=220/699, 95%CI: 28.0% - 35.1%) were due to 
Gram-negative bacteria. The most common bacterial pathogen was GBS (246 
cases, 35.2% of all isolates; incidence [per 1000 live births] 2.57), followed by 
Staphylococcus aureus (113 cases, 16.2% overall; incidence 1.18). The most 
commonly-isolated Gram-negative bacteria was Escherichia coli (85 cases, 12.2% 
overall; incidence 0.89) (Table 3,   
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Figure 1). These three bacteria contributed to 60.9% (196/322), 78.9% (150/190) 
and 52.4% (98/187) of EOD, late- onset disease (LOD, 7-27 days age) and young 
infant community-acquired sepsis (YI-CAS, 28-90 days old), respectively; Figure 2 A-
C.  
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Table 3: Incidence of vertically/ community-acquire pathogenic bacteria isolated from young infants aged 0-90 days 
Bacteria isolates 2006 N 
2007 
N 
2008 
N 
Overall 
N 
Overall 
Incidence  
Total with 
HIV-
exposure 
results 
HIV 
exposed 
HIV 
unexposed 
% of HIV-
exposed 
Soweto live births 31 338 32 350 32 033 95 721 
per 1 000 
live births 
(95% CI)     
(95% CI) 
Gram positive           
Staphylococcus aureus 23 41 49 113 1.18 (0.97-1.41)  60 15 45 25.0% 
Streptococcus agalactiae 
(GBS) 76 79 91 246 
2.57 
(2.25-2.91)  221 104 117 47.1% 
Streptococcus 
pneumoniae 6 11 12 29 
0.30 
(0.20-0.44)  17 7 10 41.2% 
Streptococcus viridans 15 12 43 70 0.73 (0.57-0.92)  21 4 17 19.0% 
Other Gram positives 2 8 11 21 0.22 (0.14-0.34)  3 0 3 0.0% 
Gram negative           
Escherichia coli 24 29 32 85 0.89 (0.71-1.10)  45 16 29 35.6% 
Klebsiella pneumoniae 10 5 9 24 0.25 (0.16-0.37)  15 8 7 53.3% 
Haemophilus influenza 
type b 2 3 4 9 
0.09 
(0.04-0.18)  3 1 2 33.3% 
Acinetobacter spp. 18 9 30 57 0.60 (0.45-0.77)  8 1 7 12.5% 
Other Gram negatives 9 12 24 45 0.47 (0.34-0.63)  12 4 8 33.3% 
Total 185 209 305 699 7.30 (6.77-7.86)  405 160 245 
39.5% 
(34.7- 44.5%) 
Other Gram positives: Streptococcus anginosus (2), Streptococcus bovis (3), Group A-, C-, D- F and G streptococcus (1 each), Streptococcus salivarius (5), 
Streptococcus pyogenes (3), Streptococcus milleri (2), Streptococcus mitis (1) 
Other Gram negatives: Enterobacter cloacae (19), Klebsiella oxytoca (5), Listeria monocytogenes (1), Proteus mirabilis (2), Pseudomonas aeruginosis (7), 
Enterobacter agglomerans (1), Salmonella typhi (1), Serratia marcescens (1), Shigella flexnerii (1)   
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Table 4: Demographics of young infants (≤90 days of age) with vertically- or community-acquired bacterial sepsis 
 
  Gender Clinical presentation Outcome Overall  
Bacteria 
isolated Total N Female Male M:F Bacteraemia Meningitis 
% of 
meningitis 
per organism 
Discharged Died CFR CFR meningitis 
Gram positive            
Staphylococcus 
aureus 113 55 48 0.9 105 8 7.1% 68 4 5.6% 0% 
Streptococcus 
agalactiae 
(GBS) 
246 108 137 1.3 148 98 39.8% 207 37 15.2% 19.6% (19/97) 
Streptococcus 
pneumoniae 29 10 13 1.3 19 10 34.5% 16 2 11.1% 
22.2% 
(2/9) 
Streptococcus 
viridans  70 28 29 1.0 70 0 0.0% 24 1 4.0% 0% 
Other Gram 
positives 21 12 7 0.6 19 2 9.5% 3 0 0.0%  
Gram negative            
Escherichia coli 85 24 50 2.1 67 18 21.2% 43 15 25.9% 31.2% (5/16) 
Klebsiella 
pneumoniae 24 10 11 1.1 18 6 25.0% 13 3 18.8% 0% 
Haemophilus 
influenza type b 9 5 1 0.2 8 1 11.1% 2 2 50.0% 0% 
Acinetobacter 
spp. 57 18 31 1.7 55 2 3.5% 5 2 28.6% 0% 
Other Gram 
negatives 45 14 23 1.6 44 1 2.2% 11 3 21.4% 0% 
Total 699 284 350 1.2 553 146 26.4% 392 69 15.0% 18.8% (26/138) 
 
CFR= Case fatality rate 
Other Gram positives: Streptococcus anginosus (2), Streptococcus bovis (3), Group A-, C-, D- F and G streptococcus (1 each), Streptococcus salivarius (5), 
Streptococcus pyogenes (3), Streptococcus milleri (2), Streptococcus mitis (1) 
Other Gram negatives: Enterobacter cloacae (19), Klebsiella oxytoca (5), Listeria monocytogenes (1), Proteus mirabilis (2), Pseudomonas aeruginosis (7), 
Enterobacter agglomerans (1), Salmonella typhi (1), Serratia marcescens (1), Shigella flexnerii (1) 
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Table 5 Incidence of invasive bacterial sepsis in 0-90 day old infants stratified by 
HIV-exposure 
 
 
Bacteria isolated  HIV-exposed HIV-unexposed  
  n Incidence (95% CI) n 
Incidence 
(95% CI) 
OR (95%CI) 
Overall (Proration 
29.9% of infants with 
missing HIV results 
presumed to be HIV-
exposed) 
Overall 
248 5.79 451 4.51 1.28 
 (5.09-6.55)  (4.10- 4.94) (1.10- 1.51) 
EOD 
109 2.54 213 2.13 1.19 
 (2.09- 3.07)  (1.85- 2.44) (0.94-1.51) 
LOD 
65 1.52 125 1.25 1.23 
 (1.17- 1.93)  (1.04- 1.49) (0.89- 1.65) 
YI-CAS 
74 1.73 113 1.13 1.59 
 (1.36- 2.17)  (0.93-1.36) (1.12- 2.07) 
Overall (Proration 
39.5% of infants with 
missing HIV results 
presumed to be HIV-
exposed) 
Overall 
276 6.44 423 4.23 1.52 
 (5.70- 7.24)  (3.84- 4.65) (1.31-1.78) 
EOD 
126 2.94 196 1.96 1.50 
 (2.45- 3.50)  (1.70-2.25) (1.19- 1.89) 
LOD 
72 1.68 118 1.18 1.42 
 (1.31-2.11)  (0.98- 1.41) (1.05- 1.93) 
YI-CAS 
78 1.82 109 1.10 1.67 
 (1.44- 2.27)  (0.89- 1.31) (1.23- 2.26) 
HIV unknown 
assumed exposed Overall 
454 10.59 245 2.45 4.36 
 (9.64- 11.61)  (2.15- 2.78) (3.71- 5.11) 
HIV unknown 
assumed unexposed Overall 
160 3.73 539 5.39 0.69 
 (3.18- 4.36)  (4.94- 5.86) (0.58- 0.83) 
 
Proration based on prevalence of HIV exposure in community (29.9%) or in cases with HIV-exposure 
results (39.5%) 
EOD- Early onset disease (0-6 days), LOD- Late onset (neonatal) disease (7-27 days), YI-CAS- Young 
infant community acquired sepsis (28-90 days) 
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Figure 1: Bacterial causes of vertically- or community-acquired culture- confirmed 
sepsis in infants (0-90 days) 
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Figure 2: Bacterial causes of vertically- or community-acquired culture- confirmed 
sepsis in young infants (0-90 days) stratified by age 
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3.1.2. Early onset disease  
 
 
Newborns admitted to the neonatal unit at CHBAH immediately after birth, and who had 
a pathogenic bacteria identified from a sterile site culture in first 72 hours of life 
contributed 83.6% (270/ 322) of the early-onset disease (EOD, 0-6 days) cases. The 
remaining EOD cases were admitted to the general paediatric ward at CHBAH between 
days 0 and 6 of life, and had a bacterium isolated from sterile site within 72 hours of 
admission. The incidence (per 1 000 live births) of culture-confirmed EOD was 3.36 
(Table 6). Almost thirty-nine percent (59/152, 95% CI: 31.0 to 47.0%) of the EOD cases 
with known HIV results were HIV-exposed. In the sensitivity analysis, HIV-exposed 
young neonates had a higher odds of presenting with bacterial sepsis than HIV-
unexposed infants (OR= 1.50, 95% CI: 1.19 – 1.89) (Table 5). The CFR was 17% 
(29/142); (Table 6, Table 7).  
 
Gram positive bacteria were present in 68.6% (n=221, 95% CI: 63.3% - 73.7%) of EODs 
episodes, whilst 31.4% (n=101, 95% CI: 26.3% - 36.7%) were due to Gram-negative 
bacteria. The most common cause of EOD was GBS (41.6%, Figure 2, incidence 1.40), 
of whom 35.7% were HIV-exposed and 15.8% (21/112) died. Sixty three percent 
(88/140) of the GBS-EOD cases presented on day 0 of life and contributed 66% 
(88/133) of all bacterial isolates identified in sepsis cases presenting on day 0  
Figure 3). Furthermore, 23.1% of the GBS EOD presented with meningitis.   
The next most prevalent EOD bacterial pathogen were Acinetobacter baumanii (n=38, 
incidence: 0.40), S. aureus (n=32, incidence: 0.33) and E. coli (n=30, incidence: 0.31; 
CFR 14.3%) (Table 6). The majority of EOD cases (88.8%; 286/322) had bacteraemia, 
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whilst the rest (n=36) presented with meningitis; 16 (44.4%) of which were culture-
confirmed on CSF and 20 (55.6%; all GBS cases) were cultured only from blood culture 
and the CSF cyto-chemistry profile was suggestive of bacterial meningitis; Table 7.  
 
 
Figure 3: Distribution of bacterial pathogens causing early-onset neonatal bacterial 
sepsis by day of life (n= 322) 
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Table 6: Incidence of vertically/ community-acquire pathogenic bacteria isolated from neonates aged 0-6 days 
Bacteria isolates 2006 N 
2007 
N 
2008 
N 
Overall 
N 
Incidence 
(95% CI)  
Total with 
HIV-
exposure 
results 
HIV 
exposed 
HIV 
unexposed 
% of HIV-
exposed 
Soweto live births 31338 32350 32033 95721 per 1000 live births      
Gram positive           
Staphylococcus 
aureus 8 14 10 32 
0.33 
(0.23-0.47)  9 3 6 33.3% 
Streptococcus 
agalactiae (GBS) 39 41 54 134 
1.40 
(1.17-1.66)  123 50 73 40.7% 
Streptococcus 
pneumoniae 0 2 0 2 
0.02 
(0.002-0.08)  0 0 0  
Streptococcus 
viridans 9 7 25 41 
0.43 
(0.31-0.58)  2 0 2 0.0% 
Other Gram 
positives 2 4 6 12 
0.13 
(0.06-0.22)  1 0 1 0.0% 
Gram negative           
Escherichia coli 14 10 6 30 0.31 (0.21-0.45)  9 4 5 44.4% 
Klebsiella 
pneumoniae 2 1 4 7 
0.07 
(0.02-0.15)  2 0 2 0.0% 
Haemophilus 
influenza type B 1 1 3 5 
0.05 
(0.01-0.12)  1 0 1 0.0% 
Acinetobacter spp. 9 6 23 38 0.40 (0.28-0.54)  1 0 1 0.0% 
Other Gram 
negatives 3 5 13 21 
0.22 
(0.14-0.34)  4 2 2 50.0% 
Total 87 91 144 322 3.36 (3.00-3.75)  152 59 93 38.8% 
  
Other Gram positives: Streptococcus anginosus, Streptococcus bovis, Group A-, C-, D- F and G streptococcus, Streptococcus salivarius, Streptococcus pyogenes, 
Streptococcus milleri, Streptococcus mitis 
Other Gram negatives: Enterobacter cloacae, Klebsiella oxytoca, Listeria monocytogenes, Proteus mirabilis, Pseudomonas aeruginosis, Enterobacter 
agglomerans, Salmonella typhi, Serratia marcescens, Shigella flexnerii 
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Table 7: Demographic and clinical presentation of early-onset (<7 days age) vertical or community-acquired bacterial 
sepsis. 
  Gender Clinical presentation Outcome 
Bacteria 
isolated Total N Female Male M:F Bacteraemia Meningitis 
% of meningitis 
per organism Discharged Died CFR 
Gram positive           
Staphylococcus 
aureus 32 13 15 1.2 32 0 0.0% 10 0 0.0% 
Streptococcus 
agalactiae (GBS) 134 60 73 1.2 103 31 23.1% 112 21 15.8% 
Streptococcus 
pneumoniae 2 1 1 1.0 2 0 0.0% 1 0 0.0% 
Streptococcus 
viridans 41 16 15 0.9 41 0 0.0% 2 0 0.0% 
Other Gram 
positives 12 9 2 0.2 12 0 0.0% 1 0 0.0% 
Gram negative           
Escherichia coli 30 11 11 1.0 28 2 6.7% 12 2 14.3% 
Klebsiella 
pneumoniae 7 4 3 0.8 7 0 0.0% 1 1 50.0% 
Haemophilus 
influenza type b 5 3 0 0.0 4 1 20.0% 1 2 66.7% 
Acinetobacter 
spp. 38 11 20 1.8 37 1 2.6% 0 1 100.0% 
Other Gram 
negatives 21 9 8 0.9 20 1 4.8% 2 2 50.0% 
Total 322 137 148 1.1 286 36 11.2% 142 29 17.0% 
 
Other Gram positives: Streptococcus anginosus, Streptococcus bovis, Group A-, C-, D- F and G streptococcus, Streptococcus salivarius, Streptococcus pyogenes, 
Streptococcus milleri, Streptococcus mitis 
Other Gram negatives: Enterobacter cloacae, Klebsiella oxytoca, Listeria monocytogenes, Proteus mirabilis, Pseudomonas aeruginosis, Enterobacter 
agglomerans, Salmonella typhi, Serratia marcescens, Shigella flexnerii 
 
 
81 
 
3.1.3. Neonatal- late onset disease  
 
All community-acquired Neonatal late-onset disease (LOD, 7-27 days) cases were 
hospitalized to the paediatric wards of CHBAH. The incidence (per 1 000 live births) 
of culture-confirmed N-LOD was 1.98; Table 8. The prevalence of HIV-exposure was 
36.9% (48/130; 95% CI: 28.6% to 45.8%) among those in whom the maternal HIV 
infection status was known (130/190; 68.4%). The overall CFR for LOD was 14.2% 
(23/162), including 14.5% for GBS-LOD cases and 26.3% for E. coli associated 
sepsis (Tables 8 & 9).  
 
Gram positive bacteria were present in 82.1% (n=156, 95%CI: 75.9% - 87.3%) of 
sepsis episodes, whilst 17.9% (n=34, 95% CI: 12.7%- 24.1%) were due to Gram-
negative bacteria. The most commonly identified bacteria associated with LOD were 
GBS (40.5%; incidence: 0.80), followed by S. aureus (23.6%; incidence: 0.52) and E. 
coli (12.1%; incidence: 0.24); Table 8. The overall prevalence of maternal HIV-
infection exposure was 36.9%, including being 56.9% in GBS LOD. HIV-exposed 
infants had an increased odds of developing sepsis compared to HIV-unexposed 
infants (OR 1.42, 95%CI: 1.05- 1.93) (Table 5). 
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Table 8: Incidence of vertically/ community-acquire pathogenic bacteria isolated from neonates aged 7-27 days 
Bacteria isolates 2006 N 
2007 
N 
2008 
N 
Overall 
N 
Incidence 
(95% CI)  
Total with 
HIV-
exposure 
results 
HIV 
exposed 
HIV 
unexposed 
% of HIV-
exposed 
Soweto live births 31338 32350 32033 95721 per 1000 live births      
Gram positive           
Staphylococcus aureus 10 19 21 50 0.52 (0.39-0.69)  29 3 26 10.3% 
Streptococcus agalactiae (GBS) 24 28 25 77 0.80 (0.63-1.01)  65 37 28 56.9% 
Streptococcus pneumoniae 2 2 2 6 0.06 (0.02-0.14)  5 2 3 40.0% 
Streptococcus viridans 0 2 15 17 0.18 (0.10-0.28)  10 1 9 10.0% 
Other Gram positives 0 2 4 6 0.06 (0.02-0.14)  1 0 1 0.0% 
Gram negative           
Escherichia coli 4 9 10 23 0.24 (0.15-0.36)  16 4 12 25.0% 
Klebsiella pneumoniae 2 1 1 4 0.04 (0.01-0.11)  3 1 2 33.3% 
Haemophilus influenza type B 0 0 0 0 0.00  0 0 0  
Acinetobacter spp. 1 1 2 4 0.04 (0.01-0.11)  0 0 0  
Other Gram negatives 0 0 3 3 0.03 (0.006-0.09)  1 0 1 0.0% 
Total 43 64 83 190 1.98 (1.71-2.29)  130 48 82 36.9% 
 
Other Gram positives: Streptococcus anginosus, Streptococcus bovis, Group A-, C-, D- F and G streptococcus, Streptococcus salivarius, Streptococcus pyogenes, 
Streptococcus milleri, Streptococcus mitis 
Other Gram negatives: Enterobacter cloacae, Klebsiella oxytoca, Listeria monocytogenes, Proteus mirabilis, Pseudomonas aeruginosis, Enterobacter 
agglomerans, Salmonella typhi, Serratia marcescens, Shigella flexnerii 
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Table 9: Demographics of young infants with vertically- or community-acquired late onset neonatal bacterial sepsis: 7-27 
days 
  Gender Clinical presentation Outcome 
Bacteria 
isolated Total N Female Male M:F Bacteraemia Meningitis 
% of 
meningitis per 
organism 
Discharged Died CFR 
Gram positive           
Staphylococcus 
aureus 50 28 19 0.7 46 4 8.0% 38 3 7.3% 
Streptococcus 
agalactiae (GBS) 77 37 40 1.1 26 51 66.2% 65 11 14.5% 
Streptococcus 
pneumoniae 6 2 3 1.5 6 0 0.0% 4 1 20.0% 
Streptococcus 
viridans 17 6 10 1.7 17 0 0.0% 14 0 0.0% 
Other Gram 
positives 6 2 3 1.5 5 1 16.7% 1 0 0.0% 
Gram negative           
Escherichia coli 23 4 16 4.0 17 6 26.1% 14 5 26.3% 
Klebsiella 
pneumoniae 4 0 3  3 1 25.0% 2 2 50.0% 
Haemophilus 
influenza type b 0 0 0  0 0  0 0  
Acinetobacter 
spp. 4 1 3 3.0 4 0 0.0% 0 0  
Other Gram 
negatives 3 0 2  3 0 0.0% 1 1 50.0% 
Total 190 80 99 1.2 127 63 31.6% 139 23 14.2% 
 
 
Other Gram positives: Streptococcus anginosus, Streptococcus bovis, Group A-, C-, D- F and G streptococcus, Streptococcus salivarius, Streptococcus pyogenes, 
Streptococcus milleri, Streptococcus mitis 
Other Gram negatives: Enterobacter cloacae, Klebsiella oxytoca, Listeria monocytogenes, Proteus mirabilis, Pseudomonas aeruginosis, Enterobacter 
agglomerans, Salmonella typhi, Serratia marcescens, Shigella flexnerii 
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3.1.4. Young infant community acquired sepsis  
 
The incidence (per 1 000 live births) of Young infant community-acquired sepsis (YI-
CAS, 28-90 days) was 1.95, of which 21.4% presented as meningitis. Gram positive 
bacteria were present in 54.5% (n=102, 95% CI: 47.1% - 61.8%) of sepsis episodes 
compared to 45.5% (n=85, 95% CI: 38.2% - 52.9%) being due to Gram-negative 
bacteria (Tables 10 & 11). 
 
Of the meningitis cases, 90% (36/40) had bacteria cultured from the cerebrospinal fluid; 
and 10% (4/40) had a bacteraemia with CSF cytology suggestive of meningitis (Table 
11). The prevalence of maternal HIV-exposure among YI-CAS cases was 43.1% 
(53/123, 95% CI: 34.2% to 52.3%) among those in whom the maternal HIV infection 
status was known. HIV-exposed infants had a greater odds of developing sepsis than 
HIV-unexposed infants on sensitivity analysis (OR 1.67, 95%CI: 1.23- 2.26, Table 5). 
The overall CFR for YI-CAS was 13.3%, including 14.3% for GBS and 32.0% for E.coli 
sepsis; Tables 10 and 11.  
The three most common bacterial pathogens were GBS (18.7%; incidence 0.37), E. coli 
(17.1%; incidence 0.33) and S. aureus (16.6%; incidence 0.32), which contributed to 
52.4% of the overall cases; Tables 10 & 11, Figure 2c. 
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Table 10: Incidence of vertically/ community-acquire pathogenic bacteria isolated from neonates aged 28-90 days 
Bacteria isolates 2006 N 
2007 
N 
2008 
N 
Overall 
N Incidence  
Total with 
HIV-
exposure 
results 
HIV 
exposed 
HIV 
unexposed 
% of HIV-
exposed 
Soweto live births 31338 32350 32033 95721 per 1000 live births      
Gram positive           
Staphylococcus 
aureus 5 8 18 31 
0.32 
(0.22-0.46)  22 9 13 40.9% 
Streptococcus 
agalactiae (GBS) 13 10 12 35 
0.37 
(0.26-0.51)  33 17 16 51.5% 
Streptococcus 
pneumoniae 4 7 10 21 
0.22 
(0.14-0.34)  12 5 7 41.7% 
Streptococcus viridans 6 3 3 12 0.13 (0.06-0.22)  9 3 6 33.3% 
Other Gram positives 0 2 1 3 
0.03 
(0.006-
0.09) 
 1 0 1 0.0% 
Gram negative           
Escherichia coli 6 10 16 32 0.33 (0.23-0.47)  20 8 12 40.0% 
Klebsiella pneumoniae 6 3 4 13 0.14 (0.07-0.23)  10 7 3 70.0% 
Haemophilus influenza 
type B 1 2 1 4 
0.04 
(0.01-0.11)  2 1 1 50.0% 
Acinetobacter spp. 8 2 5 15 0.16 (0.09-0.26)  7 1 6 14.3% 
Other Gram negatives 6 7 8 21 0.22 (0.14-0.34)  7 2 5 28.6% 
Total 55 54 78 187 1.95 (1.68-2.25)  123 53 70 43.1% 
86 
 
Table 11: Demographics of young infants with vertically- or community-acquired late onset young infant bacterial sepsis: 28-90 
days 
  Gender Clinical presentation Outcome 
Bacteria 
isolated Total N Female Male M:F Bacteraemia Meningitis 
% of 
meningitis per 
organism 
Discharged Died CFR 
Gram positive           
Staphylococcus 
aureus 31 14 14 1.0 28 3 9.7% 20 1 4.8% 
Streptococcus 
agalactiae (GBS) 35 11 24 2.2 19 16 45.7% 30 5 14.3% 
Streptococcus 
pneumoniae 21 7 9 1.3 14 7 33.3% 11 1 8.3% 
Streptococcus 
viridans 12 6 4 0.7 12 0 0.0% 8 1 11.1% 
Other Gram 
positives 3 1 2 2.0 2 1 33.3% 1 0 0.0% 
Gram negative           
Escherichia coli 32 9 23 2.6 22 10 31.3% 17 8 32.0% 
Klebsiella 
pneumoniae 13 6 5 0.8 11 2 15.4% 10 0 0.0% 
Haemophilus 
influenza type b 4 2 1 0.5 4 0 0.0% 1 0 0.0% 
Acinetobacter 
spp. 15 6 8 1.3 14 1 6.7% 5 1 16.7% 
Other Gram 
negatives 21 5 13 2.6 21 0 0.0% 8 0 0.0% 
Total 187 67 103 1.5 147 40 21.4% 111 17 13.3% 
87 
 
3.1.5. Antibiotic susceptibility of top six leading causes of bacterial sepsis. 
  
The antibiotic susceptibility profile for the most common bacterial pathogens is shown in 
Table 11. Among the Gram positive bacteria, all GBS isolates were sensitive to 
penicillin, whilst 9.1% were resistant to erythromycin.  S. aureus isolates were generally 
resistant (92.5%) to penicillin/ ampicillin, with 15.0% (16/107) being also resistant to 
methicillin. Also, 28.9%, 31.6% and 13.9% of S. aureus isolates were resistant to 
gentamicin, erythromycin and Fluorquinolones (Table 12).   
 
Among the Gram-negative bacteria, approximately a quarter of E. coli isolates were 
resistant to penicillin/ ampicillin, gentamicin and fluoroquinolones, and 7.3% were also 
resistant to third generation cephalosporins. Resistance to penicillin/ ampicillin amongst 
other Gram negative pathogens (K. pneumoniae and Aceintobacter spp.) was 60-66%; 
55% to fluoroquinolones and one-third were also resistant to third generation 
cephalosporins; Table 12.  
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Table 12: Antibiotic resistance profile for most common bacterial pathogens in young infants (0-90 days old) with 
vertically- or community-acquired sepsis 
Bacteria 
isolated Penicillin/ ampicillin Gentamicin 3
rd generation cephalosporin Erythromycin Fluoroquinolones 
  n/N 
% 
resistan
ce 
95% 
CI n/N % resistance 95% CI n/N 
% 
resistance 95% CI n/N 
% 
resistanc
e 
95% 
CI N 
% 
resista
nce 
95% 
CI 
Gram 
positive                               
Staphylococ
cus aureus 
99/ 
107 92.5% 
(85.8-
96.7) 
11/ 
38 28.9% (15.4-45.9) 0/4 0.0% (0-60.2) 25/ 79 31.6% 
(21.6-
43.1) 5/ 36 13.9% 
(4.7-
29.5) 
Streptococc
us 
agalactiae 
0/ 
134 0.0% 
(0-
2.7) 0/0 
 Not applicable 
  
 
0/ 35 0.0% (0-10.0) 6/ 66 9.1% (3.4-18.7) 0/ 0 
  
Not applicable  
Streptococc
us 
pneumonia
e 
0/ 
25 0.0% 
(0- 
1.4) 0/0 
  Not applicable 
 0/0 
 Not applicable 
  
  
0/ 10 0.0% (0-30.8) 0/ 0 
  
Not applicable  
Gram 
negative                               
Escherichia 
coli 1/4 25.0% 
(0.6-
80.6) 
14/ 
55 25.5% (14.7-39.0) 6/ 82 7.3% 
(2.7-
15.2) 2/ 3 66.7% 
(9.4-
99.2) 4/ 17 23.5% 
(6.8-
49.9) 
Klebsiella 
pneumonia
e 
2/3 66.7% (9.4-99.2) 
8/ 
17 47.1% (23.0-72.2) 8/ 24 33.3% 
(15.6-
55.3) 0/ 0     5/ 9 55.6% 
(21.2
-
86.3) 
Acinetobact
er spp. 
6/1
0 60.0% 
(26.2-
87.8) 
38/ 
48 79.2% (65.0-89.5) 16/49 32.7% 
(19.9-
47.5) 4/ 4 100.0% 
(39.8-
100) 
17/ 
31 54.8% 
(36.0
-
72.7) 
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3.2. Discussion   
 
GBS (incidence 2.57 per 1 000 live births) was the most commonly-identified 
bacterial pathogen in neonates and young infants overall in our setting, followed by 
S. aureus (incidence: 1.18) and E. coli (incidence: 0.89). These three pathogens 
contribute to 63.5% (444/699) of all sepsis cases in infants <90 days of age. Our 
observation differs from previous reports from both HICs, where GBS and E.coli are 
the most commonly isolated pathogens40, 64-66, and LMICs where S. aureus and E. 
coli dominate, but very few GBS cases are identified63, 67, 69-71. HIV-exposed infants 
had a higher than expected risk of developing sepsis than HIV-unexposed infants 
(OR 1.52, 95% CI: 1.31 to 1.78) in sensitivity analysis based on the prevalence of 
HIV-exposure of cases with known HIV-results (39.5%).  
 
The incidence (3.36 per 1000 live births) of culture-confirmed EOD in Soweto was 2-
5 fold greater compared to that reported from HICs (0.59-1.6)40, 59, 61, 62. Also, the 
incidence (per 1000 live births) was midway between the wide range reported from 
LMICs, which are reported from a low of 0.93233 to as high as 9.8234. The incidence 
of EOD in our study, however, likely represents an underestimate since up to 10% of 
women delivering at CHBAH receive intrapartum antibiotics229, which may reduce 
the sensitivity of blood cultures for diagnosing bacterial sepsis. Additionally, almost 
65% of GBS cases present on the day of birth and 21% between 24- 48 hours of 
age235. If newborn infants are not adequately investigated in epidemiological studies, 
the role of GBS could be significantly under-estimated.  
 
GBS, S. aureus and E. coli contributed 76.2% of the LOD cases, and meningeal 
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involvement was present in 31.6% of cases, including 66.2% due to GBS. Despite 
the higher rate of meningitis in this age group than in EOD, the case fatality ratio was 
lower for LOD (14.2%) than EOD (17.0%). A higher case-fatality rate in EOD cases 
(25%- 55.5%) compared to cases presenting between days 7 and 60 of life (10% -
26.1%) has also been noted in several other studies conducted in Africa 54, 236. GBS, 
E. coli and S. aureus were also the most common bacteria isolated between 29 and 
90 days of life, and together contributed 52.4% of the cases, and the case fatality 
ratio was 13.3%.  
 
Pathogens causing LOD and YI-CAS differ within and between regions. Waters et 
al237 have reported that S. aureus (14.6%), S. pneumoniae (13.9%), E. coli (11%) 
and GBS (6.9%) are the predominant pathogens in Africa, but Klebsiella species 
(33.5%), S. aureus (10.0%), E. coli (9.0%) and Pseudomonas species (9.0%) are 
most common in South East Asia, whilst  GBS contributed to only 3.0% of isolates in 
South East Asian studies237. Other meta-analyses70, 71, also report S. aureus (11- 
22%) as a dominant pathogen, with E.coli (10%) and Klebsiella species (10%) also 
being among the leading pathogens, however, the sequence of pathogens varies 
between regions, as does the contribution of other common bacteria including S. 
pneumoniae and S. pyogenes.  GBS was uncommonly isolated (<1%- 11%70, 71) in 
post-neonatal septic infants.  
 
For all young infants (0-90 days old) with HIV exposure results available, 39.5% 
were HIV-exposed. Due to the large proportion of missing data, a sensitivity analysis 
was performed. HIV-exposed infants had a 1.52 fold greater odds of developing 
culture-confirmed sepsis than HIV-unexposed infants (95% CI: 1.31- 1.78). 
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When stratified by age categories, this observation was noted in EOD, LOD and YI-
CAS categories (Table 5).    
 
When the impact of HIV-exposure on specific pathogens was considered, GBS 
sepsis was prominent, as the number of cases with available HIV results was large 
(n=221, 89.8% of all GBS cases), and the proportion HIV-exposure of overall cases 
was high (47.1%). The incidence of GBS sepsis in HIV-exposed infants was 3.63/ 
1000 live births, compared to 1.74/1000 live births in HIV-unexposed infants. A study 
conducted in Belgium also reported high incidence of GBS sepsis in HIV-exposed 
infants(15.5/1000 live births)238. The risk for GBS-EOD, GBS-LOD and GBS-YI-CAS 
were 1.55-fold (95% CI: 1.06 – 2.26); 2.99-fold (95% CI: 1.78- 5.08) and 2.41-fold 
(95% CI: 1.14 – 5.09) greater in HIV-exposed infants than HIV-unexposed infants 
respectively. This analysis was not conducted for other pathogens, due to high 
number with missing HIV-exposure results.  
 
The HIV-infection status of HIV-exposed infants was not assessed in this study, as 
the standard of care during the study period did not include neonatal HIV-PCR 
testing. HIV-PCR results were not available for the majority of HIV-exposed study 
participants. During the study period, however, the early vertical transmission rate of 
HIV to infants in Gauteng province decreased from 15.8% in 2004 to 8.1% in 2008 
due to successful implementation of PMTCT239, therefore the actual number of HIV-
infected infants would have been low. The recent implementation (in 2015/ 2016) of 
HIV-PCR testing at birth of HIV-exposed newborns in South African public health 
care facilities will mitigate this limitation in future, similar studies.  
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This study was conducted in a secondary-tertiary care facility in a relatively well-
resourced urban area of South Africa. Residents of Soweto, South Africa have good 
access to health care facilities for labour and delivery and for care of sick neonates 
and post-neonatal infants, however, the neonatal mortality rate (14.6 per 1000 live 
births) is higher than expected for an upper- middle-income country (10 per 1000 live 
births)240. A recent study in Soweto reported that the neonatal mortality rate for 
Soweto could be as high as 20 per 1000 births206. 
Many neonates and young infants who present with episodes of sepsis have other 
potentially life-threatening conditions, including complications of prematurity. The 
mortality rates reported in this chapter are crude mortality rates, and might have 
been compounded by underlying conditions unrelated to the  sepsis. 
 
This study restricted enrolment to sepsis cases which most likely to be acquired 
either vertically or from the community. Nosocomial sepsis cases and probable 
contaminants were excluded. Physiological features and exposures to potential 
pathogens varies remarkably during the neonatal period, and stratification of culture-
confirmed cases into recognized categories (e.g. EOD, 0-6 days; N-LOD, 7-27 days; 
YI-LOD, 28- 90 days) is vital to understanding pathogenesis of disease and 
implementing appropriate preventative interventions or treatments. Despite the 
majority of births in Soweto being facility-based, this study may have under-
estimated the burden of culture-confirmed sepsis in neonates and young infants, as 
up to 40% of child-deaths in Soweto occur at home15, many of whom are not 
assessed at a health care facility prior to death.    
 
Despite the most commonly-isolated bacterial pathogen, GBS, being susceptible to 
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first-line antibiotics, antimicrobial resistance is high for other bacteria, notably high 
resistance of S. aureus to penicillin/ ampicillin (92.5%). This was higher than the 
resistance noted in a recent meta-analysis (86%)70. All the S. aureus isolates tested 
at CHBAH were, however, sensitive to third generation cephalosporins.  Empiric 
antibiotic treatment does not adequately cover this pathogen.  
 
K. pneumoniae (33.3%) and Acinetobacter spp. (32.7%) displayed high proportions 
with resistance to third generation cephalosporins, which was, however, lower than 
reported in a meta-analysis (57% for Klebsiella spp. and 53% for Acinetobacter spp.) 
70. The number of isolates included in this surveillance study was small, and ongoing 
monitoring of resistance patterns in common bacterial pathogens is essential to 
inform local antimicrobial use policies.   
 
The main limitation of this study was the retrospective identification of cases and 
data collection, which led to missing important data for many of the young infants, 
which in turn limits robustness of data presented. Nevertheless, the results of this  
project contribute to the limited data available describing aetiology of community 
acquired sepsis in young infants from LMIC. In order to reduce infection-related 
neonatal deaths globally, prevention and management of neonatal infections in 
community settings must be prioritized241. This diverse spectrum of pathogens, 
especially reported in young infants 28-90 days of age, warrants consideration of a 
multifactorial approach to prevention and treatment of sepsis in young infants. 
Resource and expertise constraints make antenatal screening and IAP/risk based 
management an unachievable goal in many LMIC countries. Other strategies to 
reduce sepsis in young infants, including cord care and maternal immunisation 
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should be explored. 
 
Vaccines for administration to pregnant women to prevent GBS sepsis in their 
newborns are in clinical trial phase of development66, 214, 242. S. aureus, which was 
the second-most commonly isolated bacteria from young infants in our setting, 
colonises almost 50% of newborns within days of birth103 and is implicated in at least 
half of the omphalitis cases reported in a study from Pakistan105. Cord care with 4% 
chlorhexidine solution significantly reduces omphalitis243, 244 and neonatal 
mortality244, and should be recommended especially in LMICs where S. aureus 
sepsis is common.  
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4. RISK FACTORS FOR NEONATAL SEPSIS 
 
Characterization of the risk factors associated with neonatal sepsis may shed light 
on potential prevention strategies.  Major risk factors associated with early-onset 
neonatal group B streptococcal (GBS) disease in high-income countries have been 
well described and include prolonged membrane rupture, intrapartum fever, preterm 
delivery, and maternal colonisation with the pathogen245-247.  Factors associated with 
other pathogens known to cause neonatal sepsis are less well described.  
Prematurity (<33 weeks), prolonged rupture of membranes and intrapartum fever 
have also been identified as risk factors for invasive Escherichia coli early-onset 
sepsis in the United States111.  Although data from LMICs are limited, there is 
evidence that prolonged rupture of membranes, preterm delivery, intrapartum fever, 
birth asphyxia and labour complications are important contributors to early onset 
sepsis248, 249,250. 
 
In this chapter, the maternal and neonatal factors associated with very early-onset 
neonatal sepsis (VEOD, 0-2 days), late-onset community acquired sepsis (3-28 
days), and perinatal death in a cohort of more than 8000 mother-baby dyads 
delivered at a large public hospital in Soweto, South Africa are described by 
performance of a secondary analysis of the Prevention of Perinatal trial (published 
paper is in Appendix 4). 
 
4.1. Statistical analysis 
 
Maternal variables considered to be potential risk factors included: age (<20 years, > 
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20 years), prenatal care, start date of prenatal care (<21 weeks’ gestation, > 21 
weeks’ gestation), first birth, previous neonatal death, HIV status, diagnosed urinary 
tract infection during pregnancy, anemia, pre-gestational  or gestational diabetes 
mellitus, underlying cardiac conditions, and  syphilis infection. Intrapartum variables 
included: referral for delivery at CHBAH from a satellite birthing clinic, total number of 
vaginal exams, duration of membrane rupture, duration of labour (approximated by 
the time between randomization on admission for active labour, and delivery), intra-
amniotic infection (defined as any two of the following: fever, uterine tenderness, foul 
smelling vaginal discharge, maternal tachycardia, fetal tachycardia), multiple birth, 
mode of delivery (vaginal, emergency caesarean due to a failed vaginal birth in a 
woman with a prior caesarean, emergency caesarean for other reasons), fever, 
meconium stained amniotic fluid  (MSAF) and receipt of intrapartum antibiotics 
(documented administration of antibiotics after admission for active labour and 
excluding women with emergency caesarean deliveries who received antibiotics less 
than 1 hour before delivery). Infant variables analyzed included: birth weight, 
gestational age (preterm: <37 weeks, term: > 37 weeks) and infant gender.   
 
Univariate and multivariable analyses were performed using logistic regression in 
SAS Version 9.2 (Carey, NC, USA).  Multivariable models were evaluated starting 
with all factors that were significant at p<0.15 in univariate analysis and dropping 
non-significant factors using stepwise backwards selection.  Collinearity of 
independent variables was evaluated.  All two-way interactions in final multivariable 
models were evaluated. Throughout, two-sided P-values <0.05 were considered 
statistically significant and 95% confidence intervals were calculated.  Relative risks 
were approximated by odds ratios because sepsis and perinatal death endpoints 
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were rare in this population. 251 
 
4.2. Results 
 
Median maternal age was 26 years (interquartile range 22-31), the median 
gestational age at delivery was 39 weeks (range 23 to 44 weeks) and 3.8% 
(309/8129) infants were born prematurely (<37 weeks gestation). Eight percent 
(615/8129) of newborns had low birth weight (<2500 grams), including 0.4% 
(35/8129) who had a very low birth weight (<1500 grams). HIV results were available 
for 99% (7902/8011) women, of whom 26.4% (2090/7902) were HIV-infected.  Only 
11 women (0.1%) had not attended antenatal clinic. Women with planned caesarian 
section deliveries were excluded from continuing on the trial at arrival in labour, 
however, 23% (1867/8011) of women delivered by emergency caesarean section. 
On medical history and examination, 10.7% (854/8011) women had a urinary tract 
infection and 21.0% (1678/8011) were hypertensive during late pregnancy.   
 
Of the 8129 infants born to trial participants, 26 were stillborn and 4.8% (388/8129) 
required resuscitation just after birth. In addition to the 26 stillbirths, 56 infants died 
during the neonatal period (by 28 days of life), 80.4% (45/56) of whom died during 
the first week of life. Fifteen of these newborns died within hours of delivery, mainly 
due to severe birth asphyxia or extreme prematurity. The median age at death was 0 
days (interquartile range: 0-28).  The leading causes of death in live-born neonates 
were birth asphyxia (n=30, 52.6%), and respiratory distress of the newborn (n=7; 
12.5%). 
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Intrapartum antibiotics (IAP) were administered to 10.5% (837/ 8011) women. Of 
these women, 60% (498/837) received intravenous ampicillin (1g 6 hourly), the 
majority (>66%) in combination with metronidazole. Two women received penicillin.  
The median duration between administration of the first dose of IAP and delivery was 
14.8h (IQR: 7.8-26.7h). The most commonly documented reasons for IAP 
administration were prolonged rupture of membranes (410/837 or 49%); purulent or 
offensive vaginal discharge (90/837 or 11%); and preterm labour (48/837 or 6%). 
Only 62.9% (449/714) of women with prolonged rupture of membranes (>18 hours) 
received IAP.  
 
Hospital policy stipulates administration of IAP to women who deliver between 26 
and 33 weeks gestation, however, only 49.4% (42/85) of women eligible for IAP for 
prematurity were adequately treated. Women who present with at least one sign of 
chorioamnionitis should receive IAP as per hospital policy, however, only 10.0% 
(129/1295) of these women received IAP for the following indications: Meconium-
stained amniotic fluid ((MSAF: 92/1200 or 7.7%); offensive or purulent vaginal 
discharge (32/79 or  40.5%); maternal tachycardia (8/22 or 36.3%); fetal tachycardia 
(8/32 or 25%); maternal fever (12/17 or 70.6%) or uterine tenderness (1/1  or 100%).  
 
Of the 8103 live-born newborns, 289 fulfilled the definition (see Table 2 in methods 
chapter) for early-onset sepsis (35.7/ 1000 live births) and 34 fulfilled criteria for late 
onset disease (4.2/1000 live births). Ten percent (29/289) of the early-onset cases 
were culture confirmed with GBS being the most common pathogen (16/29) (Table 
13).  
 
99 
 
Table 13:  Characteristics of neonates with sepsis, Soweto252 
 
Characteristica (% unless otherwise 
stated) 
Clinical very  
early-onset 
sepsis 
(n=260) 
Culture-
confirmed 
very early-
onset sepsis 
b (n=29) 
Clinical late-
onset sepsis 
(n=14) 
Culture-
confirmed 
late-onset 
sepsisb 
(n=20) 
Birthweight (%)     
<1500 g 4 0 0 0 
1500-2499 g 15 21 7 10 
>2500g 80 79 93 85 
Preterm delivery (% <37 weeks) 15 10 0 5 
Apgar at 5 minutes (median, IQR) 8 (6-9) 9 (7-10) 10 (9-10) 10 (10-10) 
Resuscitation at birth (%) 39.6% 37.9% 7.1% 0% 
Median age at onset (days, IQR) 0 (0-0) 0 (0-1) 17 (13-22) 17  (14-24) 
Median length of hospital stay (days, 
IQR) 
7 (5-10) 10 (8-13) 6 (3-7) 16 (6-22) 
Infant HIV infection statusc 5 10 7 10 
Clinical signs of sepsis      
Respiratory distress (%) 98 79 86 55 
Hypotension (%) 9 14 36 10 
Pyrexia or hypothermia (%) 9 14 29 30 
Abdominal feeding problems (%) 4 17 36 50 
Bleeding diathesis (%) 0 0 0 0 
Lethargy or irritability (%) 17 28 43 45 
Central nervous system signs  
(%) 
21 17 21 20 
Laboratory signs of sepsis       
Abnormal white blood cell count 
(%) 
20 3 50 25 
Abnormal neutrophil count (%) 19 7 57 20 
Low platelet count (%) 28 17 7 5 
Elevated C reactive protein (%) 54 52 43 60 
Elevated CSF white blood cell 
count (%) 
1 7 0 30 
Outcome (%)     
Survived 94 90 93 100 
Died by day 28 of life 6 10 7d 0c 
 
aAll variables had fewer than 1% missing values except for HIV infection status which had 9% 
(28/323) missings 
bAmong the culture confirmed cases, 2 early onset and 7 late onset cases were identified by CSF 
c Infant HIV infection status was determined by PCR at 6 weeks of age 
d2 infants in each of these groups died shortly after the 28 day period (days 29-32 of life), before 
hospital discharge 
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Almost 59% (20/34) of late onset cases were culture-confirmed, with Escherichia coli 
being identified as the leading cause (n=9), followed by GBS (n=5).  The median age 
at onset for late onset cases was 14 days (interquartile range: 11-20) and only 1 late 
onset case was born prematurely.   
Fifteen percent (1205/8129) of neonates were exposed to meconium-stained 
amniotic fluid (MSAF) and 3.3% (40/ 1205) of these were diagnosed with meconium 
aspiration syndrome. Meconium aspiration syndrome was present in 10% (30/289) of 
early onset cases, and 11.3% (8/71) of perinatal deaths, but none of the neonates 
with late onset disease. 
 
In univariate analysis, low birthweight, preterm delivery and maternal factors, 
including primiparity, emergency caesarian delivery, prolonged labour and pre-
gestational diabetes mellitus, were associated with increased risk of early-onset 
sepsis (Table 14).  Fewer factors including emergency caesarian delivery and 
primiparity were associated with late onset sepsis in univariate analysis, but only 
MSAF (aOR 2.4; 95% CI: 1.1-5.0) remained significantly associated with LOD in 
multivariable analysis (Table 15). When analysis was restricted to culture-confirmed 
cases of early and late onset sepsis (29 early onset and 20 late onset cases), MSAF 
(aOR 2.7, 95% CI: 1.4-5.0), low birthweight (aOR 2.5, 95% CI: 1.2-5.4), and first birth 
(aOR 2.1, 95% CI: 1.2-3.8) were associated with increased sepsis risk on 
multivariable analysis (Table 16). 
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Table 14:  Factors associated with very early-onset sepsis, PoPS trial cohort252 
Characteristic Cases, % 
exposed  
(n=289a ) 
Non-cases, % 
exposed  
(n=7840a ) 
OR§ (95% CI) aORb (95% CI) 
Maternal     
Age <20 years 18.0 13.6 1.4 (1.0-1.9)  
Pre-gestational diabetes 
mellitus  
0.7 0.2 3.4 (0.8-14.9)  
First birth 59.5 42.2 2.0 (1.6-2.6) 1.8 (1.4-2.3) 
Multiple gestation 5.2 2.8 1.9 (1.1-3.3)  
Rupture of membranes > 18 h 13.5 8.8 1.6 (1.1-2.3)  
Duration of labour (h, 
quartiles)c 
  P=0.003  
<2.9h 21.1 24.7 REF  
2.9-5.4h 18.3 24.9 0.9 (0.6-1.3)  
5.5-9.4h 27.7 25.5 1.3 (0.8-2.3)  
>=9.5h 32.9 24.8 1.6 (1.1-2.2)  
Number of vaginal exams 
(quartiles) 
  P=0.0005 P=0.02 
<2 6.3 8.7 REF REF 
2-3 31.5 39.8 1.1 (0.7-1.9) 1.1 (0.6-1.8) 
4 18.2  19.0 1.3 (0.8-2.3) 1.2 (0.7-2.1) 
>4 44.1 32.5 1.9 (1.1-3.1) 1.6 (1.0-2.7) 
Mode of delivery     
Emergency caesarean due 
to prior cesarean 
0.7 2.0 0.4 (0.1-1.6)  
Emergency caesarean for 
other reasons 
29.1 21.1 1.5 (1.2-2.0)  
Vaginal delivery 70.2 77.0 REF  
Intrapartum antibioticsd 14.5 10.4 1.5 (1.0-2.0)  
Meconium stained amniotic 
fluid 
30.5 14.3 2.6 (2.0-3.4) 2.8 (2.2-3.7) 
     
Infant     
Birthweight     
<1500 g 3.8 0.3 14.3 (6.9-29.5) 6.5 (2.4-17.3) 
1500-2499 g 15.7 7.3 2.5 (1.8-3.4) 1.8 (1.1-2.9) 
>2500g 80.5 92.3 REF  
Preterm delivery (<37 weeks’) 14.2 3.4 4.7 (3.3-6.6) 2.6 (1.4-4.8) 
 
aAll variables had fewer than 15 missing values except for birthweight which had 49 missings (47 among non-cases) 
b Univariate: all factors with p< 0.15 are shown; all were entered into multivariable model, only those with p<0.05 are shown. 
Due to missing values, the multivariable model included 287 cases and 7793 non-cases. Apgar score was excluded from model 
because of overlap with endpoint. Only 1 case of intrapartum fever was recorded so the variable could not be analyzed 
c Duration of labour is approximated by time between randomization into the PoPS trial (which for most mothers coincided with 
onset of true labour) and delivery 
d IAP defined as any duration, excluding cesarean prophylaxis (<1 hour of antibiotics before delivery) 
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Perinatal death was associated with pregnancy-induced hypertension, pre-
gestational diabetes mellitus and anaemia on univariate analysis. Preterm delivery 
(aOR  5.9, 95% CI: 3.1-11.2), primiparity (aOR 1.7, 95% CI: 1.0-2.7), and MSAF 
(aOR 2.1, 95% CI: 1.2-3.7) had the strongest risk of death on multivariable analysis. 
(  
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Table 17). 
Primiparous women were more likely than multiparous women to have 
characteristics, including prolonged labour and higher number of per vaginal 
examinations; which were associated with poor neonatal outcomes. Characteristics 
were compared between primiparous- and multiparous women, and illustrated in 
Figure 4.  In general the magnitude of the differences were small, except for young 
maternal age (<20 years), labour duration longer than the median length, and the 
related number of vaginal exams (Figure 4).  
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Figure 4: Characteristics of primiparous and multiparous women in the Prevention of Perinatal Sepsis Trial, 
delivering at Chris Hani Baragwanath Academic Hospital, Soweto, South Africa.   
 
Groups differing by p<=0.001 are denoted by **; group differing by P<0.05 are denoted by *.  ROM=rupture of 
membranes; MSAF=meconium stained amniotic fluid 
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Table 15: Factors associated with community-acquired late onset sepsis 
 
Characteristic Cases, % exposed 
(n=34 ) 
Non-cases, % 
exposed 
(n=8087) 
ORa (95% CI) aORa (95% 
CI) 
Maternal     
First birth 58.8 42.7 1.9 (1.0-3.8)  
Mode of delivery  P=0.054   
Vaginal delivery 58.9 76.8 REF  
Emergency 
caesarean due to 
prior cesarean 
2.9 1.9 2.0 (0.3-15.1)  
Emergency 
caesarean for other 
reasons 
38.2 21.3   
2.3 (1.2-4.7) 
 
Male sex 67.7 52.2 1.9 (0.9-3.9)  
Meconium stained 
amniotic fluid 
29.4 14.8   2.4 (1.1-5.0)  
  
 
a Univariate: all factors with p< 0.15 are shown; all were entered into multivariable model, 
only those with p<0.05 are shown. Apgar score was excluded from model because of overlap 
with endpoint. Only 1 case of intrapartum fever was recorded so the variable could not be 
analyzed 
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Table 16:  Factors associated with culture confirmed very early or late onset 
sepsis 
 
Characteristic Cases, % 
exposed  
(n=49a ) 
Non-cases, % 
exposed  
(n=8080a) 
ORb (95% 
CI)) 
aORb (95% 
CI) 
Maternal     
 Age <20 years 22.5 13.7 1.8 (0.9-3.6)  
Mode of delivery   P=0.04  
Vaginal delivery 61.2 76.8 REF  
Emergency 
caesarean due to 
prior cesarean 
2.0 1.9 2.2 (1.2-3.9)  
Emergency 
caesarean for other 
reasons* 
36.7 21.2 1.3 (0.2-9.9)  
Duration of labour (h, 
quartiles)c 
    
<2.9h  12.2 24.7 REF  
2.9-5.4h 18.4 24.7 1.5 (0.5-4.2)  
5.5-9.4h 28.6 25.6 2.3 (0.9-5.9)  
>=9.5h 40.8 25.0 3.3 (1.3-8.2)  
Number of vaginal 
exams (quartiles) 
    
<2 10.2 8.6 REF  
2-3 34.7 39.5 0.7 (0.3-2.0)  
4 8.2 19.0 0.4 (0.1-1.4)  
>4 46.9 32.9 1.2 (0.5-3.2)  
First birth 63.3 42.7 2.3(1.3 -4.1) 2.1 (1.2-3.8) 
Meconium 30.6 14.7 2.6 (1.4-4.7) 2.7 (1.4-5.0) 
     
Infant     
Birthweight     
<2500 g 16.7 8.0 2.3 (1.1-4.9) 2.5 (1.2-5.4) 
Preterm delivery (<37 
weeks’) 
8.2 3.8 2.3  (0.8-6.3)  
Male 63.3 52.2 1.6 (0.9-2.8)  
a All variables had fewer than 15 missing values, except for birthweight which had 49 missings 
including 1 case 
b Univariate: all factors with p< 0.15 are shown; all were entered into multivariable models, only those 
with p<0.05 in the final model are shown. The final multivariable model is based on 8080 observations 
(48 cases).  Apgar score was excluded from model because of overlap with endpoint. Only 1 case of 
intrapartum fever was recorded so the variable could not be analyzed.  
c Duration of labour is approximated by time between randomization into the PoPS trial (which for 
most mothers coincided with onset of true labour) and delivery.  
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Table 17. Factors associated with perinatal death  
 
Characteristic Cases, % 
exposed (n=71a ) 
Non-cases, 
% exposed 
(n= 8047a) 
ORb (95% CI)) aORb (95% 
CI) 
Maternal     
Pregnancy-induced 
hypertension 
29.6 21.0 1.6 (0.9-2.6)  
Pre-gestational diabetes 
mellitus§ 
1.4 0.2 6.7 (0.9-51.4)  
Anaemia 14.1 8.7 1.7 (0.9-3.4)  
First birth 56.3 42.7 1.7 (1.1-2.8) 1.7 (1.0-2.7) 
Meconium stained 
amniotic fluid 
25.4 14.8 2.0 (1.1-3.4) 2.1 (1.2-3.7) 
Infant     
Preterm delivery (<37 
weeks’) 
16.9 3.6 5.4 (2.9-10.1) 5.9 (3.1-
11.2) 
 
aAll variables had fewer than 9 missing values, except for birthweight which had 49 missings, including 
35 among cases. Because of this, birthweight was only evaluated in the univariate models. 
b Univariate: all factors with p< 0.15 are shown; all were entered into multivariable models, only those 
with p<0.05 in the final model are shown. Apgar score was excluded from model because of overlap 
with endpoint. Only 1 case of intrapartum fever was recorded so the variable could not be analyzed. 
Cell sizes for diabetes mellitus were too small to use in the multivariable model 
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4.3. Discussion 
 
Neonatal sepsis contributes significantly to neonatal deaths globally; however, we 
present one of the first evaluations of risk factors associated with all-cause neonatal 
sepsis and perinatal death in a large cohort of facility-based births in sub-Saharan 
Africa.  
 
As this was a secondary analysis of a clinical trial cohort, it was neither a population-
based sample nor representative of all births at the facility. The rate of stillbirths on 
the PoPS trial (3.2/ 1000) was lower than the reported rate for CHBAH (26.9/1000, 
unpublished data 2005-2008, Department of Obstetrics and Gynaecology, CHBAH, 
Perinatal stats. Prof E. Buchmann), as any woman with an intrauterine death 
confirmed prior to PoPS randomisation in labour ward complex was excluded from 
continuation in the trial. The neonatal mortality rate (NMR, 6.9/1000 live births) 
recorded for the PoPS trial is lower than the national NMR (14.6/1000 live births). It 
has been reported that up to 40% of children in Soweto die at home, despite good 
access to health care facilities15. One limitation of the PoPS trial was the lack of an 
active follow-up contact at the end of the neonatal period to record maternal and 
infant adverse events and outcomes, especially ones which occurred outside 
CHBAH. The lower-than-expected NMR in the PoPS trial was probably due to 
inadequate identification and recording of neonatal deaths, rather than improved care 
or benefit of the intervention offered.  
 
Despite the perinatal mortality rate (PMR, stillbirths plus neonatal deaths in first week 
of life; 8.7/1000 births) in PoPS trial participants being an under-estimation of the 
actual PMR at CHBAH, factors associated with perinatal death were assessed.  
109 
 
Poor neonatal outcomes (death and sepsis) are often associated with prolonged 
duration of labour and prolonged rupture of membranes40, 46, which are in turn 
associated with higher number of vaginal examinations and higher rate of caesarean 
section deliveries. These features are more commonly observed in primiparous 
women, who in our setting, are also often young (<20 years).  
 
A rigorous sepsis definition, including both clinical and laboratory signs, was used. 
Preterm birth and low birthweight are recognized risk factors for neonatal sepsis, and 
our findings corroborate what has been reported from high-income countries 111, 200, 
247, 253. Two thirds of E. coli –confirmed neonatal sepsis in the USA is diagnosed in 
preterm infants111. Although effective prevention strategies for preterm delivery 
remain elusive, improved access to prenatal care, and improved maternal nutrition 
and health in LMICs might be of some benefit in reducing low birthweight. 
   
Primiparity and MSAF were each associated with approximately double the risk of 
sepsis and death in our neonatal trial participants. Meconium is rarely passed by 
preterm foetuses, and MSAF is an indicator of in-utero foetal distress254. MSAF is 
associated with intra-amniotic infection and early- and late onset sepsis in LMIC248, 
and HIC settings255. It is unclear whether the presence of meconium in the amniotic 
fluid stimulates growth of pathogens, or whether foetal infection is the stress-trigger 
which leads to passing of meconium in utero254, 256. Our rigorous clinical sepsis 
definition captured some non-infectious syndromes including meconium aspiration 
syndrome.  
  
Primiparity has occasionally been identified as a risk factor for neonatal sepsis, 
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usually only in univariate analysis or studies with limited intrapartum variables for 
evaluation257. Women delivering their first baby usually have slower progress of 
cervical dilatation during labour than multiparous women258, leading to a longer 
duration of labour. Additionally, duration between rupture of membranes and delivery 
is longer in primiparous than multiparous women. We collected information on 
duration of labour, duration between membrane rupture and delivery and total 
number of vaginal exams received; all known risk factors for sepsis; and noted that 
small differences in these characteristics exist between primiparous and multiparous 
women. Primiparous women are additionally more likely to have a combination of 
these characteristics, which in turn led to first birth remaining robustly associated with 
sepsis and perinatal death in multivariable analysis.  
 
On multivariable analysis, factors associated with neonatal sepsis were also 
associated with perinatal death. CHBAH is the referral center for satellite clinics in 
Soweto, and the threshold for referral of women with pregnancy- or labour- 
complications is low. We noted that there was an over-representation of several “high 
risk” maternal conditions, for example pregnancy induced hypertension in our trial 
participants, yet none of these conditions were associated with increased risk of 
perinatal death. The outcome diagnosis for 11% of deaths in foetal/ infant trial 
participants was documented as meconium aspiration syndrome, which may partially 
explain our observation with MSAF. Despite a pathogen not always being isolated, 
intrauterine and neonatal infections appear to contribute to a significant proportion of 
perinatal deaths.  
 
Intrapartum antibiotic exposure has been established to be effective at preventing 
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GBS-VEOD, however, is ineffective at reducing GBS-LOD and early-onset E. coli 
sepsis111, 259. The lack of a protective effect of IAP against neonatal sepsis and death 
during the perinatal period in our setting observed on multivariable analysis is 
consistent with other studies which assessed all-cause neonatal sepsis and similarly 
found no impact of IAP253.  
 
Challenges with identification of features of chorioamnionitis in a busy, regularly 
under-staffed labour ward has been highlighted by our observations that only half of 
women in preterm labour and 10% of women with at least one sign of 
chorioamnionitis received adequate risk-based IAP prior to delivery. Even in HIC 
settings, reduction of GBS-VEOD by risk based strategies was lower with culture-
based GBS screening strategies203. 
 
Several limitations were present in our analysis.  Despite using a clinical sepsis 
definition which was more rigorous than that used in previous studies, the non-
specific signs and symptoms present in neonatal sepsis reduced the specificity of the 
definition and other conditions including birth asphyxia may have been misclassified 
as sepsis. Additionally, despite our large sample size (>8000 mother-baby dyads), 
the sample size for some endpoints, including late onset disease and culture-
confirmed sepsis, was small, therefore limiting our ability to evaluate some variables 
for associations.  Most importantly, however, our trial participants differed from the 
overall CHBAH birth cohort. Trial enrolment practices restricted the number of 
preterm births on the trial compared to CHBAH births. Additionally, the population 
delivering at CHBAH had more high-risk deliveries than in the community clinics in 
Soweto, leading to these deliveries being over-represented in our trial cohort. Despite 
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this, adequate preterm, low birthweight and very low birthweight infants were 
included in the trial cohort to allow us identify these factors as significant risks for the 
endpoints under consideration.  Additionally CHBAH births capture 75% of all births 
in Soweto, so despite them not being representative of the full population, they 
capture a large portion. Moreover, the over-representation of high risk maternal 
conditions was considered a benefit to evaluate whether or not these conditions were 
associated with increased risk of sepsis or perinatal death.  
 
Most previous sepsis risk-factor analyses have been conducted in HICs and have 
focused on pathogen-specific endpoints. Few previous studies in LMICs have had a 
robust comparison group for formal risk factor assessment. Despite the South African 
Soweto population being wealthier and having better access to facility-based 
deliveries and maternity and neonatal care than many other settings in sub-Saharan 
Africa, these features also facilitated a rigorous evaluation of prenatal, intrapartum 
and demographic risk factors in an urban African setting with high maternal HIV 
prevalence.  
 
The difficulties demonstrated of implementing a risk-based IAP strategy in a busy 
labour ward in a LMIC and the failure of IAP to prevent all-cause neonatal sepsis 
prevention highlights the challenges of neonatal sepsis prevention in LMICs. 
Primiparity and MSAF are easily-identifiable risk factors for neonatal sepsis and 
death and further exploration of the mechanisms behind the association noted is 
warranted. Additionally, promising antenatal strategies aimed at preventing neonatal 
sepsis, including maternal immunisation need to be investigated.  
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5. MATERNAL HIV INFECTION AND VERTICAL TRANSMISSION OF 
PATHOGENIC BACTERIA  
 
Vertical transmission of potentially pathogenic bacteria from a colonised mother to 
her infant is a pre-requisite for vertically- acquired bacterial sepsis in neonates, 
therefore a clear understanding of the burden of maternal colonisation and timing and 
risk factors for vertical transmission is essential to assist in reducing neonatal sepsis.  
 
There is a paucity of data on the impact of maternal HIV exposure on clinical- or 
pathogen-specific burden of neonatal sepsis249.  Aberrations of the immune system in 
HIV-infected women may lead to reduced transplacental transfer of antibodies to the 
foetus in-utero260, 261 thereby potentially increasing neonatal susceptibility to sepsis. 
HIV infection has not been associated with differences in the prevalence of GBS 
vaginal colonisation compared to HIV-uninfected women262.  
 
HIV-infection in childhood led to a reversal of decades of improvement in child 
survival263. PMTCT programs have been successfully implemented in many 
countries, including South Africa, and under-5 childhood mortality rates have 
reduced, however, HIV-exposed uninfected infants and children have significantly 
higher morbidity and mortality than HIV-unexposed infants and children. This effect is 
related to poorer maternal health including a compromised immunological status, 
increased maternal mortality and early weaning of HIV-exposed infants264-268.    
 
In this chapter, the impact of maternal HIV infection on: (i) the prevalence of maternal 
vaginal colonisation with pathogens associated with neonatal sepsis; (ii) vertical 
transmission of bacterial pathogens to the newborn; and (iii) sepsis rates during the 
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very early (0-2 days) and late neonatal (3-27 days) periods is described (published 
paper attached: Appendix 5).   
 
5.1. Statistical considerations 
 
Propensity score matching was used to reduce bias with respect to important 
covariates for each defined endpoint and was used to evaluate maternal HIV 
infection as a risk factor for neonatal sepsis269,270.  We chose propensity score 
matching because covariates considered key to endpoints under consideration 
differed between HIV-infected and HIV-uninfected women. Standard modeling 
approaches provide estimates even in the absence of an appropriate comparison 
population.   
 
For maternal colonisation, the following covariates were considered:  
• Maternal age categorized as either >25 years of ≤ 25 years 
• Rupture of membranes (ROM) prior to swab collection and  
• Antibiotic use in week before delivery 
 
For vertical transmission, the following covariates were considered:  
• prolonged ROM (>18 hours),  
• antibiotic use in the week preceding labour or intrapartum antibiotic 
administration 
• number of per vaginal examinations performed during labour 
 
115 
 
For early- and late onset neonatal sepsis, the following covariates were considered: 
• mode of delivery,  
• gestational age at delivery,  
• prolonged rupture of membranes,  
• maternal fever ≥38.0ºC,  
• intrapartum antibiotic use,  
• known maternal GBS colonisation and 
•  urinary tract infections (UTIs).   
 
Multivariable logistic regression was used to estimate the propensity score for each 
mother or infant (as appropriate). The propensity score is the conditional probability 
of the mother being HIV-infected given the variables in the model. Each HIV-infected 
maternal participant was matched to an HIV-uninfected maternal participant with the 
closest propensity score. Balance for each covariate included in the relevant 
propensity score model was evaluated for HIV-infected and HIV-uninfected maternal 
participants and the model that achieved the best balance was used.  
 
The model for maternal colonisation was limited to mothers with known HIV-infection 
status included in the colonisation cohort for whom a swab result was known. The 
vertical transmission model was limited to mothers colonised with GBS, E. coli or K. 
pneumoniae, who had a known HIV-infection status, delivered vaginally, and whose 
newborn had a microbiologic swab with a result.  
 
For the VEOD and LOD sepsis endpoints, two additional comparison groups were 
considered: HIV-unexposed, uninfected (HUU) versus HIV-exposed, uninfected 
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(HEU) neonates; and HEU versus HIV-infected neonates. Propensity score models 
were constructed as above, with the appropriate outcome variable for the 
comparison, balancing on the variables listed above for VEOD and LOD.  
 
As CD4+ cell count results were only available for 34.7% (725/2090) of HIV-infected 
women, maternal CD4+ cell count was not included as a covariate.  
 
An unadjusted analysis on the total cohort was conducted to understand the 
influence of covariates associated with HIV exposure or infection status on the 
endpoints evaluated. 
Proportions were compared using Chi-square tests and relative risks and 95% 
confidence intervals were used to assess HIV as a risk factor. The denominator for 
incidence was per 1000 births. SAS version 9·1 was used for analyses.  
 
5.2. Results 
 
The HIV infection results were available for 98.5% (7894/8011) of maternal 
participants, 26.5% (2090/ 7894) of whom were HIV-infected. CD4+ results were only 
available for 34.7% (725/2090) HIV-infected mothers, the majority of whom (64.4%; 
467/725) were enrolled between June 2006 and October 2007. Of these women, just 
over half (50.8%; 368/725) had a CD4+ count of >350 cells/ mm3, 27.4% (199/725) 
had CD4+ count between 200 and 350 cells/mm3 and 21.8% (158/725) had CD4+ 
counts <200 cells/mm3. According to national guidelines, antiretroviral treatment to 
prevent mother-to-child transmission of HIV was single-dose of nevirapine (sd-NVP) 
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to mother at onset of labour and to newborn infants until 2007, when triple 
antiretroviral therapy including stavudine, lamivudine and nevirapine was offered 
from 34 weeks gestation. Of the 2090 HIV-infected women enrolled in PoPS trial, 
92.3% (1929/2090) received PMTCT medication. Most (97.6%, 1882/1929) HIV-
infected women received sd-NVP and 2.4% (46/1929) received triple antiretroviral 
therapy which was initiated a mean of 151 (range 1 to 1095) days prior to delivery. 
There were 2130 HIV-exposed infants born to 2090 HIV-infected mothers.  
 
HIV-infected – and HIV-uninfected maternal participants had several significantly 
different baseline demographic and clinical characteristics noted. HIV-infected 
women were older (p<0.0001), more likely to have urinary tract infections (13% vs. 
10%, p<0.0001), anaemia (hemoglobin <10 mg/dl, 13% vs. 7%, p<0.0001), 
tuberculosis (1.5% vs. 0.2%, p<0.0001), received antibiotics  before labour-onset 
(30% vs. 21%, p<0.0001) and received antibiotics during labour (12% vs. 10% for 
women with vaginal delivery, p<0.0001) than HIV uninfected women (Table 18). 
Although maternal fever was uncommon (0.2% overall), HIV-infected women were 
significantly more likely to have fever recorded than HIV-uninfected women (0.7% vs. 
0.05%, p<0.0001). HIV-infected women also had higher frequencies of non-elective 
caesarian sections (26% vs. 23%, p=0.006); and preterm deliveries (5.9% vs. 3.1%, 
p<0.0001) than HIV-uninfected women. The median birth weight of HIV-exposed 
newborns was significantly lower than HIV-unexposed newborns (3050 grams vs. 
3160 grams; p<0.0001) (Table 18).   
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Table 18 Maternal and newborn demographic and clinical characteristics 
stratified by maternal HIV status230 
 
 
1 Includes mode of delivery for all singletons and first-born twins only 
2 Note: Term infants: 7811 overall; 5701 HIV unexposed infants, 2005 HIV exposed infants 
 
 
 
Characteristic Overall HIV uninfected 
mothers n(%) 
HIV infected 
mothers n(%) 
p-value 
Mothers N=8011 n=5812 n=2090  
Median age in years (range)  26 (12-51) 26 (12-49) 27 (14-51) <0.0001 
Median parity (range) 1 (0-9) 1 (0-9) 1 (0-7) <0.0001 
Median gravidity (range)  2 (1-10) 2 (1-10) 2 (1-8) <0.0001 
Median gestational age (range) 39 (23-44) 39 (24-44) 39 (23-44)  
Medical history (%)      
          Urinary tract infection 854 (11) 573 (10) 275 (13) <0.0001 
           Haemoglobin <10 mg/dl 692 (9) 420 (7) 264 (13) <0.0001 
          Gestational diabetes 20 (0.2) 17 (0.3) 3 (0.1) 0.25 
          Maternal tuberculosis 42 (0.5) 10 (0.2) 32 (1.5) <0.0001 
Received antibiotics during 
pregnancy (%)  
1856 (23) 1218 (21) 617 (30) <0.0001 
Intrapartum antibiotics (IAs) in 
women with vaginal delivery. (% of 
IAs) 
629/6137  436/4494 (10) 189/1554 (12) 0.006 
Antibiotics in 7 days prior to delivery 475 (6) 318 (5) 152 (7) 0.48 
Intrapartum fever (%)  17 (0.2) 3 (0.05) 14 (0.7) <0.0001 
Prolonged rupture of membranes of 
> 18 hours at delivery (%)  
710 (9) 525 (9) 178 (9) 0.48 
Unbooked/No prenatal care (%)  11 (0.1) 6 (0.1) 3 (0.1) 0.64 
Meconium stained liquor (%)  1200 (15) 925 (16) 256 (12) <0.0001 
Delivery (%) 1     
         Spontaneous vaginal delivery 6136 (77) 4494 (77) 1554 (74) 0.007 
          Emergency caesarian section 1874 (23) 1318 (23) 536 (26) 0.006 
          Vaginal vacuum/Forceps     165 (2) 116 (2) 49 (2) 0.31 
Number of per vaginal exams during 
labour 
    
<3 3020 2213 (38) 760 (36) 0.17 
≥3 4991 3599 (62) 1330 (64)  
     
Newborn characteristics n= 8129 n= 5886 n= 2130  
Female gender 3873 (47) 2796 (48) 1028 (48) 0.57 
Twin birth (%) 118 (1) 74 (1) 40 (2) 0.038 
Pre-term2 313 (4) 181 (3) 124 (6) <0.0001 
Median birth weight (range) (grams) 3130 (480-
5630) 
3160 (670-5630) 3050 (480-4690) <0.0001 
Median Apgar 5 mins (range) 10 (0-10) 10 (0-10) 10 (0-10) 0.27 
Outcome     
  Stillborn 26 (<0) 19 (<0) 7 (<0) 0.97 
  Died shortly 
  after delivery 
15 (<0) 12 (<0) 3 (<0) 0.56 
  Surviving newborn admitted to   
  neonatal ward 
788 (10) 578 (10) 210 (10) 0.80 
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As per routine standard of care, infant HIV PCR testing was undertaken at a median 
of 42 days of age (1- 347 days). HIV PCR results were only collected by study staff 
for 64.2% (1367/2130) of HIV-exposed infants, of whom 8.2% (112/1367) were HIV-
infected. Chlorhexidine interventional wipes had no impact on vertical transmission 
rate of HIV (65/713 [9.1%] vs. 47/654 [7.2%] PCR positive in chlorhexidine vs. control 
arms, p=0.19). HIV-infected infants had a lower birth weight (median 2995 vs. 3100 
grams; p=0.001), lower median gestational age (38 vs. 39 weeks; p=0.005), and 
higher frequency of exposure to meconium stained liquor (21% vs. 11%; p=0.002) 
during labour than HIV-exposed uninfected infants.  
 
5.2.1. Vaginal colonisation and vertical transmission of genital-tract 
bacteria 
 
A total of 5146 women were enrolled onto the colonisation cohort, 99.1% 
(5099/5146) of whom had known HIV-infections status. There were 3752 HIV-
uninfected and 1347 HIV-infected women on the colonisation cohort. All but one of 
the HIV-infected women on the colonisation cohort were included in the matched 
subset analysis for assessment of vaginal colonisation (1346 HIV-uninfected and 
1346 HIV-infected women). In the total cohort, HIV-uninfected women were more 
likely to be colonised with GBS than HIV-infected women (22.0% vs. 17.1%, 
p=0.0002), however HIV-uninfected women were less likely to be colonised with E. 
coli (43% vs. 47%, p=0.0385) than HIV-infected women. There was no difference in 
colonisation with K. pneumoniae (8% vs. 7%, p=0.2189) between HIV-uninfected and 
HIV-infected women in total cohort (Table 19). 
 
120 
 
In the matched analysis, HIV-uninfected women were more likely to be colonised with 
GBS (23% vs. 17%, p=0.0002) and K. pneumoniae (10% vs. 7%, p=0.008) than HIV-
infected women. The difference seen in E. coli colonisation in total cohort was not 
observed in the matched analysis (45% vs 47%, p=0.37) (Table 19).   
Vertical transmission of GBS and K. pneumoniae was not affected by HIV-exposure 
status of the infant. The rate of vertical transmission of E. coli was, however, higher in 
HIV-exposed than HIV-unexposed neonates in the total cohort (60% vs. 53%; 
p=0.0066) and matched-subset (60% vs. 52%, p=0.015) populations (table 20).  
 
 
Table 19 Prevalence of bacterial vaginal colonisation in HIV-infected and –
uninfected women during labour.230 
 
 Total colonisation cohort Matched subset 
 HIV negative 
n=3752 
n (%) 
HIV positive 
n=1347 
n (%) 
p-value HIV negative 
n=1346  
n (%) 
HIV positive 
n=1346 
n (%) 
p-value 
Group B streptococcus (GBS) 
GBS colonised 
mothers (total) 
824 (22) 231 (17) 0.0002 307 (23) 230 (17) 0.0002 
Escherichia Coli (E.coli)  
E. coli colonised 
mothers (total) 
1624 (43) 677 (47) 0.0385 603 (45) 626 (47) 0.37 
Klebsiella pneumoniae (K. pneumoniae) 
K pneumoniae 
colonised 
mothers (total)  
301 (8) 94 (7) 0.2189 132 (10) 94 (7) 0.008 
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Table 20: Vertical transmission of pathogenic bacteria from mother to 
newborn stratified by maternal HIV-infection status230. 
 Total colonisation cohort Matched subset 
 HIV negative 
n (%) 
HIV positive 
n (%) 
p-value HIV negative 
n (%) 
HIV positive 
n (%) 
p-value 
Group B streptococcus (GBS) 
Total number 
infants born 
vaginally to GBS 
colonised 
mother. 
648 181  177 177  
GBS colonised 
vaginally born 
newborn1 
372/641 (58) 93/179 (52) 0.1467 94/174 (54) 90/175 (51) 0.63 
Escherichia coli (E. coli)  
Total number 
infants born 
vaginally to 
E.coli colonised 
mother. 
1277 460  449 449  
E. coli colonised, 
vaginally born 
newborn 
665 (53) 269 (60) 0.0066 232 (52) 263 (60) 0.015 
Klebsiella pneumoniae (K. pneumoniae)  
Total number 
infants born 
vaginally to K. 
pneumoniae 
colonised 
mother.  
241 73  69 69  
 
K. pneumoniae 
colonised, 
vaginally born 
newborn2 
74 (31) 20 (27) 0.5887 20 (29) 19 (27) 0.85 
1Nine infants born vaginally to GBS colonised mothers did not have swab collected/ processed for 
GBS: 7 HIV unexposed and 2 HIV exposed infants. 2 One infant born to an HIV-uninfected mother 
colonised by K pneumoniae did not have swab processed. 
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5.2.2. Maternal HIV-infection status and sepsis within three days of age 
(VEOD) 
 
Of the 8129 infants born to enrolled mothers, 26 were stillborn and 3.6% (290/8103) 
of the live-born infants were hospitalised for sepsis within the first three days of life. 
The majority of these infants (89.0%, 258/290) had clinical sepsis, 29 had culture-
confirmed sepsis, and 3 early neonatal deaths (<3 days of age) which did not fulfill 
the clinical sepsis definition were included after review by neonatal panelists. 
 
HIV-exposure did not affect the incidence of clinical or overall early-onset disease in 
the total cohort or matched sub-set analysis. The incidence of culture-confirmed 
early-onset disease was, however, 3.3 fold greater among HIV exposed- compared 
to HIV-unexposed infants in the matched analysis (p=0.05), and 1.67 fold increased 
in the total-cohort analysis (p=0.167; Table 21).  The incidence of VEOD (per 1000 
births) in HIV-exposed infants born to mothers with known CD4+ results was 
inversely associated with the immunological status of the mother (CD4+ 
cells/mm3<200: 75.9; 200 to 350: 40.2; >350:19.0; p=0.0065, trend is linear).   
 
The incidence (per 1000 births) of clinically-confirmed early-onset sepsis in HIV-
infected newborns (102) was significantly higher than in HIV-exposed, PCR-negative 
newborns (20.4, p=0.033) in the matched subset analysis and in the total cohort 
analysis (116 vs. 17.6; p<0.0001; table 22). HIV-exposed, uninfected newborns had a 
significantly lower incidence of early onset disease (20.6) than HIV-unexposed 
newborns (33.7; p=0.046) in the matched subset analysis and in the total cohort 
analysis (21.5 vs. 38.0; p=0.004, table 23). Culture-confirmed early-onset disease 
was unaffected by HIV-exposure in HIV-uninfected newborns in the matched-subset 
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and total-cohort analysis (Table 23).  
 
5.2.3. Maternal HIV-infection status and neonatal sepsis between days 4 
and 28 (LOD) 
 
The incidence of LOD was unaffected by HIV-exposure in the matched subset 
analysis and total cohort analysis (table 21). HIV-infected neonates had a higher 
incidence of overall LOD (26.8) than HIV-exposed, PCR-negative neonates (5.6; 
p=0.042) neonates in the total-cohort, with a similar trend observed in the matched 
analysis (30.6 vs. 10.2; p=0.62, table 22). HIV-exposure did not affect the incidence 
of LOD in HIV-uninfected infants in the matched or total-cohort analysis (table 23).  
 
The incidence of LOD was inversely associated with maternal immunological status 
(CD4+ <200 cells/mm3: 19.0; 200 to 350 cells/mm3: 10.0; and >350 cells/mm3: 8.1; 
p=0.55).     
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Table 21 Impact of in-utero HIV exposure on incidence of very early- (within 3 days) and late-onset (between 4 and 28 days 
of age) neonatal sepsis  
 
 TOTAL MATCHED SUBSET 
VERY EARLY 
ONSET DISEASE 
(VEOD) 
Total 
n=8129  
n (rate;  
95% CI) 
HIV unexposed 
n=5886 
 (rate; 95% CI) 
HIV exposed 
n=2130  
(rate; 95% CI) 
P-value 
(HIV 
unexposed 
vs. HIV 
exposed ) 
HIV 
unexposed 
n=2054  
n (rate) 
HIV 
exposed 
n=2054  
n (rate) 
P-value 
(HIV unexposed 
vs. HIV exposed 
) 
Culture-confirmed 
sepsis 
29 (3.6; 
2.4, 5.1) 
18  
(3.1; 1.8, 4.8) 
11 (5.2; 
2.6, 9.2) 
0.165 3 (1.5;  
0.3, 4.3) 
10 (4.9;  
2.3, 8.9) 
0.05 
Group B 
streptococcus 
(GBS) 
16 (2.0;  
1.1, 3.2) 
12 (2.0; 
1.0, 3.6) 
4 (1.9; 
0.5, 4.8) 
 2 (1.0;  
0.1, 3.5) 
4 (1.9;  
0.5, 5.0) 
 
Escherichia coli 2 (0.2; 
0.03, 0.9) 
0 
(0, 0.63) 
2 (0.9; 
0.1, 3.4) 
  
0 
1 (0.5)  
     
Staphylococcus 
aureus 
2 (0.2; 
0.03, 0.9) 
1 (0.2,  
(0.004, 0.9) 
1 (0.5; 
0.01, 2.6) 
  
0 
1 (0.5;  
0.0, 2.7) 
 
 Klebsiella 
pneumoniae 
1 (0.1; 
0.0003, 0.7) 
0 
(0, 0.63) 
1 (0.5; 
0.01, 2.6) 
  
0 
1 (0.5;  
0.0, 2.7) 
 
Other 8 (1.0; 
0.4, 1.9) 
5a (0.8;  
0.3, 2.0) 
3b (1.4; 
0.3, 4.1) 
 3 (1.5;  
0.3, 4.3) 
3 (1.5;  
0.3, 4.3) 
 
Clinical sepsis only 258(31.7; 28.0, 
35.8) 
202 (34.3;  
29.8, 39.3) 
55 (25.8; 
19.5,33.5) 
0.056 57 (27.8;  
21.1, 35.8) 
51 (24.8; 
18.5,32.5) 
0.56 
Deaths within 3 
days of agec 
3 (0.4; 
0.1, 1.1) 
3 (0.5; 
0.1, 1.5) 
0 
(0, 1.7) 
0.570 1 (0.5;  
0.0, 2.7) 
0 (0.0;  
0.0, 1.8) 
1.000 (Exact) 
 
Overall  
290 (35.7; 
31.7,39.9) 
223 (37.9; 
33.2, 43.1) 
66 (31.0; 
24.0,39.3) 
0.117 61 (29.7; 22.8, 
38.0) 
61 (29.7; 
22.8,38.0) 
1.000 
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LATE ONSET 
DISEASE (LOD) 
       
Culture-
confirmed (CC) 
cases 
20 (2.5;  
1.5, 3.8) 
12 (2.0;  
1.1, 3.6) 
7 (3.3; 
1.3, 6.8) 
0.310 3 (1.5; 0.3, 
4.3) 
6 (2.9; 1.1, 
6.3) 
0.51(EXACT) 
    Group B 
streptococcus 
5d (0.6; 
0.2, 1.4) 
3 (0.5; 
0.1, 1.5) 
1 (0.5; 
0.01, 2.6) 
    
      Escherichia 
coli 
8 (1.0;  
0.4, 1.9) 
6 (1.0; 
0.4, 2.2) 
2e (0.9; 
0.1, 3.4 
    
     
Staphylococcus 
aureus (S. 
aureus) 
2 (0.2,  
0.03, 0.9) 
2 (0.3;  
0.04, 1.2) 
0 
(0, 1.7) 
    
     Klebsiella spp. 2 (0.2; 
0.03, 0.9) 
0 
(0, 0.63) 
2f (0.9; 
0.1, 3.4) 
    
     Other 3 (0.4;  
0.1, 1.1) 
1g (0.2;  
0.004, 0.9) 
2h (0.9; 
0.1, 3.4) 
    
Clinical sepsis only 14 (1.7; 
 0.9, 2.9) 
8 (1.4;  
0.6, 2.7) 
6 (2.8; 
1.0, 6.1) 
0.167  
4 (1.9;  
0.5, 5.0) 
7 (3.4; 1.4, 
7.0) 
0.37 
Overall  34 (4.82; 
 2.9, 5.8) 
20 (3.4; 
2.1, 5.2) 
13 (6.1; 
3.3, 10.4) 
0.095  
7 (3.4; 1.4, 
7.0) 
13 (6.3; 3.4, 
10.8) 
0.18 
a Enterococcus faecalis (x3), Acinetobacter baumanii x2;  
b Streptococcus viridans (x2), Acinetobacter lwoffii. 
c Early deaths (<3 days) which did not fulfill EOD-CC or EOD-Clinical sepsis definitions, but included as EOD after panel review 
d One case of LOD GBS with unknown HIV result 
e One case co-infected with S. aureus 
f One co-infected with S. aureus, one with Enterococcus faecium 
g  Streptococcus species 
h  Enterococcus faecalis x 2 cases 
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Table 22 Incidence of very early and late onset sepsis in HIV exposed HIV-infected (HIV+) and HIV exposed 
uninfected (HEU) neonates. 
 
 Sepsis 
categorization 
TOTAL infants with HIV PCR results MATCHED SUBSET 
  HIV+ 
n=112 
n (rate; 95% 
CI) 
HEU 
n=1253 
n (rate; 95% CI) 
P-value 
 
HIV+ 
n= 98 
n (rate; 95% 
CI) 
HEU 
n=98 
n (rate; 95% CI) 
P-value 
 
 
 
Very  
EARLY 
ONSET 
SEPSIS 
Culture-confirmed  2 (17.9;  
2.2, 63.0) 
5 (4.0;  
1.3, 9.3) 
0.107 0 (0; 0, 36.9) 1 (10.2, 0.3, 55.5) 1.00 
Clinical sepsis only 13 (116; 
63.3,190.3) 
22 (17.6; 
11.0, 26.5) 
<0.0001 10(102.0, 
50.0,179.7) 
2 (20.4,  
2.5, 71.8) 
0.033  
Overall  15 (134; 
76.9, 211.3) 
27 (21.5; 
14.2, 31.2) 
<0.0001 10 (102.0; 
50.0,179.7) 
3 (30.6, 6.4, 86.9) 0.08 
        
 
 
 
LATE ONSET 
SEPSIS 
Culture-confirmed  2 (17.9; 2.2, 
63.0) 
5 (4.0;  
1.3, 9.3) 
0.107 2 (20.4; 2.5, 
71.8) 
0 (0; 0, 36.9) 0.50 
 
Clinical sepsis only 
1 (8.9; 
0.2, 48.7) 
2 (1.6; 
 0.2, 5.8) 
0.227 1 (10.2; 0.3, 
55.5) 
1 (10.2;  
0.3, 55.5) 
1.00 
Overall  3 (26.8; 
 5.6, 76.3) 
7 (5.6;  
2.2, 11.5) 
0.042 3 (30.6; 6.4, 
86.9) 
1 (10.2;  
0.3, 55.5) 
0.62 
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Table 23 Impact of maternal HIV infection on very early and late onset neonatal 
sepsis in HIV-exposed, uninfected (HEU) and HIV-unexposed, uninfected (HUU) 
neonates.  
 
 Sepsis 
categorization 
TOTAL HIV uninfected infants MATCHED SUBSET 
  HUU 
n=5867 
n (rate; 
95% CI) 
HEU 
n=1253 
n (rate; 95% 
CI) 
P-value 
 
HUU 
n=1216 
n (rate; 
95% CI) 
HEU 
n= 1216 
n (rate; 
95% CI) 
P-value 
 
 
 
VERY 
EARLY 
ONSET 
SEPSIS  
Culture-
confirmed  
21 (3.6; 
2.2, 5.5) 
5 (4.0;  
1.3, 9.3) 
0.797 4 (3.3; 0.9, 
8.4) 
4 (3.3; 0.9, 
8.4) 
1.000 
Clinical sepsis 
only 
202 (34.4; 
30.0, 39.4) 
22 (17.6; 
11.0, 26.5) 
0.002 37 (30.4; 
21.5, 41.7) 
21 (17.3; 
10.7, 26.3) 
0.034 
Overall  223 (38.0; 
33.3, 43.2) 
27 (21.5; 
14.2, 31.2) 
0.004 41 (33.7; 
24.3, 45.5) 
25 (20.6; 
13.3, 30.2) 
0.0459 
        
 
 
 
LATE 
ONSET 
SEPSIS 
Culture-
confirmed  
12 (2.0; 
1.1, 3.6) 
5 (4.0;  
1.3, 9.3) 
0.203 3 (2.5; 0.5, 
7.2) 
5 (4.1; 1.3, 
9.6) 
0.726 
Clinical sepsis 
only 
8 (1.4; 
0.6, 2.7) 
2 (1.6; 
0.2, 5.8) 
0.692 2 (1.6; 0.2, 
5.9) 
2 (1.6; 0.2, 
5.9) 
1.000 
 
Overall  
20 (3.4; 
2.1, 5.3) 
7 (5.6; 2.2, 
11.5) 
0.306 5 (4.1; 1.3, 
9.6) 
7 (5.8; 2.3, 
11.8) 
0.563 
  
Very early onset sepsis:  0-2 days 
Late onset sepsis: 3-<28 days 
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5.3. Discussion 
 
To our knowledge, this was the first study to have reported on the impact of maternal 
HIV infection on vertical transmission of potentially pathogenic bacteria to newborns, 
and on the relative incidence of clinical- and culture-confirmed early-onset and late-
onset disease between HIV-exposed and HIV-unexposed neonates. During the 
conduct of this trial, the maternal HIV prevalence was 29%, and antiretroviral therapy 
to prevent mother- to child transmission of HIV offered as part of routine care was 
changed in latter part of the trial from single dose nevirapine to triple therapy. HEU 
neonates have been thought to be at higher risk of developing neonatal sepsis due to 
impaired maternal transfer of antibody260, data from this study do not corroborate this 
speculation. On the contrary, VEOD rates were marginally lower in HEU than HUU in 
the total cohort and matched subset analysis; and no difference was observed for 
LOD rates between these groups.  
 
Overall 20.7% (1055/5099) of women with known HIV results enrolled on to the 
colonisation cohort were colonised vaginally with GBS at the time of labour. This 
GBS colonisation rate observed in this trial are in line with what has been reported 
from other countries during the third trimester of pregnancy (10-30%)191, 271, 272. 
 
A study from Malawi reported a non-significantly lower rate of GBS colonisation in 
HIV-infected- versus HIV-uninfected pregnant women (19.4% vs. 21.7%, p=0.32)262. 
HIV-infected women with CD4+ counts >500cells/mm3 did, however, have a 
significantly higher GBS colonisation rate than HIV-infected women with CD4+ 
counts <200cells/mm3. (AOR 2.55; 95% CI: 1.10-5.90). Co-trimoxazole use was 
129 
 
dismissed as a confounding variable for differences in colonisation observed 
between HIV-infected women with high and low CD4+ counts262. Our observation of 
higher GBS colonisation in HIV-uninfected women than HIV-infected women in both 
matched and total cohorts may be indicative of differences in characteristics not 
controlled for in the propensity score analysis which may have reduced GBS 
colonisation in HIV-infected women, for example antibiotic use earlier in pregnancy. 
On the whole, rates of maternal colonisation and vertical transmission for leading 
sepsis pathogens did not differ considerably between HIV-infected and HIV-
uninfected pregnant women.  
 
 
The number of culture-confirmed VEOD cases in this cohort was small, which limited 
our power to detect a difference in this endpoint. A marginal trend showing increased 
risk of culture-confirmed early-onset sepsis in HIV-exposed compared to HIV-
unexposed neonates was observed. Surveillance of a larger cohort of culture-
confirmed sepsis cases was conducted in Soweto during the time period when the 
PoPS trial was being conducted and the results have been described in chapter 3 
(overall sepsis) and chapter 6 (GBS) of this thesis. Although CD4+ testing of 
participants on the PoPS study was limited, we did note that HIV exposed neonates 
born to severely immunocompromised mothers (CD4+ <200 cells/mm3) were at 
higher risk of developing VEOD and LOD than those born to mothers with CD4+ 
>350 cells/mm3. Additionally, in the total cohort, there was an increased risk of VEOD 
and LOD in HIV-infected neonates compared to HIV-exposed, uninfected neonates, 
with a similar trend noted in the matched analysis, emphasizing the requirement to 
further reduce mother-to child transmission of HIV.    
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The clinical sepsis endpoint has lower specificity than a culture-confirmed sepsis 
endpoint.  
 
Several other studies have reported an increase in morbidity and mortality in HIV-
exposed infants, including during early infancy268, 273, which contrasts with our 
results. Almost 30% of deaths in African infants occur during the first 2 months of life 
266. HIV-infected infants have a very high mortality rate of 309.1 to 420.8 per 1000, 
compared to HIV-exposed, uninfected (72.5 to 98.7/1000) and HIV-unexposed (48.0 
to 91.0/ 1000)266, 265. Disease progression in African HIV-infected infants is rapid, 
with 85% of HIV-infected infants progressing to AIDS by the age of 6 months274.  
 
Our observation that some risk factors commonly associated with VEOD, including 
UTIs and prolonged ROM, were more prevalent in HIV-infected women, highlights 
the importance of adjusting for maternal factors when assessing the association 
between maternal HIV-infection and neonatal sepsis.  
 
Our use of propensity score methods, which allowed us to select an appropriate 
referent group with similar risk factors for each outcome evaluated, while still 
remaining blinded, was a strength of the study. When the conclusions obtained from 
analysis of the entire cohort differed from the matched subset, we believe that the 
matched subset analysis offers the most valid comparison between the groups with 
regard to whether maternal-infection status, newborn HIV-exposure-  or HIV-infection 
status is responsible for the differences between groups in the applicable 
comparisons. The differences between the overall cohort and matched subset 
analyses highlights the dangers of drawing conclusions about the impact of HIV 
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exposure on neonatal morbidity (or mortality) without appropriately adjusting for other 
factors.  
 
There were several limitations to our study. Due to standard of care practices in 
antenatal clinics at the time that our study was conducted, CD4+ counts were only 
available for 34.7% of HIV-infected women. Additionally, HIV-PCR testing of HIV-
exposed infants was performed at well-baby clinics in Soweto at 6 weeks of age. The 
study protocol included follow up to 4 weeks of age only, and contact with some 
maternal participants was not successful after the neonatal period. HIV-PCR results 
were only available for 64% of HIV-exposed infants. What is reassuring, however, is 
that HIV-exposed infants with and without HIV-PCR results were similar for many 
demographic and delivery variables. Vertical HIV transmission, which was not 
impacted by chlorhexidine interventional wipes229, was 8.2% in trial participants, 
which is similar to what was reported in other settings (10.3%)274 which utilized the 
same PMTCT regimen (single dose Nevirapine to mother and newborn).  
 
Our trial enrollment procedures and inclusion and exclusion criteria skewed 
enrollment away from inclusion of preterm infants on the PoPS trial (4% in PoPS vs. 
15% in CHBAH) (Personal communication: SC Velaphi). Prematurity is a recognized 
risk factor for neonatal sepsis, and our trial may have under-estimated the true rates 
in our setting. Nevertheless, a review by Thaver et al24, reported the incidence of 
clinical sepsis in infants less than 60 days of age in developing countries to be 49 to 
170 per 1 000 and 5.5/1000 for culture-confirmed sepsis. Although the incidence of 
neonatal sepsis observed in our study was close to the lower bound of this incidence 
for clinical sepsis (33.4 per 1000), we report a similar incidence of culture-confirmed 
sepsis (5.9 per 1000). The lower incidence of clinical sepsis rates in our study may 
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have been impacted by more stringent criteria used in our study for diagnosing 
“clinical sepsis”.  
 
In conclusion, reducing neonatal morbidity and mortality has been identified as a key 
focus area for public health under MDG4 which aimed to reduce under-5 mortality by 
two-thirds compared to 1990 levels275. Whilst there was a high incidence of neonatal 
sepsis in our study population, including among the highest reported incidence rates 
of invasive GBS sepsis from any LMIC, HIV-exposure does not appear to increase 
the risk of either very early- or late-onset neonatal sepsis, except among HIV-infected 
newborns and possibly among newborns of severely immunocompromised mothers. 
Consequently, we do not predict the HIV prevention roll-out in sub-Saharan Africa will 
result in important reductions in neonatal sepsis in this region, and sepsis specific 
interventions such as GBS vaccines may hold most promise in reducing neonatal 
infection-associated mortality. 
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6. GROUP B STREPTOCOCCUS SEPSIS IN YOUNG SOUTH AFRICAN 
INFANTS 
 
In 2012, almost 10% of possible severe bacterial infection in neonates globally were 
fatal, leading to an estimated 680 000 neonatal deaths129. There is a paucity of data 
on pathogen-specific causes of neonatal sepsis from low-middle income countries 
(particularly during the first day of life) and whether maternal HIV-exposure increases 
susceptibility to severe neonatal bacterial infections.  
 
The global incidence of Group B Streptococcus (GBS) was 0.53/ 1000 live births for 
2000 to 2011, making GBS a leading cause of sepsis. A meta-analysis of data mainly 
from high-income countries demonstrated marked inter- and intra-regional variation in 
the incidence of EOD (within 7 days of birth) ranging from 1.21 (95% CI: 0.5-1.91) in 
Africa to 0.02 (95% CI: 0-0.07) in South-East Asia77. Maternal GBS colonisation is a 
major risk factor for EOD, with maternal GBS colonisation prevalence varying from 
13.4% in South-East Asia to 20.9% in Africa276. Vertical transmission of GBS 
colonisation has been reported as approximately 50% from many countries including 
thee USA48, Turkey277 and Pakistan278  but lower transmission rates (38.7%) has been 
reported from Tanzania279 and higher vertical transmission rate (61%) has been 
reported from Sweden280. The marked variability of GBS- EOD is inconsistent with the 
smaller difference noted in maternal colonisation prevalence and vertical transmission. 
Maternal HIV-infection has not been associated with higher prevalence of  GBS 
colonisation229, 262 except among women with CD4+ lymphocyte >500 cells/mm3 262.   
 
The development of a trivalent GBS polysaccharide-protein conjugate vaccine (GBS-
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CV) targeted at pregnant women, aims to enhance transplacental transfer of capsular 
antibody to the foetus, which could protect against EOD and LOD66, 281. Knowledge of 
the incidence of invasive GBS- EOD and –LOD is warranted from LMICs to 
determine which serotypes should be included in a vaccine, and to prioritize 
vaccination against GBS disease. 
 
In this chapter, the clinical and microbiological epidemiology, incidence and serotype 
distribution of invasive GBS disease among young infants in a setting of high maternal 
HIV-infection prevalence are described. Additionally, the potential impact of a trivalent 
GBS-CV in reducing the national burden of invasive GBS disease was estimated. 
(Published paper attached: appendix 6) 
 
6.1. Statistical considerations 
The incidence was calculated as cases per 1000 live births. Population denominators 
for HIV-infected and HIV-uninfected pregnant women were determined by utilizing 
administrative live birth data from CHBAH and community clinics for Soweto and HIV-
prevalence survey data for the study period. There are well-established patient-referral 
protocols in Soweto, which would have limited the chance that neonates, especially 
newborns, resident outside the hospital catchment area were admitted to CHBAH. A 
sensitivity analysis of incidence was undertaken to account for those GBS cases in 
which maternal HIV-status was unknown. For the overall (2004-2008) and annual 
incidence calculations, we attributed the same prevalence of HIV-exposure to cases in 
whom HIV-exposure status was unknown as was present in those for whom it was 
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documented, with the alternate sensitivity analysis assuming either all cases with 
unknown maternal HIV-status were HIV-exposed or conversely HIV-unexposed.  
Live birth population data from 2012 for South Africa (1,168,403)282, national antenatal  
HIV prevalence data283, and GBS-disease surveillance results were utilized to 
estimate the annual national number of invasive GBS cases and deaths in HIV-
unexposed and HIV-exposed infants. Based on the conservative assumption that 
infants born at- or prior to 33 weeks gestation would not be protected against invasive 
GBS disease by vaccination of pregnant women with a GBS-CV284 and adjusting for 
the proportion of serotypes included in the current investigational trivalent GBS-CV 
(serotypes Ia, Ib and III) and a proposed pentavalent vaccine (addition of serotypes II 
and V), we estimated the number of annual vaccine-preventable invasive GBS cases 
and deaths in South Africa. As vaccine efficacy has not yet been established for GBS-
CV, hypothetical vaccine efficacy assumptions of 75% for the overall population, 85% 
for HIV-unexposed and 65% for HIV-exposed infants (based on the lower 
immunogenicity of the trivalent GBS-CV in HIV-infected pregnant women284) were 
utilized for these estimates.  
Proportions were compared using the χ2 test and Fisher’s exact test as appropriate 
and the Wilcoxon rank sum test (non-parametric) was applied for continuous 
variables. Univariate analysis was performed to determine factors associated with 
mortality due to invasive GBS disease. Throughout, two-sided p-values ≤0.05 were 
considered statistically significant and 95% confidence intervals (CIs) were calculated. 
Analyses were conducted using Stata/IC 13.0 (StataCorp, 4905 Lakeway Drive 
College Station, Texas 77845 USA). 
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6.2. Results 
 
In a 5-year period (2004-2008), a total of 389 invasive GBS cases were identified 
among young infants under 90 days old. Fifty-five percent (214/ 389) were GBS-EOD 
cases. Complete medical records were unavailable for 17 (10 EOD, 7 LOD) cases. 
These cases were included in incidence calculations but were excluded from further 
analysis. The overall incidence (per 1 000 live births) of invasive GBS disease was 
2.72 (95% CI: 2.46-3.01), with GBS-EOD incidence of 1.50 (95% CI: 1.30-1.71) and 
GBS-LOD incidence of 1.22 (95% CI: 1.05-1.42).  The incidence of both GBS-EOD 
and GBS-LOD were similar across years (table 24).  
 
Overall, 26.6% of cases were born prematurely (<37 weeks gestation), including 
29.8% of GBS-EOD and 22.3% of GBS-LOD cases. The majority (69.4%) of preterm 
births occurred at or prior to 33 weeks gestation; including 63.0% of GBS-EOD and 
80.6% of GBS-LOD cases (Table 25). Among GBS-EOD cases, 64.5% (138/214) had 
a positive culture from samples obtained on the day of birth (median age: 0 days; IQR 
0 to 1; Figure 5). The second week of life contributed the most number of cases after 
the early-onset period, with 44% of GBS-LOD cases presenting during this time period 
(GBS-LOD median age 16 days; IQR: 11, 29; Figure 5). Infants with GBS-LOD were 
5.57 (95% CI: 3.50-8.90) fold more likely to present with meningitis (61.7%) compared 
to GBS-EOD cases (22.4%; p<0.0001).  
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Table 24 Group B Streptococcus disease in young infants stratified by year and HIV-exposure status, Soweto, South 
Africa. 2004-2008235 
 
 Overall Early onset disease Late onset disease Overall 
  Overall HIV-unexposed HIV-exposed  Overall 
HIV-
unexposed 
HIV-
exposed  
HIV exposed 
vs. HIV 
unexposed 
  
n, 
incidence* 
(95% CI) 
n, incidence* 
(95% CI) 
n, incidence* 
(95% CI) 
RR (95% 
CI) 
 
n, incidence* 
(95% CI) 
n, incidence* 
(95% CI) 
n, 
incidence* 
(95% CI) 
RR (95% 
CI) 
 
Risk ratio 
(95% CI) 
2004 2.54 38, 1.51 22, 1.25 16, 2.11 
1.70 
 26, 1.03 12, 0.68 14, 1.85 
2.72 
 2.06 
(1.95;3.24) (1.07;2.07) (0.78; 1.88) (1.21;3.43) (0.83; 3.38) (0.67;1.51) (0.35;1.19) (1.01;3.10) (1.17; 6.44) (1.22; 3.47) 
2005 
3.09 45, 1.70 28, 1.51 17, 2.14 1.42  37, 1.39 12, 0.65 24, 3.01 
4.67 
 2.39 
(2.46; 3.83) (1.24;2.27) (1.00; 2.18) (1.24; 3.41) (0.73; 2.68) (0.98;1.92) (0.33;1.13) (1.93; 4.48) (2.24; 10.24) (1.51; 3.79) 
2006 
2.56 40, 1.35 21, 1.01 19, 2.14 2.11  36, 1.21 12, 0.58 24, 2.70 
4.67 
 3.04 
(2.02; 3.21) (0.96;1.84) (063; 1.55) (1.29;3.33) (1.07; 4.12) (0.85;1.68) (0.30;1.01) (1.73;4.01) (2.24; 10.24) (1.89; 4.94) 
2007 2.57 40, 1.30 26, 1.21 14, 1.52 
1.26 
 39, 1.27 22, 1.02 18, 1.95 
1.91 
 1.56 
(2.03; 3.20) (0.93;1.77) (0.79; 1.77) (0.83;2.54) (0.61; 2.50) (0.90;1.73) (0.64;1.55) (1.16;3.08) (0.97; 3.73) (0.96; 2.48) 
2008 2.87 51, 1.66 27, 1.26 24, 2.60 
2.07 
 37, 1.21 16, 0.74 21, 2.28 3.06 2.44 
(2.23;3.53) (1.24;2.18) (0.83; 1.83) (1.67;3.87) (1.15; 3.73) (0.85;1.66) (0.43;1.21) (1.41;3.48) (1.52; 6.28) (1.57; 3.80) 
Overall (N) 2.72 214, 1.50 124, 1.24 90, 2.10 
1.69 
 175, 1.22 74, 0.74 101, 2.36 
3.18 
 2.25 
(2.46;3.01) (1.30;1.71) (1.03;1.48) (1.69;2.58) (1.28; 2.24) (1.05;1.42) (0.58;0.93) (1.92;2.86) (2.34; 4.36) (1.84; 2.76) 
 
Incidence* per thousand live births  
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Figure 5: Age distribution of young infants (0-90 days of age) with invasive 
group B Streptococcus (GBS) sepsis, Soweto, South Africa, 2004-2008  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
0 1 2 3 4 5 6
%
 o
f G
BS
 c
as
es
 
Age in days 
Early onset GBS disease by age (days) n=214 
n=138 
n=46 
n=7 n=5 n=5 n=6 n=7 
0%
10%
20%
30%
40%
50%
7 to 14 15 to 21 22 to 28 29 to 60 61 to 90
%
 o
f G
BS
 c
as
es
 
Age in days 
Late onset GBS disease by age (days) n=175 
n=77 
n=39 
n=14 
n=30 
n=15 
0
10
20
30
40
50
60
70%
0 1 2 3 4 5 6
%
 o
f G
BS
 c
as
es
 
Age in days 
Early onset GBS disease by age (days) n=214 
n=138 
n=46 
n=7 n=5 n=5 n=6 n=7 
0%
10%
20%
30%
40%
50%
7 to 14 15 to 21 22 to 28 29 to 60 61 to 90
%
 o
f G
BS
 c
as
es
 
Age in days 
Late onset GBS disease by age (days) n=175 
n=77 
n=39 
n=14 
n=30 
n=15 
139 
 
Table 25 Demographics and outcomes of young infants with invasive Group B 
Streptococcus disease235 
 Overall n=372 cases 
Early Onset Disease (EOD; age <7days) 
n= 204 
Late Onset Disease (LOD; age 7-90 
days) 
n= 168 
  Overall HIV-unexposed 
HIV-
exposed Overall 
HIV-
unexposed 
HIV-
exposed 
 n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) 
Male 198/ 371 (53.4) 
109/ 204 
(53.4) 
50/103 
(48.5) 
42/ 73 
(57.5) 
89/167 
(53.3) 
35/62 
(56.5) 
45/85 
(52.9) 
HIV exposed 161/327 (49.2) 
75/179 
(41.9)   
86/148 
(58.1)   
Birth weight (grams) 
Median (range) 2795 (605-4300) 
2755 
(605-4240) 
2897.5 
(710-4240) 
2660 
(605-4220) 
2800 
(760-
4300) 
2850 
(820-4300) 
2785 
(1270-
4245) 
<1500g 37/322 (11.5) 
24/ 186 
(12.9) 
10/ 94 
(10.6) 
10/ 71 
(14.1) 
13/136 
(9.6) 
7/55 
(12.7) 
5/67 
(7.5) 
1500- <2500g 80/322 (24.8) 
48/ 186 
(25.8) 
22/ 94 
(23.4) 
20/ 71 
(28.2) 
32/136 
(23.5) 
10/55 
(18.2) 
20/67 
(29.9) 
≥2500g 205/322 (63.7) 
114/ 186 
(61.3) 
62/94 
(66.0) 
41/ 71 
(57.7) 
91/136 
(66.9) 
38/55 
(69.1) 
42/67 
(62.7) 
Gestational age (weeks) 
≤33 59/320 (18.4) 
34/181 
(18.8) 
19/96 
(19.8) 
11/68 
(16.2) 
25/139 
(18.0) 
10/57 
(17.5) 
11/68 
(16.2) 
>33- <37 26/320 (8.1) 
20/181 
(11.0) 
9/96 
(9.4) 
8/68 
(11.8) 
6/139 
(4.3) 
2/57 
(3.5) 
4/68 
(5.9) 
≥37 235/320 (73.4) 
127/181 
(70.2) 
68/96 
(70.8) 
49/68 
(72.1) 
108/139 
(77.7) 
45/57 
(78.9) 
53/68 
(77.9) 
Caesarean 
delivery 
64/331 
(19.3) 
42/190 
(22.1) 
24/96 
(25.0) 
13/73 
(17.8) 
22/141 
(15.6) 
7/57 
(12.3) 
12/70 
(17.1) 
Meconium stained 
amniotic fluid 
33/105 
(31.4) 33/88 (37.5) 21/49 (42.9) 
10/33 
(30.3)    
Mortality        
All cases 63/372 (16.9) 
30/ 204 
(14.7) 
11/ 102 
(10.8) 
12/ 74 
(16.2) 
33/168 
(19.6) 
10/62 
(16.1) 
18/ 85 
(21.2) 
Bacteremia cases 26/220 (11.8) 
18/156 
(11.5) 
7/84 
(8.3) 
6/50 
(12.0) 
8/64 
(12.5) 
0/24* 
(0.0) 
6/34* 
(17.6) 
Meningitis cases 37/152 (24.3) 
12/48 
(25.0) 
4/14 
(28.6) 
4/24 
(16.7) 
25/104 
(24.0) 
10/38 
(26.3) 
12/51 
(23.5) 
Median days of 
hospitalization 
(range) 
n=307; 
15 (0,216) 
n=172; 
13  (0, 216) 
N=90; 
12 (1, 216) 
N=62; 
13 (0, 67) 
N=135; 
20; (2, 66) 
N=52, 
16.5 (2,55) 
N=67; 
20 (4, 66) 
Median duration of 
hospitalization  
deaths (days, 
range) 
n=62; 
1 (0, 93) 
n=30; 
1.5 (0,93) 
N=11; 
2  (0, 29) 
N=12; 
2  (0, 93) 
N=32; 
1  (0, 72) 
N=10; 
1 (0,44) 
N=17; 
2  (0, 72) 
                                
      * P-value comparing HIV-exposed and HIV unexposed significant (p= 0.02)  
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6.2.1. Invasive GBS disease and the impact of HIV-exposure  
 
The maternal HIV-infection status was available for 84.1% (327/389) infants with 
invasive GBS disease, 49.2% (161/327) of whom were HIV-exposed (Table 25). 
Maternal HIV infection status results were unavailable for 12.3% of GBS-EOD cases 
and 11.9% of LOD cases. PMTCT regimens administered to mother and baby were not 
well documented in infants’ medical records (41.6%) and were therefore not analyzed 
in this study. HIV PCR results were available for 46/161 (28.6%) of HIV-exposed 
infants with GBS invasive disease, including six with GBS-EOD (all HIV PCR non-
reactive) and 40 GBS-LOD cases, 8 (20%) of whom were HIV infected.  
 
Infants with GBS-LOD were more likely to be HIV-exposed (58.1%) than infants with 
GBS-EOD (41.9%; p=0.004; Table 25). HIV-exposed and HIV-unexposed cases did 
not differ significantly overall or when stratified by EOD and LOD with regard to mode 
of delivery, preterm birth, low birth weight, exposure to meconium stained liquor (Table 
25), prolonged rupture of membranes, or IAP during labour. 
 
HIV-exposed infants had a 2.25 fold (95% CI: 1.84-2.76) higher incidence of invasive 
GBS disease (incidence: 4.46, 95% CI: 3.85-5.13) than HIV-unexposed infants 
(incidence: 1.98, 95% CI: 1.71-2.28, Table 26). This was evident for GBS-EOD (2.10 
vs. 1.24, respectively; RR 1.69; 95% CI: 1.28-2.24) and more so for GBS-LOD (2.36 
vs. 0.74, respectively; RR 3.18; 95% CI: 2.34-4.36); as well as specifically for 
bacteremia and meningitis (Table 26). These differences in incidence of invasive GBS 
disease remained significant in all sensitivity analyses for missing maternal HIV-
infection status (Table 26), except for GBS-EOD when all infants in whom HIV-
exposure status was unknown were assumed to be HIV-unexposed (Table 26).  
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Table 26 Incidence (per 1000 live births) of Invasive Group B Streptococcus sepsis (0-90 
days old) stratified by in-utero HIV-exposure status235 
 
 Overall Bacteraemia Meningitis 
HIV exposure 
status 
n, 
incidence 
(95% CI) † 
RR* (95% CI) 
 
n, incidence 
(95% CI) † 
RR* (95% CI) 
 
n, incidence 
(95% CI) † 
RR* (95% CI) 
 
Early onset disease 
Proration of HIV-exposure‡ 
Unexposed 124, 1.24 (1.03;1.48) 
1.69 
(1.28; 2.24) 
103, 1.03 
(0.84;1.25) 
1.43 
(1.03; 1.97) 
21, 0.21 
(0.13;0.32) 
3.00 
(1.63; 5.58) 
Exposed 90, 2.10 (1.69;2.58)  
63, 1.47 
(1.13;1.88)  
27, 0.63 
(0.41;0.92)  
Unknown, assume exposed 
Unexposed 
104, 1.04 
(0.85; 
1.26) 
2.47 
(1.87; 3.26) ND  ND  
Exposed 110, 2.57 (2.11,3.09)  ND  ND  
Unknown, assume unexposed 
Unexposed 
139, 1.39 
(1.17, 
1.64) 
1.26 
(0.94; 1.68) ND  ND  
Exposed 75, 1.75 (1.38;2.19)  ND  ND  
Late onset disease 
Proration of HIV-exposure‡ 
Unexposed 74, 0.74 (0.58;0.93) 
3.18 
(2.34; 4.36) 
27, 0.27 
(0.18;0.39) 
 
3.37 
(2.01; 5.73) 
 
47, 0.47 
(0.35;0.62) 
3.08 
(2.07; 4.60) 
Exposed 101, 2.36 (1.92;2.86)  
39, 0.91 
(0.65;1.24)  
62, 1.45 
(1.11;1.85)  
Unknown, assume exposed 
Unexposed 
62, 0.62 
(0.48; 
0.79) 
 
4.25 
(3.09; 5.89) 
 
ND  ND  
Exposed 113, 2.64 (2.17,3.17)  ND  ND  
Unknown, assume unexposed 
Unexposed 
89, 0.89 
(0.71, 
1.09) 
2.25 
(1.66; 3.07) ND  ND  
Exposed 86, 2.01 (1.61,2.48)  ND  ND  
Early onset 
plus late-onset 
disease, 
exposed vs. 
unexposed 
2.25 
(1.84; 
2.76) 
 1.83 (1.40, 2.39)  
3.05 
(2.20, 4.25)  
 
*RR, relative risk; ND, not done.  
† Incidence = no. cases/1,000 live births.  
‡ Based on prevalence of HIV exposure among those tested  
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6.2.2. Factors associated with mortality among invasive GBS cases 
 
The overall case fatality proportion (CFP) was 16.9%; 14.7% (30/204) of GBS-EOD 
cases died compared to 19.6% (33/168) of GBS-LOD cases (table 25). Infants with 
meningitis had a 2.4-fold greater risk of death (24.3%) than infants with bacteremia 
(11.8% OR 2.24; 95% CI: 1.33-4.35, p=0.0015; Table 25). The median duration of 
hospitalization for infants who died was one day, compared to 15 days among 
survivors (Table 25). Meningitis (p=0.002) and very low birth weight (<1500g, 
p=0.003) were associated with higher overall CFP on univariate analysis. Infants born 
≤33 weeks gestation had a higher CFP in GBS-EOD cases (p=0.008), but not in GBS-
LOD cases (p=0.68; Table 27).  
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Table 27 Infant factors associated with mortality due to invasive Group B Streptococcus disease235 
 Overall EOD LOD 
Characteristic 
Survived 
n/N (%) 
Died 
n/N (%) 
Univariable OR 
(95% CI) 
P-
value 
Survived 
n/N(%) 
Died 
n/N(%) 
Univariable OR 
(95% CI) 
P-
value 
Survived 
n/N(%) 
Died 
n/N(%) 
Univariable 
OR (95% 
CI) 
P-
valu
e 
Birth weight 
(grams) N=266 N=52   N=155 N=28   N= 111 N=24   
<1500 23 (8.7) 13 (25.0) 3.26 (1.49;7.13) 0.003 12 (7.8) 12 (42.9) 8.33 (3.07; 22.64) <0.001 11 (9.9) 1 (4.2) 0.37 (0.04; 3.04) 0.35 
1500-2499 70 (26.3) 9 (17.3) 0.74 (0.33; 1.64) 0.46 43 (27.7) 4 (14.3) 0.78 (0.24; 2.54) 0.67 27 (24.3) 5 (20.8) 0.75 (0.25; 2.22) 0.61 
≥2500 173 (65.0) 30 (57.7) REF  100 (64.5) 12 (42.9) REF  73 (65.8) 18 (75.0) REF  
Gestational age  
(weeks) N=265 N=51   N=154 N=24   N= 111 N=27   
≤33 24 (9.1) 2 (3.9) 1.79 (0.89; 3.61) 0.10 19 (12.3) 1 (4.2) 3.55 (1.40; 9.1) 0.008 5 (4.5) 1 (3.7) 0.78 (0.24; 2.52) 0.68 
>33-<37 44 (16.6) 14 (27.5) 0.47 (0.11; 2.07) 0.47 24 (15.6) 10 (41.7) 0.45 (0.06; 0.64) 0.45 20 (18.0) 4 (14.8) 0.78 (0.09; 7.04) 0.83 
>=37 197 (74.3) 35 (68.6) REF  111 (72.1) 13 (54.2) REF  86 (77.5) 22 (81.5) REF  
HIV exposed 129/272 (47.3) 30/51 (58.8) 1.58 (0.86, 2.90) 0.14         
Male gender 160/304 (52.6) 37/63 (58.7) 1.28 (0.73, 2.22) 0.38         
EOD (%) 174/309 (56.3) 30/63 (47.6) REF          
LOD (%) 135/309 (43.7) 33/63 (52.4) 1.42 (0.82, 2.44) 0.21         
Bacteraemia only 194 (62.8) 26 (41.3) REF          
Meningitis 115 (37.2) 37 (58.7) 2.40 (1.38, 4.17) 0.002         
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6.2.3. Antimicrobial susceptibility and Serotyping of GBS 
 
Antimicrobial sensitivity profiles were available for 98.9% (385/ 389) of isolates; all of 
which were sensitive to penicillin, but 5.5% (15/273) of isolates demonstrated macrolide 
resistance.  
 
Unfortunately, only 54.8% (213/389) of GBS isolates were available for serotyping, 
including 125 (58.6%) GBS-EOD and 88 (41.3%) GBS-LOD isolates. The proportion of 
isolates available for serotyping increased year-on-year (2004: 15.6%; 2005: 45.1%; 
2006: 65.8%; 2007: 63.3%; 2008: 75%).  
 
GBS serotypes Ia, Ib and III, which are included in the trivalent GBS-CV under 
development, caused 78% of GBS-EOD and almost 100% of GBS-LOD cases between 
2004 and 2008. The addition of GBS serotypes II and V to a trivalent vaccine would 
increase coverage of GBS-EOD to 93%.  
Serotype III was the most commonly-identified serotype (64.5%, 138/213), followed by 
serotype Ia (19.2%, 41/213) and together, these two serotypes accounted for 84.0% of 
all serotypes, including 74.4% of GBS-EOD and 97.7%% of GBS-LOD cases (p<0.001, 
Figure 6). The serotype distribution remained similar throughout the five years; and did 
not differ by HIV-exposure status.   
 
Serotype III was responsible for a greater proportion of GBS-meningitis (77.8%; 63/81) 
than GBS-bacteremia cases (56.8%; 75/132; p=0.002). Serotype V was more 
commonly identified in GBS-bacteremia (7.6%; 10/132) than GBS-meningitis cases 
(3/81; 3.7%; p=0.25, Figure 7). There was no difference in serotype distribution between 
survivors and those who died (p=0.51). 
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Figure 6: Group B Streptococcus serotype distribution amongst young infants 
with early-onset disease (EOD) and late onset disease (LOD) in Soweto, South 
Africa, 2004-2008.  
 
 
 
Figure 7: Distribution of group B Streptococcus serotypes causing early- and 
late- onset bacteraemia and meningitis, Soweto, South Africa, 2004-2008 
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6.2.4. Estimation of national burden and potential vaccine-preventable 
fraction of invasive GBS disease 
 
We estimate there were approximately 3 178 invasive GBS cases and 549 GBS-
related deaths in South Africa in 2012 (Table 28). This included approximately 1 639 
cases and 283 deaths in HIV-unexposed infants. Assuming a vaccine efficacy of 85% 
in these infants, approximately 1230 cases and 163 deaths could have been prevented 
by a trivalent (Ia, Ib & III) GBS-conjugate vaccine and 1354 cases and 179 deaths 
could have been prevented by a pentavalent (Ia, Ib, II, III & V).  
 
An estimated 1544 GBS-related cases and 266 GBS-related deaths occurred in South 
African HIV-exposed infants in 2012. The vaccine efficacy proposed for HIV-exposed 
infants was 65%. Using this efficacy, 866 cases (including 117 deaths) and 976 cases 
(including 129 deaths) could have been prevented using the trivalent and pentavalent 
GBS-CV respectively (table 28).  
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Table 28 Estimation of national burden of invasive Group B Streptococcus 
disease and potential annual vaccine-preventable fraction  
 
 Overall HIV unexposed HIV exposed 
National 
estimates 
n 
 
Incidence 
(95% CI) n 
Incidence 
(95% CI) n 
Incidence 
(95% CI) 
Total births 1 168 403 *  823724 †
  344679†  
Number of 
invasive GBS 
cases 
3178 ‡ 2.72 (2.62; 2.81) 1639 §
 1.99 
(1.89; 2.09) 1544 ¶
 4.48 
(4.26; 4.71) 
Number of deaths 
from invasive 
GBS # 
549 
 
0.47 
(0.43; 0.51) 283 
0.34 
(0.30; 0.39) 
266 
 
0.77 
(0.68; 0.87) 
Number of deaths 
in infants >33 
weeks gestation 
** 
420 0.36 (0.33; 0.40) 217 
0.26 
(0.23; 0.30) 204 
0.59 
(0.51; 0.68) 
       
 
Assume 
VE of  
75% 
 Assume VE of  85%  
Assume 
VE of  
65% 
 
Number of cases 
preventable by 
trivalent †† GBS-
CV 
2105 1.80 (1.73; 1.88) 1230 
1.49 
(1.14; 1.58) 886 
2.57 
(2.40; 2.75) 
Number of deaths 
preventable by 
trivalent GBS-CV 
278 0.24 (0.21; 0.27) 163 
0.20 
(0.17; 2.31) 117 
0.34 
(0.28; 0.41) 
Number of cases 
preventable by 
pentavalent ‡‡ 
GBS-CV 
2317 1.99 (1.90; 2.07) 1354 
1.64 
(1.56; 1.73) 976 
2.83 
(2.66; 3.01) 
Number of deaths 
preventable by 
pentavalent GBS-
CV 
306 0.26 (0.23; 0.29) 179 
0.22 
(0.19; 0.25) 129 
0.37 
(0.31; 0.44) 
 
* 2012 live births. 
†HIV exposed and unexposed calculated based on national HIV prevalence in pregnant women 
(29.5%). 
‡Overall GBS incidence 2.72/1000 live births.  
§GBS incidence in HIV-unexposed infants: 1.99/1000. 
¶ GBS incidence in HIV-exposed infants: 4.48/1000. 
# Total deaths in infants ≤90 days old, assuming that 15.2% are ≤33 weeks gestation with a CRF of 
26.5% and 84.8% are >33 weeks CFR of 15.6%. 
** Deaths in infants <90 days old, born at >33 weeks gestation (84.8% of infants), CFR = 15.6% 
†† Trivalent GBS-CV contains serotypes Ia, Ib& III and accounts for 88.3% of cases. 
‡‡ Pentavalent GBS-CV contains serotypes Ia, Ib, II, III &V and accounts for 97.2% of cases. 
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6.3. Discussion 
 
The incidence (per 1000 live births) of invasive GBS disease (2.72) reported in this 
surveillance study is higher than the global (0.53) and African (1.21) incidence 
estimates reported in a meta-analysis of studies conducted between 2000 to 201177. 
The incidence of invasive GBS disease in HIV-unexposed infants was 1.98 (95% 
CI:1.71- 2.28), which is similar or greater than the incidence reported in many HICs prior 
to the widespread use of IAP48. The overall incidence observed was similar to that 
observed in the same population from 1997-1999 (3.0)81, and in South African women 
of South-Asian descent (2.65) during the 1980s83.  
 
Despite similarity in the prevalence of GBS maternal vaginal colonisation at delivery276,  
the high incidence of GBS invasive disease in South Africa contrasts with the lower 
incidence reported in South East Asia and the Western Pacific. Differences in access to 
facility-based birth, presence of trained birth-care attendants, and access to health 
facilities with adequate capability to diagnose and treat invasive GBS disease are 
possible reasons for the differences noted. This is illustrated by a study conducted in 
Bangladesh in which GBS was isolated from only 1 of 30 neonates with culture-
confirmed neonatal bacteremia. More than half of the 259 reported neonatal deaths 
occurred within 24 hours of birth (many of which were community-births) and 62% were 
not investigated for bacteremia67. In our study, 65% of the GBS-EOD cases were 
diagnosed within 24 hours of birth, and the majority of these cases would likely have 
been missed if deliveries had occurred outside health care facilities or in facilities with 
limited capacity for investigating for invasive disease in newborns. Additionally, in our 
study which was conducted in a secondary- tertiary care facility, death due to invasive 
GBS disease was rapid (median 1 day from presentation).  
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These data suggest that sepsis is often established while the foetus is in-utero, 
therefore highlighting that antenatal or intrapartum interventions are required to 
prevent GBS-EOD. Additionally, up to 12% of stillbirths have been attributed to 
GBS285 and could be prevented by antenatal or intrapartum interventions.    
 
Up to 30% of infants in Soweto, South Africa are HIV-exposed, and this is contributing 
to the high incidence of GBS- invasive disease. We noted an incidence of GBS-
invasive disease in HIV-exposed infants is 4.46/ 1000 live births. In addition to the 
higher incidence of GBS-LOD observed in HIV-exposed infants compared to HIV-
unexposed infants (2.36 vs. 0.74; RR=3.18), we also observed a 1.69-fold (2.10 vs. 
1.24, 95% CI: 1.28-2.24) greater risk of GBS-EOD in HIV-exposed compared to HIV–
unexposed infants. This occurred despite our previous observation of lower 
prevalence of GBS vaginal colonisation in HIV-infected (17%) compared to HIV-
uninfected women (23%; p=0.002) at delivery and with similar rates of vertical 
colonisation of their newborns (52%-58%)230.   
A study conducted in Belgium238 and a study conducted between 2012 and 2014 at 
three large academic hospitals in Johannesburg after roll-out of combination 
antiretroviral therapy (cART) for pregnant women99 have corroborated our 
observation.  
 
The reasons for this increased risk of GBS-related sepsis in HIV-exposed infants is 
unclear, however it is possibly related to the disturbance of the delicate immunogenic 
equilibrium normally present between mother and foetus. A chronic inflammatory 
process, which is established in HIV-infected individuals to control the HIV-infection, 
stimulates increased placental pro-inflammatory cytokines and growth factors which 
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are associated with an increase in perinatal mother to child transmission of HIV and 
other co-infections. The use of cART during pregnancy recommended by the WHO 
has had varied results, with studies reporting both positive and negative impact on the 
outcome of HIV-exposed, uninfected infants. An immune reconstitution syndrome 
precipitated by initiation of cART, especially in severely immunocompromised 
pregnant women, as well as other metabolic changes can further disturb the 
immunogenic equilibrium between mother and foetus, increasing the infant’s risk of 
infection and other adverse outcomes29.   
 
Many HIV-infected women in South Africa are only diagnosed during routine antenatal 
screening HIV screening. Prenatal diagnosis of HIV and initiation of combination ART 
may lead to improved foetal and infant outcomes in HIV-exposed infants, including a 
reduction in the GBS-LOD incidence.  
 
 
We did not identify other differences in the prevalence of risk-factors for invasive GBS 
disease between HIV-exposed and HIV-unexposed cases286, however, we did not have 
population level data on prevalence rates of these  maternal risk factors for HIV-infected 
and –uninfected women. We observed a greater difference in risk of GBS-LOD than 
GBS-EOD in HIV-exposed compared to HIV-unexposed newborns, suggesting that 
factors other than well-established peri-partum EOD-associated risk-factors probably 
contribute to the increased susceptibility of GBS-invasive disease in HIV-exposed 
infants. HIV-PCR testing of HIV-exposed infants was usually only conducted at 4 to 6 
weeks of age, much later in life than the age of most of our GBS-invasive disease 
cases. We had HIV-PCR results for only 28.1% of HIV-exposed infants on the study, 
and were therefore unable to assess whether HIV-infection in young infants contributed 
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to an enhanced susceptibility to invasive GBS disease. However, none of the GBS-EOD 
cases and 20% of the GBS-LOD cases with known HIV-PCR results were diagnosed as 
being HIV-infected. The vertical transmission rate of HIV in the population during the 
course of the study was 9.6%287.  
 
We did not have adequate data on the clinical, immunological and HIV-virological 
characteristics for mothers of the HIV-exposed GBS cases on our study, and were 
unable to analyst whether aberrations of these characteristics may have contributed to 
the heightened susceptibility of invasive disease noted in HIV-exposed infants. 
 
 Numerous studies have reported an inverse association between maternal GBS 
serotype-specific antibody levels and the risk of EOD or composite of EOD/LOD in their 
infants288. Lower maternal derived-antibody levels to a number of childhood vaccine 
epitopes among HIV-exposed, uninfected infants at birth up to at least 6 weeks of age 
has been reported260, 289. As such, it is plausible that lower naturally-acquired capsular 
antibody levels in HIV-infected women may be contributing to the increased 
susceptibility to invasive GBS disease in HIV-exposed infants. This warrants further 
investigation.  
 
The serotype distribution of GBS isolates from GBS-EOD and GBS-LOD in this study 
was similar to that observed previously in the same setting81, and did not differ by the 
infant’s HIV-exposure status. Serotypes Ia, Ib and III, which are included in a trivalent 
GBS-CV currently in clinical development, caused 78% of GBS-EOD and 100% of GBS-
LOD in this study. The overall potential disease reduction of a vaccine against invasive 
GBS disease may, however, be lower than this potential coverage due to it being 
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unlikely to confer protection through antibody acquisition in neonates born at <34 weeks 
of age290. Protection against GBS-EOD in premature newborns would require 
prevention of acquisition of GBS colonisation in the mother. This is pertinent to settings 
such as ours, where 29.8% of all GBS-EOD and 31.4% of all GBS-related deaths 
occurred in premature infants despite the rate of premature birth in the community only 
being 18%.  
Continuous surveillance of GBS disease and serotype distribution is vital to identify 
changes which may impact on efficacy of GBS-CV under development. This has been 
well illustrated by ongoing surveillance in Johannesburg, which has reported a shift in 
serotype distribution in GBS-EOD cases with serotype Ia now being the most 
commonly observed invasive serotype (48.5% in 2012-2014 vs. 21.6% in 2004-2008), 
followed by III (19.7% in 2012-2014 vs. 52.8% in 2004-2008) and serotype V (18.2% 
in 2012-2014 vs. 9.6% in 2004-2008)99, 235. 
 
Conjugate vaccines (CV) for administration to pregnant women with the specific aim 
of reducing GBS –disease in young infants are under development or in clinical trials 
presently214, 284. Vaccine efficacy has not yet been established, however, utilising 
assumptions that the current investigational trivalent (serotypes Ia, Ib & III) GBS-CV 
would have no efficacy in reducing disease in infants born ≤33 weeks gestation, and 
would have 85% efficacy in HIV-unexposed infants and 65% efficacy in HIV-exposed 
infants, we estimated that 3178 GBS cases and 549 GBS-related deaths could be 
prevented annually in South Africa.  With the shift in serotypes causing GBS-EOD 
more recently99, development of a pentavalent rather than trivalent GBS-CV should 
be prioritised. An effective GBS vaccine could also be used to probe the role of GBS 
morbidity and mortality in countries with limited laboratory epidemiological capacity 291 
as well as role of GBS in causing stillbirths292.   
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7. PREVENTION OF SEPSIS WITH INTERVENTION 
 
The burden of morbidity and mortality in neonates and young infants is concentrated 
in LMICs, were access to facility-based births and interventions to prevent sepsis is 
limited. The aetiology of sepsis in LMICs is also more diverse than that reported from 
HICs. Simple and inexpensive intrapartum interventions to reduce neonatal and 
maternal post-partum sepsis have been proposed for use in LMICs. Chlorhexidine 
intravaginal washes during labour and infant skin wipes have been associated with 
significant reductions in neonatal and maternal sepsis and neonatal mortality in non-
randomised trials conducted in Malawi173 and Egypt174. Chlorhexidine solutions of up 
to 1% solution have been used safely as vaginal cleanser293, and up to 4% solution 
has been used for umbilical cord cleansing243. The non-randomised design of the two 
studies previously conducted in Africa hampered the implementation of this promising 
intervention. We conducted a large randomised, blinded trial to evaluate the efficacy 
of an intrapartum and neonatal chlorhexidine intervention in reducing early-onset 
neonatal sepsis and vertical transmission of GBS. The primary results manuscript is 
included (appendix 7).  
 
7.1. Statistical considerations 
 
The primary early-onset neonatal sepsis endpoint was evaluated based on intent-to-
treat (ITT). Efficacy of chlorhexidine wipes was calculated using the formula:   
(RCtl - RTrt) x 100 
RCtl  
   
Where RTrt  was the incidence rate in infants in chlorhexidine intervention group, and 
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RCtl was the incidence rate in infants in control group. 
For the colonisation sub-study analysis, a ‘Complier Average Causal Effect’ 
(CACE)294-296 analysis was performed to determine the biological effect of the 
chlorhexidine intervention in the population of participants defined as ‘true compliers’. 
The complexities inherent in the PoPS trial, which included both maternal and 
neonatal participants, with varied time durations between randomisation and delivery, 
necessitated the definition of compliance to allow for meaningful analysis.   Women 
who received at least one interventional wipe, administered according to protocol and 
randomisation group between one and 6 hours prior to vaginal delivery were 
considered ‘true compliers’.  
We considered the mode of delivery to be important in the vertical transmission 
analysis, as infants born by via emergency caesarean section were considered to be 
unaffected by the interventional wipe performed on the mother, as infant did not pass 
through the vagina. The maternal participants were randomised to treatment group 
prior to confirmation of mode of delivery (normal vaginal delivery vs. emergency 
caesarean delivery) by attending physician based on maternal- and/ or foetal well-
being, therefore, mode of delivery was not considered to be affected or biased by 
randomisation group, and could be used as a legitimate covariate for stratification232.  
For these reasons, only infants born vaginally and their mothers were included in the 
analysis for vertical transmission of pathogenic bacteria. 
CACE analysis was preferred to intent-to-treat analysis, as an ITT analysis would 
have reflected the combination of the biological effect of the intervention and non-
biological effects related to imperfect compliance to the protocol, rather than just 
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assessing biological effect of intervention. Details of the CACE analysis performed for 
the PoPS trial have been published in a statistical journal232.  
7.2. Results 
 
7.2.1. Participants 
 
A total of 21 723 women signed informed consent at an antenatal visit or admission 
prior to delivery during the 3.5-year trial recruitment period. Of these consented 
women, 10 927 women were assessed for continued trial eligibility on arrival in labour 
ward and 8 011 were randomised (Figure 8). A total of 2916 consented women were 
excluded on arrival in labour ward, as they did not fulfil the inclusion and exclusion 
criteria for trial continuation and receipt of interventional wipes. Sixty five consented 
women refused to participate further during labour, mainly due to discomfort of 
contractions. The majority of the remaining consented women delivered at another 
health care facility. Some were missed on arrival at CHBAH, as we only had two 
study staff members on duty in labour ward complex at any time. 
A total of 8129 infants, including 118 sets of twins were born to randomised 
participants. Swabs for assessment of colonisation with potentially pathogenic 
bacteria were collected from 5146 women prior to delivery (Figure 9 ).  
 
Baseline characteristics of maternal participants were similar between treatment arms 
(Table 29). The median age at randomization was 26 years (range: 12-51 years), and 
the median gestational age at delivery was 39 weeks (range: 23-44 weeks). HIV 
results from routine antenatal testing or pre-natal testing was available for 98.6% 
(7902/8011) participants, 26.5% (2090/7902) of whom were HIV-infected. Almost 10% 
(778/8011) women received intravenous antibiotics during labour, at least 2 hours 
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prior to delivery. Seventy seven percent (6136/8011) of randomised women delivered 
vaginally.  
 
Approximately 18% of all babies born at CHBAH during the study period were 
premature (<37 weeks gestation) (Unpublished data: CHBAH Obstetric and Neonatal 
departments), however only 4% (309/8129) babies born to PoPS participants were 
premature. The lower-than-expected rate of prematurity on the PoPS trial was in part 
related to the study procedure of consenting women at antenatal clinic, mainly during 
the third trimester of pregnancy. Additionally, many women presenting in preterm 
labour did not fulfil inclusion and exclusion criteria at labour, often due to presentation 
in late phases of labour (e.g. full cervical dilatation).  
When further stratified by maternal HIV-infection status, baseline characteristics 
remained similar between treatment arms.  
 
Maternal participants received between one and eight interventional wipes (median: 
1) prior to delivery, and 80% of women (6423 of 8011) received at least one wipe at 
least one but less than 6 hours prior to delivery. Interventional wipes were terminated 
early in 22 women overall, 18 of whom delivered vaginally (0·3%, 18/6135 vaginal 
deliveries). Reasons for early termination of wipes included face presentation (9/22), 
strong contractions (10/22) and discomfort (3/22, all of which were in chlorhexidine 
group).    
 
Neonatal interventional wipes were performed on 99% (8070/8129) of neonates born 
to maternal trial participants, at a median age of 50 minutes. Neonatal wipes were not 
performed on 41 infants who were either stillborn or severely ill at birth. Interventional 
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wipes were not performed on an additional 18 newborns during the trial for various 
reasons including staff shortages. Neonates were assessed prior to discharge home 
for adverse reactions to interventional wipes and no reactions or adverse events 
related to wipes were noted.  
 
A total of 958 neonates were admitted 976 times; 16 neonates were admitted twice, 
and one was admitted 3 times. There was no difference in rate of hospitalisation 
between chlorhexidine (485/4072 or 119/1000 births) and control neonatal 
participants (491/4057 or 121/1000 births; p=0.79).  
 
There were fewer perinatal and neonatal deaths in the chlorhexidine arm (34/4072 or 
8.3/1000 births) than in the control arm (52/4057 or 12.8/ 1000 births; p=0.05), 
including 12 and 14 stillbirths in chlorhexidine and control arms respectively. Fifteen 
(2 in chlorhexidine and 13 in control arms) neonates died within hours of birth in the 
resuscitation room from severe birth asphyxia or extreme prematurity (25 weeks 
gestation).   
 
There were an additional 45 neonatal participants who died; 20 in the chlorhexidine 
arm and 25 in the control arm (p=0·45) at a mean age of 11.2 days (median = 7.0 
days, SD 17.4). HIV-PCR results were available for 65.4% (1367/2090) of the HIV-
exposed neonates, 8.2% (112/ 1367) were HIV-infected.   
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Figure 8: Flowchart of mothers and newborns enrolled into the study evaluating 
efficacy of chlorhexidine against early-onset neonatal sepsis. 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Consented AND assessed for 
eligibility for randomization on 
arrival in labour ward 
complex n= 10 927    Excluded n= 2916    
Failed inclusion/ exclusion criteria 
review: n= 2851   
Refused to participate: n= 65    
   
Analyzed   n=4072 infants (4005 
mothers) 
(ITT, overall population)  
 
Chlorhexidine intervention                      
n= 4005 mothers; n= 4072 infants 
 
Received intervention:                
Mothers: n=4005; Infants n=4051  
Mother-infant pairs not receiving 
allocated intervention:      n= 22 
Reasons: 
Wrong wipe           n=0  
Wrong solution      n=0  
Wrong wipe & solution   n=1* 
No infant wipe done  n=21 
Control group;  
n= 4006 mothers, n= 4057 infants 
 
Received intervention: 
Mothers n= 4006 mothers; Infants n= 
4019     
Mother-infant pairs not receive allocated 
intervention:        n= 38 
Reasons: 
Wrong wipe   n=0 
Wrong solution   n=0 
Wrong wipe &solution  n=0 
No infant wipe done   n=38 
Analyzed   n=4057 infants (4006 
mothers) 
(ITT, overall population)  
Allocation 
Analysis 
Total number of randomised 
mothers n=8 011 (8 129 newborns) 
Total = 141 
Culture confirmed=14 
Clinical sepsis only= 126 
Sepsis related death=7 
 
Study outcome 
of neonatal 
sepsis 
Total = 148 
Culture confirmed=14 
Clinical sepsis only= 132 
Sepsis related death=12 
*Participant was randomised, discharged and re-admitted at a later date. On readmission, a new 
randomisation number was allocated. The wipe not done according to protocol was performed 
according to first randomisation group, which was different to final group. 
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Figure 9: Flowchart of cohort enrolled into the colonisation sub-study 
 
       
 
 
 
 
 
 
 
 
 
 
Randomised onto main trial during 
colonisation cohort phase:  n=5826 
(16May 2005- 19Oct 2007) Excluded  n=682    
Reasons: 
• Sampling/ labeling error; n=4 
• Laboratory constraints in 
sample processing; n=673    
• Mothers with swab delivered 
elsewhere n=5 
Colonisation cohort enrollment:  n=5146 
mothers; swabbed infants n=5207 
* Mother counted twice if twins both born vaginally.  
1Complier= Mother received at least one wipe ≥ 1 hour and ≤ 6 hours prior to delivery and received 
only the correct intervention. 
2Non-complier= Mother did not receive chlorhexidine wipe fulfilling criteria of compliers  
Number of mothers* colonised by 
GBS; n=401: 
Compliers1, n=316;  
Non-compliers2, (excluded from 
analysis); n=85  
 
Chlorhexidine intervention: 
 n=  2005 
Mother received allocated 
intervention n= 2005 
Did not receive allocated intervention 
n= 0 
  
Control intervention                     
              n= 1959 
Mother received allocated 
intervention n= 1959 
Did not receive allocated intervention 
n= 0 
   
Number of mothers* colonised by 
GBS; n=429 
 
 
Analysis 
Vaginal deliveries n = 3964 
(mothers-infant pairs)* 
Emergency caesarian delivery; 
n = 1208 (mother-infant pairs) 
Randomization 
Outcomes in 
newborn 
Number of newborns colonised 
with GBS; 
Newborns to Compliers; 168 
Newborns of Noncompliers: 49 
Number of newborns 
colonised with GBS; n= 234 
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Table 29: Selected demographic and clinical characteristics of mothers and 
newborns.  
 
 
* Median (range) 
 
# Intrapartum antibiotics: given at least 2 hours prior to delivery (excludes prophylaxis for caesarean 
section) 
 
+ Includes mode of delivery of all singletons and first twin only. Four second twins (2 CHX; 2 control) 
were born by caesarian section when first twin born by vaginally. All other second twins born by same 
route as first twin. 
Characteristic Chlorhexidine 
group %(n) 
Control group %(n) 
Mothers n=4005 N=4006 
Median age in years (range)  26 (14-47) 26 (12-51) 
Median gravidity (range)  2 (1-9) 2 (1-10) 
   
Medical history % (n)   
          HIV-positive 26·2 (1050) 26·2 (1036) 
          Urinary tract infection 11·2 (449) 10·1 (405) 
          Gestational diabetes 0·2 (9) 0·3 (11) 
          Maternal tuberculosis 0·5 (19) 0·6 (23) 
   
Received intrapartum antibiotics (IAs), 
excluding caesarean section prophylaxis   
9·7 (388) 9·8 (390) 
IAs in women with vaginal delivery 
 (% of IAs) 
75·0 (291) 75·9 (296) 
Received antibiotics 7 days prior to delivery 25·4 (241) 25·7 (234) 
Intrapartum fever  0·2 (8)  0·2 (8) 
Prolonged rupture of membranes of U>U 18 
hours at delivery  
9·6 (385) 8·1 (325) 
Unbooked/No prenatal care  0·3 (10) 0·03 (1) 
   
Twin birth  1·7 (67) 1·3 (51) 
Meconium stained liquor  14·9 (598) 15·1 (602) 
Delivery    
         Spontaneous vaginal delivery 76·9 (3079) 76·4 (3057) 
          Emergency caesarian section 23·1 (924) 23·6 (943) 
          Vaginal vacuum/Forceps assisted 2·0 (80) 2·1 (84) 
   
Babies n=4072 n=4057 
Female gender 46·8 (1906) 48·5 (1967) 
Pre-term  3·9 (158) 3·7 (151) 
Median birth weight (range) 3140g (480-5630) 3125 (670-5090) 
Median Apgar at 5 minute (range) 10 (0-10) 10 (0-10) 
HIV-exposed infants 25·8 (1050) 25·7 (1040) 
HIV PCR positive (% of tested) 9·1 (65 of 716) 7·2 (47 of 654) 
Outcome   
      Stillborn 0·3 (12) 0·4 (14) 
      Died shortly after delivery 0·1 (2) 0·3 (13) 
      Surviving newborns admitted to neonatal war  9·8 (397) 9·6 (390) 
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7.2.2. Very Early-onset disease 
 
Overall 289 very early-onset sepsis cases occurred, 28 of which were culture-
confirmed cases. Group B streptococcus (16/28; 57.1%, incidence 1.98/1000 live 
births) was the most commonly isolated bacterial pathogen (10 in chlorhexidine arm 
and 6 in control arm; Table 30). The rate of culture-confirmed sepsis did not differ 
between chlorhexidine and control arms (14 cases in each arm). Similarly, overall 
very early onset sepsis rates did not differ between chlorhexidine arm (126 cases; 
34.6/1000 births) and control arm (132 cases; 36.5/1000 births).  
There was no difference (efficacy 5% (-19%, 24%)) in rate between the chlorhexidine 
arm (35/1000 births or 141/4072) and control arm (36/1000 births or 148/4057; 
p=0·65; Table 31). The very early-onset sepsis rates did not differ between 
chlorhexidine and control arms when stratified by HIV-exposure status (Table 31). 
Eight-seven percent (252/289) of newborns with very early-onset sepsis were 
admitted within 4 hours of birth. 
 
Table 30: Bacteria isolated from early-onset culture-confirmed cases 
 Chlorhexidine Control 
Neonates n= 4072 n= 4057 
Group B streptococcus 10 6 
Escherichia coli 0 1 
Klebsiella pneumoniae 1 0 
Staphylococcus aureus 0 1 
Streptococcus viridans 1 1 
Acinetobacter baumanii and lwoffii 1 2 
Enterococcus faecalis and faecium 1 2 
Enterobacter 0 1 
 
7.2.3. Late-onset sepsis 
 
In total, 39 late-onset neonatal sepsis cases were identified (4.8/1000 births), 22 
(56·4%) of them in chlorhexidine arm (efficacy -29%, Table 31).  
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Table 31: Intent to treat analysis of very early onset sepsis in neonates and 
maternal post-partum sepsis by intervention group and HIV exposure status. 
 Overall n (rate) 
Maternal HIV Negative 
Status n (rate) 
Maternal HIV Positive 
Status 
n (rate) 
 Chlorhexidine Control 
Chlorhexidi
ne Control 
Chlorhexidin
e Control 
Neonates n= 4072 n= 4057 n= 2939 n= 2947 n= 1072 n= 1058 
Very Early-onset sepsis 
Culture-confirmed cases* 
meeting clinical sepsis 
definition 
11 7 6 § 5 4  § 2 
Culture-confirmed cases 
NOT meeting clinical 
sepsis definition ¶ 
3 7 2 4 1 3 
Cases with clinical 
sepsis only 126 132 98 105 28 27 
Early deaths (<3 days) 
not meeting culture-
confirmed of clinical 
definitions, but included 
after panel review 
1 2 1 2 0 0 
Overall 141 (3·5%) 148 (3·6%) 107(3·6%) 
116 
(3·9%) 33 (3·1%) 
32 
(3·0%) 
Efficacy (95% CI) overall 
Early onset sepsis 5% (-19%, 24%); p= 0·65 8% (-20%, 29%); p= 0·55 
-2% (-64%, 37%); p= 
0·94 
Late-onset neonatal sepsis 
Culture-confirmed sepsis 
meeting clinical sepsis 
definition 
4 8 1 3 3 4 
Culture-confirmed cases 
NOT meeting clinical 
sepsis definition 
9 3 6 2 3 1 
Cases with clinical 
sepsis only 9 6 7 1 2 5 
Overall 22 (0·5%) 17 (0·4%) 14 6 8 10 
Efficacy (95% CI) overall 
late-onset sepsis 
-29% (-142%, 31%); 
p=0·43 
-134% (-508%. 10%); 
p=0·07 
21% (-99%, 69%); 
p=0·62 
Maternal post-partum sepsis ǂ 
 N=4005 N=4006 n=2896 n=2916 n = 1050 n = 1040 
Culture-confirmed cases 
that fulfilled clinical 
criteria 
0 0 0 0 0 0 
Culture-confirmed only 1 ## 1 # 1 1 0 0 
Endometritis only 14 11 8* 6 5 5 
Overall 15 (0.3%) 12 (0.3%) 9 (0.3%) 7 (0.2%) 5 (0.5%) 5 (0.5%) 
Efficacy (95% CI) overall 
postpartum sepsis -25% (-167%, 41%) -29% (-247%, 52%) 1% (-240%, 71%) 
 
Data are number or number (%) unless otherwise indicated. All neonates including second twins and stillbirths 
who were delivered at hospital are included.  
 
*Very Early onset culture-confirmed sepsis Isolation of a micro-organism that is not a common contaminant 
from a normally sterile body site within the first 3 days of life. 
 
¶ Very Early onset culture-confirmed sepsis in the absence of study-specified clinical criteria of very early-
onset neonatal sepsis.  
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ǂ Maternal postpartum sepsis was defined as maternal hospitalization within 14 days of delivery for endometritis 
(at least two of: uterine tenderness, fever, foul-smelling/ purulent lochia or vaginal discharge), sterile site culture-
confirmed infection, or perineal wound infection among vaginal parturients.  
Citrobacter freundii # and E. coli ##  
§ HIV exposure results missing for one newborn with culture-confirmed, clinical early onset sepsis in chlorhexidine 
arm and for one maternal postpartum sepsis case fulfilling the clinical criteria 
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7.2.4. Maternal Postpartum sepsis 
 
Twenty-seven cases of postpartum sepsis were identified among the 8011 
randomised women, 15 in the chlorhexidine arm (3·7/1000 women) and 12 in the 
control arm (3·0/1000 women, Table 31).  None of the maternal deaths (1 in 
chlorhexidine and 3 in control group) or postpartum admissions (1 013 in 
chlorhexidine and 1 034 in control group; p=0·60) were attributed to the intervention. 
The majority (1876/2047; 91·6%) of maternal hospitalizations were for routine post-
caesarean care.  
 
7.2.5. Vertical transmission 
 
As part of the PoPS study, 5146 women and their 5207 infants were swabbed to 
determine rates of maternal vaginal colonisation and vertical transmission of 
potentially pathogenic bacteria in our population. HIV-infection status was known for 
99.1% (5099/ 5146) of the maternal participants on the colonisation cohort. Seventy 
seven percent (3946/5146) of women enrolled into the colonisation cohort delivered 
vaginally and 20.9% (825/3946) were colonised with GBS. GBS was cultured from 
54.2% (450/830) of newborns born to GBS-colonised mothers. Amongst mother-
infant dyads in colonisation cohort randomised to the chlorhexidine arm, 78.8% 
(316/401) met the “true complier” definition. No significant reduction in vertical 
transmission of GBS colonisation was noted in the chlorhexidine arm compared to 
the control arm (Efficacy -0·05% (-9·2%,7·9%), Table 32); results were similar when 
mothers receiving >2 hours intrapartum antibiotics (n=47), primarily for meconium-
stained liquor, were excluded. Vertical transmission results for E. coli and K. 
pneumoniae were similar in chlorhexidine and control arms (Table 32).  
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Table 32: Intent-to-treat analysis of vertical transmission of selected maternal 
vaginal colonizing bacteria from mother to newborns  
 
  
Neonatal Colonisation 
Status 
Chlorhexidine group Control group  Overall Efficacy 
(95% CI) 
Complier 
 
Non-complier 
Group B streptococcus 
Positive 168 (53%) 49 (58%) 234 (55%)  
 
 
        -0·05%  
   (-9·2 to 7·9%)  
Negative 135 (43%) 28 (33%) 175 (41%) 
Missing result 13 (4%) 8 (9%) 20 (5%) 
Total 316 85         429 
Escherichia coli 
Positive 361 (51%) 92 (50%) 442  (51%)  
0.3% 
(-6.0 to 5.3) Negative 298 (42%) 74 (40%) 362  (42%) 
Missing result 45 (6%) 45 (24%) 60  (7%) 
Total 704 184        864  
Klebsiella pneumoniae 
Positive 37 (29%) 6 (23%) 49  (30%)  
 
10.6% 
(-5.9 to 24.1) 
Negative 88 (69%) 18 (69%) 103  (63%) 
Missing result 3 (2%) 2 (8%) 11  (7%) 
Total 128 26          163  
 
 
Denominators in each column are the number of women colonised with the respective 
pathogen. 
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7.3. Discussion 
 
Published reviews of chlorhexidine maternal vaginal- and newborn skin cleansing180, 
182  concluded that, although two non-randomised trials from Africa173, 174 showed 
promising results in reducing neonatal sepsis, a randomised controlled trial, 
preferably conducted in a LMIC was required before implementation of the 
intervention was accepted globally.  
 
The randomised controlled trial of maternal-newborn chlorhexidine or control wipes 
that we conducted in a LMIC failed to show benefit of chlorhexidine maternal and 
neonatal wipes in preventing early-onset sepsis, despite using a chlorhexidine 
solution double the concentration of that used in the Malawi173 and Egypt174 trials. 
This was corroborated by lack of impact on vertical transmission of leading sepsis 
pathogens and on serious maternal postpartum sepsis229.  
 
Another randomised controlled trial of chlorhexidine vaginal and neonatal wipes to 
assess efficacy of intervention on neonatal sepsis and perinatal mortality was 
conducted in Karachi, Pakistan between 2005 and 2008, utilising 0.6% 
chlorhexidine297; a slightly higher concentration than what we used for the PoPS trial 
(0.5%)229. The results of the Pakistan trial297, which showed no significant reduction 
in neonatal sepsis, perinatal mortality or maternal mortality, supported our PoPS trial 
findings229. A significant reduction in neonatal skin infections (3.3% vs. 8.2%, 
p<0.0001) was the only benefit observed297.  
 
Therefore, two large randomised, controlled trials, conducted in LMIC settings229, 297 
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with high neonatal mortality rates (South African NMR= 14.6/1000, Pakistan NMR = 
54/1000 live births105), in which over 13000 women and their infants were enrolled 
have both proven that chlorhexidine interventional vaginal and neonatal skin wipes 
do not reduce the incidence of neonatal sepsis or mortality, despite previously 
reported benefits173, 174.   
  
Several reasons for the differences in results observed between the other African 
trials173, 174 and our trial have been considered, and include the individual 
randomised, controlled design of our trial compared to the non-randomised design of 
the other trials and the more stringent neonatal sepsis definition that we used.   
Additionally, the previous African trials utilized hospital staff to deliver the 
interventional wipes, and the participants in the chlorhexidine group may have 
inadvertently benefited from more intensive monitoring and general care than those 
in the non-intervention group. The other African trials did not stratify neonatal sepsis 
episode by age categories within the neonatal period. An intrapartum intervention 
like chlorhexidine wipes is unlikely to have any effect beyond the first few days of life.  
 
Neither of the other African trials173, 174 assessed vertical transmission of bacteria to 
corroborate their findings. Our finding that chlorhexidine does not interrupt vertical 
transmission suggests it is unlikely to prevent vertically-acquired neonatal infections 
in any setting or population.  
 
Pathogenic bacteria can ascend into the amniotic fluid and placenta, leading to 
colonisation of neonatal skin, chorioamnionitis and sepsis in foetus. Ascending 
infections are more commonly observed in the presence of certain risk factors 
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including prolonged rupture of membranes, however, pathogenic bacteria can also 
cross intact membranes and infect a foetus in-utero40, 46, 47. These factors allow for 
infectious processes to become established while the foetus is still in-utero. The 
large proportion of culture-confirmed and clinically evident sepsis episodes which 
present during the first 24 to 48 hours of life71, 95, 235 is evidence of this intra-uterine 
infectious process. Additionally, intra-uterine infections contribute to the large 
number of stillbirths that occur each year285, 298.  
 
Although there were significantly fewer neonatal deaths in the chlorhexidine arm 
than in the control arm in our trial, the effect on mortality was greatest in deaths that 
occurred in the first few hours after birth. Most of these early neonatal deaths were 
caused by birth asphyxia, as determined after blinded record review by a panel of 
neonatologists. This effect on mortality was unlikely to be related to the chlorhexidine 
intervention, in the light of the lack of efficacy on sepsis and vertical transmission 
endpoints.  
 
Intrapartum antibiotic use in our population (9.7% of mothers, primarily for 
meconium-stained liquor) could have blunted the efficacy of chlorhexidine by 
reducing rates of sepsis and vertical transmission in both treatment and control 
arms. The overall incidence of sepsis (36/1000 live births), the GBS-culture-
confirmed early-onset sepsis incidence (1.98/1000 live births) and the vertical 
transmission seen in our trial were similar to those observed in HICs prior to 
widespread use of IAP.   
 
Although we failed to show a reduction of vertical transmission of pathogenic 
169 
 
bacteria when using chlorhexidine vaginal wipes, reduction of vertical transmission of 
GBS has been reported using similar interventions, though administered as gels or 
douches169, 299. It is unlikely that the wipe method used in our trial was less effective 
in reducing vertical colonisation than the other methods used. Our trial included a 
cohort of GBS-colonised women which was substantially larger than cohorts from 
other trials, which individually had inadequate power to evaluate vertical 
transmission.  
 
 
Although this trial was randomised, a limitation of the study was the lack of blinding 
of midwives administering the intervention; we did not implement a true placebo due 
to concerns about detrimental effects of vaginal wipes without antisepsis. Numerous 
safeguards were established and carefully implemented to counteract this limitation, 
including the use of colourless chlorhexidine solution, and trial midwives not being 
involved in patient-care or collection of endpoint data.  
 
Despite several trials having raised hopes that chlorhexidine vaginal/ neonatal 
cleansing would be beneficial in saving newborn lives, the results of our PoPS 
trial229, which have been corroborated by a trial conducted in Pakistan297 suggest 
that implementation of this intervention is unlikely to reduce neonatal mortality from 
vertically-acquired sepsis. Other interventions are needed to reduce neonatal 
mortality.  
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8. THESIS CONCLUSION 
 
There were several major findings described in this thesis. The results of the 
surveillance study undertaken as part of this thesis, have added to the growing body 
of evidence describing the aetiology of sepsis in young infants in a middle-income 
setting. The high incidence of culture-confirmed bacterial sepsis in neonates and 
post-neonatal young infants presenting to CHBAH, and how maternal HIV-infection 
in the era prior to anti-retroviral roll-out may have increased this burden were 
described. Ongoing surveillance of bacterial pathogens causing invasive disease in 
young infants, and antibiotic susceptibility patterns is essential to assist health care 
providers develop appropriate treatment guidelines. This thesis has included two 
definitions of early onset neonatal sepsis: (i) < 3 days of age and (ii) <7 days of age. 
The source of the pathogen causing neonatal sepsis is usually maternal in neonates 
under 3 days of age, and environmental in older neonates, which supports the use of 
the <3-day cut-off, however, the most commonly utilised definition of early onset 
disease is <7 days of age. It has been recently recommended for studies to report 
separately for cases occurring <3 days and between 3-7 days of age300.  
 
Maternal recto-vaginal colonisation rates with pathogenic organisms including GBS, 
E. coli and K. pneumoniae had not been described previously in this population.  In 
this thesis we reported on the prevalence of colonisation by these bacteria in the 
women at time of delivery, as well as the rate of vertical transmission of colonising 
bacteria to their newborns. The prevalence of maternal GBS colonisation, vertical 
transmission and invasive disease incidence in our population mirrored that 
observed in other settings with high incidence of invasive GBS disease prior to 
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intervention of antenatal screening and IAP. There is a paucity of data on GBS 
colonisation rates in other LMICs, especially in SE Asia, which also reports low 
incidence of invasive GBS disease. In order to establish whether the low reported 
incidence of invasive GBS disease in SE Asia is related to low GBS colonisation 
rates, or missed case identification, we are currently co-ordinating a Bill and Melinda 
Gates Foundation funded multi-centre study which aims to describe the prevalence 
of maternal recto-vaginal colonisation, vertical transmission of GBS colonisation and 
serotype-specific capsular antibody levels in mother-infant dyads with term deliveries 
in Africa and South-East Asia.  
 
The incidence of GBS sepsis reported in South Africa235 is amongst the highest 
currently being reported globally, and has provided vital data for the planning of new 
interventions which aim to reduce GBS-EOD and LOD. Serotype data available from 
this study and subsequent GBS disease surveillance99 have informed the 
composition of polysaccharide based vaccines for administration to pregnant women 
for prevention of invasive disease in their newborns, that would be appropriate in our 
setting and are currently under clinical development. HIV-exposure significantly 
increased the infant’s risk of invasive GBS disease, and whether early diagnosis and 
initiation of antiretroviral treatment of HIV infected pregnant women, would assist in 
reducing risk of GBS associated morbidity and mortality in their infants require 
further investigation. 
 
An inexpensive chlorhexidine intervention which had previously been reported to be 
effective in reducing neonatal sepsis and mortality173, 174, was assessed in this 
project. The results of the PoPS trial229, which were corroborated by a similar trial 
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subsequently conducted in Pakistan297, described the lack of efficacy of 
chlorhexidine maternal vaginal and infant skin swabs in reducing neonatal sepsis, 
mortality and vertical transmission of pathogenic bacteria. These definitive results 
support evidence that intra-uterine infection is a significant contributor to neonatal 
sepsis, and possibly infection-related stillbirths.  
 
The outcomes of the work conducted for this thesis have supported a shift towards 
more focused research on other interventions which show promise for reducing the 
large burden of sepsis in neonates and young infants, specifically the acceleration in 
research on and development of vaccines for administration to pregnant women. 
Immunisation of pregnant women has been described as the ‘missing link’ in the 
previous efforts to identify and implement antenatal interventions to protect mothers 
and newborn infants301. 
 
Subsequent to completing the data collection for this thesis, I have been a lead 
clinical investigator in several maternal immunisation trials, including seasonal 
influenza vaccine206 and GBS-vaccine242, 302 trials. The vaccine efficacy rates for a 
trivalent influenza vaccine administered to pregnant women in reducing confirmed 
influenza were 50.4% (95% CI: 14.5 – 71.2) and 48.8% (95% CI: 11.6 – 70.4) in HIV-
uninfected women and their infants, and 57.7% (95% CI: 0.2 -  82.1) in HIV-infected 
women respectively206. 
 
Phase Ib/ II randomised trials (V98_08, Clinicaltrials.gov identifier: NCT01193920, 
V98_05; Clinicaltrials.gov identifier NCT01412801) of a trivalent GBS conjugate 
vaccine (GBS-CV) were conducted in Africa, including Soweto, South Africa between 
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2010 and 2012, and have reported that this GBS-CV is well tolerated and 
immunogenic in HIV-uninfected non-pregnant and pregnant women302 and HIV-
infected pregnant women242. The next step towards licensure of a GBS-CV is to 
conduct a phase III efficacy trial, however, challenges in conducting this trial 
including the large sample size required (~70 000 mother-infant pairs), identification 
and selection of appropriate clinical trial sites in areas of high disease burden214 and 
other programmatic issues remain to be addressed. In the interim, however, we are 
conducting a large observational study at CHBAH to establish an immune correlate 
of protection against invasive GBS-EOD and GBS-LOD (Clinicaltrials.gov number: 
NCT02215226).  
The pathway to develop and introduce a GBS-CV is gaining momentum, with 
support from organizations including the Bill & Melinda Gates Foundation216.  
 
Contributing to this effort is a manuscript which I published on the lessons learnt 
during conduct of maternal immunisation trials in Soweto303, as an extension to the 
work conducted for this thesis.  
 
Additionally, the Brighton Collaboration and World Health Organisation established 
the Global Alignment of Immunisation safety Assessment in pregnancy (GAIA) 
network in 2014, which is developing definitions for neonatal and maternal adverse 
events following maternal immunisation. I have been involved in the GAIA activities 
since July 2014, and led the working group which developed the ‘Neonatal death’ 
definition and was a member of four other working groups in 2015 (preterm birth, 
neonatal infections, pathways to preterm birth and maternal death; submitted for 
publication, Vaccine). I am also leading the ‘Low birth weight’ GAIA working group in 
2016, and am a member of the ‘microcephaly’ working group. 
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In conclusion, the results of the work undertaken for this thesis have supported the 
acceleration of research on maternal immunisation as a suitable method to prevent 
infections in neonates and young infants, and possibly infection-related stillbirths.  
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ORIGINAL STUDIES
Background: Factors associated with neonatal sepsis, an important cause of 
child mortality, are poorly described in Africa. We characterized factors asso-
ciated with early-onset (days 0–2 of life) and late-onset (days 3–28)  sepsis 
and perinatal death among infants enrolled in the Prevention of Perinatal 
Sepsis Trial (NCT00136370 at ClinicalTrials.gov), Soweto, South Africa.
Methods: Secondary analysis of 8011 enrolled mothers and their neonates. 
Prenatal and labor records were abstracted and neonatal wards were moni-
tored for hospitalized Prevention of Perinatal Sepsis–enrolled neonates. 
Endpoint definitions required clinical and laboratory signs. All univariate 
factors associated with endpoints at P < 0.15 were evaluated using multi-
variable logistic regression.
Results: About 10.5% (837/8011) of women received intrapartum antibiotic 
prophylaxis; 3.8% of enrolled versus 15% of hospital births were preterm. 
Among 8129 infants, 289 had early-onset sepsis, 34 had late-onset sepsis, 
49 had culture-confirmed neonatal sepsis and 71 died in the perinatal period. 
Factors associated with early-onset sepsis included preterm delivery [adjusted 
relative risk (aRR) = 2.6; 95% confidence interval (CI): 1.4–4.8]; low birth 
weight (<1500 g: aRR = 6.5, 95% CI: 2.4–17.3); meconium-stained amniotic 
fluid (MSAF) (aRR = 2.8, 95% CI: 2.2–3.7) and first birth (aRR = 1.8; 95% 
CI: 1.4–2.3). Preterm, low birth weight, MSAF and first birth were similarly 
associated with perinatal death and culture-confirmed sepsis. MSAF (aRR = 2.4, 
95% CI: 1.1–5.0) was associated with late-onset sepsis.
Conclusions: Preterm and low birth weight were important sepsis risk 
factors. MSAF and first birth were also associated with sepsis and death, 
warranting further exploration. Intrapartum antibiotic prophylaxis did not 
protect against all-cause sepsis or death, underscoring the need for alternate 
prevention strategies.
Key Words: group B streptococcus, newborns, sepsis, pneumonia
(Pediatr Infect Dis J 2012;31: 821–826)
Neonatal mortality accounts for 41% of deaths among children <5 years of age, globally. Among neonatal deaths, 900,000 
annually (approximately one-fourth) are due to neonatal sepsis 
and pneumonia, primarily in the first week of life among infants 
in developing countries.1 The African region includes some of the 
highest neonatal mortality rates, yet prevention strategies remain 
unsatisfactory.2 Because etiology data are limited and there may be 
a more diverse spectrum of neonatal sepsis-causing pathogens in 
Africa,2,3 prevention strategies targeting all-cause neonatal sepsis 
are particularly attractive.
In Africa, and more broadly for developing countries, few 
data are available on risk factors associated with neonatal sepsis. 
There is evidence that preterm delivery, prolonged rupture of mem-
branes and intrapartum fever likely play important roles in early-
onset sepsis, as they do in resource-rich countries.2,4 Labor compli-
cations and birth asphyxia have also been suggested as early-onset 
sepsis risk factors in a Nigerian study.5
Although HIV-infected women have a higher incidence of 
factors that may predispose to neonatal sepsis,6–9 a recent  analysis10 
confirmed that maternal HIV infection is not a direct risk factor for 
neonatal sepsis.
We assessed maternal and neonatal factors associated with 
early-onset neonatal sepsis, late-onset community acquired sepsis 
and perinatal death in a cohort of over 8000 mother-baby pairs 
delivered at a large public hospital in Soweto, South Africa.
PATIENTS AND METHODS
This is a secondary analysis of the Prevention of Perina-
tal Sepsis trial (NCT00136370 at ClinicalTrials.gov). The trial’s 
primary goal was to assess the efficacy of maternal and newborn 
chlorhexidine washes in preventing neonatal sepsis. Neither the 
 intervention11 nor maternal HIV infection status (C.L. Cutland, MD, 
et al, submitted for publication) affected neonatal sepsis, thus the 
full trial cohort was used here.
Study Population and Setting
Eight thousand eleven mothers delivering at Chris Hani-
Baragwanath Academic Hospital (CHBAH), a secondary-tertiary 
level hospital, in Soweto, South Africa, and their 8129 neonates 
were enrolled between April 1, 2004, and October 25, 2007. The 
hospital delivers three-quarters of the 30,000 annual births in 
Soweto, South Africa, providing free maternal and child care to an 
urban, low-middle and low-income population. Most of the remain-
ing births are conducted by midwives in public antenatal clinics 
that transfer women with difficult labor to CHBAH. CHBAH is 
the only public facility that admits neonates requiring hospital 
care in the Soweto region. All newborn infants who are respiratory 
depressed at birth are resuscitated according to the South African 
Paediatric Association Guidelines that are adapted from the Ameri-
can Academy of Paediatrics Neonatal Resuscitation Program.12 
Infants who need respiratory support are admitted to the neonatal 
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intensive care unit for mechanical ventilation, except for extremely 
low birth weight infants and those with severe congenital abnor-
malities and/or severe intrapartum asphyxia. Maternal screening 
for group B streptococcus (GBS) colonization and intrapartum 
antibiotic prophylaxis (IAP) is not implemented, but IAP is advo-
cated for the management of chorioamnionitis, prolonged rupture 
of membranes (≥18 hours), a subset of preterm deliveries (26–33 
weeks gestation) and prelabor rupture of membranes. Trial exclu-
sion criteria included planned cesarean section, antepartum hemor-
rhage, known severe congenital malformation, intrauterine death 
confirmed before randomization, known allergy to chlorhexidine, 
face presentation, significant genital warts or ulcers, full cervical 
dilatation at randomization and age <15 years. While refusals for 
trial participation were rare (65/10,927 women refused participa-
tion), trial enrolment procedures skewed away from enrolling pre-
term deliveries. The incidence of preterm neonates in the study 
population (3.8%) was lower than in the hospital population (15%; 
S.C. Velaphi, MD, personal communication).
Study Procedures
Participants were enrolled into the trial on presentation for 
labor.11 Study staff did not provide clinical care. Prenatal and labor 
records were abstracted for key prenatal and intrapartum variables. 
Underlying and pregnancy-induced conditions, such as gestational 
diabetes, as well as intrapartum signs and newborn gestational 
age were based on documented physician diagnosis as opposed 
to application of standardized study definitions. At CHBAH, phy-
sicians generally make clear clinical notes with problem lists on 
hypertensive disorders, diabetes mellitus in pregnancy and other 
medical disorders, and intrapartum events such as pyrexia, and pas-
sage of meconium-stained amniotic fluid (MSAF). Gestational age 
was determined either from records of an early antenatal ultrasound 
or a Ballard score done soon after birth or within the first 72 hours 
of life.
Study doctors conducted active surveillance of the neo-
natal and pediatric wards to identify neonates hospitalized from 
birth to 28 days of age. Sterile site cultures from study partici-
pants were collected at the discretion of attending physicians and 
processed per standard practice at the hospital microbiology labo-
ratory. Routine methods were used for culture and identification 
of invasive pathogens from sterile sites. Active laboratory-based 
surveillance was also conducted to confirm that all sterile site 
cultures from study neonates were captured. Information related 
to the neonatal sepsis endpoints was abstracted from medical 
records by trained study physicians. Logs at the hospital morgue 
were also reviewed routinely to ensure deaths among study par-
ticipants were captured.
Endpoint Definitions
Early-onset sepsis (EOS) was defined as sepsis occurring on 
days 0–2 of life and community-acquired late-onset sepsis (LOS) 
as that from days 3–28 of life. At least one clinical and one labora-
tory sign were required for the fulfillment of clinical sepsis, as pre-
viously published (see Appendix, Supplemental Digital Content 1, 
http://links.lww.com/INF/B211).11 Admission records of newborns 
with positive blood cultures who did not fulfill the clinical sepsis 
criteria were reviewed by 3 neonatologists to determine whether 
they captured a sepsis episode. The records of all trial infants who 
were stillborn or died within 2 hours of birth were also reviewed to 
determine whether the cause of death could be attributed to neona-
tal sepsis; no stillbirths and 2 live born, early deaths were deemed 
as clinical early-onset sepsis. Intrapartum stillbirths and deaths 
within the first 6 days of life were considered perinatal deaths.
Statistical Analysis
Maternal, intrapartum and neonatal variables analyzed as 
potential risk factors are shown in Supplemental Digital Content 
5 (http://links.lww.com/INF/B212). Univariate and multivariable 
analyses were performed using logistic regression in SAS Version 
9.2 (Carey, NC). Multivariable models were evaluated starting with 
all factors that were significant at P < 0.15 in univariate analy-
sis and dropping nonsignificant factors using stepwise backward 
selection. Collinearity of independent variables was evaluated. All 
2-way interactions in final multivariable models were evaluated. 
Throughout, 2-sided P < 0.05 was considered statistically signifi-
cant and 95% confidence intervals (CIs) were calculated. Relative 
risks were approximated by odds ratios because sepsis and perinatal 
death endpoints were rare in this population.13
RESULTS
Basic characteristics of the cohort (8011 mothers, 8129 
infants) have been described previously.11 Median maternal age was 
26 years [interquartile range (IQR): 22–31]; only 11 (0.1%) enrolled 
women had no prenatal care; 26.1% (2690/8011) had documented 
HIV infection (1.4% or 109 had unknown HIV status) and 21.0% 
(1678/8011) had hypertension. Among infants, 3.8% (309/8129) 
were born at <37 weeks’ gestation and 8.0% (615/8129) had a birth 
weight <2500 g (including 0.4% or 35 with a birth weight <1500 g), 
and 4.8% (388/8129) required resuscitation upon birth.
About 10.5% (837) of women received IAP. Among these, 
60% (498/837) received intravenous ampicillin (1 g 6 hourly), 
over two-thirds in combination with metronidazole. Only 2 women 
received penicillin. The median duration between administration of 
the first dose of IAP and delivery was 14.8 hours (IQR: 7.8–26.7 
hours). Documented reasons for IAP included prolonged rupture 
of membranes (410/837 or 49%), foul-smelling vaginal discharge 
(90/837 or 11%) and preterm labor (48/837 or 6%). Among women 
with a preterm indication (per hospital policy, delivery from 26–33 
weeks’ gestation), 49.4% (42/85) received IAP. Among women with 
rupture of membranes ≥18 hours, 62.9% (449/714) received IAP. 
Among women with at least one sign of chorioamnionitis as per 
hospital policy, 10.0% (129/1295) received IAP (MSAF: 92/1200 
or 7.7%; foul-smelling discharge: 32/79 or 40.5%; maternal tachy-
cardia: 8/22 or 36.3%; fetal tachycardia: 8/32 or 25%; maternal 
fever: 12/17 or 70.6%; uterine tenderness: 1/1 or 100%).
There were 289 cases of early-onset sepsis (35.6/1000 births). 
Ten percent (29/289) were culture confirmed; GBS was the most 
common pathogen (16/29; detailed list of pathogens in Table 1). 
There were 34 late-onset sepsis cases (4/1000 births); 20 were 
culture-confirmed, with Escherichia coli the leading cause (n = 9) 
followed by GBS (n = 5) (Table 1). The median age at onset for 
late-onset cases was 14 days (IQR: 11–20). Only 1 late-onset case 
was preterm. Eighty-two infants died by day 28 of life (10/1000 
births). The median age at death was 0 days (IQR: 0–28). The lead-
ing causes of death were intrapartum stillbirth (n = 26; 32%), birth 
asphyxia (n = 30; 37%) and respiratory distress of the newborn 
(n = 7; 9%). Among infants who died after the first week of life 
(n = 11; 13%), the primary causes were respiratory distress, sep-
sis and probable necrotizing enterocolitis. Among the trial cohort, 
14.8% (1205/8129) were exposed to MSAF and 3.3% (40/ 1205) 
of exposed were diagnosed with meconium aspiration syndrome. 
Ten percent of early-onset cases (30/289), 0% of late-onset cases, 
0% of culture-confirmed neonatal sepsis cases and 11.3% (8/71) of 
perinatal deaths had meconium aspiration syndrome.
In univariate analysis, low birth weight, preterm delivery and 
several maternal factors were associated with increased risk of early-
onset sepsis (Table 2). In multivariable analysis, low birth weight 
had the strongest association with early-onset sepsis and showed a 
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dose response with infants <1500 g at highest risk [adjusted relative 
risk (aRR) = 6.5, 95% CI: 2.4–17.3; Table 2]. In addition, MSAF 
(aRR = 2.8; 95% CI: 2.2–3.7), first birth (aRR = 1.8; 95% CI: 
1.1–2.9) and ≥4 vaginal examinations (aRR = 1.6; 95% CI: 1.0–2.7) 
remained significantly associated with early-onset sepsis (Table 2). 
Fewer factors were associated with late-onset sepsis, including first 
birth, emergency cesarean (not due to prior cesarean), male sex and 
MSAF (see Table, Supplemental Digital Content 2, http://links.
lww.com/INF/B213). In multivariable analysis, the only significant 
association was with MSAF (aRR = 2.4; 95% CI: 1.1–5.0). When 
both early- and late-onset sepsis were limited to culture-confirmed 
cases (29 early-onset and 20 late-onset cases), MSAF (aRR = 2.7, 
95% CI: 1.4–5.0), low birth weight (aRR = 2.5, 95% CI: 1.2–5.4) 
and first birth (aRR = 2.1, 95% CI: 1.2–3.8) were again associated 
with increased sepsis risk (see Table, Supplemental Digital Content 
3, http://links.lww.com/INF/B214).
Univariate factors associated with perinatal death included 
pregnancy-induced hypertension, pregestational diabetes mellitus 
and anemia, as well as first birth, MSAF and preterm delivery (see 
Table, Supplemental Digital Content 4, http://links.lww.com/INF/
B215). On multivariable analysis, preterm delivery was associated 
with the strongest risk of death (aRR = 5.9, 95% CI: 3.1–11.2). 
MSAF (aRR = 2.1, 95% CI: 1.2–3.7) and first birth (aRR = 1.7, 
95% CI: 1.0–2.7) also remained significantly associated.
To explore further the association between primiparous sta-
tus and the sepsis and perinatal death endpoints, we compared the 
characteristics of women delivering a first birth to those of women 
with prior deliveries. Primiparous women were more likely to have 
a number of characteristics associated with poor neonatal outcome, 
including age <20 years, rupture of membranes ≥18 hours, above 
the median number of vaginal examinations, above the median 
labor duration, emergency cesarean delivery, MSAF and low infant 
birth weight. While the differences between primiparious and 
multiparous women were statistically significant (P < 0.05) for 
these characteristics, in general the magnitude of the differences 
was small, except for young maternal age (29.5% versus 20%, 
P < 0.001), greater than the median labor duration (58.6% versus 
44.6%, P < 0.001), and greater than the median number of vaginal 
examinations (64.5% versus 42.5%, P < 0.001).
IAP was not significantly associated with any of the end-
points on univariate or multivariable analysis, even when forced into 
final multivariable models. When the endpoint was limited to early-
onset GBS disease (n = 16), the point estimates for IAP were con-
sistent with protection in univariate (RR = 0.57, 95% CI: 0.08–4.3) 
and multivariable models (aRR = 0.38, 95% CI: 0.04–3.6), but did 
not attain statistical significance.
DISCUSSION
Despite the important contribution of neonatal sepsis to 
global neonatal deaths, we present one of the first evaluations of 
risk factors associated with all-cause neonatal sepsis and perina-
tal death in a large cohort of facility-based births in sub-Saharan 
Africa. This was a secondary analysis of a clinical trial cohort that 
was neither population-based nor representative of all births at the 
facility; nevertheless, use of a sepsis definition involving both clin-
ical and laboratory signs and capture of an array of maternal, intra-
partum and newborn characteristics allowed for a more rigorous 
TABLE 1. Characteristics of Infants With Neonatal Sepsis, Soweto, South Africa
Characteristic*
Clinical Early-onset 
Sepsis (n = 260)
Culture-confirmed 
Early-onset Sepsis† (n = 29)
Clinical Late-onset 
Sepsis (n = 14)
Culture-confirmed 
Late-onset Sepsis (n = 20)
Birth weight (%)
 <1500 g 11 (4) 0 0 0
 1500–2499 g 39 (15) 6 (21) 9 (7) 2 (10)
 ≥2500 g 208 (80) 23 (79) 13 (93) 17 (85)
Preterm delivery (% <37 weeks) 38 (15) 3 (10) 0 1 (5)
Resuscitation at birth (%) 103 (40) 11 (38)% 1 (7.1) 0
Median age in days at onset (IQR) 0 (0–0) 0 (0–1) 17 (13–22) 17 (14–24)
Median days of hospital stay (IQR) 7 (5–10) 10 (8–13) 6 (3–7) 16 (6–22)
Infant HIV infection status‡ 12 (5) 3 (10) 1 (7) 2 (10)
Clinical signs of sepsis
 Respiratory distress (%) 255 (98) 23 (79) 12 (86) 11 (55)
 Hypotension (%) 23 (9) 4 (14) 5 (36) 2 (10)
 Pyrexia or hypothermia (%) 24 (9) 4 (14) 4 (29) 6 (30)
 Abdominal feeding  
problems (%)
10 (4) 5 (17) 5 (36) 10 (50)
 Bleeding diathesis (%) 0 0 0 0
 Lethargy or irritability (%) 45 (17) 8 (28) 6 (43) 9 (45)
 Central nervous system signs (%) 54 (21) 5 (17) 3 (21) 4 (20)
Laboratory signs of sepsis
 Abnormal white blood cell count (%) 52 (20) 1 (3) 7 (50) 5 (25)
 Abnormal neutrophil  
count (%)
50 (19) 2 (7) 8 (57) 4 (20)
 Low platelet count (%) 73 (28) 5 (17) 1 (7) 1 (5)
 Elevated C-reactive  
protein (%)
141 (54) 15 (52) 6 (43) 12 (60)
 Elevated CSF white blood cell count (%) 2 (1) 2 (7) 0 6 (30)
Outcome (%)
 Died by day 28 of life 14 (6) 3 (10) 1 (7)§ 0§
*All variables had <1% missing values except for HIV infection status which had 9% (28/323) missings.
†Among the culture-confirmed cases, 2 early-onset and 7 late-onset cases were identified by CSF. Early-onset pathogens included group B streptococcus (n = 16), Enterococcus 
faecalis (n = 3), Escherichia coli (n = 2), Staphylococcus aureus (n = 2), Acinetobacter baumannii (n = 2), viridans Streptococci (n = 2), Klebsiella pneumoniae (n = 1) and Acine-
tobacter lwoffii (n = 1). Late-onset pathogens included E. coli (n = 8), group B streptococcus (n = 5), Enterococcus faecium (n = 2), S. aureus (n = 2), Klebsiella species (n = 2) and 
Streptococcus species (n = 1). Three culture-confirmed infections were coinfections (E. coli/S. aureus; Klebsiella/S. aureus, Klebsiella/E. faecium).
‡Infant HIV infection status was determined by polymerase chain reaction at 6 weeks of age.
§Two infants in each of these groups died shortly after the 28-day period (days 29–32 of life), before hospital discharge.
Schrag et al The Pediatric Infectious Disease Journal • Volume 31, Number 8, August 2012
824 | www.pidj.com © 2012 Lippincott Williams & Wilkins
evaluation than is possible in most sub-Saharan Africa settings. Our 
findings that preterm birth and low birth weight were strongly asso-
ciated with increased risk of sepsis and perinatal death, and that 
MSAF and primiparity were each associated with approximately 
twice the risk of sepsis and death, provide a strong foundation for 
further investigation into the role of these factors in African new-
borns.
Preterm delivery and low birth weight are well-established 
neonatal sepsis risk factors in industrialized countries, and our 
finding that lowest birth weights were associated with the most 
risk is similar to what has been reported in the United States.14–17 
Biological mechanisms likely include immature skin barrier and 
immune system. For some pathogens, such as E. coli, low ges-
tational age is a driving risk factor with two-thirds of E. coli in 
the United States among preterm infants.14 Unfortunately, effec-
tive prevention strategies for preterm delivery remain elusive, 
although in resource poor settings improved maternal nutrition 
and access to prenatal care might be of some benefit in reducing 
low birth weight.
In contrast, industrialized country evaluations have not 
commonly identified significant associations between MSAF and 
sepsis. However, a strong association between MSAF and culture-
confirmed early and late-onset sepsis was reported from a tertiary 
care hospital in Tanzania,4 and a population-based evaluation of 
infants receiving a septic workup in a California health mainte-
nance organization also reported an association between MSAF 
and culture-confirmed sepsis.18 MSAF is more common among 
women delivering at term19 and was a common exposure among the 
infants in our study population (approximately 15% of deliveries). 
There are several possible explanations for the association between 
MSAF and neonatal sepsis. First, the clinical sepsis definitions we 
applied captured noninfectious syndromes including meconium 
aspiration syndrome. However, the fact that we observed signifi-
cant, similar associations between MSAF and culture-confirmed 
infections suggests that misclassification does not fully explain our 
observations. In addition, meconium may enhance the growth of 
sepsis pathogens20 and result in neurological damage that predis-
poses to late-onset sepsis. Finally, MSAF may represent sepsis-
associated fetal distress in utero.
Primiparity is rarely identified as a sepsis risk factor, 
often in univariate analysis or studies with limited intrapartum 
variables for evaluation.21 Because women delivering a first birth 
typically have longer duration between membrane rupture and 
delivery, an established sepsis risk factor, associations with first 
birth have been attributed to this. However, in our cohort, we 
collected information on duration of membrane rupture, dura-
tion of labor and total number of vaginal examinations received. 
First birth remained robustly associated with sepsis and perina-
tal death in multivariable analysis and was not simply a surro-
gate for duration-related variables. Instead, when we compared 
primiparous women with those with previous births, we found 
that first births were more likely to have a suite of characteris-
tics established in past studies as sepsis risk factors. Because the 
magnitude of these differences was generally small, we believe 
the combination of these small differences may be best captured 
by primiparous status.
TABLE 2. Factors Associated With Early-onset Sepsis, PoPS Trial Cohort, Soweto, South Africa
Characteristic
Cases, % Exposed 
(n = 289*)
Noncases, % Exposed 
(n = 7840*) OR† (95% CI) aOR† (95% CI)
Maternal
 Age <20 yr 18.0 13.6 1.4 (1.0–1.9)
 Pregestational diabetes mellitus 0.7 0.2 3.4 (0.8–14.9)
 First birth 59.5 42.2 2.0 (1.6–2.6) 1.8 (1.4–2.3)
 Multiple gestation 5.2 2.8 1.9 (1.1–3.3)
 Rupture of membranes ≥18 h 13.5 8.8 1.6 (1.1–2.3)
 Duration of labor (h, quartiles)‡ P = 0.003
  <2.9 21.1 24.7 REF
  2.9–5.4 18.3 24.9 0.9 (0.6–1.3)
  5.5–9.4 27.7 25.5 1.3 (0.8–2.3)
  ≥9.5 32.9 24.8 1.6 (1.1–2.2)
 Number of vaginal examinations (quartiles) P = 0.0005 P = 0.02
  <2 6.3 8.7 REF REF
  2–3 31.5 39.8 1.1 (0.7–1.9) 1.1 (0.6–1.8)
  4 18.2 19.0 1.3 (0.8–2.3) 1.2 (0.7–2.1)
  >4 44.1 32.5 1.9 (1.1–3.1) 1.6 (1.0–2.7)
 Mode of delivery
  Emergency cesarean due to prior cesarean 0.7 2.0 0.4 (0.1–1.6)
  Emergency cesarean for other reasons 29.1 21.1 1.5 (1.2–2.0)
  Vaginal delivery 70.2 77.0 REF
  Intrapartum antibiotics§ 14.5 10.4 1.5 (1.0–2.0)
  Meconium-stained amniotic fluid 30.5 14.3 2.6 (2.0–3.4) 2.8 (2.2–3.7)
Infant
 Birth weight
  <1500 g 3.8 0.3 14.3 (6.9–29.5) 6.5 (2.4–17.3)
  1500–2499 g 15.7 7.3 2.5 (1.8–3.4) 1.8 (1.1–2.9)
  ≥2500 g 80.5 92.3 REF
 Preterm delivery (<37 weeks) 14.2 3.4 4.7 (3.3–6.6) 2.6 (1.4–4.8)
*All variables had <15 missing values except for birth weight which had 49 missings (47 among noncases).
†Univariate: all factors with P < 0.15 are shown; all were entered into multivariable model, only those with P < 0.05 are shown. Due to missing values, the multivariable model 
included 287 cases and 7793 noncases. Apgar score was excluded from model because of overlap with endpoint. Only 1 case of intrapartum fever was recorded so the variable could 
not be analyzed.
‡Duration of labor is approximated by time between randomization into the PoPS trial (which for most mothers coincided with the onset of true labor) and delivery.
§IAP defined as any duration, excluding cesarean prophylaxis (cesarean with <1 hour of antibiotics before delivery).
aOR indicates adjusted odds ratio; OR, odds ratio; PoPS, Prevention of Perinatal Sepsis.
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Interestingly, on multivariable analysis, the same factors 
associated with neonatal sepsis were similarly associated with peri-
natal death. Because CHBAH serves as a referral center for satellite 
clinics, several “high risk” maternal conditions such as pregnancy-
induced hypertension were overrepresented in our cohort, yet none 
were associated with increased risk of perinatal death. The associa-
tion with MSAF may be partially explained by the observation that 
11% of deaths had a discharge diagnosis of meconium aspiration 
syndrome. The overlap between factors associated with sepsis and 
perinatal death may also suggest that neonatal infections contrib-
uted importantly to a portion of deaths, even though a pathogen was 
not always isolated.
Intrapartum antibiotic exposure was not associated with 
reduced risk of neonatal sepsis or perinatal death in this setting. 
The lack of a protective effect of IAP on multivariable analysis is 
consistent with other studies of all-cause neonatal sepsis, which 
have similarly found no impact of IAP.16 IAP currently is only 
established to be effective in preventing early-onset GBS disease; 
when we limited the endpoint to culture-confirmed GBS early-
onset sepsis, the point estimates for IAP protection were consist-
ent with this although the confidence intervals were wide, and the 
sample size was small. Moreover, IAP has been shown to have no 
effect on late-onset invasive GBS sepsis or on early-onset E. coli 
sepsis.14,22 Our findings also demonstrate the challenges of imple-
menting a risk-based IAP policy even in a referral center labor 
ward such as CHBAH. Only half of women delivering preterm 
and 10% of women with signs of chorioamnionitis received IAP. 
In addition, intrapartum fever, an important maternal risk factor 
for puerperal and neonatal sepsis, was only documented in the 
labor record of <1% of women, highlighting the difficulties of reli-
ably measuring and capturing signs in a busy labor ward. Even 
in industrialized country settings, IAP implementation under risk-
based strategies has proven lower than under culture-based GBS 
screening strategies.23
There are several limitations to our analysis. Although we 
used a more rigorous clinical sepsis case definition than past stud-
ies, the definition still was not specific for infection and likely cap-
tured birth asphyxia and other forms of respiratory distress. In addi-
tion, although our cohort of over 8000 mother-baby pairs was large, 
the sample size for some endpoints, particularly late-onset disease 
and culture-confirmed sepsis, remained small, limiting our abil-
ity to evaluate some variables for associations. Most importantly, 
however, our trial cohort differed from the overall CHBAH birth 
cohort, most notably in the smaller percentage of preterm births; it 
also differed from all Soweto births due to the overrepresentation 
in the CHBAH population of high risk deliveries. However, there 
were enough preterm, low birth weight and very low birth weight 
infants in the trial cohort to identify these factors as significant 
risks for the endpoints under consideration. In addition, CHBAH 
births capture three-fourths of all births in Soweto, so while they 
may not represent the full population, they capture a large portion. 
Moreover, the overrepresentation of high risk maternal conditions 
was a benefit in terms of evaluating whether these conditions were 
associated with risk of sepsis or perinatal death.
Most previous sepsis risk factor analyses have been limited 
to resource-rich settings and have focused on pathogen-specific 
endpoints. In sub-Saharan Africa, few studies have had a robust 
comparison group for formal risk factor assessment. While the 
Soweto, South Africa population is wealthier and has more access 
to care than many settings in sub-Saharan Africa, these same fea-
tures facilitated a rigorous evaluation of demographic, prenatal and 
intrapartum risk factors. The failure of IAP to prevent all-cause 
neonatal sepsis and the challenges of implementing a risk-based 
IAP strategy for targeted pathogen prevention shed light on the 
challenges of neonatal sepsis prevention in Africa through exist-
ing strategies. Further exploration of the mechanisms behind the 
association with first birth and MSAF are warranted as these are 
easily identifiable risk factor. In addition, exploration of maternal 
immunization as a strategy to prevent early newborn infections 
holds promise and Phase II trials of a GBS vaccine are currently 
underway in southern Africa.
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Appendix 5: Paper II 
Maternal HIV Infection and Vertical Transmission of
Pathogenic Bacteria
WHAT’S KNOWN ON THIS SUBJECT: Neonatal sepsis is an
important cause of under-5 childhood mortality. Infants born to
HIV-infected mothers are at increased risk of morbidity and
mortality, even if not having acquired HIV. This association needs
further study during the neonatal period.
WHAT THIS STUDY ADDS: Maternal HIV infection was associated
with increased vaginal colonization by Escherichia ecoli but not
group B Streptococcus. Neonates born to HIV-infected mothers
were only at increased risk of sepsis if they had acquired HIV-
infection, but not if HIV-uninfected.
abstract
BACKGROUND: HIV-exposed newborns may be at higher risk of sepsis
because of immune system aberrations, impaired maternal antibody
transfer and altered exposure to pathogenic bacteria.
METHODS: We performed a secondary analysis of a study (clinical
trials.gov, number NCT00136370) conducted between April 2004 and
October 2007 in South Africa. We used propensity score matching
to evaluate the association between maternal HIV infection and (1) vag-
inal colonization with bacterial pathogens; (2) vertical transmission of
pathogens to the newborn; and (3) sepsis within 3 days of birth (EOS)
or between 4–28 days of life (LOS).
RESULTS: Colonization with group B Streptococcus (17% vs 23%, P =
.0002), Escherichia coli (47% vs 45%, P = .374), and Klebsiella pneumo-
niae (7% vs 10%, P = .008) differed modestly between HIV-infected and
uninfected women, as did vertical transmission rates. Maternal HIV
infection was not associated with increased risk of neonatal EOS or
LOS, although culture-confirmed EOS was .3 times higher among
HIV-exposed infants (P = .05). When compared with HIV-unexposed,
neonates, HIV-exposed, uninfected neonates (HEU) had a lower risk of
EOS (20.6 vs 33.7 per 1000 births; P = .046) and similar rate of LOS (5.8
vs 4.1; P = .563). HIV-infected newborns had a higher risk than HEU of
EOS (134 vs 21.5; P , .0001) and LOS (26.8 vs 5.6; P = .042).
CONCLUSIONS: Maternal HIV infection was not associated with in-
creased risk of maternal bacterial colonization, vertical transmission,
EOS, or LOS. HIV-infected neonates, however, were at increased risk of
EOS and LOS. Pediatrics 2012;130:1–10
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Neonatal sepsis is a leading (26%–49%)
cause of neonatal mortality in de-
veloping countries and contributes
disproportionately to mortality among
children ,5 years of age.1,2 A recent
systematic review reported a paucity
of data on the incidence of neonatal
sepsis in sub-Saharan Africa.3 Esti-
mates of culture-confirmed neonatal
sepsis ranged between 5.46 to 21 per
1000 live births.4–6 Published studies
rarely distinguished between sepsis
occurring during the early neonatal
period (first 3 or 7 days of life), which
likely reflects bacteria acquired directly
from the mother’s genital tract, and
sepsis in older neonates which may be
acquired by vertical transmission or
through environmental exposures.
There is alsoa lackofdataon the impact
of maternal HIV exposure on clinical or
pathogen-specific burden of neonatal
sepsis.3 A maternal immune system
compromised by HIV infection may re-
sult in reduced transplacental transfer
of antibodies to the fetus in utero,7,8
possibly increasing neonatal sepsis
susceptibility. Although HIV infection
increases bacterial vaginosis9 and the
diversity of vaginal microbiota,10 it has
not been associated with any difference
in overall prevalence of group B Strep-
tococcus (GBS) vaginal colonization com-
pared with HIV-uninfected women.11
High maternal HIV prevalence rates
(5%–26%) in sub-Saharan Africa have
led to a reversal of decades of im-
provement in child survival.12 Morbidity
and mortality in HIV-infected children
is significantly higher than in HIV-
unexposed children.13,14 In addition,
HIV-exposed uninfected (HEU) infants
have a higher than expected risk of
morbidity and mortality compared with
HIV-unexposed uninfected (HUU) infants;
an effect related to maternal immunol-
ogic status and early weaning among
HIV-exposed infants.14–17
We performed a secondary analysis
of a South African cohort of .8000
mother-baby pairs to assess the impact
of maternal HIV infection on (1) the
prevalence of maternal vaginal coloni-
zation with pathogens associated with
neonatal sepsis; (2) vertical trans-
mission of bacterial pathogens to the
newborn; and (3) sepsis rates during
the early and late neonatal periods.
METHODS
This analysis reports on secondary
objectives of a cohort of women and
their newborns enrolled in the Preven-
tion of Perinatal Sepsis (PoPS) trial.18
PoPS was a randomized, placebo-
controlled trial to determine the ef-
ficacy of intrapartum chlorhexidine
maternal vaginal washes and newborn
skin wipes for reducing early-onset
neonatal sepsis and vertical acquisi-
tion of pathogenic bacteria by new-
borns. The study was conducted
between April 2004 and October 2007
and found no effect of interventional
wipes against primary end points of
overall early-onset sepsis (EOS) and ver-
tical transmission of colonizing patho-
genic bacteria.18
Study Population
Pregnant women attending an antena-
tal clinic or presenting in labor at Chris
Hani-Baragwanath Hospital, a second-
ary-tertiary level of care hospital, in
Soweto, SouthAfrica,wereenrolled into
the study. The prevalence of HIV in an-
tenatal clinic attendees in the study
population during the trial period was
29.9%.19 The study staff had no input
into clinical management of study
participants, including management of
HIV infection. The standard of care for
prevention of mother-to-child trans-
mission of HIV during the trial period
included a single dose of nevirapine
(sd-NVP) to both the HIV-infected mother
at onset of labor and the newborn. Be-
fore triple antiretroviral treatment of
HIV-infected individuals became rou-
tinely available in 2007, CD4+ and HIV
viral load testing by attending physicians
was limited. From 2007, pregnant
women with WHO Stage IV disease or
CD4+ count ,200 cells/mm3 were of-
fered treatment that included stavu-
dine, lamivudine, and nevirapine fromat
least 34 weeks gestation.20 All mothers
and newborns are provided with free
public health care in South Africa. In
total, 8011 mothers and their 8129
neonates were enrolled in the trial. HIV
polymerase chain reaction (PCR) testing
of HIV-exposed infants is offered rou-
tinely at 4 to 6 weeks of age.
Study Procedures
Details of study procedures have been
described.18 In brief, swabs of the lower
vagina were obtained from maternal
participants from May 2005 onward
before administering the first study
interventional wipe. A surface swab of
the umbilicus, nares, and outer ear for
culture was collected from neonates
after delivery but before bath and study
wipe. Swabs were cultured for Strepto-
coccus agalactiae (GBS), Escherichia
coli, and Klebsiella pneumoniae by
using standard methods.18
Study doctors conducted active surveil-
lance of neonatal and pediatric wards to
identify hospitalized study neonates and
abstracted information related to neo-
natal sepsis end points from medical
records. Sterile site cultures were col-
lected at the discretion of attending
physicians before initiation of antibiotic
treatment and processed per standard
practice at the hospital microbiology
laboratory. Blood was sampled for bac-
terial growth by using the BacT/Alert
microbial system (Organon Teknika,
Durham, NC). Routine methods were
used for culture and identification of
invasive pathogens from other sterile
sites. Active laboratory-based surveil-
lance was conducted to confirm that
all sterile site cultures obtained from
study neonates were captured. Mater-
nal CD4+ T-lymphocyte count results
2 CUTLAND et al
were documented when available as
part of standard of care.
End Point Definitions
Maternal vaginal colonization was de-
fined as isolation of GBS, E coli, or
K pneumoniae from vaginal swabs
collected during labor before the first
interventional wipe. Vertical transmis-
sion of bacteria was defined as neo-
natal surface colonization at birth with
the same bacterium isolated from the
maternal vagina. Early-onset sepsis
(EOS) was defined as sepsis occurring
within the first 3 days of life and late-
onset sepsis (LOS) as that from the
fourth to 28th day of life (Table 1).
Culture-confirmed episodes of sepsis
not fulfilling clinical sepsis criteria and
records of all stillborn infants and
neonates dying within 2 hours of birth
were reviewed by 3 neonatologists
to determine if the case represented
a sepsis episode. Neonatal and mater-
nal HIV infection status was based on
documented HIV testing results; those
with unknown status were excluded
from analyses involving HIV infection
status.
Statistical Considerations
To specifically evaluate maternal HIV
infection as a neonatal sepsis-related
risk factor, we used propensity score
matching to reduce biaswith respect to
important covariates for each defined
end point.21,22 Covariates considered
for impact on end points included: (1)
for maternal vaginal colonization: ma-
ternal age (. or #25 years), rupture
of membranes (ROM) before swab col-
lection, and history of antibiotics in
week before delivery; (2) for vertical
transmission: prolonged ROM, antibi-
otic use in week preceding labor and
intrapartum, number of per vaginal
examinations; and (3) for early- and
late-onset neonatal sepsis: mode of de-
livery, gestational age, prolonged ROM,
maternal fever $38.0°C, intrapartum
antibiotic use, known maternal GBS
colonization and urinary tract infec-
tions (UTIs). We chose propensity score
matching because key covariates dif-
fered between HIV-infected and HIV-
uninfected women, and standard
modeling approaches provide esti-
mates even in the absence of an ap-
propriate comparison population.
We used multivariable logistic regres-
sion to estimate the propensity score for
each mother (or infant). The propensity
score is the conditional probability of
the mother being HIV-infected given the
variables in themodel.Wematchedeach
HIV-infectedmother to anHIV-uninfected
motherwith the closest propensity score.
For each propensity score matched
analysis, balance for each covariate in-
cluded in the model was evaluated for
HIV-infected and HIV-uninfected mothers.
Thepropensityscoremodel thatachieved
the best balance was used. The model
for maternal colonization was limited to
mothers with known HIV result and
TABLE 1 Neonatal Sepsis End Point Definitions
Early-onset culture confirmed sepsis: isolation of a microorganism that is not a common contaminant (include, but are not limited by, the following list: Coagulase-
negative Staphylococcus, Bacillus,Micrococcus, Propionibacterium, Stomatococcus, Gamella, Prevotella, Corynebacterium) from a normally sterile body site within
the first 3 d of life
Early-onset clinical sepsis: A neonate hospitalized within 3 d of life and who, in the absence of another recognizable congenital infection, had at least one laboratory
criterion and either respiratory distress (1 criterion required) or at least 2 clinical criteria (see below).
Late-onset sepsis: Either culture-confirmed sepsis or clinical sepsis in an infant with symptom onset between 3 and 28 d of life.
Late-onset culture confirmed sepsis: isolation of a microorganism that is not a common contaminant from a normally sterile body site between 3 and 28 d of life.
Late-onset clinical sepsis: A neonate hospitalized between 3 and 28 d of life with at least 1 laboratory criterion and either respiratory distress (2 criteria required),
OR one feature of respiratory distress and one other clinical criterion OR at least 2 other clinical criteria.
Early-onset sepsis: Either early-onset culture-confirmed sepsis or clinical sepsis in the absence of another recognizable congenital infection, as defined below.
Clinical Criteria Definition
Respiratory distress Respiratory rate.60 breaths/min; cyanosis, chest wall indrawing, grunting on
expiration, respiratory distress noted in medical records
Hypotension Defined as mean arterial pressure , 2 SDs from mean for weight/age
Pyrexia or hypothermia Axillary temperature.38.0°C, not attributable to external warming, or axillary
temperature ,36.0°C
Abdominal/ feeding problems Abdominal distension OR feeding intolerance (.20% residual over 24 h), or poor
feeding after feeding well, or . 2 episodes of emesis
Bleeding diathesis Defined as petechiae, ecchymosis, mucous membrane bleeding, pulmonary
hemorrhage, or excessive oozing from venipuncture sites
Lethargy or irritability Noted by medical staff in absence of other central nervous system symptoms
Central nervous system Seizures, or bulging fontanelle, or single witnessed episode of apnea
Laboratory criteria
White blood cell count (WCC) WCC ,5 3 109/L OR .25 3 109/L in the absence of receiving corticosteroids;
Absolute neutrophil count (ANC) ANC ,1·75 3 109/L or .15 3 109/L
Platelet count ,150 3 109/L
C-reactive protein . 10·0 mg/L (early-onset sepsis) OR .40 mg/L (late-onset sepsis)
Elevated cerebrospinal fluid white blood cell (WBC) count .30 3 106/L WBC in absence of significant red blood cells
Previously published as Supplementary webappendix.18
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colonization swab with a result. The
model for vertical transmission was
limited to mothers with a known HIV
result, vaginal delivery, a colonization
swab with a positive result (ie, for GBS,
E coli, or K pneumoniae) and a new-
born with a microbiologic swab result.
For the EOS and LOS sepsis end points,
we considered 2 additional comparison
groups: HUU versus HEU neonates and
HEU versus HIV-infected neonates. We
built propensity score models as above,
with the appropriate outcome variable
for the comparison, balancing on the
variables listed above for EOS and LOS.
CD4+ cell count results were available
for only 34.7% (725/2090) of HIV-infected
women, thus maternal CD4+ cell count
was not included as a covariate.
Wealso conductedunadjustedanalyses
on the total cohort to understand the
influence of covariates associated with
HIV exposure or infection status on the
endpoints evaluated.
x2 tests were used to compare pro-
portions. Relative risks and 95% con-
fidence intervals were used to assess
HIV as a risk factor. Denominator for
incidence was per 1000 births. Anal-
yses were conducted by using SAS
version 9·1.
Ethics Consideration
The study was approved by the Human
Research Ethics Committee of the Uni-
versity of the Witwatersrand, South
Africa and the Institutional Review
Boardof theCenters forDiseaseControl
and Prevention, USA. Written, informed
consent was obtained from the mother
before any study procedure was un-
dertaken. The trial was registered at
ClinicalTrials.gov (NCT00136370).
RESULTS
HIV infection status was available for
98.5% (7894/8011) of mothers, 26.5%
(2090/ 7894) ofwhomwereHIV infected.
Among HIV-infected women with CD4+
results available (725/2090), 21.8%
(158/725) had CD4+ counts,200 cells/
mm3, 27.4% (199/725) between 200 and
350 cells/mm3, and 50.8% (368/725)
.350 cells/mm3. The majority of CD4+
results available (467/725, 64.4%) were
from women enrolled between June
2006 and October 2007. Antiretroviral
treatment to prevent mother-to-child
transmission of HIV was provided to
92.3% (1929/2090) of HIV-infected moth-
ers, including 97.6% (1882/1929) who
received sd-NVP and 2.4% (46/1929) who
received triple antiretroviral therapy,
which was initiated a mean of 151
(range 1 to 1095) days before delivery.
Overall, 2130 newborns were born to
2090 HIV-infected mothers.
Significant differences in baseline de-
mographic and clinical characteristics
of HIV-infected and -uninfectedmothers
included HIV-infected women being
older (P , .0001) and more likely to
have UTIs (13% vs 10%), hemoglobin
,10 mg/dL (13% vs 7%), tuberculosis
(1.5% vs 0.2%), receive antibiotics be-
fore labor onset (30% vs 21%) and
during labor (12% vs 10% for women
with vaginal delivery); P , .01 for all
observations (Table 2). HIV-infected com-
pared with -uninfected women had
higher frequencies of fever during labor
(0.7% vs 0.05%); nonelective caesarian
sections (26% vs 23%); and premature
deliveries (5.9% vs 3.1%). HIV-exposed
newborns had lower birth weights than
HUU neonates (Table 2).
Infant HIV PCR testing was undertaken
atamedianof42daysofage(1–347days)
in 64.2% (1367/2130) of HIV-exposed
infants, of whom 8.2% (112/1367) were
HIV infected. Chlorhexidine wipes did
not affect vertical HIV transmission
rate (65/713 [9.1%] vs 47/654 [7.2%]
PCR positive in interventional versus
control arms, P = .19). Differences in
baseline demographics among HIV-
exposed neonates with PCR testing
results included that HIV-infected com-
pared with HEU neonates had a lower
median gestational age (38 vs 39 weeks;
P = .005), lower birth weight (median
2995 vs 3100 g; P = .001) and higher
frequency of exposure to meconium-
stained liquor (21% vs 11%; P = .002)
during labor.
Vaginal Colonization and Vertical
Transmission of Genital-Tract
Bacteria
The total colonization cohort included
5099 (3752 HIV-uninfected, 1347 HIV-
infected) women with known HIV sta-
tus. The matched subset analysis for
assessment of vaginal colonization in-
cluded 1346 HIV-infected and 1346 HIV-
uninfected participants. HIV-infected
women were less likely to be colonized
than HIV-uninfected women with GBS
(17%vs23%;P= .0002), orKpneumoniae
(7% vs 10%; P = .008) in the matched
subset analysis. In the total cohort,
prevalence of GBS colonization was
similar to that observed in thematched
analysis, whereas higher rates of E coli
colonization (47% v. 43%, P = .039) and
no difference in K pneumoniae coloni-
zation were observed in HIV-infected
compared with HIV-uninfected women
(Table 3).
There was no difference in the rate of
vertical acquisition of GBS or K pneu-
moniae in HIV-exposed compared with
HUU newborns. The rate of vertical
acquisition of E coli was, however,
greater in HIV-exposed than HUU neo-
nates in thematched-subset populations
(60% vs 52%, respectively; P = .015) as
well as in the total cohort (60% vs 53%;
P = .0066; Table 4)
Maternal HIV-Infection Status and
Sepsis Within 3 Days of Age (EOS)
Two hundred and ninety (3.6%) of the
8129 infantswerehospitalized forsepsis
within the first 3 days of life; 29 (0.36%)
with culture-confirmed sepsis and 258
(3.2%)with clinical sepsis. The incidence
of EOS did not differ significantly be-
tween HIV-exposed and HUU neonates in
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thematchedsubset analysisor the total
cohort.Theincidenceofculture-confirmed
EOSwas, however, 3.3-fold greater among
HIV-exposed compared with HUU in the
matched analysis (P = .05), and 1.67-fold
increased in the total-cohort analysis (P=
.167; Table 5). In the total cohort,
among HIV-exposed neonates born to
mothers with CD4+ results, the inci-
dence of EOS (per 1000 births) was
inversely associated with the immu-
nologic status of the mother (CD4+
cells/mm3 ,200, 75.9; 200–350, 40.2;
.350, 19.0; P = .0065, trend is linear).
AmongHIV-exposednewborns testedby
HIV PCR, therewas ahigher incidence of
clinically diagnosed EOS in HIV-infected
(102) compared with HEU newborns
(30.6) in the matched subset analysis
(P = .033), with a similar increase in the
total-cohort analysis (P, .0001; Table 6).
In the matched-subset analysis, HEU
newborns had a lower incidence (20.6/
1000 births) of EOS than HUU newborns
TABLE 2 Maternal and Newborn Demographic and Clinical Characteristics Stratified by HIV Status
Characteristic Overall HIV-Uninfected Mothers, n (%) HIV-Infected Mothers, n (%) P
Mothers n = 8011 n = 5812 n = 2090
Median age in years (range) 26 (12–51) 26 (12–49) 27 (14–51) ,.0001
Median parity (range) 1 (0–9) 1 (0–9) 1 (0–7) ,.0001
Median gravidity (range) 2 (1–10) 2 (1–10) 2 (1–8) ,.0001
Median gestational age (range) 39 (23–44) 39 (24–44) 39 (23–44)
Medical history (%)
Urinary tract infection 854 (11) 573 (10) 275 (13) ,.0001
Hemoglobin ,10 mg/dL 692 (9) 420 (7) 264 (13) ,.0001
Gestational diabetes 20 (0.2) 17 (0.3) 3 (0.1) .25
Maternal tuberculosis 42 (0.5) 10 (0.2) 32 (1.5) ,.0001
Received antibiotics during pregnancy (%) 1856 (23) 1218 (21) 617 (30) ,.0001
Intrapartum antibiotics (IAs) in women with vaginal delivery
(% of IAs)
629/6137 436/4494 (10) 189/1554 (12) .006
Antibiotics in 7 d before delivery 475 (6) 318 (5) 152 (7) .48
Intrapartum fever (%) 17 (0.2) 3 (0.05) 14 (0.7) ,.0001
Prolonged rupture of membranes of $18 h at delivery (%) 710 (9) 525 (9) 178 (9) .48
Unbooked/no prenatal care (%) 11 (0.1) 6 (0.1) 3 (0.1) .64
Meconium stained liquor (%) 1200 (15) 925 (16) 256 (12) ,.0001
Delivery (%)a
Spontaneous vaginal delivery 6136 (77) 4494 (77) 1554 (74) .007
Emergency caesarian delivery 1874 (23) 1318 (23) 536 (26) .006
Vaginal vacuum/forceps assisted 165 (2) 116 (2) 49 (2) .31
Number of per vaginal examinations during labor
,3 3020 2213 (38) 760 (36) .17
$3 4991 3599 (62) 1330 (64)
Newborns n = 8129 n = 5886 n = 2130
Female gender 3873 (47) 2796 (48) 1028 (48) .57
Twin birth (%) 118 (1) 74 (1) 40 (2) .038
Pretermb 313 (4) 181 (3) 124 (6) ,.0001
Median birth weight, g (range) 3130 (480-5630) 3160 (670-5630) 3050 (480-4690) ,.0001
Median Apgar 5 min (range) 10 (0-10) 10 (0-10) 10 (0-10) .27
Outcome
Stillborn 26 (,0) 19 (,0) 7 (,0) .97
Died shortly after delivery 15 (,0) 12 (,0) 3 (,0) .56
Surviving newborn admitted to neonatal ward 788 (10) 578 (10) 210 (10) .80
a Includes mode of delivery for all singletons and first-born twins only.
b Note: Term infants: 7811 overall; 5701 HIV-unexposed infants, 2005 HIV-exposed infants.
TABLE 3 Prevalence of Bacterial Vaginal Colonization in HIV-infected and -uninfected Women During Labor
Total Colonization Cohort Matched Subset
HIV-negative
(n = 3752),n (%)
HIV-positive
(n = 1347),n (%)
P HIV-negative
(n = 1346),n (%)
HIV-positive
(n = 1346),n (%)
P
GBS
GBS-colonized mothers (total) 824 (22) 231 (17) .0002 307 (23) 230 (17) .0002
E coli
E coli-colonized mothers (total) 1624 (43) 677 (47) .0385 603 (45) 626 (47) .37
K pneumoniae
K pneumoniae-colonized mothers (total) 301 (8) 94 (7) .2189 132 (10) 94 (7) .008
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(33.7; P = .045); with a similar difference
observed in the total-cohort analysis (P=
.004; Table 7). There was no difference in
incidence of culture-confirmed EOS be-
tween HEU and HUU in the matched-
subset or total-cohort analysis.
Maternal HIV-Infection Status and
Neonatal Sepsis Between Days 4
and 28 (LOS)
The incidence of LOS was similar be-
tween HIV-unexposed and HIV-exposed
neonates in the matched analysis and
total cohort (Table 5). Among HIV-
exposed neonates, the incidence of
LOS was greater in HIV-infected (26.8)
than HEU (5.6; P = .042) neonates in the
total cohort, with a similar trend ob-
served in the matched analysis (30.6 vs
10.2; P = .62; Table 6). The incidence of
LOS did not differ between HEU and HUU
in thematched or total-cohort analysis,
Table 7.
Among neonates with maternal CD4+
results available, the incidence of LOS
was inversely associatedwithmaternal
immunologic status (CD4+,200 cells/
mm3, 19.0; 200–350 cells/mm3, 10.0;
and .350 cells/mm3, 8.1; P = .55).
DISCUSSION
To our knowledge, this is the first study
to have reported on the impact of ma-
ternal HIV infection on vertical transmis-
sion of bacteria to newborns, and on the
relative incidenceofEOSandLOSbetween
HIV-exposed and HIV-unexposed neo-
nates. Our data come from a setting of
high maternal HIV infection (29%), high
usage of nevirapine to preventmother-
to-child HIV transmission, and extremely
low usage of triple antiretroviral ther-
apyamongmothers.Whereasithasbeen
hypothesized that HEU neonates are at
higher risk of developing sepsis due
to impaired maternal transfer of anti-
body,7 data from our study do not cor-
roborate such speculation. On the
contrary, EOS rates were marginally
lower in HEU than HUU in the total
cohort and matched subset analysis;
and no difference was observed for
LOS rates between these groups.
The absence of an increased risk of
GBS colonization among HIV-infected
women in our study is supported by
another recently published study from
Malawi, which found no evidence of in-
creased GBS colonization associated
with HIV, except in women with CD4+
counts .500mm3.11 Overall, our obser-
vations that maternal colonization and
vertical transmission rates for leading
sepsis pathogens did not differ consider-
ably between HIV-infected and -uninfected
mothers lend support to our observa-
tion that HIV-exposed and -unexposed
newborns did not differ in neonatal
sepsis risk. Although the number of
culture-confirmed EOS cases in our co-
hort was small, limiting our power to
detect a difference in this end point, we
believe that the marginal trend in
culture-confirmed EOS does not belie
a true difference in risk between HIV-
exposed and -unexposed newborns.
However, we acknowledge that the
clinical sepsis end point has lower
specificity than an invasive sepsis end
point, and thus, culture-confirmed trends
may not match clinical sepsis trends.
Our study, however, did identify that
EOS rates were higher in HIV-infected
neonates. HIV exposed neonates born
to severely immunocompromized moth-
ers (CD4+ ,200 cells/mm3) were at
higher risk of developing EOS and LOS
than those born to mothers with CD4+
.350 cells/mm3. This observation, how-
ever, requires further corroboration be-
cause CD4+ testing was very limited. The
increased risk of EOS and LOSamongHIV-
infected compared with HEU in the to-
tal cohort and a similar trend in the
matched analysis, emphasize the need
to further reduce mother-to-child trans-
mission of HIV.
Data from our study are in contrast to
other studies that have reported an
increase in morbidity and mortality in
HIV-exposed infants, including during
early infancy.13,23 Mortality rate in Af-
rican HEU infants is 72.5 to 98.7/1000,
compared with 48.0 to 91.0/1000 in HUU
infants and 309.1 to 420.8/1000 in HIV-
infected infants,14,16 with almost 30% of
these deaths occurring in first 8 weeks
TABLE 4 Vertical Transmission of Pathogenic Bacteria From Mother to Newborn Stratified by Maternal HIV-Infection Status
Total Colonization Cohort Matched Subset
HIV-negative, n (%) HIV-positive, n (%) P HIV-negative, n (%) HIV-positive, n (%) P
GBS
Total number infants born vaginally to GBS-colonized mother. 648 181 177 177
GBS-colonized vaginally born newborna 372/641 (58) 93/179 (52) .1467 94/174 (54) 90/175 (51) .63
E coli
Total number infants born vaginally to E coli-colonizedmother. 1277 460 449 449
E coli-colonized, vaginally born newborn 665 (53) 269 (60) .0066 232 (52) 263 (60) .015
K pneumoniae
Total number infants born vaginally to K pneumoniae-
colonized mother.
241 73 69 69
K pneumoniae-colonized, vaginally born newbornb 74 (31) 20 (27) .5887 20 (29) 19 (27) .85
a Nine infants born vaginally to GBS-colonized mothers did not have swab collected/ processed for GBS: 7 HIV-unexposed and 2 HIV-exposed infants.
b One infant born to an HIV-uninfected mother colonized by K pneumoniae did not have swab processed.
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of life.14 This is particularly pertinent
because disease progression in African
HIV-infected infants is rapid, including
85% of infants progressing to severe
AIDS by 6 months of age.24 Our data
are also not consistent with the data
reported from a study in Belgium, in
which the incidence of neonatal GBS
sepsis, especially LOS, was greater in
HIV-exposed (1.55%) than HIV-unexposed
(0.08%) newborns.25
The importance of adjusting for mater-
nal factors when assessing the associ-
ation between maternal HIV infection
and neonatal sepsis is evident from
our observation that many risk factors
commonly associated with EOS, in-
cluding prolonged ROM and UTIs, were
more prevalent in HIV-infected women.
A major strength of our study was the
utilization of propensity score methods
tobetterevaluateassociationsbetween
our comparison groups. Propensity
score matching allowed us to select an
appropriate referent group similar on
known or suspected risk factors for
each outcome evaluated while blinded
to the outcome. When conclusions
drawn from the entire cohort differ
from the matched subset, we believe
the matched subset gives the most
valid comparison between the groups
with regard to whether maternal-
infection status, newborn HIV-exposure
or HIV-infection status is responsible
for the differences between groups in
the applicable comparisons. The differ-
ences between the entire cohort and
matched subset analyses highlights the
dangers of drawing conclusions about
the impact of HIV exposure on neonatal
morbidity (or mortality) without appro-
priately adjusting for other factors.
Our study does, however, have some
limitations including that CD4+ results
were available for only 34.7% of HIV-
infected women, and HIV testing was
only undertaken in 64% of HIV-exposed
infants. It is reassuring that infantswith
HIV testing were similar to infants
without HIV testing for the variables
available, although the paucity of ma-
ternal CD4+ count data prevented us
from ascertaining whether this vari-
able differed between the 2 groups.
Incidentally, vertical transmission rate
of HIV infection observed in our study
(8.2%), where sd-NVP was recom-
mended for the mother and newborn,
was not affected by chlorhexidine inter-
ventional wipes and consistent with the
transmission rate reported elsewhere
with the same regimen (10.3%).24 A fur-
ther limitation of our study included that
our enrollment procedures and in-
clusion and exclusion criteria skewed
enrollment away from inclusion of pre-
term infants. The incidence of preterm
neonates in our study population was
lower than in the hospital population
(4% vs 15%, respectively) (S. C. Velaphi,
personal communication, January 10,
2011). Consequently, because prematu-
rity is a recognized risk factor for neo-
natal sepsis, the rates of EOS and LOS
TABLE 6 Incidence of Early- and Late-Onset Sepsis in HIV-exposed HIV-infected (HIV+) and HIV-exposed Uninfected (HEU) Neonates
Sepsis Categorization Total Infants With HIV PCR Results Matched Subset
HIV+ (n = 112),n
(rate; 95% CI)
HEU(n = 1253),n
(rate; 95% CI)
P HIV+(n = 98),n
(rate; 95% CI)
HEU(n = 98),n
(rate; 95% CI)
P
Early-onset sepsis
Culture-confirmed 2 (17.9; 2.2, 63.0) 5 (4.0; 1.3, 9.3) .107 0 (0; 0, 36.9) 1 (10.2, 0.3, 55.5) 1.00
Clinical sepsis only 13 (116; 63.3190.3) 22 (17.6; 11.0, 26.5) ,.0001 10 (102.0, 50.0179.7) 2 (20.4, 2.5, 71.8) .033
Overall 15 (134; 76.9, 211.3) 27 (21.5; 14.2, 31.2) ,.0001 10 (102.0; 50.0179.7) 3 (30.6, 6.4, 86.9) .08
Late-onset sepsis
Culture-confirmed 2 (17.9; 2.2, 63.0) 5 (4.0; 1.3, 9.3) .107 2 (20.4; 2.5, 71.8) 0 (0; 0, 36.9) .50
Clinical sepsis only 1 (8.9; 0.2, 48.7) 2 (1.6; 0.2, 5.8) .227 1 (10.2; 0.3, 55.5) 1 (10.2; 0.3, 55.5) 1.00
Overall 3 (26.8; 5.6, 76.3) 7 (5.6; 2.2, 11.5) .042 3 (30.6; 6.4, 86.9) 1 (10.2; 0.3, 55.5) .62
TABLE 7 Impact of Maternal HIV Infection on Early- and Late-Onset Neonatal Sepsis in HIV-exposed, Uninfected (HEU) and HIV-unexposed, Uninfected
(HUU) Neonates
Sepsis Categorization Total HIV Uninfected Infants Matched Subset
HUU(n = 5867),n
(rate; 95% CI)
HEU(n = 1253),n
(rate; 95% CI)
P HUU(n = 1216),n
(rate; 95% CI)
HEU(n = 1216),n
(rate; 95% CI)
P
Early-onset sepsis
Culture-confirmed 21 (3.6; 2.2, 5.5) 5 (4.0; 1.3, 9.3) .797 4 (3.3; 0.9, 8.4) 4 (3.3; 0.9, 8.4) 1.000
Clinical sepsis only 202 (34.4; 30.0, 39.4) 22 (17.6; 11.0, 26.5) .002 37 (30.4; 21.5, 41.7) 21 (17.3; 10.7, 26.3) .034
Overall 223 (38.0; 33.3, 43.2) 27 (21.5; 14.2, 31.2) .004 41 (33.7; 24.3, 45.5) 25 (20.6; 13.3, 30.2) .0459
Late-onset sepsis
Culture-confirmed 12 (2.0; 1.1, 3.6) 5 (4.0; 1.3, 9.3) .203 3 (2.5; 0.5, 7.2) 5 (4.1; 1.3, 9.6) .726
Clinical sepsis only 8 (1.4; 0.6, 2.7) 2 (1.6; 0.2, 5.8) .692 2 (1.6; 0.2, 5.9) 2 (1.6; 0.2, 5.9) 1.000
Overall 20 (3.4; 2.1, 5.3) 7 (5.6; 2.2, 11.5) .306 5 (4.1; 1.3, 9.6) 7 (5.8; 2.3, 11.8) .563
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reported in our study may underestimate
the true rates of neonatal sepsis in our
setting. Nevertheless,a recent review re-
ported that the incidence of clinical sepsis
in infants ,60 days in developing coun-
tries was 49 to 170 per 1000 and 5.5 per
1000 for culture-confirmed sepsis.26 Al-
though the incidence of neonatal sepsis
observed in our study was toward the
lower boundof this for clinical sepsis (33.4
per 1000), we report a similar incidence of
culture-confirmed sepsis (5.9 per 1000).
The lower incidenceof clinical sepsis rates
in our study may have been influenced by
more stringent criteria used in our study
for diagnosing “clinical sepsis.”
CONCLUSIONS
Reducing neonatal morbidity and mor-
tality has been identified as a key focus
area for public health under Millennium
development goal number 4, which
aims at reducing under-5 mortality by
two-thirds in comparison with 1990
levels.1 Although there was a high in-
cidence of neonatal sepsis in our study
population, including among the high-
est reported incidence rates of GBS sepsis
from any developing country, maternal
HIV infection does not appear to increase
the risk of either early- or late-onset
neonatal sepsis, except among new-
borns with HIV infection and possibly
among newborns of severely immuno-
compromizedmothers. Consequently, we
do not predict the HIV prevention roll-out
in sub-Saharan Africa will result in im-
portant reductions in neonatal sepsis
in this region, and sepsis-specific inter-
ventions such as GBS vaccines may hold
most promise in reducing neonatal
infection-associated mortality.
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Appendix 6: Paper III 
Although	group	B	Streptococcus	(GBS)	is	a	leading	cause	
of	severe	invasive	disease	in	young	infants	worldwide,	epi-
demiologic	 data	 and	 knowledge	about	 risk	 factors	 for	 the	
disease	are	 lacking	from	low-	 to	middle-income	countries.	
To	 determine	 the	 epidemiology	 of	 invasive	 GBS	 disease	
among	 young	 infants	 in	 a	 setting	with	 high	maternal	HIV	
infection,	we	conducted	hospital-based	surveillance	during	
2004–2008	in	Soweto,	South	Africa.	Overall	GBS	incidence	
was	2.72	cases/1,000	live	births	(1.50	and	1.22,	respective-
ly,	among	infants	with	early-onset	disease	[EOD]	and	late-
onset	[LOD]	disease).	Risk	for	EOD	and	LOD	was	higher	for	
HIV-exposed	 than	HIV-unexposed	 infants.	GBS	serotypes	
Ia	and	III	accounted	for	84.0%	of	cases,	and	16.9%	of	 in-
fected	infants	died.	We	estimate	that	use	of	trivalent	GBS	
vaccine	(serotypes	Ia,	Ib,	and	III)	could	prevent	2,105	inva-
sive	GBS	cases	and	278	deaths	annually	among	infants	in	
South	Africa;	therefore,	vaccination	of	all	pregnant	women	
in	this	country	should	be	explored.
In 2013, a total of 41.6% (2.6 million) of deaths worldwide in children <5 years of age occurred in neonates; 76.7% 
occurred within 6 days after birth (1). Furthermore, in 2012, 
≈6.9 million probable cases of severe bacterial infections 
and 680,000 associated deaths occurred among neonates 
(2). Nevertheless, there is a paucity of data from low- and 
middle-income countries on pathogen-specific causes of 
neonatal sepsis, particularly during the first day of life, and 
it is unknown whether in utero HIV exposure increases sus-
ceptibility to severe neonatal bacterial infections.
Group B Streptococcus (GBS) is a leading cause of 
severe invasive disease in young infants. A meta-analysis 
dominated by studies from high-income countries estimated 
global incidence of 0.53 cases/1,000 live births during 2000–
2011 (3). Considerable intra- and interregional variation in 
the incidence of invasive early-onset disease (EOD; disease 
in 0- to 6-day-old infants ) was observed (3–5), ranging from 
1.21 cases/1,000 live births (95% CI 0.5–1.91) in Africa to 
0.02 cases/1,000 live births (95% CI 0–0.07) in Southeast 
Asia (3). This variability is inconsistent with the lesser dif-
ference in prevalence of maternal GBS colonization, the 
major risk factor for EOD, in women from different regions 
(20.9% in Africa, 13.4% in Southeast Asia) (6). Maternal 
HIV infection has not been associated with a higher preva-
lence of GBS colonization (7,8), except among women with 
CD4+ lymphocyte counts of >500 cells/mm3 (8).
Providing intrapartum antimicrobial drug prophylaxis 
(IAP) to women identified as rectovaginally colonized by 
GBS at 35–37 weeks’ of pregnancy has been associated 
with a >80.0% reduction in EOD (9); however, this strat-
egy is logistically challenging to implement and maintain 
in resource-constrained settings. Furthermore, IAP has not 
decreased the incidence of late-onset disease (LOD; dis-
ease in 7- to 90-day-old infants) (10).
Progress has been made in the development of a triva-
lent GBS polysaccharide–protein conjugate vaccine (GBS-
CV), which is targeted for use in pregnant women; the goal 
is to enhance transplacental transfer of capsular antibody 
to the fetus (1,8–10), which could protect against EOD and 
LOD. Improved estimates of the incidence of invasive GBS 
disease are needed from low- and middle-income countries 
to contextualize the prioritization of GBS vaccination and 
determine whether temporal changes in invasive serotypes 
should be considered in the design of serotype-specific 
GBS vaccine.
We evaluated the clinical and microbiological epide-
miology, incidence, and serotype distribution of invasive 
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Increased	Risk	for	GBS	in	Infants	Exposed	to	HIV
GBS disease among young infants in a setting with a high 
prevalence of maternal HIV infection. A secondary aim 
was to estimate the potential effect of a trivalent GBS-CV 
in reducing the number of invasive GBS cases nationally.
Materials and Methods
Study Setting and Design
During 2004–2008, we undertook hospital-based surveil-
lance of culture-confirmed invasive bacterial sepsis in in-
fants 0–90 days of age at Chris Hani Baragwanath Aca-
demic Hospital (CHBAH), a public secondary–tertiary 
health care facility in Soweto, South Africa. CHBAH is 
the only public hospital in Soweto with neonatal care fa-
cilities; ≈90.0% of all hospitalizations from the community 
occur in this hospital. Soweto is a predominantly black-
African community and has 1.4 million inhabitants, includ-
ing 125,000 children <5 years of age and a birth cohort of 
≈28,000/year (11); ≈21,000 are delivered at CHBAH and 
7,000 are delivered at 1 of 6 community-based midwife ob-
stetric units. Women with potentially complicated deliver-
ies at midwife obstetric units and clinically ill newborns are 
referred to CHBAH by ambulance. 
Health care for pregnant women and children is pro-
vided free of charge in South Africa (12). Most deliveries 
in Soweto (95.0%) (E. Buchmann, pers. comm., 2014 Jul 
19) and in South Africa as a whole (87.3% in 2010) (13) 
occur in health facilities. Voluntary counseling and testing 
for HIV is offered at antenatal clinics; >96.0% of preg-
nant women accept testing (C. Mnyani, pers. comm,, 2014 
Jul 28). Single-dose nevirapine, administered as standard 
of care to women in labor and their newborns to prevent 
mother-to-child HIV transmission, was supplemented in 
2007 with triple antiretroviral therapy to immunocompro-
mised women (<350 CD4+ cells/mm3) from 34 weeks’ ges-
tation onward.
During the surveillance period, HIV prevalence 
in pregnant women remained stable at 29.9% (14), and 
≈18.0% of all children were born prematurely (<37 weeks 
gestational age) or had a low birthweight (<2,500 g) 
(CHBAH, unpub. data). Gestational age was determined 
on the basis of the available obstetric or neonatal assess-
ments by attending physicians. Healthy newborns are rou-
tinely discharged home 12 h after vaginal or 72 h after 
cesarian delivery.
At CHBAH, newborns with signs and symptoms of 
severe illness at birth or before discharge from postnatal 
wards are admitted to the neonatal unit; infants who are 
discharged home after delivery and subsequently return 
for suspected bacterial infections are hospitalized in the 
general pediatric wards. Investigation and treatment of 
neonates and young infants with suspected invasive bacte-
rial disease were conducted according to standard of care 
by attending physicians. Investigations included com-
plete blood cell counts and blood cultures for all infants. 
Lumbar punctures (to obtain cerebrospinal fluid [CSF] 
samples for biochemistry, microscopy, and antimicrobial 
drug sensitivity testing and culture) were limited to infants 
with GBS-positive cultures of blood samples obtained at 
birth and to all infants admitted from the community for 
suspected sepsis. Sterile-site cultures were processed at 
the National Health Laboratory Service (NHLS). Blood 
cultures were evaluated by using the BacT/Alert micro-
bial system (Organon Teknika, Durham, NC, USA). GBS 
isolates were retrieved from NHLS, stored at –70°C, and 
serotyped by latex agglutination (15). During the sur-
veillance period, empiric treatment for suspected sepsis 
consisted of intravenous penicillin and gentamicin for 
neonates and ampicillin and gentamicin for infants 1–12 
months of age; case-patients with suspected meningitis 
received ampicillin and cefotaxime empirically.
Maternal screening for rectovaginal GBS coloniza-
tion during pregnancy is not routinely performed in public 
health facilities in South Africa. Before 2007, CHBAH 
IAP guidelines recommended administration of intrave-
nous ampicillin (1 g/6 h) and oral metronidazole (400 
mg 3×/d) for suspected chorioamnionitis and prolonged 
rupture of membranes. In January 2007, targeted risk-
based IAP was implemented for possible GBS infection 
in women with preterm labor, a previous infant infected 
with GBS, or a GBS-positive culture; treatment consisted 
of an initial 2-g dose of intravenous ampicillin, followed 
by intravenous ampicillin (1 g/4 h) until delivery. During 
the surveillance period, 10.5% of women received IAP 
during labor (16).
Infants 0–90 days of age who were admitted to CH-
BAH with GBS isolated from a normally sterile site were 
identified through screening of ward admissions and micro-
biological records within 24 h of identification of GBS. We 
also undertook an audit of the NHLS database to identify 
all invasive pathogens isolated from infants over the study 
period. Invasive GBS disease was categorized as bactere-
mia if identified in blood only and as meningitis if identi-
fied from CSF or if there was CSF cytologic evidence of 
purulent meningitis (>5 leukocytes/mm3; adjusted in trau-
matic lumbar punctures to allow 1 leukocyte/500 erythro-
cytes) in an infant with GBS bacteremia.
Demographic, birth, maternal HIV infection status, 
and other clinical data were abstracted from infants’ medi-
cal records by study doctors. HIV exposure was deter-
mined by abstracting antenatal HIV test results of mothers 
and supplemented by HIV ELISA results from maternal or 
infant blood tests conducted by attending physicians. The 
HIV infection status of HIV-exposed infants was deter-
mined by using a qualitative HIV PCR at the discretion of 
the attending physician.
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Statistical Considerations
Incidence was calculated as cases per 1,000 live births. Ad-
ministrative live birth data from CHBAH and community 
clinics for Soweto and HIV prevalence survey data for the 
surveillance period were used to determine population de-
nominators for HIV-infected and -uninfected women. Es-
tablished patient referral protocols limited the chance that 
neonates, especially newborns, living outside the hospital 
catchment area were admitted to CHBAH. A sensitivity 
analysis of incidence was undertaken to account for GBS 
case-patients for whom maternal HIV status was unknown. 
For overall and annual incidence calculations, we attrib-
uted the prevalence of HIV exposure among case-patients 
with known exposure status to case-patients with unknown 
exposure status. Alternate sensitivity analyses assumed all 
cases with unknown maternal HIV status were HIV-ex-
posed or, conversely, HIV-unexposed.
On the basis of 2012 population data for number of 
live births in South Africa (1,168,403) (17) and national 
prevalence of HIV infection in pregnant women (29.5%) 
(18), we used our study data to estimate annual national 
number of invasive GBS cases and deaths and stratified 
estimates by HIV exposure. We estimated the number 
of annual vaccine-preventable invasive GBS cases and 
deaths in South Africa on the basis of the conservative 
assumption that administration of GBS-CV to pregnant 
women (19) would not protect against invasive GBS dis-
ease in infants born at <33 weeks’ gestation, and we ad-
justed for the proportion of serotypes included in the cur-
rent experimental trivalent GBS-CV (Ia, Ib, and III) and 
a future pentavalent vaccine (addition of serotypes II and 
V). These estimates were based on hypothetical vaccine 
efficacy assumptions of 75.0% for the overall population; 
85.0% for HIV-unexposed infants; and 65.0% for HIV-
exposed infants, as determined on the basis of the lower 
immunogenicity of trivalent GBS-CV in HIV-infected 
pregnant women (19).
Proportions were compared by using the χ2 and Fisher 
exact tests, as appropriate; Wilcoxon rank sum test (non-
parametric) was applied for continuous variables. Univari-
ate analysis was performed to determine factors associated 
with GBS-related death. Two-sided p values <0.05 were 
considered statistically significant, and 95% CIs were cal-
culated. Analyses were conducted by using STATA/IC 
13.0 (StataCorp, College Station, TX, USA).
Ethics Consideration
The study was approved by the Human Research Ethics 
Committee, University of the Witwatersrand (M03–10–07 
and M10–367) and the institutional review board of the 
Centers for Disease Control and Prevention. Mothers of 
infants prospectively identified with invasive GBS disease 
signed informed, written consent. Consent was waived by 
the ethics committees for retrospective review of records of 
cases identified after discharge or death of the infant.
Results
During the surveillance period, 389 invasive GBS cases 
were identified in infants 0–90 days of age; 214 (55.0%) 
cases were EOD. Complete medical records were unavail-
able for 17 cases (10 EOD, 7 LOD), which were included 
in incidence calculations but not in univariable analysis. 
Overall incidence of invasive GBS was 2.72 cases/1,000 
live births (95% CI 2.46–3.01). EOD incidence was 1.50 
cases/1,000 live births (95% CI 1.30–1.71), and LOD inci-
dence was 1.22 cases/1,000 live births (95% CI 1.05–1.42); 
incidences for both were generally similar across years 
(data not shown). Overall, 26.6% of case-patients were 
born prematurely, including 29.8% of EOD and 22.3% of 
LOD case-patients. Most (69.4%) preterm births occurred 
at <33 weeks’ gestation, including 63.0% and 80.6% of 
those for EOD and LOD case-patients, respectively (on-
line Technical Appendix Table 1, http://wwwnc.cdc.gov/
EID/article/21/4/14-1562-Techapp1.pdf). Of the 214 EOD 
case-patients, 138 (64.5%) had positive culture results for 
blood samples obtained at birth (median age 0 days, inter-
quartile range 0–1; Figure 1, panel A). Forty-four percent 
of LOD cases were detected during week 2 of life (median 
age 16 days, interquartile range 11–29; Figure 1, panel B). 
Infants with LOD were 5.57-fold (95% CI 3.50–8.90) more 
likely than infants with EOD to have meningitis (61.7% vs. 
22.4%; p<0.0001).
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Figure 1.	Age	distribution	of	young	infants	(0–90	days	of	age)	
with	invasive	group	B	Streptococcus	(GBS)	sepsis,	Soweto,	South	
Africa,	2004–2008.	A)	Distribution	for	214	infants	with	early-onset	
disease.	B)	Distribution	for	175	infants	with	late-onset	disease.
Increased	Risk	for	GBS	in	Infants	Exposed	to	HIV
Invasive GBS Disease and HIV Exposure
Maternal HIV infection status was available for 327 
(84.1%) GBS case-patients, of whom 161 (49.2%) were 
HIV-exposed (online Technical Appendix Table 1). HIV-
exposure data were unavailable for 12.3% of EOD and 
11.9% of LOD case-patients. Regimens to prevent moth-
er-to-child HIV transmission were documented in only 
41.6% of the infants’ medical records and were therefore 
not analyzed in this study. HIV PCR results were avail-
able for 46 (28.6%) of 161 HIV-exposed infants: 6 had 
EOD (all nonreactive results) and 40 had LOD (8 [20.0%] 
had reactive results).
Infants with LOD were more likely than those with 
EOD to be HIV-exposed (58.1% vs. 41.9%; p = 0.004) (on-
line Technical Appendix Table 1). HIV-exposed and -un-
exposed case-patients overall or when stratified by EOD 
and LOD did not differ substantially with regard to mode 
of delivery, preterm birth, and low birthweight (online 
Technical Appendix Table 1) or to exposure to meconium-
stained liquor, prolonged rupture of membranes, or IAP 
during labor (data not shown).
The incidence of invasive GBS disease was 2.25-fold 
(95% CI 1.84–2.76) greater in HIV-exposed than HIV-un-
exposed infants (4.46 cases/1,000 live births [95% CI 3.85–
5.13] vs. 1.98 cases/1,000 live births [95% CI 1.71–2.28]) 
(Table 1). The higher incidence of GBS disease in HIV-
exposed compared with HIV-unexposed infants was evi-
dent for EOD case-patients (2.10 vs. 1.24 cases/1,000 live 
births, respectively; risk ratio 1.69, 95% CI 1.28–2.24) and 
more so for LOD case-patients (2.36 vs. 0.74 cases/1,000 
live births, respectively; risk ratio 3.18, 95% CI 2.34–4.36). 
Bacteremia and meningitis incidence was also higher in 
HIV-exposed than HIV-unexposed infants (Table 1). These 
differences in incidence of invasive GBS disease remained 
significant in all sensitivity analyses in which missing ma-
ternal HIV infection status were extrapolated (Table 1), ex-
cept for EOD when infants with unknown HIV-exposure 
status were assumed to be HIV-unexposed (Table 1).
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Table 1. Incidence	of	invasive	group	B	Streptococcus sepsis	in	0- to	90-day-old	infants,	by	in	utero	exposure	to	HIV,	Soweto,	South	
Africa,	2004–2008* 
HIV	exposure	status 
Overall  Bacteremia  Meningitis 
No.	cases,	
incidence	
(95%	CI)† 
RR  
(95	%	CI) 
No. cases,	
incidence	
(95%	CI) † 
RR  
(95%CI) 
No.	cases,	
incidence	
(95%	CI) † 
RR  
(95%	CI) 
Early-onset	disease         
 Proration	of	unknown	exposure‡         
  Unexposed 124,	1.24	
(1.03–1.48) 
1.69	 
(1.28–2.24) 
 103,	1.03	
(0.84–1.25) 
1.43	 
(1.03–1.97) 
 21,	0.21	
(0.13–0.32) 
3.00	 
(1.63–5.58) 
  Exposed 90,	2.10	
(1.69–2.58) 
  63,	1.47	
(1.13–1.88) 
  27,	0.63	
(0.41–0.92) 
 
 Unknown,	assume	exposed         
  Unexposed 104,	1.04	
(0.85–1.26) 
2.47	 
(1.87–3.26) 
 ND   ND  
  Exposed 110,	2.57	
(2.11–3.09) 
  ND   ND  
 Unknown,	assume	unexposed         
  Unexposed 139,	1.39	
(1.17–1.64) 
1.26	 
(0.94–1.68) 
 ND   ND  
  Exposed 75,	1.75	
(1.38–2.19) 
  ND   ND  
Late-onset	disease         
 Proration	of	unknown	exposure‡         
  Unexposed 74,	0.74	
(0.58–0.93) 
3.18	 
(2.34–4.36) 
 27,	0.27	
(0.18–0.39) 
3.37	 
(2.01–5.73) 
 47,	0.47	
(0.35–0.62) 
3.08	 
(2.07–4.60) 
  Exposed 101,	2.36	
(1.92–2.86) 
  39,	0.91	
(0.65–1.24) 
  62,	1.45	
(1.11–1.85) 
 
 Unknown,	assume	exposed         
  Unexposed 62,	0.62	
(0.48–0.79) 
4.25	 
(3.09–5.89) 
 ND   ND  
  Exposed 113,	2.64	
(2.17–3.17) 
  ND   ND  
 Unknown,	assume	unexposed         
  Unexposed 89,	0.89	
(0.71–1.09) 
2.25	 
(1.66–3.07) 
 ND   ND  
  Exposed 86,	2.01	
(1.61–2.48) 
  ND   ND  
Early-onset	plus	late-onset	disease,	
exposed	vs. unexposed 
2.25	 
(1.84–2.76) 
  1.83	 
(1.40–2.39) 
  3.05	 
(2.20–4.25) 
 
*RR,	relative	risk;	ND,	not	done. 
†Incidence = no. cases/1,000 live births. 
‡Based on prevalence of HIV exposure among those tested. 
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Factors Associated with Death among Infants  
with Invasive GBS
The overall case-fatality rate (CFR) was 16.9%; the CFR 
for meningitis (24.3%) was 2.4-fold greater than that for 
bacteremia (11.8%; odds ratio 2.24, 95% CI 1.33–4.35; p 
= 0.0015). The median duration of hospitalization was 1 
day for infants who died and 15 days for those who sur-
vived (online Technical Appendix Table 1). In univariate 
analysis, meningitis and very low birthweight (<1,500 g) 
were associated with a higher overall CFR (p = 0.002 and p 
= 0.003, respectively). Prematurity (<33 weeks’ gestation) 
was associated with a higher CFR in EOD but not LOD 
case-patients (p = 0.008 and p = 0.68, respectively) (online 
Technical Appendix Table 2).
Antimicrobial Drug Susceptibility and Serotyping of GBS
Antimicrobial drug sensitivity profiles were available for 385 
(98.9%) of 389 isolates; all were penicillin sensitive. Macro-
lide resistance was prevalent in 15 (5.5%) of 273 of isolates.
Of 389 isolates, 213 (54.8%) were available for se-
rotyping, including 125 (58.6%) from EOD case-patients 
and 88 (41.3%) from LOD case-patients. The proportion of 
isolates available for serotyping increased each year: 2004, 
15.6%; 2005, 45.1%; 2006, 65.8%; 2007, 63.3%; 2008, 
75.0%. Overall, serotypes Ia and III accounted for 84.0% 
of all serotypes (19.2% [41/213] and 64.8% [138/213], re-
spectively) and for 74.4% of EOD and 97.7% of LOD cases 
(p<0.001; Figure 2). Serotype distribution remained similar 
throughout the study and did not differ by HIV-exposure 
status (data not shown). Overall, a greater proportion of 
meningitis than bacteremia cases were caused by serotype 
III (77.8% [63/81] vs. 56.8% [75/132]; p = 0.002), and se-
rotype V was more commonly identified in bacteremia than 
meningitis cases (7.6% [10/132] vs. 3.7% [3/81]; p = 0.25; 
online Technical Appendix Figure). Serotype distribution 
between survivors and nonsurvivors did not differ (p = 
0.51; data not shown).
Nationwide Number and Potential Vaccine-Preventable 
Fraction of Invasive GBS Disease
We estimated ≈3,178 invasive GBS cases and 549 GBS-
associated deaths among South Africa’s 2012 birth cohort 
(Table 2). For HIV-unexposed and -exposed infants, these 
estimates represent ≈1,639 and 1,544 cases and 283 and 
266 deaths, respectively. On the basis of the predefined es-
timated efficacy of trivalent GBS vaccine to protect infants 
born at >33 weeks gestation, we estimated that, each year, 
1,230 cases of invasive GBS disease and 163 deaths could 
be prevented in HIV-unexposed infants and 886 cases and 
117 deaths could be prevented in HIV-exposed infants 
(Table 2).
Discussion
We report a high overall incidence of invasive GBS dis-
ease in Soweto (2.72 cases/1,000 live births), which is 
greater than global (0.53 cases/1,000) and African (1.21 
cases/1,000) incidence estimates reported in a meta-analy-
sis of studies conducted during 2000–2011 (3). That over-
all estimate included an incidence of 1.98 cases/1,000 live 
births (95% CI 1.71– 2.28) among HIV-unexposed infants, 
which is similar to or greater than incidences reported in 
many resource-rich countries before the widespread use of 
IAP (20). Furthermore, the observed overall incidence was 
similar to that for the same population a decade earlier (3.0 
cases/1,000 live births) (21) and to that for women of South 
Asian descent in South Africa during the 1980s (2.65 cas-
es/1,000 live births) (22). Despite the 2007 implementation 
of a risk-based IAP strategy at CHBAH, the high incidence 
of GBS disease has persisted, indicating the limited effect 
of the strategy in a resource-restricted setting with high ma-
ternal HIV infection prevalence. The limited effect could 
indicate poor strategy adherence or that the strategy missed 
most women whose newborns were at risk for EOD.
The high incidence of invasive GBS disease in South 
Africa contrasts with the lower incidence reported in South 
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Figure 2.	Group	B	
Streptococcus	serotype	
distribution	among	125	patients	
with	early-onset	disease	(EOD)	
and	88	patients	with	late-onset	
disease	(LOD),	Soweto,	South	
Africa,	2004–2008.
Increased	Risk	for	GBS	in	Infants	Exposed	to	HIV
Asia and the Western Pacific, despite similarity in preva-
lence of maternal vaginal GBS colonization at delivery 
(6). Possible reasons for this discrepancy include differ-
ences in delivery location, presence of trained birth-care 
attendants, and access to health facilities with adequate ca-
pability to diagnose and treat invasive GBS disease. Possi-
ble reasons for differences are exemplified by the findings 
in a study conducted in Bangladesh (23), which reported 
that only 1 of 30 culture-confirmed neonatal bacteremia 
cases was caused by GBS; however, >50.0% of the 259 re-
ported neonatal deaths (many among infants born outside 
health care facilities) occurred within 24 h of birth, and 
62.0% of those cases were not investigated for bactere-
mia. Our finding that 64.5% of EOD cases were diagnosed 
within 24 h of birth highlights the effect that births outside 
of health care facilities or where there is limited capacity 
for investigating invasive disease in newborns could have 
on measuring the incidence of EOD. Also, even though 
case-patients were treated in a secondary–tertiary hospital, 
death caused by invasive GBS disease was rapid (median 
1 d from hospitalization).
In our study, the overall incidence of GBS dis-
ease in HIV-exposed infants was 4.46 cases/1,000 live 
births. The high prevalence of maternal HIV infection 
is contributing to the high incidence of GBS disease in 
South Africa, which corroborates data from a Belgium 
study that reported an incidence of 15.5 cases/1,000 live 
births (i.e., 5 cases/322 infants, predominantly LOD) in 
HIV-exposed infants, compared with 0.8 cases/1,000 
live births (i.e., 16 cases/20,158 infants) in HIV-un-
exposed infants (24). Our study was not designed to 
evaluate whether the lower threshold used for inves-
tigating for sepsis in HIV-exposed than for HIV-unex-
posed infants may have contributed to ascertainment 
bias. However, such bias is unlikely because the thresh-
old for investigating for sepsis among neonates is low in 
general at CHBAH; an investigation is done only when 
clinically indicated.
In addition to the higher incidence of LOD observed 
in HIV-exposed compared with HIV-unexposed infants, 
we observed that risk for EOD was 1.69-fold (95% CI 
1.28–2.24) greater in HIV-exposed infants. This in-
creased risk was present despite our previous observa-
tion that the prevalence of vaginal GBS colonization at 
delivery was lower in HIV-infected than HIV-uninfected 
women (17.0% vs. 23.0%; p = 0.002), even though rates 
of vertical colonization were similar for their newborns 
(52.0%–58.0%) (25). Although our study did not identify 
other differences in prevalence of risk factors for inva-
sive GBS disease between HIV-exposed and -unexposed 
infants (26), we did not have population-level data on 
prevalence rates of these maternal risk factors for HIV-
infected and -uninfected women. However, the observa-
tion of a greater difference in risk for LOD than EOD in 
HIV-exposed newborns compared with HIV-unexposed 
newborns suggests that risk factors other than peripartum 
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Table 2. Estimated	annual	number	of	invasive	GBS	disease	cases	and	associated	deaths	and	potential	annual	vaccine-preventable	
fraction,	South	Africa* 
National	estimates 
Overall 
 
HIV unexposed† 
 
HIV exposed† 
No. Incidence	(95%	CI) No. Incidence	(95%	CI) No. Incidence	(95%	CI) 
Births 1,168,403‡   823,724   34,4679  
Invasive	GBS	cases 3,178§ 2.72	(2.62–2.81)  1,639¶ 1.99	(1.89–2.09)  1,544# 4.48	(4.26–4.71) 
Invasive	GBS-associated	deaths        
 No	total** 549 0.47	(0.43–0.51)  283 0.34	(0.30–0.39)  266 0.77	(0.68–0.87) 
 No.	in	infants	born	at	>33	 
 weeks’ gestation†† 
420 0.36	(0.33–0.40)  217 0.26	(0.23–0.30)  204 0.59	(0.51–0.68) 
Vaccine-preventable	cases	and	deaths        
 Trivalent	GBS-CV‡‡         
  Cases 2,105§§ 1.80	(1.73–1.88)  1,230¶¶ 1.49	(1.14–1.58)  886## 2.57	(2.40–2.75) 
  Deaths 278§§ 0.24	(0.21–0.27)  163¶¶ 0.20	(0.17–2.31)  117## 0.34	(0.28–0.41) 
 Pentavalent	GBS-CV***         
  Cases 2,317§§ 1.99	(1.90–2.07)  1,354¶¶ 1.64	(1.56–1.73)  976## 2.83	(2.66–3.01) 
  Deaths 306§§ 0.26	(0.23–0.29)  179¶¶ 0.22	(0.19–0.25)  129## 0.37	(0.31–0.44) 
*GBS,	group	B	Streptococcus; GBS-CV,	GBS	polysaccharide–protein	conjugate	vaccine. 
†HIV-exposed	and	-unexposed	values	were	calculated	on	the	basis	of	national	HIV	prevalence	in	pregnant	women	(29.5%).	Incidence	values	represent	
cases/1,000	live	births. 
‡2012 live births. 
§Overall	GBS	incidence	is	2.72/1,000	live	births. 
¶GBS	incidence	for	HIV-unexposed	infants	is	1.99/1,000	live	births. 
#GBS	incidence	in	HIV-exposed	infants	is	4.48/1,000	live	births. 
**Total	deaths	in	infants	<90	days	old,	assuming	15.2%	were	born	at	<33	weeks	of	gestation	and	have	a	case-fatality	rate	(CFR)	of	26.5%	and	assuming	
84.8%	were	born	at	>33	weeks	of	gestation	and	have	a	CFR	of	15.6%. 
††Deaths in infants <90 days	old	who	were	born	at	>33	weeks	of	gestation	(84.8%	of	infants);	CFR	15.6%. 
‡‡Trivalent GBS-CV	contains	serotypes	Ia,	Ib,	and	III,	which	account	for	88.3%	of	cases. 
§§Assuming	vaccine	efficacy	of	75%. 
¶¶Assuming	vaccine	efficacy	of	85%. 
##Assuming	vaccine efficacy	of	65%. 
***Pentavalent	GBS-CV	contains	serotypes	Ia,	Ib,	II,	III,	and	V,	which	account	for	97.2%	of	cases. 
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EOD–associated risk factors likely contribute to the 
heightened susceptibility of invasive disease in HIV-ex-
posed infants. We were unable to determine whether HIV 
infection in the neonates contributed to an enhanced sus-
ceptibility to invasive GBS disease. None of the newborns 
with EOD for whom HIV testing was done were HIV- 
positive, whereas 20.0% (8/40) of tested LOD case-pa-
tients were HIV-positive. The population-based vertical 
transmission rate of HIV during the course of the study 
was 9.6% (27). A further limitation of our study was the 
lack of data on the clinical, immunologic, and HIV-vi-
rologic characteristics of the HIV-infected women and 
analysis of whether these characteristics could have con-
tributed to a heightened susceptibility of invasive disease 
in their neonates.
Multiple studies have reported an inverse association 
between maternal GBS serotype–specific antibody levels 
and an infant’s risk for EOD and LOD (28). Lower levels of 
maternally derived antibodies to several childhood vaccine 
epitopes have been reported in HIV-exposed but uninfected 
infants at birth to at least 6 weeks of age (29,30). Thus, it is 
plausible that lower naturally acquired capsular antibody in 
HIV-infected women may contribute to increased suscepti-
bility to invasive GBS disease in HIV-exposed infants; this 
possibility warrants further investigation. The increased 
incidence of invasive GBS disease in HIV-exposed but un-
infected infants could also be due to observed perturbations 
of their immune systems (31,32).
The serotype distribution of GBS isolates from EOD 
and LOD cases in this study was similar to that observed 
previously (21) and did not differ by HIV-exposure status. 
Serotypes Ia, Ib, and III, which are included in the current 
investigational trivalent GBS-CV, covered 78% of EOD 
and 100% of LOD invasive isolates in this study. How-
ever, the overall potential disease reduction of a vaccine 
against invasive GBS disease may be lower than this po-
tential coverage because the vaccine is unlikely to confer 
protection through antibody acquisition in neonates born 
at <34 weeks’ gestation (33). The protection of premature 
newborns against EOD would require prevention of GBS 
acquisition from the mother. This strategy is pertinent to 
settings like ours, in which 29.8% of all EOD-associated 
and 31.4% of all GBS-associated deaths occurred in prema-
ture infants despite the rate of premature birth in the com-
munity being only 18.0%.
Using a conservative approach of assuming no effi-
cacy against invasive GBS disease in infants born at <33 
weeks’ gestation and vaccine efficacy of 85% and 65% in 
HIV-unexposed and HIV-exposed infants, respectively, 
we estimate that vaccination of pregnant women with the 
current investigational trivalent conjugate vaccine could 
potentially prevent 3,178 GBS cases and 549 GBS-asso-
ciated deaths annually in South Africa. An effective GBS 
vaccine could also be used to probe the possible role of 
GBS in causing sickness and death in countries with lim-
ited epidemiologic laboratory capacity (34) and in causing 
stillbirths (35).
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Chlorhexidine maternal-vaginal and neonate body wipes in 
sepsis and vertical transmission of pathogenic bacteria in 
South Africa: a randomised, controlled trial
Clare L Cutland, Shabir A Madhi, Elizabeth R Zell, Locadiah Kuwanda, Martin Laque, Michelle Groome, Rachel Gorwitz, Michael C Thigpen, 
Roopal Patel, Sithembiso C Velaphi, Peter Adrian, Keith Klugman, Anne Schuchat, Stephanie J Schrag, and the PoPS Trial Team*
Summary
Background About 500 000 sepsis-related deaths per year arise in the fi rst 3 days of life. On the basis of results from 
non-randomised studies, use of vaginal chlorhexidine wipes during labour has been proposed as an intervention for 
the prevention of early-onset neonatal sepsis in developing countries. We therefore assessed the effi  cacy of 
chlorhexidine in early-onset neonatal sepsis and vertical transmission of group B streptococcus.
Methods In a trial in Soweto, South Africa, 8011 women (aged 12–51 years) were randomly assigned in a 1:1 ratio to 
chlorhexidine vaginal wipes or external genitalia water wipes during active labour, and their 8129 newborn babies 
were assigned to full-body (intervention group) or foot (control group) washes with chlorhexidine at birth, respectively. 
In a subset of mothers (n=5144), we gathered maternal lower vaginal swabs and neonatal skin swabs after delivery to 
assess colonisation with potentially pathogenic bacteria. Primary outcomes were neonatal sepsis in the fi rst 3 days of 
life and vertical transmission of group B streptococcus. Analysis was by intention to treat. The trial is registered with 
ClinicalTrials.gov, number NCT00136370.
Findings Rates of neonatal sepsis did not diff er between the groups (chlorhexidine 141 [3%] of 4072 vs control 148 [4%] 
of 4057; p=0·6518). Rates of colonisation with group B streptococcus in newborn babies born to mothers in the 
chlorhexidine (217 [54%] of 401) and control groups (234 [55%] of 429] did not diff er (effi  cacy –0·05%, 
95% CI –9·5 to 7·9).
Interpretation Because chlorhexidine intravaginal and neonatal wipes did not prevent neonatal sepsis or the vertical 
acquisition of potentially pathogenic bacteria among neonates, we need other interventions to reduce childhood 
mortality. 
Funding US Agency for International Development, National Vaccine Program Offi  ce and Centers for Disease 
Control’s Antimicrobial Resistance Working Group, and Bill & Melinda Gates Foundation. 
Introduction
About 900 000 sepsis-associated neonatal deaths per 
year arise in developing countries, mainly in the fi rst 
week of life.1,2 Early-onset sepsis poses unique 
opportunities for prevention because of intrapartum, 
vertical transmission of bacteria to newborn babies. For 
example, widespread use of targeted prophylaxis with 
intrapartum antibiotics in the USA coincided with a 
70% reduction in early-onset group B streptococcal 
disease.3–5 Logistical and resource limitations, however, 
prevent use of intrapartum antibiotics in developing 
countries. Additionally, the increased diversity of 
sepsis-causing pathogens in developing countries6 
draws attention to the potential value of a syndrome-based 
rather than pathogen-specifi c approach to prevention. 
Maternal deaths are also increased in developing 
countries with about half the 500 000 deaths per year 
arising in sub-Saharan Africa.7
Use of intravaginal washes during labour with 
chlorhexidine, a commonly available wide-spectrum 
microbicide, has been proposed as a cheap, simple, and 
accessible intervention that could potentially reduce 
neonatal and maternal post-partum sepsis in developing 
countries.8–10 Vaginal washes with intrapartum 
chlorhexidine are postulated to reduce neonatal sepsis by 
preventing newborn acquisition of bacteria that colonise 
the mother’s vagina during labour and delivery. 
Chlorhexidine is safe and well tolerated as a vaginal 
cleanser in pregnant women in solutions of up to 1% 
concentration11 and in solutions of up to 4% as a cleanser 
for the newborn umbilical cord.12
In two non-randomised studies in Africa, use of 
chlorhexidine wipes to clean the birth canal and 
newborn baby was associated with signifi cant reductions 
(50–75%) in neonatal and maternal sepsis-associated 
morbidity and neonatal mortality.13,14 Despite these 
fi ndings, the absence of a defi nitive randomised, 
controlled trial has impeded widespread acceptance 
and implementation of chlorhexidine wipes.9,15,16 The 
conclusions drawn from reviews about the use of 
chlorhexidine for cleansing the maternal vaginal canal 
and newborn skin9,10,15,17 are that a randomised controlled 
trial, preferably done in a developing country, is needed 
before this intervention is accepted globally. In a 
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Cochrane meta-analysis18 of randomised or quasi-
randomised trials, vertical transmission of group B 
streptococcus, but not early-onset infection with this 
bacterium18 or maternal or neonatal infections caused 
by other pathogens, was reduced signifi cantly by use of 
chlorhexidine.17,19 We therefore assessed the effi  cacy of 
intrapartum and neonatal chlorhexidine in reducing 
early-onset neonatal sepsis and vertical transmission of 
group B streptococcus. 
Methods
Study setting
The study was undertaken at Chris Hani-Baragwanath 
Hospital, Soweto, South Africa; three-quarters of 
30 000 babies born every year in Soweto are delivered in 
this hospital. This referral centre provides free maternal 
and child care to an urban, middle-income and low-
income population; it is the only local public hospital 
that admits neonates. Maternal screening for colonisation 
with group B streptococcus and prophylaxis with 
intrapartum antibiotics are not routine but are part of a 
maternal risk-factor-based strategy that is advocated for 
the management of chorioamnionitis. The facility 
provides an active HIV voluntary testing programme 
with an ante natal HIV prevalence of 35 360 (30%) of 
118 188 pregnant women during the trial.
Participants
Pregnant women (aged 12–51 years) were screened for 
enrolment antenatally or in the labour ward, and were 
reassessed for eligibility during active labour before 
randomisation and planned migration from study area in 
the fi rst month after delivery. Exclusion criteria were 
planned caesarean section, antepartum haemorrhage, 
known severe congenital malformation, intrauterine 
death confi rmed before randomisation, known allergy to 
chlorhexidine, face presentation, many genital warts or 
ulcers, full cervical dilatation, and age younger than 
15 years.
Mothers provided informed, written consent for trial 
participation for themselves and their newborns babies. 
The study was approved by the human research ethics 
committee of the University of Witwatersrand, Soweto, 
South Africa, and the institutional review board of the 
Centers for Disease Control and Prevention, Atlanta, GA, 
USA. The study was monitored by an independent data 
and safety monitoring board that undertook a masked 
review of the study conduct and safety of participants in 
the study, including one unmasked interim analysis for 
effi  cacy.
Randomisation and masking
Random assignment of patients into the trial was initiated 
on April 1, 2004, and completed on Oct 25, 2007. The 
sponsor generated the randomisation numbers using 
SAS (version 9.0) and assigned them in blocks of 
50 participants. The forms were preprinted, sealed in 
opaque envelopes, and opened sequentially by study 
midwives when participants were randomly assigned. 
Commercially available, 5% colourless, and mildly 
odoured chlorhexidine gluconate was diluted every week 
to 0·5% with autoclaved tap water that was suitable for 
drinking and stored in 1 L opaque bottles at room 
temperature. Autoclaved tap water was used as the 
control. Bottles containing chlorhexidine solution and 
water were not labelled with the solution name but were 
labelled with a code and date of preparation. Study 
midwives were aware of the intervention they were 
administering. The rest of the study team, including 
those gathering endpoint data, were unaware of the 
treatment allocations. Laboratory staff  were also unaware 
of mother and neonate pairings. Study staff  had no role 
in the management of the patients. 
Intervention
Chlorhexidine was tested for activity with spectro-
photometric and biological tests. The control and 
chlorhexidine solutions were tested for sterility before 
and after use. 
The midwives wrapped cotton pads soaked in water 
or chlorhexidine around their gloved fi ngers. In the 
chlorhexidine group, the midwives rotated their 
examining fi ngers circumferentially over the cervix and 
vaginal walls, and wiped the external genitalia; in the 
4006 mothers and 4057 neonates assigned
to control group
4006 mothers and 4019 neonates 
given intervention
38 mother–neonate pairs not
given intervention
0 wrong wipe
0 wrong solution
0 wrong wipe and solution
38 no neonatal wipe done
4005 mothers and 4072 neonates assigned 
to chlorhexidine group
4005 mothers and 4051 neonates
given intervention
22 mother–neonate pairs not
given intervention
0 wrong wipe
0 wrong solution
1* wrong wipe and solution
21 no neonatal wipe done
8011 mothers (8129 neonates) randomly assigned
10 927 women consented and were assessed for 
  eligibility on arrival in labour ward
2916 excluded
2851 did not meet inclusion criteria
65 refused to participate
4072 neonates (4005 mothers) analysed 
(ITT, overall population)
141 neonates with sepsis
        (7 sepsis-related deaths)
14 culture confirmed
126 clinical sepsis only
     1 early death†
148 neonates with sepsis 
         (12 sepsis-related deaths)
14 culture confirmed
132 clinical sepsis only
     2 early deaths†
4057 neonates (4006 mothers) analysed 
(ITT, overall population)
Allocation
Analysis
Study outcome
of neonatal 
sepsis
Figure 1: Trial profi le
ITT=intention to treat. *Participant was randomly assigned, discharged, and readmitted at a later date, and was 
allocated a new randomisation number on readmission; the wipe that was not done according to protocol was done 
according to the fi rst randomisation group, which was diff erent to the fi nal group. †Did not meet criteria.
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control group, only the external genitalia were wiped to 
avoid any risk of vaginal wipes in the absence of 
antisepsis. Doctors were not allowed to enter the cubicle 
or nursery when a midwife was doing the inter-
ventional wipes.
Neonates in the chlorhexidine group were wiped from 
head to toe, avoiding the face and ears, as soon as 
possible after birth with cotton pads soaked in 
chlorhexidine solution. Neonates in the control group 
were given a chlorhexidine foot wipe (chlorhexidine was 
used as a neonatal control solution instead of water to 
assist in blinding and design of the case report form). 
All babies were bathed in water as per standard of care 
before being wiped.
Procedures
The midwives gathered information about baseline 
characteristics from labour records, and interviewed 
mothers about side-eff ects of the wipes. Trained doctors 
prospectively identifi ed mothers admitted to hospital 
within 14 days of delivery, or neonates within 28 days of 
birth, and gathered information related to the sepsis 
endpoints from medical records. Sterile site cultures 
were gathered at the discretion of the attending 
physicians and processed at the hospital microbiology 
laboratory with routine methods including the 
BacT/Alert microbial system (Organon Teknika, 
Durham, NC, USA) for blood culture. Active 
laboratory-based surveillance was done to ensure that 
all sterile-site cultures from admitted neonates were 
captured. External clinical research associates monitored 
all trial procedures. Additionally, trial-independent 
clinicians reviewed all maternal and neonatal deaths, 
and serious adverse events that were assessed to be 
possibly related to trial intervention.
Colonisation substudy
On randomisation, a swab of the lower vagina was 
obtained from the mothers from May 16, 2005, to 
Oct 19, 2007. Surface swabs of the umbilicus, nares, and 
outer ear were gathered for culture from neonates after 
delivery but before the neonate was bathed and wiped.
Swabs were inoculated into Amies medium and 
processed within 48 h. For isolation of group B 
streptococcus, swabs were inoculated onto 5% horse 
blood agar with and without colistin (10 μg/mL) and 
nalidixic acid (15 μg/mL) and into Todd-Hewitt broth 
(2 mL) supplemented with gentamicin (8 μg/mL) and 
nalidixic acid (15 μg/mL), followed by inoculation onto 
5% horse blood agar. Gram-positive β-haemolytic colonies 
were identifi ed as group B streptococcus by CAMP 
(Christie, Atkins, and Munch-Petersen) positive test, 
inability to hydrolyse esculin, and group B antigen latex 
agglutination (Omega Diagnostics, Scotland, UK). 
Escherichia coli and Klebsiella pneumoniae were inoculated 
onto MacConkey agar, and colonies were identifi ed by 
standard biochemical tests. 
Sepsis defi nitions
We defi ned early-onset sepsis as arising within the fi rst 
3 days of life and including culture-confi rmed or clinical 
sepsis on the basis of clinical and laboratory signs. Cases 
of late-onset sepsis had symptom onset between 3 days 
and 28 days of age (webappendix p 1). Vertical 
transmission was defi ned as surface colonisa tion of the 
newborn baby at birth with the same bacterium isolated 
from the mother’s vagina during vaginal delivery. 
Post-partum sepsis was defi ned as admission of the 
mother to hospital within 14 days of delivery for 
endometritis (at least two of uterine tenderness, fever, 
foul-smelling or purulent lochia, or vaginal discharge), 
culture-confi rmed infection of sterile site, or perineal 
wound infection among vaginal parturients.
Statistical analysis
A background rate of early-onset sepsis of 30 per 
1000 livebirths was estimated during a prestudy hospital 
audit. On the basis of α 0·05 and 90% power, a sample size 
of 3581 mother–baby pairs was needed per group to detect 
a 40% effi  cacy of the intervention. Thus, we targeted a total 
of 8000 mother–baby pairs. For the colonisation substudy, 
1470 mother–neonate pairs per group were needed to 
1959 mothers assigned to control group
1959 given intervention
0 not given intervention
2005 mothers assigned to chlorhexidine 
group
2005 given intervention
0 not given intervention
5146 mothers and 5207 swabbed neonates in 
colonisation cohort phase
5826 women randomly assigned in main trial during
colonisation cohort phase
682 excluded
4 labelling/sampling error
673 laboratory constraints in 
processing samples
5 mothers with swab delivered 
elsewhere
 
401 colonised with group B streptococcus
316 compliers†
85 non-compliers‡
217 neonates colonised with group B 
 streptococcus
168 born to compliers
49 born to non-compliers
234 neonates colonised with group B 
streptococcus
429 colonised with group B streptococcus
3964 vaginal deliveries (mother–neonate 
pairs)*
1208 emergency caesarean delivery 
(mother–infant pairs)
Randomisation
Analysis
Outcomes in
neonates
Figure 2: Colonisation substudy profi le
*Mother was counted twice if both twins were delivered vaginally. †Mother given at least one wipe 1–6 h before 
delivery, and was given only the correct intervention. ‡Mother was not given chlorhexidine wipe 1–6 h before 
delivery, therefore did not meet the criteria for compliers.
See Online for webappendix
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detect a 30% reduction in vertical transmission of group B 
streptococcus between the mother and child on the basis 
of a 25% prevalence of maternal colonisation with this 
bacterium. This number was adjusted to a total of 3600 to 
allow for compliance failures.
Data were reviewed for accuracy, consistency, and com-
pleteness before double data-entry into custom-designed 
databases. Consistency checks and data validation were 
done regularly.
An analytical plan was approved by the trial’s steering 
committee before database locking and unmasking. 
Analyses were done with SAS (version 9.1). The primary 
endpoint of sepsis was assessed on an intention-to-treat 
basis. Effi  cacy of chlorhexidine wipes was calculated with 
the formula
RTrt was the incidence rate in infants in the intervention 
group, and RCtl was the incidence rate in infants in the 
control group. The colonisation analysis focused on the 
subset of women with a vaginal delivery who had positive 
colonisation status and met inclusion criteria. Because 
the objective was to elucidate the mechanism by which 
chlorhexidine might aff ect sepsis, we did an analysis 
of complier-average causal eff ect20–22 to estimate 
the intention-to-treat eff ect among true compliers 
(webappendix pp 2–3). We defi ned compliance as women 
being given only wipes of the assigned treatment and at 
least one wipe between 1 h and 6 h before delivery. A 
p value of less than 0·05 was considered signifi cant. 
Throughout, twins were counted as independent births, 
and stillborn neonates were included in the intention-
to-treat analyses.
The trial is registered with ClinicalTrials.gov, number 
NCT00136370.
Role of the funding source
The sponsors of the study had no role in study design, 
data gathering, analysis, interpretation, dissemination, 
or in the decision to submit this report for publication. 
The corresponding author had full access to the data and 
the fi nal responsibility for the decision to submit for 
publication.
Results
Figure 1 shows the trial profi le; fi gure 2 shows the 
substudy profi le. Table 1 shows that the baseline 
characteristics of participants were similar in the 
chlorhexidine and control groups. The median 
gestational age at delivery was 39 weeks (range 23–44); 
about 10% of mothers were given intrapartum antibiotics 
(table 1). HIV results were available for 7902 (99%) of 
8011 mothers, and 2090 (26%) of these were infected 
with HIV. 1867 (23%) of 8011 women had a caesarean 
delivery. Of 8129 infants born, 309 (4%) were born 
before 37 weeks’ gestation. When further stratifi ed by 
maternal HIV status, baseline characteristics remained 
similar in the chlorhexidine and control groups (data 
not shown). 
Mothers were given a median of one (range 1–8) wipe 
during labour. 6423 (80%) of 8011 women had one or 
more wipes at least 1 h and not more than 6 h before 
delivery. Use of interventional wipes was stopped early in 
18 (<1%) of 6135 women who had a vaginal delivery. Use 
of wipes was stopped early in nine mothers because of 
the presentation of the neonate’s face, ten because of 
Chlorhexidine Control
Mothers
n 4005 4006
Age (years) 26 (22–31) 26 (22–31)
Gravidity 2 (1–3) 2 (1–3)
Medical history
HIV-positive 1050 (26%) 1036 (26%)
Urinary tract infection 449 (11%) 405 (10%)
Gestational diabetes 9 (<1%) 11 (<1%)
Maternal tuberculosis 19 (<1%) 23 (<1%)
Given intrapartum antibiotics* 388 (10%) 390 (10%)
Intrapartum antibiotics in women with vaginal delivery† 291 (75%) 296 (76%)
Given antibiotics 7 days before delivery‡ 241 (25%) 234 (26%)
Intrapartum fever 8 (<1%) 8 (<1%)
Rupture of membranes (delivery ≥18 h) 385 (10%) 325 (8%)
Unbooked or no prenatal care 10 (<1%) 1 (<1%)
Twin birth 67 (2%) 51 (1%)
Meconium-stained amniotic fl uid 598 (15%) 602 (15%)
Delivery§ 
Spontaneous vaginal delivery 3079 (77%) 3057 (76%)
Emergency caesarean delivery 924 (23%)) 943 (24%)
Vaginal vacuum or forceps assisted 80 (2%) 84 (2%)
Newborn babies
n 4072 4057
Girl 1906 47%) 1967 (48%)
Preterm 158 (4%) 151 (4%)
Birthweight (g) 3140 (2850–3465) 3125 (2850–3450)
Apgar at 5 min 10 (10–10) 10 (10–10)
HIV-exposed infants 1050 (26%) 1040 (26%)
HIV PCR-positive¶ 65 (9%) 47 (7%)
Outcome
Stillborn 12 (<1%) 14 (<1%)
Died soon after delivery 2 (<1%) 13 (<1%)
Surviving neonates admitted 397 (10%) 390 (10%)
Data are median (IQR) or number (%), unless otherwise indicated. *At least 2 h before delivery (excludes prophylaxis 
for caesarean section). †Denominator is the number of women given intrapartum antibiotics. ‡Denominator is the 
number of women who had been given any antibiotics during pregnancy: 949 in chlorhexidine group and 912 in 
control group. §Includes mode of delivery of all singletons and fi rst twins only; four second twins (2 in chlorhexidine 
group, and 2 in control group) were delivered by caesarean section after the fi rst twin was delivered vaginally; other 
second twins were delivered by the same route as the fi rst twin; denominator was 4003 in the chlorhexidine group, 
and 4000 in the control group because eight mothers delivered at another centre and therefore these data were not 
available. ¶Data are number (%) of neonates tested—ie, 716 in chlorhexidine group, and 654 in control group.
Table 1: Selected demographic and clinical characteristics of mothers and newborn babies in the 
chlorhexidine and control groups
RCtl–RTrt
RCtl
×100%
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strong contractions, and three (all in chlorhexidine 
group) as a result of discomfort.
8070 (99%) of 8129 neonates had wipes at a median of 
50 min (IQR 30–70) after birth. 41 of 59 neonates did not 
have a wipe because they were stillborn or severely ill. No 
reactions to wipes were noted at discharge. No neonatal 
adverse or serious adverse events related to the intervention 
were reported. 958 neonates were admitted 976 times, 
16 were admitted twice, and one was admitted three times. 
Overall, fewer neonates died in the chlorhexidine group 
Overall Maternal HIV-negative status Maternal HIV-positive status
Chlorhexidine Control Chlorhexidine Control Chlorhexidine Control
Neonates
n 4072 4057 2939 2947 1072 1058
Bacteria cultured
Group B streptococcus 10 6 ·· ·· ·· ··
Escherichia coli 0 1 ·· ·· ·· ··
Klebsiella pneumoniae 1 0 ·· ·· ·· ··
Staphylococcus aureus 0 1 ·· ·· ·· ··
Streptococcus viridans 1 1 ·· ·· ·· ··
Acinetobacter baumannii and lwoffi  i 1 2 ·· ·· ·· ··
Enterococcus faecalis and faecium 1 2 ·· ·· ·· ··
Enterobacter 0 1 ·· ·· ·· ··
Early-onset sepsis
Culture-confi rmed cases* meeting defi nition 
for clinical sepsis
11 7 6† 5 4† 2
Culture-confi rmed cases not meeting 
defi nition for clinical sepsis defi nition‡
3 7 2 4 1 3
Cases with clinical sepsis only 126 132 98 105 28 27
Early deaths (<3 days) not meeting culture-
confi rmed* or clinical defi nitions, but included 
as early-onset sepsis after panel review
1 2 1 2 0 0
Total 141 (3%) 148 (4%) 107 (4%) 116 (4%) 33 (3%) 32 (3%)
Overall effi  cacy (95% CI) 5% (–19 to 24); 
p=0·6518
·· 8% (–20 to 29); 
p=0·5527
·· –2% (–64 to 37); 
p=0·9425
··
Late-onset sepsis
Culture-confi rmed sepsis meeting criteria for 
clinical sepsis
4 8 1 3 3 4
Culture-confi rmed cases not meeting 
defi nition for clinical sepsis 
9 3 6 2 3 1
Cases with clinical sepsis only 9 6 7 1 2 5
Total 22 (<1%) 17 (<1%) 14 (<1%) 6 (<1%) 8 (<1%) 10 (<1%)
Overall effi  cacy (95% CI) –29%  (–142 to 31); 
p=0·4289
·· –134% (–508 to 10); 
p=0·0722
·· 21% (–99 to 69); 
p=0·6161
··
Mothers with post-partum sepsis
n 4005 4006 2896 2916 1050 1040
Bacteria cultured
Citrobacter freundii 0 1 ·· ·· ·· ··
Escherichia coli 1 0 ·· ·· ·· ··
Culture-confi rmed cases meeting clinical criteria 0 0 0 0 0 0
Culture-confi rmed only 1 1 1 1 0 0
Endometritis only 14 11 8† 6 5 5
Total 15 (<1%) 12 (<1%) 9 (<1%) 7 (<1%) 5 (<1%) 5 (<1%)
Overall effi  cacy (95% CI) –25% (–167 to 41); 
p=0·5626
·· –29% (–247 to 52); 
p=0·6069
·· 1% (–240  to 71); 
p=0·9879
Data are number or number (%), unless otherwise indicated. All neonates (including second twins and stillborn neonates) who were delivered in a hospital are included.  
*Early-onset culture-confi rmed sepsis—ie, isolation of a microorganism that is not a common contaminant from a site on the neonate’s body that is usually sterile within the fi rst 
3 days of life. †Data for HIV were missing for one newborn baby with culture-confi rmed, clinical early-onset sepsis in the chlorhexidine group and for one mother with post-partum 
sepsis meeting the clinical criteria. ‡Early onset culture-confi rmed sepsis in the absence of study-specifi ed clinical criteria of early-onset neonatal sepsis.
Table 2: Intent-to-treat analysis of early-onset sepsis in neonates and maternal post-partum sepsis by intervention group and HIV exposure status
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(34 of 4072 [8·3 per 1000 births]) than in the control group 
(52 of 4057 [12·8 per 1000 births]; p=0·0490) but there 
were no diff erences in the rates of admission to hospital 
(485 of 4072 [119 per 1000 births]) vs 491 of 4057 [121 per 
1000 births]; p=0·7901). 26 (3·2 per 1000 births) deliveries 
resulted in stillbirths (12 in chlorhexidine group and 14 in 
control group; p=0·6852) and 15 (2 in chlorhexidine group 
and 13 in control group; p=0·0043) neonates died in the 
resuscitation room within 9 h after birth. 13 neonates 
(11 in control group) died of birth asphyxia, and twins in 
the control group died of extreme prematurity (25 weeks’ 
gestation). Of 45 remaining neonatal deaths that occurred, 
20 were in the chlorhexidine group and 25 in the 
control group (p=0·4473). Mean age at outcome was 
11·2 days (SD 17·4) and median was 7 days (IQR 4–11). 
112 (8%) of 1370 HIV-exposed, tested neonates were 
infected with this virus.
Overall, 289 cases of early-onset sepsis occurred, with 
no diff erence in rates in the chlorhexidine (34·6 per 1000 
births) and control groups (36·5 per 1000 births; table 2). 
Similarly, the rates of culture-confi rmed sepsis (14 
episodes in each group) and clinically diagnosed 
early-onset sepsis did not diff er (table 2). Group B 
streptococcus was the most commonly identifi ed 
pathogen from sterile sites in early-onset sepsis (16 [57%] 
of 28 cultured bacteria; incidence 2·0 per 1000 livebirths). 
Rates of early-onset sepsis did not diff er in the 
chlorhexidine and placebo groups when further stratifi ed 
by the status of maternal HIV infection (table 2). 
252 (87%) of 289 newborn babies with early-onset sepsis 
were admitted within 4 h after birth. 39 cases (4·8 per 
1000 births) of late-onset sepsis occurred—22 (56%) in 
the chlorhexidine group (table 2). 
27 of 8011 women had post-partum sepsis (15 in 
chlorhexidine group [3·7 per 1000]; 12 in control group 
[3·0 per 1000]; table 2). Maternal deaths (1 in chlorhexidine 
group and 3 in control group) or post-partum admissions 
(1013 in chlorhexidine group and 1034 in control group; 
p=0·5951) were not attributed to the intervention. Most 
mothers (1876 [92%] of 2047) were admitted to hospital 
for routine care after caesarean delivery. 
3964 (77%) of 5146 women in the colonisation 
substudy had vaginal deliveries; 825 (21%) of these were 
colonised with group B streptococcus. This bacterium 
was cultured from 450 (54%) of 830 newborn babies 
born to mothers colonised with group B streptococcus. 
316 (79%) of 401 mother–infant pairs in the chlorhexidine 
group met the defi nition of a true complier. The rates of 
colonisation with group B streptococcus in neonates 
were similar in the chlorhexidine and control groups, 
without substantial reduction in vertical transmission 
(table 3); results were similar when data were excluded 
for mothers who were given intrapartum antibiotics for 
more than 2 h (n=47), mainly for meconium-stained 
amniotic fl uid. Results for E coli and K pneumoniae were 
similar in the two groups (table 3).
Discussion
Use of maternal and neonatal chlorhexidine wipes did 
not prevent the occurrence of early-onset sepsis. This 
absence of benefi t was corroborated by the lack of eff ect 
on vertical transmission of the main sepsis-causing 
pathogens, and on serious maternal post-partum 
sepsis.
Diff erences between our study and other African 
studies13,14 include our use of a stringent defi nition of 
neonatal sepsis, controlled randomisation of individuals, 
and use of 0·5% chlorhexidine solution instead of 
0·25%. Additionally, even though substantial reductions 
were reported in neonatal and maternal sepsis in the 
chlorhexidine groups in these studies in Malawi and 
Egypt,13,14 vertical transmission of bacteria was not 
assessed to corroborate the results. Furthermore, 
because staff  were not employed to deliver the 
intervention in these African trials,13,14 mothers who 
were assigned to the intervention group might have 
inadvertently benefi ted from more intensive monitoring 
and general care than might have those in the 
non-intervention group. In these studies,13,14 episodes of 
sepsis were not stratifi ed by neonatal age, even though 
a chlorhexidine intervention is unlikely to have an eff ect 
after the fi rst few days of life. Only 57·8% of cases of 
neonatal sepsis in the Malawi study occurred in 
neonates younger than 48 h.13 Similarities between 
studies include timing and number of wipes, and 
eligibility criteria, although we included mothers who 
were in preterm labour.
Our results suggest that chlorhexidine is unlikely to 
prevent vertically acquired neonatal infections in any 
setting or population. Because vertically acquired 
Chlorhexidine Control Overall effi  cacy (95% CI)
Complier Non-complier
Group B streptococcus
Positive 168 (53%) 49 (58%) 234 (55%) ··
Negative 135 (43%) 28 (33%) 175 (41%) ··
Missing result 13 (4%) 8 (9%) 20 (5%) ··
Total 316 85 429 0·05% (–9·2 to 7·9)
Escherichia coli
Positive 361 (51%) 92 (50%) 442 (51%) ··
Negative 298 (42%) 74 (40%) 362 (42%) ··
Missing result 45 (6%) 18 (24%) 60 (7%) ··
Total 704 184 864 0·3% (–6·0 to 5·3)
Klebsiella pneumoniae
Positive 37 (29%) 6 (23%) 49 (30%) ··
Negative 88 (69%) 18 (69%) 103 (63%) ··
Missing result 3 (2%) 2 (8%) 11 (7%) ··
Total 128 26 163 10·6% (–5·9 to 24·1)
Data are number (%) or number, unless otherwise indicated; denominators in each column are the number of women 
colonised with the respective pathogen.
Table 3: Intent-to-treat analysis of vertical transmission of selected maternal-vaginal colonising bacteria 
from mother to newborn babies in the chlorhexidine and control groups, by neonatal colonisation status
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pathogens can cross intact membranes, causing 
infections of the amniotic fl uid and stillbirths,23 
vaccination of mothers against dominant bacterial patho-
gens warrants further study. The results of a review6 of 
pathogens associated with neonatal sepsis in developing 
countries suggest that many neonatal infections might 
be acquired environmentally. Few data are available from 
developing countries about sepsis during the fi rst 3 days 
of life; since this period is when most vertically acquired 
sepsis occurs, such data are urgently needed to clarify the 
contribution of vertical transmission to neonatal 
mortality. 
Although much fewer neonates died in the chlor-
hexidine group than in the control group in our trial, the 
eff ect on mortality was greatest within hours of birth, at 
which time the main cause of death was birth asphyxia, 
as assessed after a panel of neonatologists, who were 
unaware of treatment assignment, reviewed the records. 
The lack of eff ect of chlorhexidine on neonatal sepsis or 
vertical transmission of bacteria suggests that the eff ect 
on mortality was not likely to be the result of the 
chlorhexidine intervention. The use of intrapartum 
antibiotics in our population of mothers (mainly for 
meconium-stained amniotic fl uid) could have reduced 
the effi  cacy of chlorhexidine through the reduction in the 
rates of sepsis and vertical transmission in treatment and 
control groups. However, the incidence of overall sepsis 
remained high, and the incidences of culture-confi rmed 
infection with group B streptococcus and vertical 
transmission were similar to those reported in 
industrialised countries before the widespread use of 
prophylaxis with intrapartum antibiotics.
Although we did not show a reduction in vertical 
transmission of pathogenic bacteria with use of 
chlorhexidine vaginal wipes, reduction of vertical 
transmission of group B streptococcus has been reported 
with similar interventions.18,19,24 Although unlikely, the 
chlorhexidine wipe method that we used might have 
been less eff ective at reducing vertical transmission than 
the use of douching or gel application in other studies, 
However, our cohort of mothers colonised with group B 
streptococcus was substantially larger than the cohorts in 
other studies,18,19,24 which on their own were inadequately 
powered for the assessment of vertical transmission.
A limitation of our study was that midwives were 
aware of the intervention that they were administering. 
Also, we did not use a true placebo because of the 
concerns about the detrimental eff ects of using vaginal 
wipes without antisepsis. Several safeguards, including 
the use of colourless chlorhexidine solution, and nursing 
staff  not being involved in patient care or gathering 
endpoint data, were established and maintained to 
counteract this limitation. 
Although several trials have raised hopes that 
chlorhexidine vaginal and neonatal cleansing would be 
benefi cial in saving the lives of newborn babies, the 
results from our trial suggest that use of chlorhexidine 
wipes is unlikely to reduce neonatal mortality from 
vertically acquired sepsis. Other neonatal interventions 
are needed to achieve the Millennium Developmental 
Goal of reduction in childhood mortality.
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individuals, including images where individuals' eyes have been blacked out or images
depicting victims of abuse.
15. If the requester is translating the material, the following translation disclaimer must be
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included:
The materials reused with permission from the American Academy of Pediatrics
("AAP") appeared originally in English, published by the AAP. The AAP assumes no
responsibility for any inaccuracy or error in the contents of these materials,
including any inaccuracy or error arising from the translation from English.
16. Other Terms and Conditions:
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+1­978­646­2777.
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Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is confined to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However figures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com)
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not specifically granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is finally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions.  If
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deemed automatically revoked and shall be void as if never granted.  Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted.  Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective officers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as specifically authorized
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11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in a writing
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions.  These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction.  In the event of
any conflict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you.  Notice of such denial will be made using the contact information provided by you. 
Failure to receive such notice will not alter or invalidate the denial.  In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to specific license types:
15. Translation: This permission is granted for non­exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper­text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
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Licensing material from an Elsevier book: A hyper­text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password­protected and made available only to
bona fide students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write­up of research results and analysis, it has not been peer­
reviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the final versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to find, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society­owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes author­
incorporated changes suggested during submission, peer review and editor­author
communications.
Authors can share their accepted author manuscript:
         immediately
via their non­commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation­only research collaboration work­group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation­only work group on
commercial sites with which Elsevier has an agreement
         after the embargo period
via non­commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement
In all cases accepted manuscripts should:
         link to the formal publication via its DOI
         bear a CC­BY­NC­ND license ­ this is easy to do
         if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.
Published journal article (JPA): A published journal article (PJA) is the definitive final
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record of published research that appears or will appear in the journal and embodies all
value­adding publishing activities including peer review co­ordination, copy­editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full­text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to find, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are affiliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author­selected end­user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:  
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
 
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re­use of these open access articles is defined by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modified in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, figures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC­BY license allows users to copy, to create extracts, abstracts and new
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works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY­NC­SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by­nc­sa/4.0.
CC BY NC ND: The CC BY­NC­ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by­nc­nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
         Associating advertising with the full text of the Article
         Charging fees for document delivery or access
         Article aggregation
         Systematic distribution via e­mail lists or share buttons
Posting or linking by commercial companies for use by customers of those companies.
 
20. Other Conditions:
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Questions? customercare@copyright.com or +1­855­239­3415 (toll free in the US) or
+1­978­646­2777.
